

DOCKET NO.: 411USPFM311

PATENT



5

NOVEL G PROTEIN-COUPLED RECEPTORS

10 CROSS-REFERENCE TO RELATED APPLICATIONS

The present application is a continuation-in-part of Application Ser. No. 09/714,449, filed 2000 November 16, which claims priority of Application Serial No. 60/165,838, filed 1999 November 16; Serial No. 60/166,071, filed 1999 November 17; Serial No. 60/166,678 filed 1999 November 19; Serial No. 60/173,396, filed 1999 December 28; Serial No. 60/184,129, filed 2000 February 22; Serial No. 60/188,114, filed 2000 March 9; Serial No. 60/185,421, filed 2000 February 28; Serial No. 60/186,811, filed 2000 March 3; Serial No. 60/186,530, filed 2000 March 2; Serial No. 60/207,094, filed 2000 May 25; Serial No. 60/203,111, filed 2000 May 8; Serial No. 60/190,310, filed 2000 March 17; Serial No. 60/201,190, filed 2000 May 2; Serial No. 20 60/185,554, filed 2000 February 28; Serial No. 60/198,568, filed 2000 April 20; and Serial No. 60/190,800, filed 2000 March 21, each of which is hereby incorporated by reference in its entirety.

FIELD OF THE INVENTION

25 The present invention relates generally to the fields of genetics and cellular and molecular biology. More particularly, the invention relates to novel G protein coupled receptors, to polynucleotides that encode such novel receptors, to reagents such as antibodies, probes, primers and kits comprising such antibodies, probes, primers related to the same, and to methods which use the novel G protein coupled receptors, 30 polynucleotides or reagents.

BACKGROUND OF THE INVENTION

The G protein-coupled receptors (GPCRs) form a vast superfamily of cell surface receptors which are characterized by an amino-terminal extracellular domain, a carboxyl-terminal intracellular domain, and a serpentine structure that passes through the cell membrane seven times. Hence, such receptors are sometimes also referred to as seven transmembrane (7TM) receptors. These seven transmembrane domains define three extracellular loops and three intracellular loops, in addition to the amino- and carboxy-terminal domains. The extracellular portions of the receptor have a role in recognizing and binding one or more extracellular binding partners (e.g., ligands), whereas the intracellular portions have a role in recognizing and communicating with downstream molecules in the signal transduction cascade.

The G protein-coupled receptors bind a variety of ligands including calcium ions, hormones, chemokines, neuropeptides, neurotransmitters, nucleotides, lipids, odorants, and even photons, and are important in the normal (and sometimes the aberrant) function of many cell types. [See generally Strosberg, *Eur. J. Biochem.* 196:1-10 (1991) and Bohm *et al.*, *Biochem J.* 322:1-18 (1997).] When a specific ligand binds to its corresponding receptor, the ligand typically stimulates the receptor to activate a specific heterotrimeric guanine-nucleotide-binding regulatory protein (G-protein) that is coupled to the intracellular portion of the receptor. The G protein in turn transmits a signal to an effector molecule within the cell, by either stimulating or inhibiting the activity of that effector molecule. These effector molecules include adenylate cyclase, phospholipases and ion channels. Adenylate cyclase and phospholipases are enzymes that are involved in the production of the second messenger molecules cAMP, inositol triphosphate and diacyglycerol. It is through this sequence of events that an extracellular ligand stimuli exerts intracellular changes through a G protein-coupled receptor. Each such receptor has its own characteristic primary structure, expression pattern, ligand-binding profile, and intracellular effector system.

Because of the vital role of G protein-coupled receptors in the communication between cells and their environment, such receptors are attractive targets for therapeutic

DOCKET NO.: 411USPHRM311

PATENT

intervention, for example by activating or antagonizing such receptors. For receptors having a known ligand, the identification of agonists or antagonists may be sought specifically to enhance or inhibit the action of the ligand. Some G protein-coupled receptors have roles in disease pathogenesis (*e.g.*, certain chemokine receptors that act 5 as HIV co-receptors may have a role in AIDS pathogenesis), and are attractive targets for therapeutic intervention even in the absence of knowledge of the natural ligand of the receptor. Other receptors are attractive targets for therapeutic intervention by virtue of their expression pattern in tissues or cell types that are themselves attractive targets for therapeutic intervention. Examples of this latter category of receptors include 10 receptors expressed in immune cells, which can be targeted to either inhibit autoimmune responses or to enhance immune responses to fight pathogens or cancer; and receptors expressed in the brain or other neural organs and tissues, which are likely targets in the treatment of schizophrenia, depression, bipolar disease, or other 15 neurological disorders. This latter category of receptor is also useful as a marker for identifying and/or purifying (*e.g.*, via fluorescence-activated cell sorting) cellular subtypes that express the receptor. Unfortunately, only a limited number of G protein receptors from the central nervous system (CNS) are known. Thus, a need exists for G protein-coupled receptors that have been identified and show promise as targets for therapeutic intervention in a variety of animals, including humans.

20

SUMMARY OF THE INVENTION

The present invention relates to an isolated nucleic acid molecule that comprises a nucleotide sequence that encodes a polypeptide comprising an amino acid sequence homologous to even numbered sequences ranging from SEQ ID NO: 2 to SEQ ID NO: 25 94, SEQ ID NO: 186 and SEQ ID NO: 192, or a fragment thereof. The nucleic acid molecule encodes at least a portion of nGPCR-x. In some embodiments, the nucleic acid molecule comprises a sequence that encodes a polypeptide comprising even numbered sequences ranging from SEQ ID NO: 2 to SEQ ID NO: 94, SEQ ID NO: 186 and SEQ ID NO: 192, or a fragment thereof. In some embodiments, the nucleic acid 30 molecule comprises a sequence homologous to odd numbered sequences ranging from SEQ ID NO: 1 to SEQ ID NO: 93, SEQ ID NO: 185 and SEQ ID NO: 191, or a fragment thereof. In some embodiments, the nucleic acid molecule comprises a

DOCKET NO.: 411USPHRM311

PATENT

sequence selected from the group consisting of odd numbered sequences ranging from SEQ ID NO: 1 to SEQ ID NO: 93, SEQ ID NO: 185 and SEQ ID NO: 191, and fragments thereof.

According to some embodiments, the present invention provides vectors which 5 comprise the nucleic acid molecule of the invention. In some embodiments, the vector is an expression vector.

According to some embodiments, the present invention provides host cells which comprise the vectors of the invention. In some embodiments, the host cells comprise expression vectors.

10 The present invention provides an isolated nucleic acid molecule comprising a nucleotide sequence complementary to at least a portion of a sequence from an odd numbered sequence ranging from SEQ ID NO: 1 to SEQ ID NO: 93, SEQ ID NO: 185 and SEQ ID NO: 191, said portion comprising at least 10 nucleotides.

15 The present invention provides a method of producing a polypeptide comprising a sequence from an even numbered sequence ranging from SEQ ID NO: 2 to SEQ ID NO: 94, SEQ ID NO: 186 and SEQ ID NO: 192, or a homolog or fragment thereof. The method comprising the steps of introducing a recombinant expression vector that includes a nucleotide sequence that encodes the polypeptide into a compatible host cell, growing the host cell under conditions for expression of the polypeptide and recovering 20 the polypeptide.

The present invention provides an isolated antibody which binds to an epitope on a polypeptide comprising a sequence from an even numbered sequence ranging from SEQ ID NO: 2 to SEQ ID NO: 94, SEQ ID NO: 186 and SEQ ID NO: 192, or a homolog or fragment thereof.

25 The present invention provides a method of inducing an immune response in a mammal against a polypeptide comprising a sequence from an even numbered sequence ranging from SEQ ID NO: 2 to SEQ ID NO: 94, SEQ ID NO: 186 and SEQ ID NO: 192, or a homolog or fragment thereof. The method comprises administering to a mammal an amount of the polypeptide sufficient to induce said immune response.

30 The present invention provides a method for identifying a compound which binds nGPCR-x. The method comprises the steps of: contacting nGPCR-x with a compound and determining whether the compound binds nGPCR-x.

DOCKET NO.: 411USPHRM311

PATENT

The present invention provides a method for identifying a compound which binds a nucleic acid molecule encoding nGPCR-x. The method comprises the steps of contacting said nucleic acid molecule encoding nGPCR-x with a compound and determining whether said compound binds said nucleic acid molecule.

5 The present invention provides a method for identifying a compound which modulates the activity of nGPCR-x. The method comprises the steps of contacting nGPCR-x with a compound and determining whether nGPCR-x activity has been modulated.

10 The present invention provides a method of identifying an animal homolog of nGPCR-x. The method comprises the steps screening a nucleic acid database of the animal with an odd numbered sequence ranging from SEQ ID NO: 1 to SEQ ID NO: 93, SEQ ID NO: 185 and SEQ ID NO: 191, or a portion thereof and determining whether a portion of said library or database is homologous to said odd numbered sequence ranging from SEQ ID NO: 1 to SEQ ID NO: 93, SEQ ID NO: 185 and SEQ 15 ID NO: 191, or portion thereof.

15 The present invention provides a method of identifying an animal homolog of nGPCR-x. The methods comprises the steps screening a nucleic acid library of the animal with a nucleic acid molecule having an odd numbered nucleotide sequence ranging from SEQ ID NO: 1 to SEQ ID NO: 93, SEQ ID NO: 185 and SEQ ID NO: 191, or a portion thereof; and determining whether a portion of said library or database is homologous to said odd numbered nucleotide sequence ranging from SEQ ID NO: 1 to SEQ ID NO: 93, SEQ ID NO: 185 and SEQ ID NO: 191, or a portion thereof.

Another aspect of the present invention relates to methods of screening a human subject to diagnose a disorder affecting the brain or genetic predisposition therefor.

20 The methods comprise the steps of assaying nucleic acid of a human subject to determine a presence or an absence of a mutation altering an amino acid sequence, expression, or biological activity of at least one nGPCR that is expressed in the brain. The nGPCR comprise an amino acid sequence selected from the group consisting of: SEQ ID NO:74, SEQ ID NO:186, SEQ ID NO:78, SEQ ID NO:80, SEQ ID NO:82, 25 SEQ ID NO:84, SEQ ID NO:86, SEQ ID NO:90, and SEQ ID NO:94, and allelic variants thereof. A diagnosis of the disorder or predisposition is made from the presence or absence of the mutation. The presence of a mutation altering the amino

DOCKET NO.: 411USPHRM311

PATENT

acid sequence, expression, or biological activity of the nGPCR in the nucleic acid correlates with an increased risk of developing the disorder.

The present invention further relates to methods of screening for a nGPCR-40 or nGPCR-54 hereditary schizophrenia genotype in a human patient. The methods

5 comprise the steps of providing a biological sample comprising nucleic acid from the patient, in which the nucleic acid includes sequences corresponding to alleles of nGPCR-40 or nGPCR-54. The presence of one or more mutations in the nGPCR-40 allele or the nGPCR-54 allele is detected indicative of a hereditary schizophrenia genotype.

10 The present invention provides kits for screening a human subject to diagnose schizophrenia or a genetic predisposition therefor. The kits include an oligonucleotide useful as a probe for identifying polymorphisms in a human nGPCR-40 gene or a human nGPCR-54 gene. The oligonucleotide comprises 6-50 nucleotides in a sequence that is identical or complementary to a sequence of a wild type human nGPCR-40 or 15 nGPCR-54 gene sequence or nGPCR-40 or nGPCR-54 coding sequence, except for one sequence difference selected from the group consisting of a nucleotide addition, a nucleotide deletion, or nucleotide substitution. The kit also includes a media packaged with the oligonucleotide. The media contains information for identifying polymorphisms that correlate with schizophrenia or a genetic predisposition therefor, 20 the polymorphisms being identifiable using the oligonucleotide as a probe.

The present invention further relates to methods of identifying nGPCR allelic variants that correlates with mental disorders. The methods comprise the steps of providing biological samples that comprise nucleic acid from a human patient diagnosed with a mental disorder, or from the patient's genetic progenitors or progeny, 25 and detecting in the nucleic acid the presence of one or more mutations in an nGPCR that is expressed in the brain. The nGPCR comprises an amino acid sequence selected from the group consisting of SEQ ID NO:74, SEQ ID NO:186, SEQ ID NO:78, SEQ ID NO:80, SEQ ID NO:82, SEQ ID NO:84, SEQ ID NO:86, SEQ ID NO:90, and SEQ ID NO:94, and allelic variants thereof. The nucleic acid includes sequences corresponding to the gene or genes encoding nGPCR. The one or more mutations detected indicate an allelic variant that correlates with a mental disorder.

DOCKET NO.: 411USPHRM311

PATENT

The present invention further relates to purified polynucleotides comprising nucleotide sequences encoding alleles of nGPCR-40 or nGPCR-54 from a human with schizophrenia. The polynucleotide hybridizes to the complement of SEQ ID NO:83 or of SEQ ID NO:85 under the following hybridization conditions: (a) hybridization for 5 16 hours at 42°C in a hybridization solution comprising 50% formamide, 1% SDS, 1 M NaCl, 10% dextran sulfate and (b) washing 2 times for 30 minutes at 60°C in a wash solution comprising 0.1x SSC and 1% SDS. The polynucleotide that encodes nGPCR-40 or nGPCR-54 amino acid sequence of the human differs from SEQ ID NO:84 or SEQ ID NO:86 by at least one residue.

10 The present invention also provides methods for identifying a modulator of biological activity of nGPCR-40 or nGPCR-54 comprising the steps of contacting a cell that expresses nGPCR-40 or nGPCR-54 in the presence and in the absence of a putative modulator compound and measuring nGPCR-40 or nGPCR-54 biological activity in the cell. The decreased or increased nGPCR-40 or nGPCR-54 biological activity in the 15 presence versus absence of the putative modulator is indicative of a modulator of biological activity.

16 The present invention further provides methods to identify compounds useful for the treatment of schizophrenia. The methods comprise the steps of contacting a composition comprising nGPCR-40 with a compound suspected of binding nGPCR-40 or contacting a composition comprising nGPCR-54 with a compound suspected of binding nGPCR-54. The binding between nGPCR-40 and the compound suspected of binding nGPCR-40 or between nGPCR-54 and the compound suspected of binding nGPCR-54 is detected. Compounds identified as binding nGPCR-40 or nGPCR-54 are candidate compounds useful for the treatment of schizophrenia.

20 The present invention further provides methods for identifying a compound useful as a modulator of binding between nGPCR-40 and a binding partner of nGPCR-40 or between nGPCR-54 and a binding partner of nGPCR-54. The methods comprise the steps of contacting the binding partner and a composition comprising nGPCR-40 or nGPCR-54 in the presence and in the absence of a putative modulator compound and 25 detecting binding between the binding partner and nGPCR-40 or nGPCR-54.

Decreased or increased binding between the binding partner and nGPCR-40 or nGPCR-54 in the presence of the putative modulator, as compared to binding in the absence of

DOCKET NO.: 411USPHRM311

PATENT

the putative modulator is indicative a modulator compound useful for the treatment of schizophrenia.

Another aspect of the present invention relates to methods of purifying a G protein from a sample containing a G protein. The methods comprise the steps of
5 contacting the sample with an nGPCR for a time sufficient to allow the G protein to form a complex with the nGPCR; isolating the complex from remaining components of the sample; maintaining the complex under conditions which result in dissociation of the G protein from the nGPCR; and isolating said G protein from the nGPCR.

10 DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS

Definitions

Various definitions are made throughout this document. Most words have the meaning that would be attributed to those words by one skilled in the art. Words specifically defined either below or elsewhere in this document have the meaning
15 provided in the context of the present invention as a whole and as are typically understood by those skilled in the art.

"Synthesized" as used herein and understood in the art, refers to polynucleotides produced by purely chemical, as opposed to enzymatic, methods. "Wholly" synthesized DNA sequences are therefore produced entirely by chemical means, and
20 "partially" synthesized DNAs embrace those wherein only portions of the resulting DNA were produced by chemical means.

By the term "region" is meant a physically contiguous portion of the primary structure of a biomolecule. In the case of proteins, a region is defined by a contiguous portion of the amino acid sequence of that protein.

25 The term "domain" is herein defined as referring to a structural part of a biomolecule that contributes to a known or suspected function of the biomolecule. Domains may be co-extensive with regions or portions thereof; domains may also incorporate a portion of a biomolecule that is distinct from a particular region, in addition to all or part of that region. Examples of GPCR protein domains include, but
30 are not limited to, the extracellular (*i.e.*, N-terminal), transmembrane and cytoplasmic (*i.e.*, C-terminal) domains, which are co-extensive with like-named regions of GPCRs; each of the seven transmembrane segments of a GPCR; and each of the loop segments

DOCKET NO.: 411USPHRM311

PATENT

(both extracellular and intracellular loops) connecting adjacent transmembrane segments.

As used herein, the term “activity” refers to a variety of measurable indicia suggesting or revealing binding, either direct or indirect; affecting a response, i.e.

5 having a measurable affect in response to some exposure or stimulus, including, for example, the affinity of a compound for directly binding a polypeptide or polynucleotide of the invention, or, for example, measurement of amounts of upstream or downstream proteins or other similar functions after some stimulus or event.

Unless indicated otherwise, as used herein, the abbreviation in lower case (gpcr) 10 refers to a gene, cDNA, RNA or nucleic acid sequence, while the upper case version (GPCR) refers to a protein, polypeptide, peptide, oligopeptide, or amino acid sequence. The term “nGPCR-x” refers to any of the nGPCRs taught herein, while specific reference to a nGPCR (for example nGPCR-5) refers only to that specific nGPCR.

As used herein, the term “antibody” is meant to refer to complete, intact 15 antibodies, and Fab, Fab’, F(ab)2, and other fragments thereof. Complete, intact antibodies include monoclonal antibodies such as murine monoclonal antibodies, chimeric antibodies and humanized antibodies.

As used herein, the term “binding” means the physical or chemical interaction 20 between two proteins or compounds or associated proteins or compounds or combinations thereof. Binding includes ionic, non-ionic, Hydrogen bonds, Van der Waals, hydrophobic interactions, etc. The physical interaction, the binding, can be either direct or indirect, indirect being through or due to the effects of another protein or compound. Direct binding refers to interactions that do not take place through or due to the effect of another protein or compound but instead are without other 25 substantial chemical intermediates. Binding may be detected in many different manners. As a non-limiting example, the physical binding interaction between a nGPCR-x of the invention and a compound can be detected using a labeled compound. Alternatively, functional evidence of binding can be detected using, for example, a cell transfected with and expressing a nGPCR-x of the invention. Binding of the 30 transfected cell to a ligand of the nGPCR that was transfected into the cell provides functional evidence of binding. Other methods of detecting binding are well-known to those of skill in the art.

DOCKET NO.: 411USPHRM311

PATENT

As used herein, the term "compound" means any identifiable chemical or molecule, including, but not limited to, small molecule, peptide, protein, sugar, nucleotide, or nucleic acid, and such compound can be natural or synthetic.

As used herein, the term "complementary" refers to Watson-Crick basepairing 5 between nucleotide units of a nucleic acid molecule.

As used herein, the term "contacting" means bringing together, either directly or indirectly, a compound into physical proximity to a polypeptide or polynucleotide of the invention. The polypeptide or polynucleotide can be in any number of buffers, salts, solutions etc. Contacting includes, for example, placing the compound into a 10 beaker, microtiter plate, cell culture flask, or a microarray, such as a gene chip, or the like, which contains the nucleic acid molecule, or polypeptide encoding the nGPCR or fragment thereof.

As used herein, the phrase "homologous nucleotide sequence," or "homologous amino acid sequence," or variations thereof, refers to sequences characterized by a 15 homology, at the nucleotide level or amino acid level, of at least the specified percentage. Homologous nucleotide sequences include those sequences coding for isoforms of proteins. Such isoforms can be expressed in different tissues of the same organism as a result of, for example, alternative splicing of RNA. Alternatively, isoforms can be encoded by different genes. Homologous nucleotide sequences include 20 nucleotide sequences encoding for a protein of a species other than humans, including, but not limited to, mammals. Homologous nucleotide sequences also include, but are not limited to, naturally occurring allelic variations and mutations of the nucleotide sequences set forth herein. A homologous nucleotide sequence does not, however, include the nucleotide sequence encoding other known GPCRs. Homologous amino 25 acid sequences include those amino acid sequences which contain conservative amino acid substitutions and which polypeptides have the same binding and/or activity. A homologous amino acid sequence does not, however, include the amino acid sequence encoding other known GPCRs. Percent homology can be determined by, for example, the Gap program (Wisconsin Sequence Analysis Package, Version 8 for Unix, Genetics 30 Computer Group, University Research Park, Madison WI), using the default settings, which uses the algorithm of Smith and Waterman (Adv. Appl. Math., 1981, 2, 482-489, which is incorporated herein by reference in its entirety).

DOCKET NO.: 411USPHRM311

PATENT

As used herein, the term "isolated" nucleic acid molecule refers to a nucleic acid molecule (DNA or RNA) that has been removed from its native environment.

Examples of isolated nucleic acid molecules include, but are not limited to, recombinant DNA molecules contained in a vector, recombinant DNA molecules maintained in a heterologous host cell, partially or substantially purified nucleic acid molecules, and synthetic DNA or RNA molecules.

As used herein, the terms "modulates" or "modifies" means an increase or decrease in the amount, quality, or effect of a particular activity or protein.

As used herein, the term "oligonucleotide" refers to a series of linked nucleotide residues which has a sufficient number of bases to be used in a polymerase chain reaction (PCR). This short sequence is based on (or designed from) a genomic or cDNA sequence and is used to amplify, confirm, or reveal the presence of an identical, similar or complementary DNA or RNA in a particular cell or tissue. Oligonucleotides comprise portions of a DNA sequence having at least about 10 nucleotides and as many as about 50 nucleotides, preferably about 15 to 30 nucleotides. They are chemically synthesized and may be used as probes.

As used herein, the term "probe" refers to nucleic acid sequences of variable length, preferably between at least about 10 and as many as about 6,000 nucleotides, depending on use. They are used in the detection of identical, similar, or complementary nucleic acid sequences. Longer length probes are usually obtained from a natural or recombinant source, are highly specific and much slower to hybridize than oligomers. They may be single- or double-stranded and carefully designed to have specificity in PCR, hybridization membrane-based, or ELISA-like technologies.

The term "preventing" refers to decreasing the probability that an organism contracts or develops an abnormal condition.

The term "treating" refers to having a therapeutic effect and at least partially alleviating or abrogating an abnormal condition in the organism.

The term "therapeutic effect" refers to the inhibition or activation factors causing or contributing to the abnormal condition. A therapeutic effect relieves to some extent one or more of the symptoms of the abnormal condition. In reference to the treatment of abnormal conditions, a therapeutic effect can refer to one or more of the following: (a) an increase in the proliferation, growth, and/or differentiation of

DOCKET NO.: 411USPHRM311

PATENT

cells; (b) inhibition (*i.e.*, slowing or stopping) of cell death; (c) inhibition of degeneration; (d) relieving to some extent one or more of the symptoms associated with the abnormal condition; and (e) enhancing the function of the affected population of cells. Compounds demonstrating efficacy against abnormal conditions can be

5 identified as described herein.

The term “abnormal condition” refers to a function in the cells or tissues of an organism that deviates from their normal functions in that organism. An abnormal condition can relate to cell proliferation, cell differentiation, cell signaling, or cell survival. An abnormal condition may also include obesity, diabetic complications such

10 as retinal degeneration, and irregularities in glucose uptake and metabolism, and fatty acid uptake and metabolism.

Abnormal cell proliferative conditions include cancers such as fibrotic and mesangial disorders, abnormal angiogenesis and vasculogenesis, wound healing, psoriasis, diabetes mellitus, and inflammation.

15 Abnormal differentiation conditions include, but are not limited to, neurodegenerative disorders, slow wound healing rates, and slow tissue grafting healing rates. Abnormal cell signaling conditions include, but are not limited to, psychiatric disorders involving excess neurotransmitter activity.

20 Abnormal cell survival conditions may also relate to conditions in which programmed cell death (apoptosis) pathways are activated or abrogated. A number of protein kinases are associated with the apoptosis pathways. Aberrations in the function of any one of the protein kinases could lead to cell immortality or premature cell death.

25 The term “administering” relates to a method of incorporating a compound into cells or tissues of an organism. The abnormal condition can be prevented or treated when the cells or tissues of the organism exist within the organism or outside of the organism. Cells existing outside the organism can be maintained or grown in cell culture dishes. For cells harbored within the organism, many techniques exist in the art to administer compounds, including (but not limited to) oral, parenteral, dermal, injection, and aerosol applications. For cells outside of the organism, multiple

30 techniques exist in the art to administer the compounds, including (but not limited to) cell microinjection techniques, transformation techniques and carrier techniques.

DOCKET NO.: 411USPHRM311

PATENT

The abnormal condition can also be prevented or treated by administering a compound to a group of cells having an aberration in a signal transduction pathway to an organism. The effect of administering a compound on organism function can then be monitored. The organism is preferably a mouse, rat, rabbit, guinea pig or goat, more 5 preferably a monkey or ape, and most preferably a human.

By "amplification" it is meant increased numbers of DNA or RNA in a cell compared with normal cells. "Amplification" as it refers to RNA can be the detectable presence of RNA in cells, since in some normal cells there is no basal expression of RNA. In other normal cells, a basal level of expression exists, therefore in these cases 10 amplification is the detection of at least 1 to 2-fold, and preferably more, compared to the basal level.

As used herein, the phrase "stringent hybridization conditions" or "stringent conditions" refers to conditions under which a probe, primer, or oligonucleotide will hybridize to its target sequence, but to no other sequences. Stringent conditions are 15 sequence-dependent and will be different in different circumstances. Longer sequences hybridize specifically at higher temperatures. Generally, stringent conditions are selected to be about 5°C lower than the thermal melting point (T_m) for the specific sequence at a defined ionic strength and pH. The T_m is the temperature (under defined ionic strength, pH and nucleic acid concentration) at which 50% of the probes 20 complementary to the target sequence hybridize to the target sequence at equilibrium. Since the target sequences are generally present in excess, at T_m , 50% of the probes are occupied at equilibrium. Typically, stringent conditions will be those in which the salt concentration is less than about 1.0 M sodium ion, typically about 0.01 to 1.0 M sodium ion (or other salts) at pH 7.0 to 8.3 and the temperature is at least about 30°C 25 for short probes, primers or oligonucleotides (e.g. 10 to 50 nucleotides) and at least about 60°C for longer probes, primers or oligonucleotides. Stringent conditions may also be achieved with the addition of destabilizing agents, such as formamide.

The amino acid sequences are presented in the amino to carboxy direction, from 30 left to right. The amino and carboxy groups are not presented in the sequence. The nucleotide sequences are presented by single strand only, in the 5' to 3' direction, from left to right. Nucleotides and amino acids are represented in the manner recommended

DOCKET NO.: 411USPHRM311

PATENT

by the IUPAC-IUB Biochemical Nomenclature Commission or (for amino acids) by three letters code.

Polynucleotides

The present invention provides purified and isolated polynucleotides (e.g., DNA sequences and RNA transcripts, both sense and complementary antisense strands, both single- and double-stranded, including splice variants thereof) that encode unknown G protein-coupled receptors heretofore termed novel GPCRs, or nGPCRs. These genes are described herein and designated herein collectively as nGPCR-x (where x is 1, 3, 4, 5, 9, 11, 12, 14, 15, 18, 16, 17, 20, 21, 22, 24, 27, 28, 31, 32, 33, 34, 35, 36, 37, 38, 40, 41, 53, 54, 55, 56, 57, 58, 59, or 60). That is, these genes are described herein and designated herein as nGPCR-1 (also referred to as beGPCR-1), nGPCR-3 (also referred to as beGPCR-3), nGPCR-4 (also referred to as beGPCR-4), nGPCR-5 (also referred to as beGPCR-5 and TL-GPCR-5), nGPCR-9 (also referred to as beGPCR-9), nGPCR-11 (also referred to as beGPCR-11), nGPCR-12 (also referred to as beGPCR-12), nGPCR-14 (also referred to as beGPCR-14), nGPCR-15 (also referred to as beGPCR-15), nGPCR-18 (also referred to as beGPCR-18), nGPCR-16 (also referred to as beGPCR-16), nGPCR-17 (also referred to as beGPCR-17), nGPCR-20 (also referred to as beGPCR-20), nGPCR-21 (also referred to as beGPCR-21), nGPCR-22 (also referred to as beGPCR-22), nGPCR-24 (also referred to as beGPCR-24), nGPCR-27 (also referred to as beGPCR-27), nGPCR-28 (also referred to as beGPCR-28), nGPCR-31 (also referred to as beGPCR-31), nGPCR-32 (also referred to as beGPCR-32), nGPCR-33 (also referred to as beGPCR-33), nGPCR-34 (also referred to as beGPCR-34), nGPCR-35 (also referred to as beGPCR-35), nGPCR-36 (also referred to as beGPCR-36), nGPCR-37 (also referred to as beGPCR-37), nGPCR-38 (also referred to as beGPCR-38), nGPCR-40 (also referred to as beGPCR-40), nGPCR-41 (also referred to as beGPCR-41), nGPCR-53, nGPCR-54, nGPCR-55, nGPCR-56, nGPCR-57, nGPCR-58, nGPCR-59, and nGPCR-60. Table 1 below identifies the novel gene sequence nGPCR-x designation, the SEQ ID NO: of the gene sequence, the SEQ ID NO: of the polypeptide encoded thereby, and the U.S. Provisional Application in which the gene sequence has been disclosed.

Table 1

nGPCR	Nucleotide	Amino acid	Originally	nGPCR	Nucleotide	Amino acid	Originally
-------	------------	------------	------------	-------	------------	------------	------------

DOCKET NO.: 411USPHRM311

PATENT

	Sequence (SEQ ID NO:)	Sequence (SEQ ID NO:)	filed in:		Sequence (SEQ ID NO:)	Sequence (SEQ ID NO:)	filed in:
1	1	2	A	32	39	40	B
1	73	74	E	33	41	42	C
3	3	4	A	34	43	44	C
3	185	186	P	35	45	46	C
4	5	6	A	36	47	48	C
5	7	8	A	37	49	50	C
5	75	76	F	38	51	52	C
9	9	10	A	40	53	54	C
9	77	78	G	40	83	84	J
11	11	12	A	41	55	56	C
11	79	80	H	53	57	58	D
12	13	14	A	54	59	60	D
14	15	16	A	54	85	86	K
14	191	192	herein				
15	17	18	A	55	61	62	D
18	19	20	A	56	63	64	D
16	21	22	B	56	87	88	L
16	81	82	I	56	89	90	M
17	23	24	B	57	65	66	D
20	25	26	B	58	67	68	D
21	27	28	B	58	91	92	N
22	29	30	B	58	93	94	O
24	31	32	B	59	69	70	D
27	33	34	B	60	71	72	D
28	35	36	B				
31	37	38	B				

Legend

A= Ser. No. 60/165,838
 B= Ser. No. 60/166,071
 5 C= Ser. No. 60/166,678
 D= Ser. No. 60/173,396
 E= Ser. No. 60/184,129
 F= Ser. No. 60/188,114
 G= Ser. No. 60/185,421
 10 H= Ser. No. 60/186,811

I= Ser. No. 60/186,530
 J= Ser. No. 60/207,094
 K= Ser. No. 60/203,111
 L= Ser. No. 60/190,310
 M= Ser. No. 60/201,190
 N= Ser. No. 60/185554
 O= Ser. No. 60/190,800
 P= Ser. No. 60/198,568

When a specific nGPCR is identified (for example nGPCR-5), it is understood that only that specific nGPCR is being referred to.

As described in Example 4 below, the genes encoding nGPCR-1 (nucleic acid sequence SEQ ID NO: 1, SEQ ID NO: 73, amino acid sequence SEQ ID NO: 2, SEQ ID NO:74), nGPCR-9 (nucleic acid sequence SEQ ID NO:9, SEQ ID NO:77, amino acid sequence SEQ ID NO:10, SEQ ID NO:78), nGPCR-11 (nucleic acid sequence SEQ ID NO:11, SEQ ID NO:79, amino acid sequence SEQ ID NO:12, SEQ ID NO:80), nGPCR-16 (nucleic acid sequence SEQ ID NO: 21, SEQ ID NO:81, amino acid sequence SEQ ID NO: 22, SEQ ID NO:82), nGPCR-40 (nucleic acid sequence SEQ ID NO:53, SEQ ID NO:83, amino acid sequence SEQ ID NO:54, SEQ ID

DOCKET NO.: 411USPHRM311

PATENT

NO:84), nGPCR-54 (nucleic acid sequence SEQ ID NO:59, SEQ ID NO:85, amino acid sequence SEQ ID NO:60, SEQ ID NO: 86), nGPCR-56 (nucleic acid sequence SEQ ID NO:63, SEQ ID NO:87, SEQ ID NO:89, amino acid sequence SEQ ID NO:64, SEQ ID NO: 88, SEQ ID NO:90), nGPCR-58 (nucleic acid sequence SEQ ID NO:67, 5 SEQ ID NO:91, SEQ ID NO:93, amino acid sequence SEQ ID NO:68, SEQ ID NO: 92, SEQ ID NO:94) and nGPCR-3 (nucleic acid sequence SEQ ID NO:3, SEQ ID NO:185, amino acid sequence SEQ ID NO:4, SEQ ID NO: 186) have been detected in brain tissue indicating that these n-GPCR-x proteins are neuroreceptors.

The invention provides purified and isolated polynucleotides (*e.g.*, cDNA, 10 genomic DNA, synthetic DNA, RNA, or combinations thereof, whether single- or double-stranded) that comprise a nucleotide sequence encoding the amino acid sequence of the polypeptides of the invention. Such polynucleotides are useful for recombinantly expressing the receptor and also for detecting expression of the receptor in cells (*e.g.*, using Northern hybridization and *in situ* hybridization assays). Such 15 polynucleotides also are useful in the design of antisense and other molecules for the suppression of the expression of nGPCR-x in a cultured cell, a tissue, or an animal; for therapeutic purposes; or to provide a model for diseases or conditions characterized by aberrant nGPCR-x expression. Specifically excluded from the definition of polynucleotides of the invention are entire isolated, non-recombinant native 20 chromosomes of host cells. A preferred polynucleotide has the sequence of the sequence set forth in odd numbered sequences ranging from SEQ ID NO: 1 to SEQ ID NO: 93, SEQ ID NO: 185 and SEQ ID NO:191, which correspond to naturally occurring nGPCR-x sequences. It will be appreciated that numerous other polynucleotide sequences exist that also encode nGPCR-x having the sequence set forth 25 in even numbered sequences ranging from SEQ ID NO: 2 to SEQ ID NO: 94, SEQ ID NO: 186 and SEQ ID NO:192, due to the well-known degeneracy of the universal genetic code.

The invention also provides a purified and isolated polynucleotide comprising a nucleotide sequence that encodes a mammalian polypeptide, wherein the 30 polynucleotide hybridizes to a polynucleotide having the sequence set forth in odd numbered sequences ranging from SEQ ID NO: 1 to SEQ ID NO: 93, SEQ ID NO:

DOCKET NO.: 411USPHRM311

PATENT

185, and SEQ ID NO:191, or the non-coding strand complementary thereto, under the following hybridization conditions:

(a) hybridization for 16 hours at 42°C in a hybridization solution comprising 50% formamide, 1% SDS, 1 M NaCl, 10% dextran sulfate; and

5 (b) washing 2 times for 30 minutes each at 60°C in a wash solution comprising 0.1% SSC, 1% SDS. Polynucleotides that encode a human allelic variant are highly preferred.

10 The present invention relates to molecules which comprise the gene sequences that encode the nGPCRs; constructs and recombinant host cells incorporating the gene sequences; the novel GPCR polypeptides encoded by the gene sequences; antibodies to the polypeptides and homologs; kits employing the polynucleotides and polypeptides, and methods of making and using all of the foregoing. In addition, the present invention relates to homologs of the gene sequences and of the polypeptides and methods of making and using the same.

15 Genomic DNA of the invention comprises the protein-coding region for a polypeptide of the invention and is also intended to include allelic variants thereof. It is widely understood that, for many genes, genomic DNA is transcribed into RNA transcripts that undergo one or more splicing events wherein intron (*i.e.*, non-coding regions) of the transcripts are removed, or “spliced out.” RNA transcripts that can be 20 spliced by alternative mechanisms, and therefore be subject to removal of different RNA sequences but still encode a nGPCR-x polypeptide, are referred to in the art as splice variants which are embraced by the invention. Splice variants comprehended by the invention therefore are encoded by the same original genomic DNA sequences but arise from distinct mRNA transcripts. Allelic variants are modified forms of a wild-type gene sequence, the modification resulting from recombination during 25 chromosomal segregation or exposure to conditions which give rise to genetic mutation. Allelic variants, like wild type genes, are naturally occurring sequences (as opposed to non-naturally occurring variants that arise from *in vitro* manipulation).

30 The invention also comprehends cDNA that is obtained through reverse transcription of an RNA polynucleotide encoding nGPCR-x (conventionally followed

DOCKET NO.: 411USPHRM311

PATENT

by second strand synthesis of a complementary strand to provide a double-stranded DNA).

Preferred DNA sequences encoding human nGPCR-x polypeptides are set out in odd numbered sequences ranging from SEQ ID NO: 1 to SEQ ID NO: 93, SEQ ID NO: 185 and SEQ ID NO: 191. A preferred DNA of the invention comprises a double stranded molecule along with the complementary molecule (the “non-coding strand” or “complement”) having a sequence unambiguously deducible from the coding strand according to Watson-Crick base-pairing rules for DNA. Also preferred are other polynucleotides encoding the nGPCR-x polypeptide of even numbered sequences ranging from SEQ ID NO: 2 to SEQ ID NO: 94, SEQ ID NO: 186 and SEQ ID NO: 192 which differ in sequence from the polynucleotides of odd numbered sequences ranging from SEQ ID NO: 1 to SEQ ID NO: 93, SEQ ID NO: 185 and SEQ ID NO: 192, by virtue of the well-known degeneracy of the universal nuclear genetic code.

In a preferred embodiment, the isolated nucleic acid molecule comprises a nucleotide sequence which encodes a fragment of polypeptide comprising a sequence of SEQ ID NO: 192. The fragment of the polypeptide comprising a sequence of SEQ ID NO: 192 comprises at least one or more amino acid residues from one or more of the following regions of SEQ ID NO: 192: amino acid residues 1 to 42 of SEQ ID NO: 192; amino acid residues 68 to 77 of SEQ ID NO: 192; amino acid residues 185 to 200 of SEQ ID NO: 192; or amino acid residues 293 to 513 of SEQ ID NO: 192.

In a preferred embodiment, the isolated nucleic acid comprises a nucleotide sequence of SEQ ID NO: 191, and fragments thereof, that encode a polypeptide having a sequence of SEQ ID NO: 192, or fragments thereof. The fragment of the nucleotide sequence of SEQ ID NO: 191 comprises at least one or more nucleotides from one or 25 more of the following regions of SEQ ID NO: 191: nucleotides 1 to 193 of SEQ ID NO: 191; nucleotides 612 to 644 of SEQ ID NO: 191; nucleotides 697 to 706 of SEQ ID NO: 191; nucleotides 1011 to 1049 of SEQ ID NO: 191; nucleotides 1051 to 1057 of SEQ ID NO: 191; nucleotides 1090 to 1096 of SEQ ID NO: 191; or nucleotides 1141 to 1642 of SEQ ID NO: 191.

30 The invention further embraces other species, preferably mammalian, homologs of the human nGPCR-x DNA. Species homologs, sometimes referred to as “orthologs,” in general, share at least 35%, at least 40%, at least 45%, at least 50%, at

DOCKET NO.: 411USPHRM311

PATENT

least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homology with human DNA of the invention. Generally, percent sequence “homology” with respect to polynucleotides of the invention may be calculated as the percentage of nucleotide bases in the candidate sequence that are identical to nucleotides in the nGPCR-x sequence set forth in odd numbered sequences ranging from SEQ ID NO: 1 to SEQ ID NO: 93, SEQ ID NO: 185 and SEQ ID NO:191, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity.

10 Polynucleotides of the invention permit identification and isolation of polynucleotides encoding related nGPCR-x polypeptides, such as human allelic variants and species homologs, by well-known techniques including Southern and/or Northern hybridization, and polymerase chain reaction (PCR). Examples of related polynucleotides include human and non-human genomic sequences, including allelic variants, as well as polynucleotides encoding polypeptides homologous to nGPCR-x and structurally related polypeptides sharing one or more biological, immunological, and/or physical properties of nGPCR-x. Non-human species genes encoding proteins homologous to nGPCR-x can also be identified by Southern and/or PCR analysis and are useful in animal models for nGPCR-x disorders. Knowledge of the sequence of a human nGPCR-x DNA also makes possible through use of Southern hybridization or 20 polymerase chain reaction (PCR) the identification of genomic DNA sequences encoding nGPCR-x expression control regulatory sequences such as promoters, operators, enhancers, repressors, and the like. Polynucleotides of the invention are also useful in hybridization assays to detect the capacity of cells to express nGPCR-x. Polynucleotides of the invention may also provide a basis for diagnostic methods useful 25 for identifying a genetic alteration(s) in a nGPCR-x locus that underlies a disease state or states, which information is useful both for diagnosis and for selection of therapeutic strategies.

According to the present invention, the nGPCR-x nucleotide sequences disclosed herein may be used to identify homologs of the nGPCR-x, in other animals, 30 including but not limited to humans and other mammals, and invertebrates. Any of the nucleotide sequences disclosed herein, or any portion thereof, can be used, for example, as probes to screen databases or nucleic acid libraries, such as, for example, genomic or

DOCKET NO.: 411USPHRM311

PATENT

cDNA libraries, to identify homologs, using screening procedures well known to those skilled in the art. Accordingly, homologs having at least 50%, more preferably at least 60%, more preferably at least 70%, more preferably at least 80%, more preferably at least 90%, more preferably at least 95%, and most preferably at least 100% homology with nGPCR-x sequences can be identified.

5 The disclosure herein of full-length polynucleotides encoding nGPCR-x polypeptides makes readily available to the worker of ordinary skill in the art every possible fragment of the full-length polynucleotide.

One preferred embodiment of the present invention provides an isolated nucleic acid molecule comprising a sequence homologous to odd numbered sequences selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:93, SEQ ID NO: 185 and SEQ ID NO:191, and fragments thereof. Another preferred embodiment provides an isolated nucleic acid molecule comprising a sequence selected from the group of odd numbered sequences consisting of SEQ ID NO:1 to SEQ ID NO:93, SEQ ID NO:185 and SEQ ID NO:191, and fragments thereof.

10 As used in the present invention, fragments of nGPCR-x-encoding polynucleotides comprise at least 10, and preferably at least 12, 14, 16, 18, 20, 25, 50, or 75 consecutive nucleotides of a polynucleotide encoding nGPCR-x. Preferably, fragment polynucleotides of the invention comprise sequences unique to the nGPCR-x-encoding polynucleotide sequence, and therefore hybridize under highly stringent or moderately stringent conditions only (*i.e.*, “specifically”) to polynucleotides encoding nGPCR-x (or fragments thereof). Polynucleotide fragments of genomic sequences of the invention comprise not only sequences unique to the coding region, but also include fragments of the full-length sequence derived from introns, regulatory regions, and/or other non-translated sequences. Sequences unique to polynucleotides of the invention are recognizable through sequence comparison to other known polynucleotides, and can be identified through use of alignment programs routinely utilized in the art, *e.g.*, those made available in public sequence databases. Such sequences also are recognizable from Southern hybridization analyses to determine the number of 15 fragments of genomic DNA to which a polynucleotide will hybridize. Polynucleotides of the invention can be labeled in a manner that permits their detection, including radioactive, fluorescent, and enzymatic labeling.

20

DOCKET NO.: 411USPHRM311

PATENT

Fragment polynucleotides are particularly useful as probes for detection of full-length or fragments of nGPCR-x polynucleotides. One or more polynucleotides can be included in kits that are used to detect the presence of a polynucleotide encoding nGPCR-x, or used to detect variations in a polynucleotide sequence encoding nGPCR-

5 x.

The invention also embraces DNAs encoding nGPCR-x polypeptides that hybridize under moderately stringent or high stringency conditions to the non-coding strand, or complement, of the polynucleotides set forth in odd numbered sequences ranging from SEQ ID NO: 1 to SEQ ID NO: 93, SEQ ID NO: 185 and SEQ ID

10 NO:192.

Exemplary highly stringent hybridization conditions are as follows: hybridization at 42°C in a hybridization solution comprising 50% formamide, 1% SDS, 1 M NaCl, 10% Dextran sulfate, and washing twice for 30 minutes at 60°C in a wash solution comprising 0.1 X SSC and 1% SDS. It is understood in the art that conditions 15 of equivalent stringency can be achieved through variation of temperature and buffer, or salt concentration as described Ausubel *et al.* (Eds.), Protocols in Molecular Biology, John Wiley & Sons (1994), pp. 6.0.3 to 6.4.10. Modifications in hybridization conditions can be empirically determined or precisely calculated based on the length and the percentage of guanosine/cytosine (GC) base pairing of the probe. The 20 hybridization conditions can be calculated as described in Sambrook, *et al.*, (Eds.), Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press: Cold Spring Harbor, New York (1989), pp. 9.47 to 9.51.

With the knowledge of the nucleotide sequence information disclosed in the present invention, one skilled in the art can identify and obtain nucleotide sequences 25 which encode nGPCR-x from different sources (*i.e.*, different tissues or different organisms) through a variety of means well known to the skilled artisan and as disclosed by, for example, Sambrook et al., "Molecular cloning: a laboratory manual", Second Edition, Cold Spring Harbor Press, Cold Spring Harbor, NY (1989), which is incorporated herein by reference in its entirety.

30 For example, DNA that encodes nGPCR-x may be obtained by screening of mRNA, cDNA, or genomic DNA with oligonucleotide probes generated from the

DOCKET NO.: 411USPHRM311

PATENT

nGPCR-x gene sequence information provided herein. Probes may be labeled with a detectable group, such as a fluorescent group, a radioactive atom or a chemiluminescent group in accordance with procedures known to the skilled artisan and used in conventional hybridization assays, as described by, for example, Sambrook *et al.*

5 A nucleic acid molecule comprising any of the nGPCR-x nucleotide sequences described above can alternatively be synthesized by use of the polymerase chain reaction (PCR) procedure, with the PCR oligonucleotide primers produced from the nucleotide sequences provided herein. See U.S. Patent Numbers 4,683,195 to Mullis *et al.* and 4,683,202 to Mullis. The PCR reaction provides a method for selectively 10 increasing the concentration of a particular nucleic acid sequence even when that sequence has not been previously purified and is present only in a single copy in a particular sample. The method can be used to amplify either single- or double-stranded DNA. The essence of the method involves the use of two oligonucleotide probes to serve as primers for the template-dependent, polymerase mediated replication of a 15 desired nucleic acid molecule.

A wide variety of alternative cloning and *in vitro* amplification methodologies are well known to those skilled in the art. Examples of these techniques are found in, for example, Berger *et al.*, *Guide to Molecular Cloning Techniques*, Methods in Enzymology 152, Academic Press, Inc., San Diego, CA (Berger), which is incorporated 20 herein by reference in its entirety.

Automated sequencing methods can be used to obtain or verify the nucleotide sequence of nGPCR-x. The nGPCR-x nucleotide sequences of the present invention are believed to be 100% accurate. However, as is known in the art, nucleotide sequence obtained by automated methods may contain some errors. Nucleotide 25 sequences determined by automation are typically at least about 90%, more typically at least about 95% to at least about 99.9% identical to the actual nucleotide sequence of a given nucleic acid molecule. The actual sequence may be more precisely determined using manual sequencing methods, which are well known in the art. An error in a sequence which results in an insertion or deletion of one or more nucleotides may result 30 in a frame shift in translation such that the predicted amino acid sequence will differ from that which would be predicted from the actual nucleotide sequence of the nucleic acid molecule, starting at the point of the mutation.

DOCKET NO.: 411USPHRM311

PATENT

The nucleic acid molecules of the present invention, and fragments derived therefrom, are useful for screening for restriction fragment length polymorphism (RFLP) associated with certain disorders, as well as for genetic mapping.

5 The polynucleotide sequence information provided by the invention makes possible large-scale expression of the encoded polypeptide by techniques well known and routinely practiced in the art.

Vectors

Another aspect of the present invention is directed to vectors, or recombinant expression vectors, comprising any of the nucleic acid molecules described above.

10 Vectors are used herein either to amplify DNA or RNA encoding nGPCR-x and/or to express DNA which encodes nGPCR-x. Preferred vectors include, but are not limited to, plasmids, phages, cosmids, episomes, viral particles or viruses, and integratable DNA fragments (*i.e.*, fragments integratable into the host genome by homologous recombination). Preferred viral particles include, but are not limited to, adenoviruses, 15 baculoviruses, parvoviruses, herpesviruses, poxviruses, adeno-associated viruses, Semliki Forest viruses, vaccinia viruses, and retroviruses. Preferred expression vectors include, but are not limited to, pcDNA3 (Invitrogen) and pSVL (Pharmacia Biotech). Other expression vectors include, but are not limited to, pSPORT™ vectors, pGEM™ vectors (Promega), pPROEXvectors™ (LTI, Bethesda, MD), Bluescript™ vectors 20 (Stratagene), pQE™ vectors (Qiagen), pSE420™ (Invitrogen), and pYES2™(Invitrogen).

Expression constructs preferably comprise GPCR-x-encoding polynucleotides operatively linked to an endogenous or exogenous expression control DNA sequence and a transcription terminator. Expression control DNA sequences include promoters, 25 enhancers, operators, and regulatory element binding sites generally, and are typically selected based on the expression systems in which the expression construct is to be utilized. Preferred promoter and enhancer sequences are generally selected for the ability to increase gene expression, while operator sequences are generally selected for the ability to regulate gene expression. Expression constructs of the invention may also 30 include sequences encoding one or more selectable markers that permit identification of host cells bearing the construct. Expression constructs may also include sequences that facilitate, and preferably promote, homologous recombination in a host cell. Preferred

DOCKET NO.: 411USPHRM311

PATENT

constructs of the invention also include sequences necessary for replication in a host cell.

Expression constructs are preferably utilized for production of an encoded protein, but may also be utilized simply to amplify a nGPCR-x-encoding polynucleotide sequence. In preferred embodiments, the vector is an expression vector wherein the polynucleotide of the invention is operatively linked to a polynucleotide comprising an expression control sequence. Autonomously replicating recombinant expression constructs such as plasmid and viral DNA vectors incorporating polynucleotides of the invention are also provided. Preferred expression vectors are replicable DNA constructs in which a DNA sequence encoding nGPCR-x is operably linked or connected to suitable control sequences capable of effecting the expression of the nGPCR-x in a suitable host. DNA regions are operably linked or connected when they are functionally related to each other. For example, a promoter is operably linked or connected to a coding sequence if it controls the transcription of the sequence.

Amplification vectors do not require expression control domains, but rather need only the ability to replicate in a host, usually conferred by an origin of replication, and a selection gene to facilitate recognition of transformants. The need for control sequences in the expression vector will vary depending upon the host selected and the transformation method chosen. Generally, control sequences include a transcriptional promoter, an optional operator sequence to control transcription, a sequence encoding suitable mRNA ribosomal binding and sequences which control the termination of transcription and translation.

Preferred vectors preferably contain a promoter that is recognized by the host organism. The promoter sequences of the present invention may be prokaryotic, eukaryotic or viral. Examples of suitable prokaryotic sequences include the P_R and P_L promoters of bacteriophage lambda (The bacteriophage Lambda, Hershey, A. D., Ed., Cold Spring Harbor Press, Cold Spring Harbor, NY (1973), which is incorporated herein by reference in its entirety; Lambda II, Hendrix, R. W., Ed., Cold Spring Harbor Press, Cold Spring Harbor, NY (1980), which is incorporated herein by reference in its entirety); the trp, recA, heat shock, and lacZ promoters of *E. coli* and the SV40 early promoter (Benoist *et al. Nature*, 1981, 290, 304-310, which is incorporated herein by reference in its entirety). Additional promoters include, but are not limited to, mouse

DOCKET NO.: 411USPHRM311

PATENT

mammary tumor virus, long terminal repeat of human immunodeficiency virus, maloney virus, cytomegalovirus immediate early promoter, Epstein Barr virus, Rous sarcoma virus, human actin, human myosin, human hemoglobin, human muscle creatine, and human metallothionein.

5 Additional regulatory sequences can also be included in preferred vectors. Preferred examples of suitable regulatory sequences are represented by the Shine-Dalgarno of the replicase gene of the phage MS-2 and of the gene cII of bacteriophage lambda. The Shine-Dalgarno sequence may be directly followed by DNA encoding nGPCR-x and result in the expression of the mature nGPCR-x protein.

10 Moreover, suitable expression vectors can include an appropriate marker that allows the screening of the transformed host cells. The transformation of the selected host is carried out using any one of the various techniques well known to the expert in the art and described in Sambrook *et al.*, *supra*.

15 An origin of replication can also be provided either by construction of the vector to include an exogenous origin or may be provided by the host cell chromosomal replication mechanism. If the vector is integrated into the host cell chromosome, the latter may be sufficient. Alternatively, rather than using vectors which contain viral origins of replication, one skilled in the art can transform mammalian cells by the method of co-transformation with a selectable marker and nGPCR-x DNA. An 20 example of a suitable marker is dihydrofolate reductase (DHFR) or thymidine kinase (*see*, U.S. Patent No. 4,399,216).

25 Nucleotide sequences encoding GPCR-x may be recombined with vector DNA in accordance with conventional techniques, including blunt-ended or staggered-ended termini for ligation, restriction enzyme digestion to provide appropriate termini, filling in of cohesive ends as appropriate, alkaline phosphatase treatment to avoid undesirable joining, and ligation with appropriate ligases. Techniques for such manipulation are disclosed by Sambrook *et al.*, *supra* and are well known in the art. Methods for construction of mammalian expression vectors are disclosed in, for example, Okayama *et al.*, *Mol. Cell. Biol.*, 1983, 3, 280, Cosman *et al.*, *Mol. Immunol.*, 30 1986, 23, 935, Cosman *et al.*, *Nature*, 1984, 312, 768, EP-A-0367566, and WO 91/18982, each of which is incorporated herein by reference in its entirety.

Host cells

DOCKET NO.: 411USPHRM311

PATENT

According to another aspect of the invention, host cells are provided, including prokaryotic and eukaryotic cells, comprising a polynucleotide of the invention (or vector of the invention) in a manner that permits expression of the encoded nGPCR-x polypeptide. Polynucleotides of the invention may be introduced into the host cell as 5 part of a circular plasmid, or as linear DNA comprising an isolated protein coding region or a viral vector. Methods for introducing DNA into the host cell that are well known and routinely practiced in the art include transformation, transfection, electroporation, nuclear injection, or fusion with carriers such as liposomes, micelles, ghost cells, and protoplasts. Expression systems of the invention include bacterial, 10 yeast, fungal, plant, insect, invertebrate, vertebrate, and mammalian cells systems.

The invention provides host cells that are transformed or transfected (stably or transiently) with polynucleotides of the invention or vectors of the invention. As stated above, such host cells are useful for amplifying the polynucleotides and also for expressing the nGPCR-x polypeptide or fragment thereof encoded by the 15 polynucleotide.

In still another related embodiment, the invention provides a method for producing a nGPCR-x polypeptide (or fragment thereof) comprising the steps of growing a host cell of the invention in a nutrient medium and isolating the polypeptide or variant thereof from the cell or the medium. Because nGPCR-x is a seven 20 transmembrane receptor, it will be appreciated that, for some applications, such as certain activity assays, the preferable isolation may involve isolation of cell membranes containing the polypeptide embedded therein, whereas for other applications a more complete isolation may be preferable.

According to some aspects of the present invention, transformed host cells 25 having an expression vector comprising any of the nucleic acid molecules described above are provided. Expression of the nucleotide sequence occurs when the expression vector is introduced into an appropriate host cell. Suitable host cells for expression of the polypeptides of the invention include, but are not limited to, prokaryotes, yeast, and eukaryotes. If a prokaryotic expression vector is employed, then the appropriate host 30 cell would be any prokaryotic cell capable of expressing the cloned sequences. Suitable prokaryotic cells include, but are not limited to, bacteria of the genera *Escherichia, Bacillus, Salmonella, Pseudomonas, Streptomyces, and Staphylococcus.*

DOCKET NO.: 411USPHRM311

PATENT

If an eukaryotic expression vector is employed, then the appropriate host cell would be any eukaryotic cell capable of expressing the cloned sequence. Preferably, eukaryotic cells are cells of higher eukaryotes. Suitable eukaryotic cells include, but are not limited to, non-human mammalian tissue culture cells and human tissue culture cells. Preferred host cells include, but are not limited to, insect cells, HeLa cells, Chinese hamster ovary cells (CHO cells), African green monkey kidney cells (COS cells), human 293 cells, and murine 3T3 fibroblasts. Propagation of such cells in cell culture has become a routine procedure (*see*, *Tissue Culture*, Academic Press, Kruse and Patterson, eds. (1973), which is incorporated herein by reference in its entirety).

In addition, a yeast host may be employed as a host cell. Preferred yeast cells include, but are not limited to, the genera *Saccharomyces*, *Pichia*, and *Kluveromyces*. Preferred yeast hosts are *S. cerevisiae* and *P. pastoris*. Preferred yeast vectors can contain an origin of replication sequence from a 2T yeast plasmid, an autonomously replication sequence (ARS), a promoter region, sequences for polyadenylation, sequences for transcription termination, and a selectable marker gene. Shuttle vectors for replication in both yeast and *E. coli* are also included herein.

Alternatively, insect cells may be used as host cells. In a preferred embodiment, the polypeptides of the invention are expressed using a baculovirus expression system (*see*, Luckow *et al.*, *Bio/Technology*, **1988**, 6, 47, *Baculovirus Expression Vectors: A Laboratory Manual*, O'Rielly *et al.* (Eds.), W.H. Freeman and Company, New York, **1992**, and U.S. Patent No. 4,879,236, each of which is incorporated herein by reference in its entirety). In addition, the MAXBAC™ complete baculovirus expression system (Invitrogen) can, for example, be used for production in insect cells.

Host cells of the invention are a valuable source of immunogen for development of antibodies specifically immunoreactive with nGPCR-x. Host cells of the invention are also useful in methods for the large-scale production of nGPCR-x polypeptides wherein the cells are grown in a suitable culture medium and the desired polypeptide products are isolated from the cells, or from the medium in which the cells are grown, by purification methods known in the art, *e.g.*, conventional chromatographic methods including immunoaffinity chromatography, receptor affinity chromatography, hydrophobic interaction chromatography, lectin affinity chromatography, size exclusion filtration, cation or anion exchange chromatography, high pressure liquid

DOCKET NO.: 411USPHRM311

PATENT

chromatography (HPLC), reverse phase HPLC, and the like. Still other methods of purification include those methods wherein the desired protein is expressed and purified as a fusion protein having a specific tag, label, or chelating moiety that is recognized by a specific binding partner or agent. The purified protein can be cleaved to yield the desired protein, or can be left as an intact fusion protein. Cleavage of the fusion component may produce a form of the desired protein having additional amino acid residues as a result of the cleavage process.

Knowledge of nGPCR-x DNA sequences allows for modification of cells to permit, or increase, expression of endogenous nGPCR-x. Cells can be modified (e.g., by homologous recombination) to provide increased expression by replacing, in whole or in part, the naturally occurring nGPCR-x promoter with all or part of a heterologous promoter so that the cells express nGPCR-x at higher levels. The heterologous promoter is inserted in such a manner that it is operatively linked to endogenous nGPCR-x encoding sequences. (See, for example, PCT International Publication No. 10 WO 94/12650, PCT International Publication No. WO 92/20808, and PCT International Publication No. WO 91/09955.) It is also contemplated that, in addition to heterologous promoter DNA, amplifiable marker DNA (e.g., ada, dhfr, and the multifunctional CAD gene which encodes carbamoyl phosphate synthase, aspartate transcarbamylase, and dihydroorotase) and/or intron DNA may be inserted along with the heterologous promoter DNA. If linked to the nGPCR-x coding sequence, amplification of the marker DNA by standard selection methods results in 15 co-amplification of the nGPCR-x coding sequences in the cells.

Knock-outs

The DNA sequence information provided by the present invention also makes possible the development (e.g., by homologous recombination or "knock-out" strategies; see Capecchi, *Science* 244:1288-1292 (1989), which is incorporated herein by reference) of animals that fail to express functional nGPCR-x or that express a variant of nGPCR-x. Such animals (especially small laboratory animals such as rats, rabbits, and mice) are useful as models for studying the *in vivo* activities of nGPCR-x and modulators of nGPCR-x.

Antisense

DOCKET NO.: 411USPHRM311

PATENT

Also made available by the invention are anti-sense polynucleotides that recognize and hybridize to polynucleotides encoding nGPCR-x. Full-length and fragment anti-sense polynucleotides are provided. Fragment antisense molecules of the invention include (i) those that specifically recognize and hybridize to nGPCR-x RNA (as determined by sequence comparison of DNA encoding nGPCR-x to DNA encoding other known molecules). Identification of sequences unique to nGPCR-x encoding polynucleotides can be deduced through use of any publicly available sequence database, and/or through use of commercially available sequence comparison programs. After identification of the desired sequences, isolation through restriction digestion or amplification using any of the various polymerase chain reaction techniques well known in the art can be performed. Anti-sense polynucleotides are particularly relevant to regulating expression of nGPCR-x by those cells expressing nGPCR-x mRNA.

Antisense nucleic acids (preferably 10 to 30 base-pair oligonucleotides) capable of specifically binding to nGPCR-x expression control sequences or nGPCR-x RNA are introduced into cells (e.g., by a viral vector or colloidal dispersion system such as a liposome). The antisense nucleic acid binds to the nGPCR-x target nucleotide sequence in the cell and prevents transcription and/or translation of the target sequence. Phosphorothioate and methylphosphonate antisense oligonucleotides are specifically contemplated for therapeutic use by the invention. The antisense oligonucleotides may be further modified by adding poly-L-lysine, transferrin polylysine, or cholesterol moieties at their 5' end. Suppression of nGPCR-x expression at either the transcriptional or translational level is useful to generate cellular or animal models for diseases/conditions characterized by aberrant nGPCR-x expression.

Antisense oligonucleotides, or fragments of odd numbered nucleotide sequences ranging from SEQ ID NO: 1 to SEQ ID NO: 93, SEQ ID NO: 185 and SEQ ID NO:191, or sequences complementary or homologous thereto, derived from the nucleotide sequences of the present invention encoding nGPCR-x are useful as diagnostic tools for probing gene expression in various tissues. For example, tissue can be probed *in situ* with oligonucleotide probes carrying detectable groups by conventional autoradiography techniques to investigate native expression of this enzyme or pathological conditions relating thereto. Antisense oligonucleotides are

DOCKET NO.: 411USPHRM311

PATENT

preferably directed to regulatory regions of odd numbered nucleotide sequences ranging from SEQ ID NO: 1 to SEQ ID NO: 93, SEQ ID NO: 185 and SEQ ID NO:191, or mRNA corresponding thereto, including, but not limited to, the initiation codon, TATA box, enhancer sequences, and the like.

5 **Transcription factors**

The nGPCR-x sequences taught in the present invention facilitate the design of novel transcription factors for modulating nGPCR-x expression in native cells and animals, and cells transformed or transfected with nGPCR-x polynucleotides. For example, the Cys₂-His₂ zinc finger proteins, which bind DNA via their zinc finger domains, have been shown to be amenable to structural changes that lead to the 10 recognition of different target sequences. These artificial zinc finger proteins recognize specific target sites with high affinity and low dissociation constants, and are able to act as gene switches to modulate gene expression. Knowledge of the particular nGPCR-x target sequence of the present invention facilitates the engineering of zinc finger 15 proteins specific for the target sequence using known methods such as a combination of structure-based modeling and screening of phage display libraries (Segal *et al.*, Proc. Natl. Acad. Sci. (USA) 96:2758-2763 (1999); Liu *et al.*, Proc. Natl. Acad. Sci. (USA) 94:5525-5530 (1997); Greisman *et al.*, Science 275:657-661 (1997); Choo *et al.*, J. Mol. Biol. 273:525-532 (1997)). Each zinc finger domain usually recognizes three or 20 more base pairs. Since a recognition sequence of 18 base pairs is generally sufficient in length to render it unique in any known genome, a zinc finger protein consisting of 6 tandem repeats of zinc fingers would be expected to ensure specificity for a particular sequence (Segal *et al.*) The artificial zinc finger repeats, designed based on nGPCR-x sequences, are fused to activation or repression domains to promote or suppress 25 nGPCR-x expression (Liu *et al.*) Alternatively, the zinc finger domains can be fused to the TATA box-binding factor (TBP) with varying lengths of linker region between the zinc finger peptide and the TBP to create either transcriptional activators or repressors (Kim *et al.*, Proc. Natl. Acad. Sci. (USA) 94:3616-3620 (1997). Such proteins and polynucleotides that encode them, have utility for modulating nGPCR-x expression *in* 30 *vivo* in both native cells, animals and humans; and/or cells transfected with nGPCR-x-encoding sequences. The novel transcription factor can be delivered to the target cells by transfecting constructs that express the transcription factor (gene therapy), or by

DOCKET NO.: 411USPHRM311

PATENT

introducing the protein. Engineered zinc finger proteins can also be designed to bind RNA sequences for use in therapeutics as alternatives to antisense or catalytic RNA methods (McColl *et al.*, Proc. Natl. Acad. Sci. (USA) 96:9521-9526 (1997); Wu *et al.*, Proc. Natl. Acad. Sci. (USA) 92:344-348 (1995)). The present invention contemplates 5 methods of designing such transcription factors based on the gene sequence of the invention, as well as customized zinc finger proteins, that are useful to modulate nGPCR-x expression in cells (native or transformed) whose genetic complement includes these sequences.

Polypeptides

10 The invention also provides purified and isolated mammalian nGPCR-x polypeptides encoded by a polynucleotide of the invention. Presently preferred is a human nGPCR-x polypeptide comprising the amino acid sequence set out in even numbered sequences ranging from SEQ ID NO: 2 to SEQ ID NO: 94, SEQ ID NO: 186 and SEQ ID NO:192, or fragments thereof comprising an epitope specific to the 15 polypeptide. By "epitope specific to" is meant a portion of the nGPCR receptor that is recognizable by an antibody that is specific for the nGPCR, as defined in detail below.

Although the sequences provided are particular human sequences, the invention is intended to include within its scope other human allelic variants; non-human mammalian forms of nGPCR-x, and other vertebrate forms of nGPCR-x.

20 It will be appreciated that extracellular epitopes are particularly useful for generating and screening for antibodies and other binding compounds that bind to receptors such as nGPCR-x. Thus, in another preferred embodiment, the invention provides a purified and isolated polypeptide comprising at least one extracellular domain (*e.g.*, the N-terminal extracellular domain or one of the three extracellular 25 loops) of nGPCR-x. Purified and isolated polypeptides comprising the N-terminal extracellular domain of nGPCR-x are highly preferred. Also preferred is a purified and isolated polypeptide comprising a nGPCR-x fragment selected from the group consisting of the N-terminal extracellular domain of nGPCR-x, transmembrane domains of nGPCR-x, an extracellular loop connecting transmembrane domains of nGPCR-x, the 30 C-terminal cytoplasmic region of nGPCR-x, and fusions thereof. Such fragments may be continuous portions of the native receptor. However, it will also be appreciated that

DOCKET NO.: 411USPHRM311

PATENT

knowledge of the nGPCR-x gene and protein sequences as provided herein permits recombining of various domains that are not contiguous in the native protein. Using a FORTRAN computer program called "tmtrest.all" [Parodi *et al.*, Comput. Appl. Biosci. 5:527-535 (1994)], nGPCR-x was shown to contain transmembrane-spanning domains.

5 The invention also embraces polypeptides that have at least 99%, at least 95%, at least 90%, at least 85%, at least 80%, at least 75%, at least 70%, at least 65%, at least 60%, at least 55% or at least 50% identity and/or homology to the preferred polypeptide of the invention. Percent amino acid sequence "identity" with respect to the preferred polypeptide of the invention is defined herein as the percentage of amino acid residues in the candidate sequence that are identical with the residues in the 10 nGPCR-x sequence after aligning both sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity, and not considering any conservative substitutions as part of the sequence identity. Percent sequence "homology" with respect to the preferred polypeptide of the invention is defined herein as the percentage 15 of amino acid residues in the candidate sequence that are identical with the residues in the nGPCR-x sequence after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity, and also considering any conservative substitutions as part of the sequence identity.

20 In one aspect, percent homology is calculated as the percentage of amino acid residues in the smaller of two sequences which align with identical amino acid residue in the sequence being compared, when four gaps in a length of 100 amino acids may be introduced to maximize alignment [Dayhoff, in Atlas of Protein Sequence and Structure, Vol. 5, p. 124, National Biochemical Research Foundation, Washington, D.C. (1972), incorporated herein by reference].

25 Polypeptides of the invention may be isolated from natural cell sources or may be chemically synthesized, but are preferably produced by recombinant procedures involving host cells of the invention. Use of mammalian host cells is expected to provide for such post-translational modifications (*e.g.*, glycosylation, truncation, lipidation, and phosphorylation) as may be needed to confer optimal biological activity 30 on recombinant expression products of the invention. Glycosylated and non-glycosylated forms of nGPCR-x polypeptides are embraced by the invention.

DOCKET NO.: 411USPHRM311

PATENT

The invention also embraces variant (or analog) nGPCR-x polypeptides. In one example, insertion variants are provided wherein one or more amino acid residues supplement a nGPCR-x amino acid sequence. Insertions may be located at either or both termini of the protein, or may be positioned within internal regions of the nGPCR-x amino acid sequence. Insertional variants with additional residues at either or both termini can include, for example, fusion proteins and proteins including amino acid tags or labels.

10 Insertion variants include nGPCR-x polypeptides wherein one or more amino acid residues are added to a nGPCR-x acid sequence or to a biologically active fragment thereof.

15 Variant products of the invention also include mature nGPCR-x products, *i.e.*, nGPCR-x products wherein leader or signal sequences are removed, with additional amino terminal residues. The additional amino terminal residues may be derived from another protein, or may include one or more residues that are not identifiable as being derived from specific proteins. nGPCR-x products with an additional methionine residue at position -1 (Met^{-1} -nGPCR-x) are contemplated, as are variants with additional methionine and lysine residues at positions -2 and -1 (Met^{-2} - Lys^{-1} -nGPCR-x). Variants of nGPCR-x with additional Met, Met-Lys, Lys residues (or one or more basic residues in general) are particularly useful for enhanced recombinant protein 20 production in bacterial host cells.

25 The invention also embraces nGPCR-x variants having additional amino acid residues that result from use of specific expression systems. For example, use of commercially available vectors that express a desired polypeptide as part of a glutathione-S-transferase (GST) fusion product provides the desired polypeptide having an additional glycine residue at position -1 after cleavage of the GST component from the desired polypeptide. Variants that result from expression in other vector systems are also contemplated.

Insertional variants also include fusion proteins wherein the amino terminus and/or the carboxy terminus of nGPCR-x is/are fused to another polypeptide.

30 In another aspect, the invention provides deletion variants wherein one or more amino acid residues in a nGPCR-x polypeptide are removed. Deletions can be effected at one or both termini of the nGPCR-x polypeptide, or with removal of one or more

DOCKET NO.: 411USPHRM311

PATENT

non-terminal amino acid residues of nGPCR-x. Deletion variants, therefore, include all fragments of a nGPCR-x polypeptide.

The invention also embraces polypeptide fragments of the even numbered sequences ranging from SEQ ID NO: 2 to SEQ ID NO: 94, SEQ ID NO: 186 and SEQ ID NO:192, wherein the fragments maintain biological (e.g., ligand binding and/or intracellular signaling) immunological properties of a nGPCR-x polypeptide.

In one preferred embodiment of the invention, an isolated nucleic acid molecule comprises a nucleotide sequence that encodes a polypeptide comprising an amino acid sequence homologous to even numbered sequences selected from the group consisting of: SEQ ID NO:2 to SEQ ID NO:94, SEQ ID NO: 186 and SEQ ID NO:192, and fragments thereof, wherein the nucleic acid molecule encoding at least a portion of nGPCR-x. In a more preferred embodiment, the isolated nucleic acid molecule comprises a sequence that encodes a polypeptide comprising even numbered sequences selected from the group consisting of SEQ ID NO:2 to SEQ ID NO: 94, SEQ ID NO: 186 and SEQ ID NO:192, and fragments thereof.

As used in the present invention, polypeptide fragments comprise at least 5, 10, 15, 20, 25, 30, 35, or 40 consecutive amino acids of the even numbered sequences ranging from SEQ ID NO: 2 to SEQ ID NO: 94, SEQ ID NO: 186 and SEQ ID NO:192. Preferred polypeptide fragments display antigenic properties unique to, or specific for, human nGPCR-x and its allelic and species homologs. Fragments of the invention having the desired biological and immunological properties can be prepared by any of the methods well known and routinely practiced in the art.

In still another aspect, the invention provides substitution variants of nGPCR-x polypeptides. Substitution variants include those polypeptides wherein one or more amino acid residues of a nGPCR-x polypeptide are removed and replaced with alternative residues. In one aspect, the substitutions are conservative in nature; however, the invention embraces substitutions that are also non-conservative. Conservative substitutions for this purpose may be defined as set out in Tables 2, 3, or 4 below.

Variant polypeptides include those wherein conservative substitutions have been introduced by modification of polynucleotides encoding polypeptides of the invention. Amino acids can be classified according to physical properties and

DOCKET NO.: 411USPHRM311**PATENT**

contribution to secondary and tertiary protein structure. A conservative substitution is recognized in the art as a substitution of one amino acid for another amino acid that has similar properties. Exemplary conservative substitutions are set out in Table 2 (from WO 97/09433, page 10, published March 13, 1997 (PCT/GB96/02197, filed 9/6/96),

5 immediately below.

DOCKET NO.: 411USPHRM311

PATENT

Table 2
Conservative Substitutions I

<u>SIDE CHAIN CHARACTERISTIC</u>	<u>AMINO ACID</u>
Aliphatic	
Non-polar	G A P I L V
Polar - uncharged	C S T M N Q
Polar - charged	D E K R
Aromatic	H F W Y
Other	N Q D E

Alternatively, conservative amino acids can be grouped as described in
 5 Lehninger, Biochemistry, Second Edition; Worth Publishers, Inc. NY, NY (1975),
 pp.71-77] as set out in Table 3, below.

Table 3
Conservative Substitutions II

<u>SIDE CHAIN CHARACTERISTIC</u>	<u>AMINO ACID</u>
Non-polar (hydrophobic)	
A. Aliphatic:	A L I V P
B. Aromatic:	F W
C. Sulfur-containing:	M
D. Borderline:	G
Uncharged-polar	
A. Hydroxyl:	S T Y
B. Amides:	N Q
C. Sulfhydryl:	C
D. Borderline:	G
Positively Charged (Basic):	K R H
Negatively Charged (Acidic):	D E

As still another alternative, exemplary conservative substitutions are set out in
 Table 4, below.

Table 4
Conservative Substitutions III

Original Residue	Exemplary Substitution
Ala (A)	Val, Leu, Ile
Arg (R)	Lys, Gln, Asn
Asn (N)	Gln, His, Lys, Arg
Asp (D)	Glu
Cys (C)	Ser
Gln (Q)	Asn

DOCKET NO.: 411USPHRM311

PATENT

Glu (E)	Asp
His (H)	Asn, Gln, Lys, Arg
Ile (I)	Leu, Val, Met, Ala, Phe,
Leu (L)	Ile, Val, Met, Ala, Phe
Lys (K)	Arg, Gln, Asn
Met (M)	Leu, Phe, Ile
Phe (F)	Leu, Val, Ile, Ala
Pro (P)	Gly
Ser (S)	Thr
Thr (T)	Ser
Trp (W)	Tyr
Tyr (Y)	Trp, Phe, Thr, Ser
Val (V)	Ile, Leu, Met, Phe, Ala

It should be understood that the definition of polypeptides of the invention is intended to include polypeptides bearing modifications other than insertion, deletion, or substitution of amino acid residues. By way of example, the modifications may be 5 covalent in nature, and include for example, chemical bonding with polymers, lipids, other organic, and inorganic moieties. Such derivatives may be prepared to increase circulating half-life of a polypeptide, or may be designed to improve the targeting capacity of the polypeptide for desired cells, tissues, or organs. Similarly, the invention further embraces nGPCR-x polypeptides that have been covalently modified to include 10 one or more water-soluble polymer attachments such as polyethylene glycol, polyoxyethylene glycol, or polypropylene glycol. Variants that display ligand binding properties of native nGPCR-x and are expressed at higher levels, as well as variants that provide for constitutively active receptors, are particularly useful in assays of the invention; the variants are also useful in providing cellular, tissue and animal models of 15 diseases/conditions characterized by aberrant nGPCR-x activity.

In a related embodiment, the present invention provides compositions comprising purified polypeptides of the invention. Preferred compositions comprise, in addition to the polypeptide of the invention, a pharmaceutically acceptable (*i.e.*, sterile and non-toxic) liquid, semisolid, or solid diluent that serves as a pharmaceutical 20 vehicle, excipient, or medium. Any diluent known in the art may be used. Exemplary diluents include, but are not limited to, water, saline solutions, polyoxyethylene sorbitan monolaurate, magnesium stearate, methyl- and propylhydroxybenzoate, talc,

DOCKET NO.: 411USPHRM311

PATENT

alginates, starches, lactose, sucrose, dextrose, sorbitol, mannitol, glycerol, calcium phosphate, mineral oil, and cocoa butter.

Variants that display ligand binding properties of native nGPCR-x and are expressed at higher levels, as well as variants that provide for constitutively active receptors, are particularly useful in assays of the invention; the variants are also useful in assays of the invention and in providing cellular, tissue and animal models of diseases/conditions characterized by aberrant nGPCR-x activity.

The G protein-coupled receptor functions through a specific heterotrimeric guanine-nucleotide-binding regulatory protein (G-protein) coupled to the intracellular portion of the G protein-coupled receptor molecule. Accordingly, the G protein-coupled receptor has a specific affinity to G protein. G proteins specifically bind to guanine nucleotides. Isolation of G proteins provides a means to isolate guanine nucleotides. G Proteins may be isolated using commercially available anti-G protein antibodies or isolated G protein-coupled receptors. Similarly, G proteins may be detected in a sample isolated using commercially available detectable anti-G protein antibodies or isolated G protein-coupled receptors.

According to the present invention, the isolated n-GPCR-x proteins of the present invention are useful to isolate and purify G proteins from samples such as cell lysates. Example 15 below sets forth an example of isolation of G proteins using isolated nGPCR-x proteins. Such methodolgy may be used in place of the use of commercially available anti-G protein antibodies which are used to isolate G proteins. Moreover, G proteins may be detected using nGPCR-x proteins in place of commercially available detectable anti-G protein antibodies. Since nGPCR-x proteins specifically bind to G proteins, they can be employed in any specific use where G protein specific affinity is required, such as those uses where commercially available anti-G protein antibodies are employed.

Antibodies

Also comprehended by the present invention are antibodies (*e.g.*, monoclonal and polyclonal antibodies, single chain antibodies, chimeric antibodies, bifunctional/bispecific antibodies, humanized antibodies, human antibodies, and complementary determining region (CDR)-grafted antibodies, including compounds which include CDR sequences which specifically recognize a polypeptide of the

DOCKET NO.: 411USPHRM311

PATENT

invention) specific for nGPCR-x or fragments thereof. Preferred antibodies of the invention are human antibodies that are produced and identified according to methods described in WO93/11236, published June 20, 1993, which is incorporated herein by reference in its entirety. Antibody fragments, including Fab, Fab', F(ab')₂, and F_v, are 5 also provided by the invention. The term "specific for," when used to describe antibodies of the invention, indicates that the variable regions of the antibodies of the invention recognize and bind nGPCR-x polypeptides exclusively (*i.e.*, are able to distinguish nGPCR-x polypeptides from other known GPCR polypeptides by virtue of measurable differences in binding affinity, despite the possible existence of localized 10 sequence identity, homology, or similarity between nGPCR-x and such polypeptides). It will be understood that specific antibodies may also interact with other proteins (for example, *S. aureus* protein A or other antibodies in ELISA techniques) through interactions with sequences outside the variable region of the antibodies, and, in particular, in the constant region of the molecule. Screening assays to determine 15 binding specificity of an antibody of the invention are well known and routinely practiced in the art. For a comprehensive discussion of such assays, see Harlow *et al.* (Eds.), Antibodies A Laboratory Manual; Cold Spring Harbor Laboratory; Cold Spring Harbor, NY (1988), Chapter 6. Antibodies that recognize and bind fragments of the nGPCR-x polypeptides of the invention are also contemplated, provided that the 20 antibodies are specific for nGPCR-x polypeptides. Antibodies of the invention can be produced using any method well known and routinely practiced in the art.

The invention provides an antibody that is specific for the nGPCR-x of the invention. Antibody specificity is described in greater detail below. However, it should be emphasized that antibodies that can be generated from polypeptides that have 25 previously been described in the literature and that are capable of fortuitously cross-reacting with nGPCR-x (*e.g.*, due to the fortuitous existence of a similar epitope in both polypeptides) are considered "cross-reactive" antibodies. Such cross-reactive antibodies are not antibodies that are "specific" for nGPCR-x. The determination of whether an antibody is specific for nGPCR-x or is cross-reactive with another known 30 receptor is made using any of several assays, such as Western blotting assays, that are well known in the art. For identifying cells that express nGPCR-x and also for

DOCKET NO.: 411USPHRM311

PATENT

modulating nGPCR-x-ligand binding activity, antibodies that specifically bind to an extracellular epitope of the nGPCR-x are preferred.

In one preferred variation, the invention provides monoclonal antibodies.

Hybridomas that produce such antibodies also are intended as aspects of the invention.

5 In yet another variation, the invention provides a humanized antibody. Humanized antibodies are useful for *in vivo* therapeutic indications.

In another variation, the invention provides a cell-free composition comprising polyclonal antibodies, wherein at least one of the antibodies is an antibody of the invention specific for nGPCR-x. Antisera isolated from an animal is an exemplary 10 composition, as is a composition comprising an antibody fraction of an antisera that has been resuspended in water or in another diluent, excipient, or carrier.

In still another related embodiment, the invention provides an anti-idiotypic antibody specific for an antibody that is specific for nGPCR-x.

15 It is well known that antibodies contain relatively small antigen binding domains that can be isolated chemically or by recombinant techniques. Such domains are useful nGPCR-x binding molecules themselves, and also may be reintroduced into human antibodies, or fused to toxins or other polypeptides. Thus, in still another embodiment, the invention provides a polypeptide comprising a fragment of a nGPCR-x-specific antibody, wherein the fragment and the polypeptide bind to the nGPCR-x.

20 By way of non-limiting example, the invention provides polypeptides that are single chain antibodies and CDR-grafted antibodies.

25 Non-human antibodies may be humanized by any of the methods known in the art. In one method, the non-human CDRs are inserted into a human antibody or consensus antibody framework sequence. Further changes can then be introduced into the antibody framework to modulate affinity or immunogenicity.

30 Antibodies of the invention are useful for, *e.g.*, therapeutic purposes (by modulating activity of nGPCR-x), diagnostic purposes to detect or quantitate nGPCR-x, and purification of nGPCR-x. Kits comprising an antibody of the invention for any of the purposes described herein are also comprehended. In general, a kit of the invention also includes a control antigen for which the antibody is immunospecific.

Compositions

DOCKET NO.: 411USPHRM311

PATENT

Mutations in the nGPCR-x gene that result in loss of normal function of the nGPCR-x gene product underlie nGPCR-x-related human disease states. The invention comprehends gene therapy to restore nGPCR-x activity to treat those disease states.

Delivery of a functional nGPCR-x gene to appropriate cells is effected *ex vivo*, *in situ*, or *in vivo* by use of vectors, and more particularly viral vectors (*e.g.*, adenovirus, adeno-associated virus, or a retrovirus), or *ex vivo* by use of physical DNA transfer methods (*e.g.*, liposomes or chemical treatments). See, for example, Anderson, *Nature*, supplement to vol. 392, no. 6679, pp.25-20 (1998). For additional reviews of gene therapy technology see Friedmann, *Science*, 244: 1275-1281 (1989); Verma, *Scientific American*: 68-84 (1990); and Miller, *Nature*, 357: 455-460 (1992). Alternatively, it is contemplated that in other human disease states, preventing the expression of, or inhibiting the activity of, nGPCR-x will be useful in treating disease states. It is contemplated that antisense therapy or gene therapy could be applied to negatively regulate the expression of nGPCR-x.

Another aspect of the present invention is directed to compositions, including pharmaceutical compositions, comprising any of the nucleic acid molecules or recombinant expression vectors described above and an acceptable carrier or diluent. Preferably, the carrier or diluent is pharmaceutically acceptable. Suitable carriers are described in the most recent edition of *Remington's Pharmaceutical Sciences*, A. Osol, a standard reference text in this field, which is incorporated herein by reference in its entirety. Preferred examples of such carriers or diluents include, but are not limited to, water, saline, Ringer's solution, dextrose solution, and 5% human serum albumin. Liposomes and nonaqueous vehicles such as fixed oils may also be used. The formulations are sterilized by commonly used techniques.

Also within the scope of the invention are compositions comprising polypeptides, polynucleotides, or antibodies of the invention that have been formulated with, *e.g.*, a pharmaceutically acceptable carrier.

The invention also provides methods of using antibodies of the invention. For example, the invention provides a method for modulating ligand binding of a nGPCR-x comprising the step of contacting the nGPCR-x with an antibody specific for the nGPCR-x, under conditions wherein the antibody binds the receptor.

DOCKET NO.: 411USPHRM311

PATENT

5 GPCRs that may be expressed in the brain, such as nGPCR-x, provide an indication that aberrant nGPCR-x signaling activity may correlate with one or more neurological or psychological disorders. The invention also provides a method for treating a neurological or psychiatric disorder comprising the step of administering to a mammal in need of such treatment an amount of an antibody-like polypeptide of the invention that is sufficient to modulate ligand binding to a nGPCR-x in neurons of the mammal. nGPCR-x may also be expressed in other tissues, including but not limited to, peripheral blood lymphocytes, pancreas, ovary, uterus, testis, salivary gland, thyroid gland, kidney, adrenal gland, liver, bone marrow, prostate, fetal liver, colon, muscle, 10 and fetal brain, and may be found in many other tissues. Within the brain, nGPCR-x mRNA transcripts may be found in many tissues, including, but not limited to, frontal lobe, hypothalamus, pons, cerebellum, caudate nucleus, and medulla. Tissues and brain regions where specific nGPCRs of the present invention are expressed are identified in the Examples below.

15 **Kits**

20 The present invention is also directed to kits, including pharmaceutical kits. The kits can comprise any of the nucleic acid molecules described above, any of the polypeptides described above, or any antibody which binds to a polypeptide of the invention as described above, as well as a negative control. The kit preferably comprises additional components, such as, for example, instructions, solid support, reagents helpful for quantification, and the like.

25 In another aspect, the invention features methods for detection of a polypeptide in a sample as a diagnostic tool for diseases or disorders, wherein the method comprises the steps of: (a) contacting the sample with a nucleic acid probe which hybridizes under hybridization assay conditions to a nucleic acid target region of a polypeptide having the sequence of even numbered sequences ranging from SEQ ID NO: 2 to SEQ ID NO: 94, SEQ ID NO: 186 and SEQ ID NO:192, said probe comprising the nucleic acid sequence encoding the polypeptide, fragments thereof, and the complements of the sequences and fragments; and (b) detecting the presence or amount of the probe:target 30 region hybrid as an indication of the disease.

In preferred embodiments of the invention, the disease is selected from the group consisting of thyroid disorders (*e.g.* thyreotoxicosis, myxoedema); renal failure;

DOCKET NO.: 411USPHRM311

PATENT

inflammatory conditions (*e.g.*, Crohn's disease); diseases related to cell differentiation and homeostasis; rheumatoid arthritis; autoimmune disorders; movement disorders; CNS disorders (*e.g.*, pain including migraine; stroke; psychotic and neurological disorders, including anxiety, schizophrenia, manic depression, anxiety, generalized 5 anxiety disorder, post-traumatic-stress disorder, depression, bipolar disorder, delirium, dementia, severe mental retardation; dyskinesias, such as Huntington's disease or Tourette's Syndrome; attention disorders including ADD and ADHD, and degenerative disorders such as Parkinson's, Alzheimer's; movement disorders, including ataxias, supranuclear palsy, *etc.*); infections, such as viral infections caused by HIV-1 or HIV-2; 10 metabolic and cardiovascular diseases and disorders (*e.g.*, type 2 diabetes, obesity, anorexia, hypotension, hypertension, thrombosis, myocardial infarction, cardiomyopathies, atherosclerosis, *etc.*); proliferative diseases and cancers (*e.g.*, different cancers such as breast, colon, lung, *etc.*, and hyperproliferative disorders such as psoriasis, prostate hyperplasia, *etc.*); hormonal disorders (*e.g.*, male/female hormonal 15 replacement, polycystic ovarian syndrome, alopecia, *etc.*); and sexual dysfunction, among others.

As described above and in Example 4 below, the genes encoding nGPCR-1 (nucleic acid sequence SEQ ID NO: 1, SEQ ID NO: 73, amino acid sequence SEQ ID NO: 2, SEQ ID NO:74), nGPCR-9 (nucleic acid sequence SEQ ID NO:9, SEQ ID NO:77, amino acid sequence SEQ ID NO:10, SEQ ID NO:78), nGPCR-11 (nucleic acid sequence SEQ ID NO:11, SEQ ID NO:79, amino acid sequence SEQ ID NO:12, SEQ ID NO:80), nGPCR-16 (nucleic acid sequence SEQ ID NO: 21, SEQ ID NO:81, amino acid sequence SEQ ID NO: 22, SEQ ID NO:82), nGPCR-40 (nucleic acid sequence SEQ ID NO:53, SEQ ID NO:83, amino acid sequence SEQ ID NO:54, SEQ 20 ID NO:84), nGPCR-54 (nucleic acid sequence SEQ ID NO:59, SEQ ID NO:85, amino acid sequence SEQ ID NO:60, SEQ ID NO: 86), nGPCR-56 (nucleic acid sequence SEQ ID NO:63, SEQ ID NO:87, SEQ ID NO:89, amino acid sequence SEQ ID NO:64, SEQ ID NO: 88, SEQ ID NO:90), nGPCR-58 (nucleic acid sequence SEQ ID NO:67, SEQ ID NO:91, SEQ ID NO:93, amino acid sequence SEQ ID NO:68, SEQ ID NO: 25 92, SEQ ID NO:94) and nGPCR-3 (nucleic acid sequence SEQ ID NO:3, SEQ ID NO:185, amino acid sequence SEQ ID NO:4, SEQ ID NO: 186) have been detected in brain tissue indicating that these n-GPCR-x proteins are neuroreceptors. Kits may be

DOCKET NO.: 411USPHRM311

PATENT

designed to detect either expression of polynucleotides encoding these proteins or the proteins themselves in order to identify tissue as being neurological. For example, oligonucleotide hybridization kits can be provided which include a container having an oligonucleotide probe specific for the n-GPCR-x-specific DNA and optionally, 5 containers with positive and negative controls and/or instructions. Similarly, PCR kits can be provided which include a container having primers specific for the n-GPCR-x-specific sequences, DNA and optionally, containers with size markers, positive and negative controls and/or instructions.

Hybridization conditions should be such that hybridization occurs only with the 10 genes in the presence of other nucleic acid molecules. Under stringent hybridization conditions only highly complementary nucleic acid sequences hybridize. Preferably, such conditions prevent hybridization of nucleic acids having 1 or 2 mismatches out of 20 contiguous nucleotides. Such conditions are defined *supra*.

The diseases for which detection of genes in a sample could be diagnostic 15 include diseases in which nucleic acid (DNA and/or RNA) is amplified in comparison to normal cells. By "amplification" is meant increased numbers of DNA or RNA in a cell compared with normal cells.

The diseases that could be diagnosed by detection of nucleic acid in a sample 20 preferably include central nervous system and metabolic diseases. The test samples suitable for nucleic acid probing methods of the present invention include, for example, cells or nucleic acid extracts of cells, or biological fluids. The samples used in the above-described methods will vary based on the assay format, the detection method and the nature of the tissues, cells or extracts to be assayed. Methods for preparing nucleic acid extracts of cells are well known in the art and can be readily adapted in order to 25 obtain a sample that is compatible with the method utilized.

Alternatively, immunoassay kits can be provided which have containers container having antibodies specific for the n-GPCR-x-protein and optionally, containers with positive and negative controls and/or instructions.

Kits may also be provided useful in the identification of GPCR binding partners 30 such as natural ligands or modulators (agonists or antagonists). Substances useful for treatment of disorders or diseases preferably show positive results in one or more *in vitro* assays for an activity corresponding to treatment of the disease or disorder in

DOCKET NO.: 411USPHRM311

PATENT

question. Substances that modulate the activity of the polypeptides preferably include, but are not limited to, antisense oligonucleotides, agonists and antagonists, and inhibitors of protein kinases.

Methods of inducing immune response

5 Another aspect of the present invention is directed to methods of inducing an immune response in a mammal against a polypeptide of the invention by administering to the mammal an amount of the polypeptide sufficient to induce an immune response. The amount will be dependent on the animal species, size of the animal, and the like but can be determined by those skilled in the art.

10 **Methods of identifying ligands**

The invention also provides assays to identify compounds that bind nGPCR-x. One such assay comprises the steps of: (a) contacting a composition comprising a nGPCR-x with a compound suspected of binding nGPCR-x; and (b) measuring binding between the compound and nGPCR-x. In one variation, the composition comprises a 15 cell expressing nGPCR-x on its surface. In another variation, isolated nGPCR-x or cell membranes comprising nGPCR-x are employed. The binding may be measured directly, *e.g.*, by using a labeled compound, or may be measured indirectly by several techniques, including measuring intracellular signaling of nGPCR-x induced by the compound (or measuring changes in the level of nGPCR-x signaling).

20 Specific binding molecules, including natural ligands and synthetic compounds, can be identified or developed using isolated or recombinant nGPCR-x products, nGPCR-x variants, or preferably, cells expressing such products. Binding partners are useful for purifying nGPCR-x products and detection or quantification of nGPCR-x products in fluid and tissue samples using known immunological procedures. Binding 25 molecules are also manifestly useful in modulating (*i.e.*, blocking, inhibiting or stimulating) biological activities of nGPCR-x, especially those activities involved in signal transduction.

The DNA and amino acid sequence information provided by the present invention also makes possible identification of binding partner compounds with which 30 a nGPCR-x polypeptide or polynucleotide will interact. Methods to identify binding partner compounds include solution assays, *in vitro* assays wherein nGPCR-x polypeptides are immobilized, and cell-based assays. Identification of binding partner

DOCKET NO.: 411USPHRM311

PATENT

compounds of nGPCR-x polypeptides provides candidates for therapeutic or prophylactic intervention in pathologies associated with nGPCR-x normal and aberrant biological activity.

The invention includes several assay systems for identifying nGPCR-x binding partners. In solution assays, methods of the invention comprise the steps of (a) contacting a nGPCR-x polypeptide with one or more candidate binding partner compounds and (b) identifying the compounds that bind to the nGPCR-x polypeptide. Identification of the compounds that bind the nGPCR-x polypeptide can be achieved by isolating the nGPCR-x polypeptide/binding partner complex, and separating the binding partner compound from the nGPCR-x polypeptide. An additional step of characterizing the physical, biological, and/or biochemical properties of the binding partner compound is also comprehended in another embodiment of the invention. In one aspect, the nGPCR-x polypeptide/binding partner complex is isolated using an antibody immunospecific for either the nGPCR-x polypeptide or the candidate binding partner compound.

In still other embodiments, either the nGPCR-x polypeptide or the candidate binding partner compound comprises a label or tag that facilitates its isolation, and methods of the invention to identify binding partner compounds include a step of isolating the nGPCR-x polypeptide/binding partner complex through interaction with the label or tag. An exemplary tag of this type is a poly-histidine sequence, generally around six histidine residues, that permits isolation of a compound so labeled using nickel chelation. Other labels and tags, such as the FLAG® tag (Eastman Kodak, Rochester, NY), well known and routinely used in the art, are embraced by the invention.

In one variation of an *in vitro* assay, the invention provides a method comprising the steps of (a) contacting an immobilized nGPCR-x polypeptide with a candidate binding partner compound and (b) detecting binding of the candidate compound to the nGPCR-x polypeptide. In an alternative embodiment, the candidate binding partner compound is immobilized and binding of nGPCR-x is detected. Immobilization is accomplished using any of the methods well known in the art, including covalent bonding to a support, a bead, or a chromatographic resin, as well as non-covalent, high affinity interactions such as antibody binding, or use of

DOCKET NO.: 411USPHRM311

PATENT

streptavidin/biotin binding wherein the immobilized compound includes a biotin moiety. Detection of binding can be accomplished (i) using a radioactive label on the compound that is not immobilized, (ii) using of a fluorescent label on the non-immobilized compound, (iii) using an antibody immunospecific for the non-immobilized compound, (iv) using a label on the non-immobilized compound that excites a fluorescent support to which the immobilized compound is attached, as well as other techniques well known and routinely practiced in the art.

The invention also provides cell-based assays to identify binding partner compounds of a nGPCR-x polypeptide. In one embodiment, the invention provides a 10 method comprising the steps of contacting a nGPCR-x polypeptide expressed on the surface of a cell with a candidate binding partner compound and detecting binding of the candidate binding partner compound to the nGPCR-x polypeptide. In a preferred embodiment, the detection comprises detecting a calcium flux or other physiological event in the cell caused by the binding of the molecule.

Another aspect of the present invention is directed to methods of identifying 15 compounds that bind to either nGPCR-x or nucleic acid molecules encoding nGPCR-x, comprising contacting nGPCR-x, or a nucleic acid molecule encoding the same, with a compound, and determining whether the compound binds nGPCR-x or a nucleic acid molecule encoding the same. Binding can be determined by binding assays which are 20 well known to the skilled artisan, including, but not limited to, gel-shift assays, Western blots, radiolabeled competition assay, phage-based expression cloning, co-fractionation by chromatography, co-precipitation, cross linking, interaction trap/two-hybrid analysis, southwestern analysis, ELISA, and the like, which are described in, for example, *Current Protocols in Molecular Biology*, 1999, John Wiley & Sons, NY, 25 which is incorporated herein by reference in its entirety. The compounds to be screened include (which may include compounds which are suspected to bind nGPCR-x, or a nucleic acid molecule encoding the same), but are not limited to, extracellular, intracellular, biologic or chemical origin. The methods of the invention also embrace ligands, especially neuropeptides, that are attached to a label, such as a radiolabel (e.g., 30 ^{125}I , ^{35}S , ^{32}P , ^{33}P , ^3H), a fluorescence label, a chemiluminescent label, an enzymic label and an immunogenic label. Modulators falling within the scope of the invention include, but are not limited to, non-peptide molecules such as non-peptide mimetics,

DOCKET NO.: 411USPHRM311

PATENT

non-peptide allosteric effectors, and peptides. The nGPCR-x polypeptide or polynucleotide employed in such a test may either be free in solution, attached to a solid support, borne on a cell surface or located intracellularly or associated with a portion of a cell. One skilled in the art can, for example, measure the formation of 5 complexes between nGPCR-x and the compound being tested. Alternatively, one skilled in the art can examine the diminution in complex formation between nGPCR-x and its substrate caused by the compound being tested.

In another embodiment of the invention, high throughput screening for 10 compounds having suitable binding affinity to nGPCR-x is employed. Briefly, large numbers of different small peptide test compounds are synthesized on a solid substrate. The peptide test compounds are contacted with nGPCR-x and washed. Bound nGPCR-x is then detected by methods well known in the art. Purified polypeptides of the invention can also be coated directly onto plates for use in the aforementioned drug screening techniques. In addition, non-neutralizing antibodies can be used to capture 15 the protein and immobilize it on the solid support.

Generally, an expressed nGPCR-x can be used for HTS binding assays in conjunction with its defined ligand, in this case the corresponding neuropeptide that activates it. The identified peptide is labeled with a suitable radioisotope, including, but not limited to, ¹²⁵I, ³H, ³⁵S or ³²P, by methods that are well known to those skilled in 20 the art. Alternatively, the peptides may be labeled by well-known methods with a suitable fluorescent derivative (Baindur *et al.*, *Drug Dev. Res.*, **1994**, 33, 373-398; Rogers, *Drug Discovery Today*, **1997**, 2, 156-160). Radioactive ligand specifically bound to the receptor in membrane preparations made from the cell line expressing the recombinant protein can be detected in HTS assays in one of several standard ways, 25 including filtration of the receptor-ligand complex to separate bound ligand from unbound ligand (Williams, *Med. Res. Rev.*, **1991**, 11, 147-184; Sweetnam *et al.*, *J. Natural Products*, **1993**, 56, 441-455). Alternative methods include a scintillation proximity assay (SPA) or a FlashPlate format in which such separation is unnecessary (Nakayama, *Cur. Opinion Drug Disc. Dev.*, **1998**, 1, 85-91 Bossé *et al.*, *J. Biomolecular Screening*, **1998**, 3, 285-292.). Binding of fluorescent ligands can be detected in various ways, including fluorescence energy transfer (FRET), direct spectrophotofluorometric analysis of bound ligand, or fluorescence polarization 30

DOCKET NO.: 411USPHRM311

PATENT

(Rogers, *Drug Discovery Today*, 1997, 2, 156-160; Hill, *Cur. Opinion Drug Disc. Dev.*, 1998, 1, 92-97).

Other assays may be used to identify specific ligands of a nGPCR-x receptor, including assays that identify ligands of the target protein through measuring direct 5 binding of test ligands to the target protein, as well as assays that identify ligands of target proteins through affinity ultrafiltration with ion spray mass spectroscopy/HPLC methods or other physical and analytical methods. Alternatively, such binding interactions are evaluated indirectly using the yeast two-hybrid system described in Fields *et al.*, *Nature*, 340:245-246 (1989), and Fields *et al.*, *Trends in Genetics*, 10:286-10 292 (1994), both of which are incorporated herein by reference. The two-hybrid system is a genetic assay for detecting interactions between two proteins or polypeptides. It can be used to identify proteins that bind to a known protein of interest, or to delineate domains or residues critical for an interaction. Variations on this methodology have been developed to clone genes that encode DNA binding 15 proteins, to identify peptides that bind to a protein, and to screen for drugs. The two-hybrid system exploits the ability of a pair of interacting proteins to bring a transcription activation domain into close proximity with a DNA binding domain that binds to an upstream activation sequence (UAS) of a reporter gene, and is generally performed in yeast. The assay requires the construction of two hybrid genes encoding 20 (1) a DNA-binding domain that is fused to a first protein and (2) an activation domain fused to a second protein. The DNA-binding domain targets the first hybrid protein to the UAS of the reporter gene; however, because most proteins lack an activation domain, this DNA-binding hybrid protein does not activate transcription of the reporter gene. The second hybrid protein, which contains the activation domain, cannot by 25 itself activate expression of the reporter gene because it does not bind the UAS. However, when both hybrid proteins are present, the noncovalent interaction of the first and second proteins tethers the activation domain to the UAS, activating transcription of the reporter gene. For example, when the first protein is a GPCR gene product, or fragment thereof, that is known to interact with another protein or nucleic acid, this 30 assay can be used to detect agents that interfere with the binding interaction. Expression of the reporter gene is monitored as different test agents are added to the system. The presence of an inhibitory agent results in lack of a reporter signal.

DOCKET NO.: 411USPHRM311

PATENT

The function of nGPCR-x gene products is unclear and no ligands have yet been found which bind the gene product. The yeast two-hybrid assay can also be used to identify proteins that bind to the gene product. In an assay to identify proteins that bind to a nGPCR-x receptor, or fragment thereof, a fusion polynucleotide encoding both a nGPCR-x receptor (or fragment) and a UAS binding domain (*i.e.*, a first protein) may be used. In addition, a large number of hybrid genes each encoding a different second protein fused to an activation domain are produced and screened in the assay.

Typically, the second protein is encoded by one or more members of a total cDNA or genomic DNA fusion library, with each second protein-coding region being fused to the activation domain. This system is applicable to a wide variety of proteins, and it is not even necessary to know the identity or function of the second binding protein. The system is highly sensitive and can detect interactions not revealed by other methods; even transient interactions may trigger transcription to produce a stable mRNA that can be repeatedly translated to yield the reporter protein.

Other assays may be used to search for agents that bind to the target protein. One such screening method to identify direct binding of test ligands to a target protein is described in U.S. Patent No. 5,585,277, incorporated herein by reference. This method relies on the principle that proteins generally exist as a mixture of folded and unfolded states, and continually alternate between the two states. When a test ligand binds to the folded form of a target protein (*i.e.*, when the test ligand is a ligand of the target protein), the target protein molecule bound by the ligand remains in its folded state. Thus, the folded target protein is present to a greater extent in the presence of a test ligand which binds the target protein, than in the absence of a ligand. Binding of the ligand to the target protein can be determined by any method that distinguishes between the folded and unfolded states of the target protein. The function of the target protein need not be known in order for this assay to be performed. Virtually any agent can be assessed by this method as a test ligand, including, but not limited to, metals, polypeptides, proteins, lipids, polysaccharides, polynucleotides and small organic molecules.

Another method for identifying ligands of a target protein is described in Wieboldt *et al.*, Anal. Chem., 69:1683-1691 (1997), incorporated herein by reference. This technique screens combinatorial libraries of 20-30 agents at a time in solution

DOCKET NO.: 411USPHRM311

PATENT

phase for binding to the target protein. Agents that bind to the target protein are separated from other library components by simple membrane washing. The specifically selected molecules that are retained on the filter are subsequently liberated from the target protein and analyzed by HPLC and pneumatically assisted electrospray (ion spray) ionization mass spectroscopy. This procedure selects library components with the greatest affinity for the target protein, and is particularly useful for small molecule libraries.

Other embodiments of the invention comprise using competitive screening assays in which neutralizing antibodies capable of binding a polypeptide of the invention specifically compete with a test compound for binding to the polypeptide. In this manner, the antibodies can be used to detect the presence of any peptide that shares one or more antigenic determinants with nGPCR-x. Radiolabeled competitive binding studies are described in A.H. Lin *et al. Antimicrobial Agents and Chemotherapy*, 1997, vol. 41, no. 10. pp. 2127-2131, the disclosure of which is incorporated herein by reference in its entirety.

As described above and in Example 4 below, the genes encoding nGPCR-1 (nucleic acid sequence SEQ ID NO: 1, SEQ ID NO: 73, amino acid sequence SEQ ID NO: 2, SEQ ID NO:74), nGPCR-9 (nucleic acid sequence SEQ ID NO:9, SEQ ID NO:77, amino acid sequence SEQ ID NO:10, SEQ ID NO:78), nGPCR-11 (nucleic acid sequence SEQ ID NO:11, SEQ ID NO:79, amino acid sequence SEQ ID NO:12, SEQ ID NO:80), nGPCR-16 (nucleic acid sequence SEQ ID NO: 21, SEQ ID NO:81, amino acid sequence SEQ ID NO: 22, SEQ ID NO:82), nGPCR-40 (nucleic acid sequence SEQ ID NO:53, SEQ ID NO:83, amino acid sequence SEQ ID NO:54, SEQ ID NO:84), nGPCR-54 (nucleic acid sequence SEQ ID NO:59, SEQ ID NO:85, amino acid sequence SEQ ID NO:60, SEQ ID NO: 86), nGPCR-56 (nucleic acid sequence SEQ ID NO:63, SEQ ID NO:87, SEQ ID NO:89, amino acid sequence SEQ ID NO:64, SEQ ID NO: 88, SEQ ID NO:90), nGPCR-58 (nucleic acid sequence SEQ ID NO:67, SEQ ID NO:91, SEQ ID NO:93, amino acid sequence SEQ ID NO:68, SEQ ID NO: 92, SEQ ID NO:94), and nGPCR-3 (nucleic acid sequence SEQ ID NO:3, SEQ ID NO:185, amino acid sequence SEQ ID NO:4, SEQ ID NO: 186) have been detected in brain tissue indicating that these n-GPCR-x proteins are neuroreceptors. Accordingly, natural binding partners of these molecules include neurotransmitters.

DOCKET NO.: 411USPHRM311

PATENT

Identification of modulating agents

The invention also provides methods for identifying a modulator of binding between a nGPCR-x and a nGPCR-x binding partner, comprising the steps of: (a) contacting a nGPCR-x binding partner and a composition comprising a nGPCR-x in the presence and in the absence of a putative modulator compound; (b) detecting binding between the binding partner and the nGPCR-x; and (c) identifying a putative modulator compound or a modulator compound in view of decreased or increased binding between the binding partner and the nGPCR-x in the presence of the putative modulator, as compared to binding in the absence of the putative modulator.

10 nGPCR-x binding partners that stimulate nGPCR-x activity are useful as agonists in disease states or conditions characterized by insufficient nGPCR-x signaling (*e.g.*, as a result of insufficient activity of a nGPCR-x ligand). nGPCR-x binding partners that block ligand-mediated nGPCR-x signaling are useful as nGPCR-x antagonists to treat disease states or conditions characterized by excessive nGPCR-x signaling. In addition nGPCR-x modulators in general, as well as nGPCR-x polynucleotides and polypeptides, are useful in diagnostic assays for such diseases or conditions.

20 In another aspect, the invention provides methods for treating a disease or abnormal condition by administering to a patient in need of such treatment a substance that modulates the activity or expression of a polypeptide having the sequence of even numbered sequences ranging from SEQ ID NO: 2 to SEQ ID NO: 94, SEQ ID NO: 186 and SEQ ID NO:192.

25 Agents that modulate (*i.e.*, increase, decrease, or block) nGPCR-x activity or expression may be identified by incubating a putative modulator with a cell containing a nGPCR-x polypeptide or polynucleotide and determining the effect of the putative modulator on nGPCR-x activity or expression. The selectivity of a compound that modulates the activity of nGPCR-x can be evaluated by comparing its effects on nGPCR-x to its effect on other GPCR compounds. Selective modulators may include, for example, antibodies and other proteins, peptides, or organic molecules that 30 specifically bind to a nGPCR-x polypeptide or a nGPCR-x-encoding nucleic acid. Modulators of nGPCR-x activity will be therapeutically useful in treatment of diseases and physiological conditions in which normal or aberrant nGPCR-x activity is

DOCKET NO.: 411USPHRM311

PATENT

involved. nGPCR-x polynucleotides, polypeptides, and modulators may be used in the treatment of such diseases and conditions as infections, such as viral infections caused by HIV-1 or HIV-2; pain; cancers; Parkinson's disease; hypotension; hypertension; and psychotic and neurological disorders, including anxiety, schizophrenia, manic

5 depression, delirium, dementia, severe mental retardation and dyskinesias, such as Huntington's disease or Tourette's Syndrome, among others. nGPCR-x polynucleotides and polypeptides, as well as nGPCR-x modulators, may also be used in diagnostic assays for such diseases or conditions.

Methods of the invention to identify modulators include variations on any of the 10 methods described above to identify binding partner compounds, the variations including techniques wherein a binding partner compound has been identified and the binding assay is carried out in the presence and absence of a candidate modulator. A modulator is identified in those instances where binding between the nGPCR-x polypeptide and the binding partner compound changes in the presence of the candidate 15 modulator compared to binding in the absence of the candidate modulator compound. A modulator that increases binding between the nGPCR-x polypeptide and the binding partner compound is described as an enhancer or activator, and a modulator that decreases binding between the nGPCR-x polypeptide and the binding partner compound is described as an inhibitor.

20 The invention also comprehends high-throughput screening (HTS) assays to identify compounds that interact with or inhibit biological activity (*i.e.*, affect enzymatic activity, binding activity, *etc.*) of a nGPCR-x polypeptide. HTS assays permit screening of large numbers of compounds in an efficient manner. Cell-based HTS systems are contemplated to investigate nGPCR-x receptor-ligand interaction. 25 HTS assays are designed to identify "hits" or "lead compounds" having the desired property, from which modifications can be designed to improve the desired property. Chemical modification of the "hit" or "lead compound" is often based on an identifiable structure/activity relationship between the "hit" and the nGPCR-x polypeptide.

30 Another aspect of the present invention is directed to methods of identifying compounds which modulate (*i.e.*, increase or decrease) activity of nGPCR-x comprising contacting nGPCR-x with a compound, and determining whether the

DOCKET NO.: 411USPHRM311

PATENT

compound modifies activity of nGPCR-x. The activity in the presence of the test compared is measured to the activity in the absence of the test compound. Where the activity of the sample containing the test compound is higher than the activity in the sample lacking the test compound, the compound will have increased activity.

5 Similarly, where the activity of the sample containing the test compound is lower than the activity in the sample lacking the test compound, the compound will have inhibited activity.

The present invention is particularly useful for screening compounds by using nGPCR-x in any of a variety of drug screening techniques. The compounds to be 10 screened include (which may include compounds which are suspected to modulate nGPCR-x activity), but are not limited to, extracellular, intracellular, biologic or chemical origin. The nGPCR-x polypeptide employed in such a test may be in any form, preferably, free in solution, attached to a solid support, borne on a cell surface or located intracellularly. One skilled in the art can, for example, measure the formation 15 of complexes between nGPCR-x and the compound being tested. Alternatively, one skilled in the art can examine the diminution in complex formation between nGPCR-x and its substrate caused by the compound being tested.

The activity of nGPCR-x polypeptides of the invention can be determined by, for example, examining the ability to bind or be activated by chemically synthesized 20 peptide ligands. Alternatively, the activity of nGPCR-x polypeptides can be assayed by examining their ability to bind calcium ions, hormones, chemokines, neuropeptides, neurotransmitters, nucleotides, lipids, odorants, and photons. Alternatively, the activity of the nGPCR-x polypeptides can be determined by examining the activity of effector molecules including, but not limited to, adenylate cyclase, phospholipases and ion 25 channels. Thus, modulators of nGPCR-x polypeptide activity may alter a GPCR receptor function, such as a binding property of a receptor or an activity such as G protein-mediated signal transduction or membrane localization. In various embodiments of the method, the assay may take the form of an ion flux assay, a yeast growth assay, a non-hydrolyzable GTP assay such as a $[^{35}\text{S}]\text{-GTP}$ S assay, a cAMP 30 assay, an inositol triphosphate assay, a diacylglycerol assay, an Aequorin assay, a Luciferase assay, a FLIPR assay for intracellular Ca^{2+} concentration, a mitogenesis assay, a MAP Kinase activity assay, an arachidonic acid release assay (e.g., using $[^3\text{H}]$ -

PATENT

arachidonic acid), and an assay for extracellular acidification rates, as well as other binding or function-based assays of nGPCR-x activity that are generally known in the art. In several of these embodiments, the invention comprehends the inclusion of any of the G proteins known in the art, such as G₁₆, G₁₅, or chimeric G_{qds5}, G_{qs5}, G_{qo5}, G_{q25}, and the like. nGPCR-x activity can be determined by methodologies that are used to assay for FaRP activity, which is well known to those skilled in the art. Biological activities of nGPCR-x receptors according to the invention include, but are not limited to, the binding of a natural or an unnatural ligand, as well as any one of the functional activities of GPCRs known in the art. Non-limiting examples of GPCR activities include transmembrane signaling of various forms, which may involve G protein association and/or the exertion of an influence over G protein binding of various guanidylate nucleotides; another exemplary activity of GPCRs is the binding of accessory proteins or polypeptides that differ from known G proteins.

The modulators of the invention exhibit a variety of chemical structures, which can be generally grouped into non-peptide mimetics of natural GPCR receptor ligands, peptide and non-peptide allosteric effectors of GPCR receptors, and peptides that may function as activators or inhibitors (competitive, uncompetitive and non-competitive) (e.g., antibody products) of GPCR receptors. The invention does not restrict the sources for suitable modulators, which may be obtained from natural sources such as plant, animal or mineral extracts, or non-natural sources such as small molecule libraries, including the products of combinatorial chemical approaches to library construction, and peptide libraries. Examples of peptide modulators of GPCR receptors exhibit the following primary structures: GLGPRPLRFamide, GNSFLRFamide, GGPQGPLRFamide, GPSGPLRFamide, PDVDHVFLRFamide, and pyro-EDVDHVFLRFamide.

Other assays can be used to examine enzymatic activity including, but not limited to, photometric, radiometric, HPLC, electrochemical, and the like, which are described in, for example, *Enzyme Assays: A Practical Approach*, eds. R. Eisenthal and M. J. Danson, 1992, Oxford University Press, which is incorporated herein by reference in its entirety.

The use of cDNAs encoding GPCRs in drug discovery programs is well-known; assays capable of testing thousands of unknown compounds per day in high-throughput

DOCKET NO.: 411USPHRM311

PATENT

screens (HTSs) are thoroughly documented. The literature is replete with examples of the use of radiolabelled ligands in HTS binding assays for drug discovery (see Williams, *Medicinal Research Reviews*, 1991, 11, 147-184.; Sweetnam, *et al.*, *J. Natural Products*, 1993, 56, 441-455 for review). Recombinant receptors are preferred 5 for binding assay HTS because they allow for better specificity (higher relative purity), provide the ability to generate large amounts of receptor material, and can be used in a broad variety of formats (see Hodgson, *Bio/Technology*, 1992, 10, 973-980; each of which is incorporated herein by reference in its entirety).

A variety of heterologous systems is available for functional expression of 10 recombinant receptors that are well known to those skilled in the art. Such systems include bacteria (Strosberg, *et al.*, *Trends in Pharmacological Sciences*, 1992, 13, 95-98), yeast (Pausch, *Trends in Biotechnology*, 1997, 15, 487-494), several kinds of insect 15 cells (Vanden Broeck, *Int. Rev. Cytology*, 1996, 164, 189-268), amphibian cells (Jayawickreme *et al.*, *Current Opinion in Biotechnology*, 1997, 8, 629-634) and several mammalian cell lines (CHO, HEK293, COS, etc.; see Gerhardt, *et al.*, *Eur. J. 20 Pharmacology*, 1997, 334, 1-23). These examples do not preclude the use of other possible cell expression systems, including cell lines obtained from nematodes (PCT application WO 98/37177).

In preferred embodiments of the invention, methods of screening for 25 compounds that modulate nGPCR-x activity comprise contacting test compounds with nGPCR-x and assaying for the presence of a complex between the compound and nGPCR-x. In such assays, the ligand is typically labeled. After suitable incubation, free ligand is separated from that present in bound form, and the amount of free or uncomplexed label is a measure of the ability of the particular compound to bind to nGPCR-x.

It is well known that activation of heterologous receptors expressed in recombinant systems results in a variety of biological responses, which are mediated by G proteins expressed in the host cells. Occupation of a GPCR by an agonist results in exchange of bound GDP for GTP at a binding site on the G_a subunit; one can use a 30 radioactive, non-hydrolyzable derivative of GTP, GTP γ [³⁵S], to measure binding of an agonist to the receptor (Sim *et al.*, *Neuroreport*, 1996, 7, 729-733). One can also use this binding to measure the ability of antagonists to bind to the receptor by decreasing

DOCKET NO.: 411USPHRM311

PATENT

binding of GTP γ [³⁵S] in the presence of a known agonist. One could therefore construct a HTS based on GTP γ [³⁵S] binding, though this is not the preferred method.

The G proteins required for functional expression of heterologous GPCRs can be native constituents of the host cell or can be introduced through well-known recombinant technology. The G proteins can be intact or chimeric. Often, a nearly universally competent G protein (e.g., G α 16) is used to couple any given receptor to a detectable response pathway. G protein activation results in the stimulation or inhibition of other native proteins, events that can be linked to a measurable response.

Examples of such biological responses include, but are not limited to, the following: the ability to survive in the absence of a limiting nutrient in specifically engineered yeast cells (Pausch, *Trends in Biotechnology*, 1997, 15, 487-494); changes in intracellular Ca²⁺ concentration as measured by fluorescent dyes (Murphy, *et al.*, *Cur. Opinion Drug Disc. Dev.*, 1998, 1, 192-199). Fluorescence changes can also be used to monitor ligand-induced changes in membrane potential or intracellular pH; an automated system suitable for HTS has been described for these purposes (Schroeder, *et al.*, *J. Biomolecular Screening*, 1996, 1, 75-80). Melanophores prepared from *Xenopus laevis* show a ligand-dependent change in pigment organization in response to heterologous GPCR activation; this response is adaptable to HTS formats (Jayawickreme *et al.*, *Cur. Opinion Biotechnology*, 1997, 8, 629-634). Assays are also available for the measurement of common second messengers, including cAMP, phosphoinositides and arachidonic acid, but these are not generally preferred for HTS.

Preferred methods of HTS employing these receptors include permanently transfected CHO cells, in which agonists and antagonists can be identified by the ability to specifically alter the binding of GTP γ [³⁵S] in membranes prepared from these cells. In another embodiment of the invention, permanently transfected CHO cells could be used for the preparation of membranes which contain significant amounts of the recombinant receptor proteins; these membrane preparations would then be used in receptor binding assays, employing the radiolabelled ligand specific for the particular receptor. Alternatively, a functional assay, such as fluorescent monitoring of ligand-induced changes in internal Ca²⁺ concentration or membrane potential in permanently transfected CHO cells containing each of these receptors individually or in combination

PATENT

would be preferred for HTS. Equally preferred would be an alternative type of mammalian cell, such as HEK293 or COS cells, in similar formats. More preferred would be permanently transfected insect cell lines, such as *Drosophila* S2 cells. Even more preferred would be recombinant yeast cells expressing the *Drosophila* 5 *melanogaster* receptors in HTS formats well known to those skilled in the art (e.g., Pausch, *Trends in Biotechnology*, 1997, 15, 487-494).

The invention contemplates a multitude of assays to screen and identify inhibitors of ligand binding to nGPCR-x receptors. In one example, the nGPCR-x receptor is immobilized and interaction with a binding partner is assessed in the 10 presence and absence of a candidate modulator such as an inhibitor compound. In another example, interaction between the nGPCR-x receptor and its binding partner is assessed in a solution assay, both in the presence and absence of a candidate inhibitor compound. In either assay, an inhibitor is identified as a compound that decreases binding between the nGPCR-x receptor and its binding partner. Another contemplated 15 assay involves a variation of the dihybrid assay wherein an inhibitor of protein/protein interactions is identified by detection of a positive signal in a transformed or transfected host cell, as described in PCT publication number WO 95/20652, published August 3, 1995.

Candidate modulators contemplated by the invention include compounds 20 selected from libraries of either potential activators or potential inhibitors. There are a number of different libraries used for the identification of small molecule modulators, including: (1) chemical libraries, (2) natural product libraries, and (3) combinatorial libraries comprised of random peptides, oligonucleotides or organic molecules. Chemical libraries consist of random chemical structures, some of which are analogs of 25 known compounds or analogs of compounds that have been identified as "hits" or "leads" in other drug discovery screens, some of which are derived from natural products, and some of which arise from non-directed synthetic organic chemistry. Natural product libraries are collections of microorganisms, animals, plants, or marine organisms which are used to create mixtures for screening by: (1) fermentation and 30 extraction of broths from soil, plant or marine microorganisms or (2) extraction of plants or marine organisms. Natural product libraries include polyketides, non-ribosomal peptides, and variants (non-naturally occurring) thereof. For a review, see

DOCKET NO.: 411USPHRM311

PATENT

Science 282:63-68 (1998). Combinatorial libraries are composed of large numbers of peptides, oligonucleotides, or organic compounds as a mixture. These libraries are relatively easy to prepare by traditional automated synthesis methods, PCR, cloning, or proprietary synthetic methods. Of particular interest are non-peptide combinatorial 5 libraries. Still other libraries of interest include peptide, protein, peptidomimetic, multiparallel synthetic collection, recombinatorial, and polypeptide libraries. For a review of combinatorial chemistry and libraries created therefrom, see Myers, Curr. 10 Opin. Biotechnol. 8:701-707 (1997). Identification of modulators through use of the various libraries described herein permits modification of the candidate "hit" (or "lead") to optimize the capacity of the "hit" to modulate activity.

Still other candidate inhibitors contemplated by the invention can be designed and include soluble forms of binding partners, as well as such binding partners as chimeric, or fusion, proteins. A "binding partner" as used herein broadly encompasses non-peptide modulators, as well as such peptide modulators as neuropeptides other than 15 natural ligands, antibodies, antibody fragments, and modified compounds comprising antibody domains that are immunospecific for the expression product of the identified nGPCR-x gene.

The polypeptides of the invention are employed as a research tool for 20 identification, characterization and purification of interacting, regulatory proteins. Appropriate labels are incorporated into the polypeptides of the invention by various methods known in the art and the polypeptides are used to capture interacting molecules. For example, molecules are incubated with the labeled polypeptides, washed to remove unbound polypeptides, and the polypeptide complex is quantified. Data obtained using different concentrations of polypeptide are used to calculate values 25 for the number, affinity, and association of polypeptide with the protein complex.

Labeled polypeptides are also useful as reagents for the purification of molecules with which the polypeptide interacts including, but not limited to, inhibitors. In one embodiment of affinity purification, a polypeptide is covalently coupled to a chromatography column. Cells and their membranes are extracted, and various cellular 30 subcomponents are passed over the column. Molecules bind to the column by virtue of their affinity to the polypeptide. The polypeptide-complex is recovered from the column, dissociated and the recovered molecule is subjected to protein sequencing.

DOCKET NO.: 411USPHRM311

PATENT

This amino acid sequence is then used to identify the captured molecule or to design degenerate oligonucleotides for cloning the corresponding gene from an appropriate cDNA library.

Alternatively, compounds may be identified which exhibit similar properties to the ligand for the nGPCR-x of the invention, but which are smaller and exhibit a longer half time than the endogenous ligand in a human or animal body. When an organic compound is designed, a molecule according to the invention is used as a "lead" compound. The design of mimetics to known pharmaceutically active compounds is a well-known approach in the development of pharmaceuticals based on such "lead" compounds. Mimetic design, synthesis and testing are generally used to avoid randomly screening a large number of molecules for a target property. Furthermore, structural data deriving from the analysis of the deduced amino acid sequences encoded by the DNAs of the present invention are useful to design new drugs, more specific and therefore with a higher pharmacological potency.

Comparison of the protein sequence of the present invention with the sequences present in all the available databases showed a significant homology with the transmembrane portion of G protein coupled receptors. Accordingly, computer modeling can be used to develop a putative tertiary structure of the proteins of the invention based on the available information of the transmembrane domain of other proteins. Thus, novel ligands based on the predicted structure of nGPCR-x can be designed.

In a particular embodiment, the novel molecules identified by the screening methods according to the invention are low molecular weight organic molecules, in which case a composition or pharmaceutical composition can be prepared thereof for oral intake, such as in tablets. The compositions, or pharmaceutical compositions, comprising the nucleic acid molecules, vectors, polypeptides, antibodies and compounds identified by the screening methods described herein, can be prepared for any route of administration including, but not limited to, oral, intravenous, cutaneous, subcutaneous, nasal, intramuscular or intraperitoneal. The nature of the carrier or other ingredients will depend on the specific route of administration and particular embodiment of the invention to be administered. Examples of techniques and protocols that are useful in this context are, *inter alia*, found in Remington's Pharmaceutical

DOCKET NO.: 411USPHRM311

PATENT

Sciences, 16th edition, Osol, A (ed.), **1980**, which is incorporated herein by reference in its entirety.

5 The dosage of these low molecular weight compounds will depend on the disease state or condition to be treated and other clinical factors such as weight and condition of the human or animal and the route of administration of the compound. For treating human or animals, between approximately 0.5 mg/kg of body weight to 500 mg/kg of body weight of the compound can be administered. Therapy is typically administered at lower dosages and is continued until the desired therapeutic outcome is observed.

10 The present compounds and methods, including nucleic acid molecules, polypeptides, antibodies, compounds identified by the screening methods described herein, have a variety of pharmaceutical applications and may be used, for example, to treat or prevent unregulated cellular growth, such as cancer cell and tumor growth. In a particular embodiment, the present molecules are used in gene therapy. For a review of 15 gene therapy procedures, see *e.g.* Anderson, *Science*, **1992**, 256, 808-813, which is incorporated herein by reference in its entirety.

20 The present invention also encompasses a method of agonizing (stimulating) or antagonizing a nGPCR-x natural binding partner associated activity in a mammal comprising administering to said mammal an agonist or antagonist to one of the above disclosed polypeptides in an amount sufficient to effect said agonism or antagonism. One embodiment of the present invention, then, is a method of treating diseases in a mammal with an agonist or antagonist of the protein of the present invention comprises administering the agonist or antagonist to a mammal in an amount sufficient to agonize or antagonize nGPCR-x-associated functions.

25 In an effort to discover novel treatments for diseases, biomedical researchers and chemists have designed, synthesized, and tested molecules that inhibit the function of protein polypeptides. Some small organic molecules form a class of compounds that modulate the function of protein polypeptides. Examples of molecules that have been reported to inhibit the function of protein kinases include, but are not limited to, bis 30 monocyclic, bicyclic or heterocyclic aryl compounds (PCT WO 92/20642, published November 26, 1992 by Maguire *et al.*), vinylene-azaindole derivatives (PCT WO 94/14808, published July 7, 1994 by Ballinari *et al.*), 1-cyclopropyl-4-pyridyl-

DOCKET NO.: 411USPHRM311

PATENT

quinolones (U.S. Patent No. 5,330,992), styryl compounds (U.S. Patent No. 5,217,999), styryl-substituted pyridyl compounds (U.S. Patent No. 5,302,606), certain quinazoline derivatives (EP Application No. 0 566 266 A1), seleoindoles and selenides (PCT WO 94/03427, published February 17, 1994 by Denny *et al.*), tricyclic polyhydroxylic compounds (PCT WO 92/21660, published December 10, 1992 by Dow), and benzylphosphonic acid compounds (PCT WO 91/15495, published October 17, 1991 by Dow *et al.*), all of which are incorporated by reference herein, including any drawings.

Exemplary diseases and conditions amenable to treatment based on the present invention include, but are not limited to, thyroid disorders (*e.g.* thyreotoxicosis, myxoedema); renal failure; inflammatory conditions (*e.g.*, Chron's disease); diseases related to cell differentiation and homeostasis; rheumatoid arthritis; autoimmune disorders; movement disorders; CNS disorders (*e.g.*, pain including migraine; stroke; psychotic and neurological disorders, including anxiety, schizophrenia, manic depression, anxiety, generalized anxiety disorder, post-traumatic-stress disorder, depression, bipolar disorder, delirium, dementia, severe mental retardation; dyskinesias, such as Huntington's disease or Tourette's Syndrome; attention disorders including ADD and ADHD, and degenerative disorders such as Parkinson's, Alzheimer's; movement disorders, including ataxias, supranuclear palsy, *etc.*); infections, such as viral infections caused by HIV-1 or HIV-2; metabolic and cardiovascular diseases and disorders (*e.g.*, type 2 diabetes, obesity, anorexia, hypotension, hypertension, thrombosis, myocardial infarction, cardiomyopathies, atherosclerosis, *etc.*); proliferative diseases and cancers (*e.g.*, different cancers such as breast, colon, lung, *etc.*, and hyperproliferative disorders such as psoriasis, prostate hyperplasia, *etc.*); hormonal disorders (*e.g.*, male/female hormonal replacement, polycystic ovarian syndrome, alopecia, *etc.*); sexual dysfunction, among others.

Compounds that can traverse cell membranes and are resistant to acid hydrolysis are potentially advantageous as therapeutics as they can become highly bioavailable after being administered orally to patients. However, many of these protein inhibitors only weakly inhibit function. In addition, many inhibit a variety of protein kinases and will therefore cause multiple side effects as therapeutics for diseases.

DOCKET NO.: 411USPHRM311

PATENT

Some indolinone compounds, however, form classes of acid resistant and membrane permeable organic molecules. WO 96/22976 (published August 1, 1996 by Ballinari *et al.*) describes hydrosoluble indolinone compounds that harbor tetralin, naphthalene, quinoline, and indole substituents fused to the oxindole ring. These 5 bicyclic substituents are in turn substituted with polar groups including hydroxylated alkyl, phosphate, and ether substituents. U.S. Patent Application Serial Nos. 08/702,232, filed August 23, 1996, entitled "Indolinone Combinatorial Libraries and Related Products and Methods for the Treatment of Disease" by Tang *et al.* (Lyon & Lyon Docket No. 221/187) and 08/485,323, filed June 7, 1995, entitled "Benzylidene-10 Z-Indoline Compounds for the Treatment of Disease" by Tang *et al.* (Lyon & Lyon Docket No. 223/298) and International Patent Publication WO 96/22976, published August 1, 1996 by Ballinari *et al.*, all of which are incorporated herein by reference in their entirety, including any drawings, describe indolinone chemical libraries of 15 indolinone compounds harboring other bicyclic moieties as well as monocyclic moieties fused to the oxindole ring. Applications 08/702,232, filed August 23, 1996, entitled "Indolinone Combinatorial Libraries and Related Products and Methods for the Treatment of Disease" by Tang *et al.* (Lyon & Lyon Docket No. 221/187), 08/485,323, filed June 7, 1995, entitled "Benzylidene-Z-Indoline Compounds for the Treatment of Disease" by Tang *et al.* (Lyon & Lyon Docket No. 223/298), and WO 96/22976, 20 published August 1, 1996 by Ballinari *et al.* teach methods of indolinone synthesis, methods of testing the biological activity of indolinone compounds in cells, and inhibition patterns of indolinone derivatives, both of which are incorporated by reference herein, including any drawings.

Other examples of substances capable of modulating kinase activity include, but 25 are not limited to, tyrphostins, quinazolines, quinoxolines, and quinolines. The quinazolines, tyrphostins, quinolines, and quinoxolines referred to above include well-known compounds such as those described in the literature. For example, representative publications describing quinazolines include Barker *et al.*, EPO Publication No. 0 520 722 A1; Jones *et al.*, U.S. Patent No. 4,447,608; Kabbe *et al.*, 30 U.S. Patent No. 4,757,072; Kaul and Vougioukas, U.S. Patent No. 5, 316,553; Kreighbaum and Comer, U.S. Patent No. 4,343,940; Pegg and Wardleworth, EPO Publication No. 0 562 734 A1; Barker *et al.*, Proc. of Am. Assoc. for Cancer Research

DOCKET NO.: 411USPHRM311

PATENT

32:327 (1991); Bertino, J.R., Cancer Research 3:293-304 (1979); Bertino, J.R., Cancer Research 9(2 part 1):293-304 (1979); Curtin *et al.*, Br. J. Cancer 53:361-368 (1986); Fernandes *et al.*, Cancer Research 43:1117-1123 (1983); Ferris *et al.* J. Org. Chem. 44(2):173-178; Fry *et al.*, Science 265:1093-1095 (1994); Jackman *et al.*, Cancer Research 51:5579-5586 (1981); Jones *et al.* J. Med. Chem. 29(6):1114-1118; Lee and Skibo, Biochemistry 26(23):7355-7362 (1987); Lemus *et al.*, J. Org. Chem. 54:3511-3518 (1989); Ley and Seng, Synthesis 1975:415-522 (1975); Maxwell *et al.*, Magnetic Resonance in Medicine 17:189-196 (1991); Mini *et al.*, Cancer Research 45:325-330 (1985); Phillips and Castle, J. Heterocyclic Chem. 17(19):1489-1596 (1980); Reece *et al.*, Cancer Research 47(11):2996-2999 (1977); Sculier *et al.*, Cancer Immunol. and Immunother. 23:A65 (1986); Sikora *et al.*, Cancer Letters 23:289-295 (1984); and Sikora *et al.*, Analytical Biochem. 172:344-355 (1988), all of which are incorporated herein by reference in their entirety, including any drawings.

Quinoxaline is described in Kaul and Vougioukas, U.S. Patent No. 5,316,553, incorporated herein by reference in its entirety, including any drawings.

Quinolines are described in Dolle *et al.*, J. Med. Chem. 37:2627-2629 (1994); MaGuire, J. Med. Chem. 37:2129-2131 (1994); Burke *et al.*, J. Med. Chem. 36:425-432 (1993); and Burke *et al.* BioOrganic Med. Chem. Letters 2:1771-1774 (1992), all of which are incorporated by reference in their entirety, including any drawings.

Tyrphostins are described in Allen *et al.*, Clin. Exp. Immunol. 91:141-156 (1993); Anafi *et al.*, Blood 82:12:3524-3529 (1993); Baker *et al.*, J. Cell Sci. 102:543-555 (1992); Bilder *et al.*, Amer. Physiol. Soc. pp. 6363-6143:C721-C730 (1991); Brunton *et al.*, Proceedings of Amer. Assoc. Cancer Rsch. 33:558 (1992); Bryckaert *et al.*, Experimental Cell Research 199:255-261 (1992); Dong *et al.*, J. Leukocyte Biology 53:53-60 (1993); Dong *et al.*, J. Immunol. 151(5):2717-2724 (1993); Gazit *et al.*, J. Med. Chem. 32:2344-2352 (1989); Gazit *et al.*, J. Med. Chem. 36:3556-3564 (1993); Kaur *et al.*, Anti-Cancer Drugs 5:213-222 (1994); King *et al.*, Biochem. J. 275:413-418 (1991); Kuo *et al.*, Cancer Letters 74:197-202 (1993); Levitzki, A., The FASEB J. 6:3275-3282 (1992); Lyall *et al.*, J. Biol. Chem. 264:14503-14509 (1989); Peterson *et al.*, The Prostate 22:335-345 (1993); Pillemer *et al.*, Int. J. Cancer 50:80-85 (1992); Posner *et al.*, Molecular Pharmacology 45:673-683 (1993); Rendu *et al.*, Biol. Pharmacology 44(5):881-888 (1992); Sauro and Thomas, Life Sciences 53:371-376

DOCKET NO.: 411USPHRM311

PATENT

(1993); Sauro and Thomas, *J. Pharm. and Experimental Therapeutics* 267(3):119-1125 (1993); Wolbring *et al.*, *J. Biol. Chem.* 269(36):22470-22472 (1994); and Yoneda *et al.*, *Cancer Research* 51:4430-4435 (1991); all of which are incorporated herein by reference in their entirety, including any drawings.

5 Other compounds that could be used as modulators include oxindolinones such as those described in U.S. patent application Serial No. 08/702,232 filed August 23, 1996, incorporated herein by reference in its entirety, including any drawings.

Methods of determining the dosages of compounds to be administered to a patient and modes of administering compounds to an organism are disclosed in U.S. 10 Application Serial No. 08/702,282, filed August 23, 1996 and International patent publication number WO 96/22976, published August 1 1996, both of which are incorporated herein by reference in their entirety, including any drawings, figures or tables. Those skilled in the art will appreciate that such descriptions are applicable to the present invention and can be easily adapted to it.

15 The proper dosage depends on various factors such as the type of disease being treated, the particular composition being used and the size and physiological condition of the patient. Therapeutically effective doses for the compounds described herein can be estimated initially from cell culture and animal models. For example, a dose can be formulated in animal models to achieve a circulating concentration range that initially 20 takes into account the IC₅₀ as determined in cell culture assays. The animal model data can be used to more accurately determine useful doses in humans.

Plasma half-life and biodistribution of the drug and metabolites in the plasma, tumors and major organs can also be determined to facilitate the selection of drugs most appropriate to inhibit a disorder. Such measurements can be carried out. For example, 25 HPLC analysis can be performed on the plasma of animals treated with the drug and the location of radiolabeled compounds can be determined using detection methods such as X-ray, CAT scan and MRI. Compounds that show potent inhibitory activity in the screening assays, but have poor pharmacokinetic characteristics, can be optimized by altering the chemical structure and retesting. In this regard, compounds displaying 30 good pharmacokinetic characteristics can be used as a model.

Toxicity studies can also be carried out by measuring the blood cell composition. For example, toxicity studies can be carried out in a suitable animal

DOCKET NO.: 411USPHRM311

PATENT

model as follows: 1) the compound is administered to mice (an untreated control mouse should also be used); 2) blood samples are periodically obtained via the tail vein from one mouse in each treatment group; and 3) the samples are analyzed for red and white blood cell counts, blood cell composition and the percent of lymphocytes versus polymorphonuclear cells. A comparison of results for each dosing regime with the controls indicates if toxicity is present.

At the termination of each toxicity study, further studies can be carried out by sacrificing the animals (preferably, in accordance with the American Veterinary Medical Association guidelines Report of the American Veterinary Medical Assoc.

10 Panel on Euthanasia, Journal of American Veterinary Medical Assoc., 202:229-249, 1993). Representative animals from each treatment group can then be examined by gross necropsy for immediate evidence of metastasis, unusual illness or toxicity. Gross abnormalities in tissue are noted and tissues are examined histologically. Compounds causing a reduction in body weight or blood components are less preferred, as are 15 compounds having an adverse effect on major organs. In general, the greater the adverse effect the less preferred the compound.

For the treatment of cancers the expected daily dose of a hydrophobic pharmaceutical agent is between 1 to 500 mg/day, preferably 1 to 250 mg/day, and most preferably 1 to 50 mg/day. Drugs can be delivered less frequently provided 20 plasma levels of the active moiety are sufficient to maintain therapeutic effectiveness. Plasma levels should reflect the potency of the drug. Generally, the more potent the compound the lower the plasma levels necessary to achieve efficacy.

nGPCR-x mRNA transcripts may be found in many tissues, including, but not limited to, brain, peripheral blood lymphocytes, pancreas, ovary, uterus, testis, salivary 25 gland, kidney, adrenal gland, liver, bone marrow, prostate, fetal liver, colon, muscle, and fetal brain, and may be found in many other tissues. Within the brain, nGPCR-x mRNA transcripts may be found in many tissues, including, but not limited to, frontal lobe, hypothalamus, pons, cerebellum, caudate nucleus, and medulla. Tissues and brain regions where specific nGPCR mRNA transcripts are expressed are identified in the 30 Examples, below.

Odd numbered nucleotide sequences ranging from SEQ ID NO: 1 to SEQ ID NO: 93, SEQ ID NO: 185 and SEQ ID NO:191 will, as detailed above, enable

DOCKET NO.: 411USPHRM311

PATENT

screening the endogenous neurotransmitters/hormones/ligands which activate, agonize, or antagonize nGPCR-x and for compounds with potential utility in treating disorders including, but not limited to, thyroid disorders (*e.g.* thyreotoxicosis, myxoedema); renal failure; inflammatory conditions (*e.g.*, Chron's disease); diseases related to cell differentiation and homeostasis; rheumatoid arthritis; autoimmune disorders; movement disorders; CNS disorders (*e.g.*, pain including migraine; stroke; psychotic and neurological disorders, including anxiety, schizophrenia, manic depression, anxiety, generalized anxiety disorder, post-traumatic-stress disorder, depression, bipolar disorder, delirium, dementia, severe mental retardation; dyskinesias, such as

5 Huntington's disease or Tourette's Syndrome; attention disorders including ADD and ADHD, and degenerative disorders such as Parkinson's, Alzheimer's; movement disorders, including ataxias, supranuclear palsy, *etc.*); infections, such as viral infections caused by HIV-1 or HIV-2; metabolic and cardiovascular diseases and disorders (*e.g.*, type 2 diabetes, obesity, anorexia, hypotension, hypertension,

10 thrombosis, myocardial infarction, cardiomyopathies, atherosclerosis, *etc.*); proliferative diseases and cancers (*e.g.*, different cancers such as breast, colon, lung, *etc.*, and hyperproliferative disorders such as psoriasis, prostate hyperplasia, *etc.*); hormonal disorders (*e.g.*, male/female hormonal replacement, polycystic ovarian syndrome, alopecia, *etc.*); sexual dysfunction, among others.

15

20 For example, nGPCR-x may be useful in the treatment of respiratory ailments such as asthma, where T cells are implicated by the disease. Contraction of airway smooth muscle is stimulated by thrombin. Cicala *et al* (1999) Br J Pharmacol 126:478-484. Additionally, in bronchiolitis obliterans, it has been noted that activation of thrombin receptors may be deleterious. Hauck *et al.* (1999) Am J Physiol 277:L22-L29. Furthermore, mast cells have also been shown to have thrombin receptors. Cirino *et al* (1996) J Exp Med 183:821-827. nGPCR-x may also be useful in remodeling of airway structure s in chronic pulmonary inflammation via stimulation of fibroblast procollagen synthesis. See, *e.g.*, Chambers *et al.* (1998) Biochem J 333:121-127; Trejo *et al.* (1996) J Biol Chem 271:21536-21541.

25

30 In another example, increased release of sCD40L and expression of CD40L by T cells after activation of thrombin receptors suggests that nGPCR-x may be useful in

DOCKET NO.: 411USPHRM311

PATENT

the treatment of unstable angina due to the role of T cells and inflammation. See Aukrust *et al.* (1999) *Circulation* 100:614-620.

A further example is the treatment of inflammatory diseases, such as psoriasis, inflammatory bowel disease, multiple sclerosis, rheumatoid arthritis, and thyroiditis.

5 Due to the tissue expression profile of nGPCR-x, inhibition of thrombin receptors may be beneficial for these diseases. See, *e.g.*, Morris *et al.* (1996) *Ann Rheum Dis* 55:841-843. In addition to T cells, NK cells and monocytes are also critical cell types which contribute to the pathogenesis of these diseases. See, *e.g.*, Naldini & Carney (1996) *Cell Immunol* 172:35-42; Hoffman & Cooper (1995) *Blood Cells Mol Dis* 21:156-167; 10 Colotta *et al.* (1994) *Am J Pathol* 144:975-985.

Expression of nGPCR-x in bone marrow and spleen may suggest that it may play a role in the proliferation of hematopoietic progenitor cells. See DiCuccio *et al.* (1996) *Exp Hematol* 24:914-918.

As another example, nGPCR-x may be useful in the treatment of acute and/or 15 traumatic brain injury. Astrocytes have been demonstrated to express thrombin receptors. Activation of thrombin receptors may be involved in astrogliosis following brain injury. Therefore, inhibition of receptor activity may be beneficial for limiting neuroinflammation. Scar formation mediated by astrocytes may also be limited by inhibiting thrombin receptors. See, *e.g.*, Pindon *et al.* (1998) *Eur J Biochem* 255:766-20 774; Ubl & Reiser. (1997) *Glia* 21:361-369; Grabham & Cunningham (1995) *J Neurochem* 64:583-591.

nGPCR-x receptor activation may mediate neuronal and astrocyte apoptosis and prevention of neurite outgrowth. Inhibition would be beneficial in both chronic and acute brain injury. See, *e.g.*, Donovan *et al.* (1997) *J Neurosci* 17:5316-5326; Turgeon 25 *et al* (1998) *J Neurosci* 18:6882-6891; Smith-Swintosky *et al.* (1997) *J Neurochem* 69:1890-1896; Gill *et al.* (1998) *Brain Res* 797:321-327; Suidan *et al.* (1996) *Semin Thromb Hemost* 22:125-133.

The attached Sequence Listing contains the sequences of the polynucleotides and polypeptides of the invention and is incorporated herein by reference in its entirety.

30 As described above and in Example 4 below, the genes encoding nGPCR-1 (nucleic acid sequence SEQ ID NO: 1, SEQ ID NO: 73, amino acid sequence SEQ ID NO: 2, SEQ ID NO:74), nGPCR-9 (nucleic acid sequence SEQ ID NO:9, SEQ ID

DOCKET NO.: 411USPHRM311

PATENT

NO:77, amino acid sequence SEQ ID NO:10, SEQ ID NO:78), nGPCR-11 (nucleic acid sequence SEQ ID NO:11, SEQ ID NO:79, amino acid sequence SEQ ID NO:12, SEQ ID NO:80), nGPCR-16 (nucleic acid sequence SEQ ID NO: 21, SEQ ID NO:81, amino acid sequence SEQ ID NO: 22, SEQ ID NO:82), nGPCR-40 (nucleic acid sequence SEQ ID NO:53, SEQ ID NO:83, amino acid sequence SEQ ID NO:54, SEQ ID NO:84), nGPCR-54 (nucleic acid sequence SEQ ID NO:59, SEQ ID NO:85, amino acid sequence SEQ ID NO:60, SEQ ID NO: 86), nGPCR-56 (nucleic acid sequence SEQ ID NO:63, SEQ ID NO:87, SEQ ID NO:89, amino acid sequence SEQ ID NO:64, SEQ ID NO: 88, SEQ ID NO:90), nGPCR-58 (nucleic acid sequence SEQ ID NO:3, SEQ ID NO:185, amino acid sequence SEQ ID NO:4, SEQ ID NO: 186) have been detected in brain tissue indicating that these n-GPCR-x proteins are neuroreceptors. The identification of modulators such as agonists and antagonists is therefore useful for the identification of compounds useful to treat neurological diseases and disorders. Such neurological diseases and disorders, including but are not limited to, schizophrenia, affective disorders, ADHD/ADD (*i.e.*, Attention Deficit-Hyperactivity Disorder/Attention Deficit Disorder), and neural disorders such as Alzheimer's disease, Parkinson's disease, migraine, and senile dementia as well as depression, anxiety, bipolar disease, epilepsy, neuritis, neurasthenia, neuropathy, neuroses, and the like.

Methods of Screening Human Subjects

20 Thus in yet another embodiment, the invention provides genetic screening procedures that entail analyzing a person's genome -- in particular their alleles for GPCRs of the invention -- to determine whether the individual possesses a genetic characteristic found in other individuals that are considered to be afflicted with, or at risk for, developing a mental disorder or disease of the brain that is suspected of having 25 a hereditary component. For example, in one embodiment, the invention provides a method for determining a potential for developing a disorder affecting the brain in a human subject comprising the steps of analyzing the coding sequence of one or more GPCR genes from the human subject; and determining development potential for the disorder in said human subject from the analyzing step.

30 More particularly, the invention provides a method of screening a human subject to diagnose a disorder affecting the brain or genetic predisposition therefor, comprising the steps of: (a) assaying nucleic acid of a human subject to determine a

DOCKET NO.: 411USPHRM311

PATENT

presence or an absence of a mutation altering the amino acid sequence, expression, or biological activity of at least one seven transmembrane receptor that is expressed in the brain, wherein the seven transmembrane receptor comprises an amino acid sequence selected from the group consisting of SEQ ID NOS: 74, 186, 78, 80, 82, 84, 86, 90, and 94, or an allelic variant thereof, and wherein the nucleic acid corresponds to the gene encoding the seven transmembrane receptor; and (b) diagnosing the disorder or predisposition from the presence or absence of said mutation, wherein the presence of a mutation altering the amino acid sequence, expression, or biological activity of allele in the nucleic acid correlates with an increased risk of developing the disorder. In 10 preferred variations, the seven transmembrane receptor is nGPCR-40 or nGPCR-54 comprising amino acid sequences set forth in SEQ ID NO: 84 for nGPCR-40 and SEQ ID NO: 86 for nGPCR-54, or an allelic variant thereof, and the disease is schizophrenia.

By "human subject" is meant any human being, human embryo, or human fetus. 15 It will be apparent that methods of the present invention will be of particular interest to individuals that have themselves been diagnosed with a disorder affecting the brain or have relatives that have been diagnosed with a disorder affecting the brain.

By "screening for an increased risk" is meant determination of whether a 20 genetic variation exists in the human subject that correlates with a greater likelihood of developing a disorder affecting the brain than exists for the human population as a whole, or for a relevant racial or ethnic human sub-population to which the individual belongs. Both positive and negative determinations (i.e., determinations that a genetic predisposition marker is present or is absent) are intended to fall within the scope of screening methods of the invention. In preferred embodiments, the presence of a 25 mutation altering the sequence or expression of at least one nGPCR-40 or nGPCR-54 seven transmembrane receptor allele in the nucleic acid is correlated with an increased risk of developing schizophrenia, whereas the absence of such a mutation is reported as a negative determination.

The "assaying" step of the invention may involve any techniques available for 30 analyzing nucleic acid to determine its characteristics, including but not limited to well-known techniques such as single-strand conformation polymorphism analysis (SSCP) [Orita *et al.*, *Proc Natl. Acad. Sci. USA*, 86: 2766-2770 (1989)]; heteroduplex analysis

DOCKET NO.: 411USPHRM311

PATENT

[White *et al.*, *Genomics*, 12: 301-306 (1992)]; denaturing gradient gel electrophoresis analysis [Fischer *et al.*, *Proc. Natl. Acad. Sci. USA*, 80: 1579-1583 (1983); and Riesner *et al.*, *Electrophoresis*, 10: 377-389 (1989)]; DNA sequencing; RNase cleavage [Myers *et al.*, *Science*, 230: 1242-1246 (1985)]; chemical cleavage of mismatch techniques 5 [Rowley *et al.*, *Genomics*, 30: 574-582 (1995); and Roberts *et al.*, *Nucl. Acids Res.*, 25: 3377-3378 (1997)]; restriction fragment length polymorphism analysis; single nucleotide primer extension analysis [Shumaker *et al.*, *Hum. Mutat.*, 7: 346-354 (1996); and Pastinen *et al.*, *Genome Res.*, 7: 606-614 (1997)]; 5' nuclease assays [Pease *et al.*, *Proc. Natl. Acad. Sci. USA*, 91:5022-5026 (1994)]; DNA Microchip analysis [Ramsay, 10 G., *Nature Biotechnology*, 16: 40-48 (1999); and Chee *et al.*, U.S. Patent No. 5,837,832]; and ligase chain reaction [Whiteley *et al.*, U.S. Patent No. 5,521,065]. [See generally, Schafer and Hawkins, *Nature Biotechnology*, 16: 33-39 (1998).] All of the foregoing documents are hereby incorporated by reference in their entirety.

Thus, in one preferred embodiment involving screening nGPCR-40 or nGPCR-15 54 sequences, for example, the assaying step comprises at least one procedure selected from the group consisting of: (a) determining a nucleotide sequence of at least one codon of at least one nGPCR-40 or nGPCR-54 allele of the human subject; (b) performing a hybridization assay to determine whether nucleic acid from the human subject has a nucleotide sequence identical to or different from one or more reference sequences; (c) performing a polynucleotide migration assay to determine whether nucleic acid from the human subject has a nucleotide sequence identical to or different from one or more reference sequences; and (d) performing a restriction endonuclease digestion to determine whether nucleic acid from the human subject has a nucleotide sequence identical to or different from one or more reference sequences. 20

25 In a highly preferred embodiment, the assaying involves sequencing of nucleic acid to determine nucleotide sequence thereof, using any available sequencing technique. [See, *e.g.*, Sanger *et al.*, *Proc. Natl. Acad. Sci. (USA)*, 74: 5463-5467 (1977) (dideoxy chain termination method); Mirzabekov, *TIBTECH*, 12: 27-32 (1994) (sequencing by hybridization); Drmanac *et al.*, *Nature Biotechnology*, 16: 54-58 (1998); U.S. Patent No. 5,202,231; and *Science*, 260: 1649-1652 (1993) (sequencing by hybridization); Kieleczawa *et al.*, *Science*, 258: 1787-1791 (1992) (sequencing by primer walking); (Douglas *et al.*, *Biotechniques*, 14: 824-828 (1993) (Direct sequencing

DOCKET NO.: 411USPHRM311

PATENT

of PCR products); and Akane *et al.*, *Biotechniques* 16: 238-241 (1994); Maxam and Gilbert, *Meth. Enzymol.*, 65: 499-560 (1977) (chemical termination sequencing), all incorporated herein by reference.] The analysis may entail sequencing of the entire nGPCR gene genomic DNA sequence, or portions thereof; or sequencing of the entire 5 seven transmembrane receptor coding sequence or portions thereof. In some circumstances, the analysis may involve a determination of whether an individual possesses a particular allelic variant, in which case sequencing of only a small portion of nucleic acid -- enough to determine the sequence of a particular codon characterizing the allelic variant -- is sufficient. This approach is appropriate, for example, when 10 assaying to determine whether one family member inherited the same allelic variant that has been previously characterized for another family member, or, more generally, whether a person's genome contains an allelic variant that has been previously characterized and correlated with a mental disorder having a heritable component.

In another highly preferred embodiment, the assaying step comprises 15 performing a hybridization assay to determine whether nucleic acid from the human subject has a nucleotide sequence identical to or different from one or more reference sequences. In a preferred embodiment, the hybridization involves a determination of whether nucleic acid derived from the human subject will hybridize with one or more oligonucleotides, wherein the oligonucleotides have nucleotide sequences that 20 correspond identically to a portion of the GPCR gene sequence taught herein, such as the nGPCR-40 or nGPCR-54 coding sequence set forth in SEQ ID NOS: 83 for nGPCR-40 or 85 for nGPCR-54, or that correspond identically except for one mismatch. The hybridization conditions are selected to differentiate between perfect sequence complementarity and imperfect matches differing by one or more bases. 25 Such hybridization experiments thereby can provide single nucleotide polymorphism sequence information about the nucleic acid from the human subject, by virtue of knowing the sequences of the oligonucleotides used in the experiments.

Several of the techniques outlined above involve an analysis wherein one 30 performs a polynucleotide migration assay, *e.g.*, on a polyacrylamide electrophoresis gel (or in a capillary electrophoresis system), under denaturing or non-denaturing conditions. Nucleic acid derived from the human subject is subjected to gel electrophoresis, usually adjacent to (or co-loaded with) one or more reference nucleic

DOCKET NO.: 411USPHRM311

PATENT

acids, such as reference GPCR-encoding sequences having a coding sequence identical to all or a portion of SEQ ID NOS: 83 or 85 (or identical except for one known polymorphism). The nucleic acid from the human subject and the reference sequence(s) are subjected to similar chemical or enzymatic treatments and then 5 electrophoresed under conditions whereby the polynucleotides will show a differential migration pattern, unless they contain identical sequences. [See generally Ausubel *et al.* (eds.), *Current Protocols in Molecular Biology*, New York: John Wiley & Sons, Inc. (1987-1999); and Sambrook *et al.*, (eds.), *Molecular Cloning, A Laboratory Manual*, Cold Spring Harbor, New York: Cold Spring Harbor Laboratory Press (1989), 10 both incorporated herein by reference in their entirety.]

In the context of assaying, the term “nucleic acid of a human subject” is intended to include nucleic acid obtained directly from the human subject (e.g., DNA or RNA obtained from a biological sample such as a blood, tissue, or other cell or fluid sample); and also nucleic acid derived from nucleic acid obtained directly from the 15 human subject. By way of non-limiting examples, well known procedures exist for creating cDNA that is complementary to RNA derived from a biological sample from a human subject, and for amplifying (e.g., via polymerase chain reaction (PCR)) DNA or RNA derived from a biological sample obtained from a human subject. Any such derived polynucleotide which retains relevant nucleotide sequence information of the 20 human subject’s own DNA/RNA is intended to fall within the definition of “nucleic acid of a human subject” for the purposes of the present invention.

In the context of assaying, the term “mutation” includes addition, deletion, and/or substitution of one or more nucleotides in the GPCR gene sequence (e.g., as compared to the seven transmembrane receptor-encoding sequences set forth of SEQ 25 ID NOS: 74, 186, 78, 80, 82, 84, 86, 90, and 94) and other polymorphisms that occur in introns (where introns exist) and that are identifiable via sequencing, restriction fragment length polymorphism, or other techniques. The various activity examples provided herein permit determination of whether a mutation modulates activity of the relevant receptor in the presence or absence of various test substances.

30 In a related embodiment, the invention provides methods of screening a person’s genotype with respect to GPCR’s of the invention, and correlating such genotypes with diagnoses for disease or with predisposition for disease (for genetic

DOCKET NO.: 411USPHRM311

PATENT

counseling). For example, the invention provides a method of screening for an nGPCR-40 or nGPCR-54 hereditary schizophrenia genotype in a human patient, comprising the steps of: (a) providing a biological sample comprising nucleic acid from the patient, the nucleic acid including sequences corresponding to said patient's nGPCR-40 or nGPCR-54 alleles; (b) analyzing the nucleic acid for the presence of a mutation or mutations; (c) determining an nGPCR-40 or nGPCR-54 genotype from the analyzing step; and (d) correlating the presence of a mutation in an nGPCR-40 or nGPCR-54 allele with a hereditary schizophrenia genotype. In a preferred embodiment, the biological sample is a cell sample containing human cells that contain genomic DNA of the human subject. The analyzing can be performed analogously to the assaying described in preceding paragraphs. For example, the analyzing comprises sequencing a portion of the nucleic acid (e.g., DNA or RNA), the portion comprising at least one codon of the nGPCR-40 or nGPCR-54 alleles.

Although more time consuming and expensive than methods involving nucleic acid analysis, the invention also may be practiced by assaying protein of a human subject to determine the presence or absence of an amino acid sequence variation in GPCR protein from the human subject. Such protein analyses may be performed, *e.g.*, by fragmenting GPCR protein via chemical or enzymatic methods and sequencing the resultant peptides; or by Western analyses using an antibody having specificity for a particular allelic variant of the GPCR.

The invention also provides materials that are useful for performing methods of the invention. For example, the present invention provides oligonucleotides useful as probes in the many analyzing techniques described above. In general, such oligonucleotide probes comprise 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 25 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 nucleotides that have a sequence that is identical, or exactly complementary, to a portion of a human GPCR gene sequence taught herein (or allelic variant thereof), or that is identical or exactly complementary except for one nucleotide substitution. In a preferred embodiment, the oligonucleotides have a sequence that corresponds in the foregoing manner to a human GPCR coding sequence taught herein, and in particular, the coding sequences set forth in SEQ ID NO: 83 and 85. In one variation, an oligonucleotide probe of the invention is purified and isolated. In another

DOCKET NO.: 411USPHRM311

PATENT

variation, the oligonucleotide probe is labeled, *e.g.*, with a radioisotope, chromophore, or fluorophore. In yet another variation, the probe is covalently attached to a solid support. [See generally Ausubel *et al.* And Sambrook *et al.*, *supra*.]

In a related embodiment, the invention provides kits comprising reagents that 5 are useful for practicing methods of the invention. For example, the invention provides a kit for screening a human subject to diagnose schizophrenia or a genetic predisposition therefor, comprising, in association: (a) an oligonucleotide useful as a probe for identifying polymorphisms in a human nGPCR-40 or nGPCR-54 seven transmembrane receptor gene, the oligonucleotide comprising 6-50 nucleotides that 10 have a sequence that is identical or exactly complementary to a portion of a human nGPCR-40 or nGPCR-54 gene sequence or nGPCR-40 or nGPCR-54 coding sequence, except for one sequence difference selected from the group consisting of a nucleotide addition, a nucleotide deletion, or nucleotide substitution; and (b) a media packaged 15 with the oligonucleotide containing information identifying polymorphisms identifiable with the probe that correlate with schizophrenia or a genetic predisposition therefor. Exemplary information-containing media include printed paper package inserts or packaging labels; and magnetic and optical storage media that are readable by computers or machines used by practitioners who perform genetic screening and counseling services. The practitioner uses the information provided in the media to 20 correlate the results of the analysis with the oligonucleotide with a diagnosis. In a preferred variation, the oligonucleotide is labeled.

In still another embodiment, the invention provides methods of identifying those allelic variants of GPCRs of the invention that correlate with mental disorders. For example, the invention provides a method of identifying a seven transmembrane 25 allelic variant that correlates with a mental disorder, comprising steps of: (a) providing a biological sample comprising nucleic acid from a human patient diagnosed with a mental disorder, or from the patient's genetic progenitors or progeny; (b) analyzing the nucleic acid for the presence of a mutation or mutations in at least one seven transmembrane receptor that is expressed in the brain, wherein the at least one seven 30 transmembrane receptor comprises an amino acid sequence selected from the group consisting of SEQ ID NOS: 74, 186, 78, 80, 82, 84, 86, 90, and 94 or an allelic variant thereof, and wherein the nucleic acid includes sequence corresponding to the gene or

DOCKET NO.: 411USPHRM311

PATENT

genes encoding the at least one seven transmembrane receptor; (c) determining a genotype for the patient for the at least one seven transmembrane receptor from said analyzing step; and (d) identifying an allelic variant that correlates with the mental disorder from the determining step. To expedite this process, it may be desirable to 5 perform linkage studies in the patients (and possibly their families) to correlate chromosomal markers with disease states. The chromosomal localization data provided herein facilitates identifying an involved GPCR with a chromosomal marker.

The foregoing method can be performed to correlate GPCR's of the invention to a number of disorders having hereditary components that are causative or that 10 predispose persons to the disorder. For example, in one preferred variation, the disorder is schizophrenia, and the at least one seven transmembrane receptor comprises nGPCR-40 having an amino acid sequence set forth in SEQ ID NO: 84 or an allelic variant thereof.

Also contemplated as part of the invention are polynucleotides that comprise the 15 allelic variant sequences identified by such methods, and polypeptides encoded by the allelic variant sequences, and oligonucleotide and oligopeptide fragments thereof that embody the mutations that have been identified. Such materials are useful in *in vitro* cell-free and cell-based assays for identifying lead compounds and therapeutics for treatment of the disorders. For example, the variants are used in activity assays, 20 binding assays, and assays to screen for activity modulators described herein. In one preferred embodiment, the invention provides a purified and isolated polynucleotide comprising a nucleotide sequence encoding a nGPCR-40 or nGPCR-54 receptor allelic variant identified according to the methods described above; and an oligonucleotide that comprises the sequences that differentiate the allelic variant from the nGPCR-40 or 25 nGPCR-54 sequences set forth in SEQ ID NOS: 83 and 88. The invention also provides a vector comprising the polynucleotide (preferably an expression vector); and a host cell transformed or transfected with the polynucleotide or vector. The invention also provides an isolated cell line that is expressing the allelic variant GPCR polypeptide; purified cell membranes from such cells; purified polypeptide; and 30 synthetic peptides that embody the allelic variation amino acid sequence. In one particular embodiment, the invention provides a purified polynucleotide comprising a nucleotide sequence encoding a nGPCR-40 seven transmembrane receptor protein of a

PATENT

human that is affected with schizophrenia; wherein said polynucleotide hybridizes to the complement of SEQ ID NO: 83 under the following hybridization conditions: (a) hybridization for 16 hours at 42°C in a hybridization solution comprising 50% formamide, 1% SDS, 1 M NaCl, 10% dextran sulfate and (b) washing 2 times for 30 minutes at 60°C in a wash solution comprising 0.1x SSC and 1% SDS; and wherein the polynucleotide encodes a nGPCR-40 amino acid sequence that differs from SEQ ID NO: 84 by at least one residue.

An exemplary assay for using the allelic variants is a method for identifying a modulator of nGPCR-x biological activity, comprising the steps of: (a) contacting a cell expressing the allelic variant in the presence and in the absence of a putative modulator compound; (b) measuring nGPCR-x biological activity in the cell; and (c) identifying a putative modulator compound in view of decreased or increased nGPCR-x biological activity in the presence versus absence of the putative modulator.

Additional features of the invention will be apparent from the following Examples. Examples 1, 2, 4, 11, 12, and 13 are actual, while the remaining Examples are prophetic. Additional features and variations of the invention will be apparent to those skilled in the art from the entirety of this application, including the detailed description, and all such features are intended as aspects of the invention. Likewise, features of the invention described herein can be re-combined into additional embodiments that also are intended as aspects of the invention, irrespective of whether the combination of features is specifically mentioned above as an aspect or embodiment of the invention. Also, only such limitations which are described herein as critical to the invention should be viewed as such; variations of the invention lacking limitations which have not been described herein as critical are intended as aspects of the invention.

DOCKET NO.: 411USPHRM311

PATENT

EXAMPLES**EXAMPLE 1: IDENTIFICATION OF nGPCR-X**

A. Database search

The Celera database was searched using known GPCR receptors as query sequences to find patterns suggestive of novel G protein-coupled receptors. Positive hits were further analyzed with the GCG program BLAST to determine which ones were the most likely candidates to encode G protein-coupled receptors, using the standard (default) alignment produced by BLAST as a guide.

Briefly, the BLAST algorithm, which stands for Basic Local Alignment Search Tool is suitable for determining sequence similarity (Altschul *et al.*, *J. Molec. Biol.*, 1990, 215, 403-410, which is incorporated herein by reference in its entirety). Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information (<http://www.ncbi.nlm.nih.gov/>). This algorithm involves first identifying high scoring sequence pair (HSPs) by identifying short words of length W in the query sequence that either match or satisfy some positive-valued threshold score T when aligned with a word of the same length in a database sequence. T is referred to as the neighborhood word score threshold (Altschul *et al.*, *supra*). These initial neighborhood word hits act as seeds for initiating searches to find HSPs containing them. The word hits are extended in both directions along each sequence for as far as the cumulative alignment score can be increased. Extension for the word hits in each direction are halted when: 1) the cumulative alignment score falls off by the quantity X from its maximum achieved value; 2) the cumulative score goes to zero or below, due to the accumulation of one or more negative-scoring residue alignments; or 3) the end of either sequence is reached. The Blast algorithm parameters W , T and X determine the sensitivity and speed of the alignment. The Blast program uses as defaults a word length (W) of 11, the BLOSUM62 scoring matrix (see Henikoff *et al.*, *Proc. Natl. Acad. Sci. USA*, 1992, 89, 10915-10919, which is incorporated herein by reference in its entirety) alignments (B) of 50, expectation (E) of 10, $M=5$, $N=4$, and a comparison of both strands.

The BLAST algorithm (Karlin *et al.*, *Proc. Natl. Acad. Sci. USA*, 1993, 90, 5873-5787, which is incorporated herein by reference in its entirety) and Gapped BLAST perform a statistical analysis of the similarity between two sequences. One

measure of similarity provided by the BLAST algorithm is the smallest sum probability (P(N)), which provides an indication of the probability by which a match between two nucleotide or amino acid sequences would occur by chance. For example, a nucleic acid is considered similar to a GPCR gene or cDNA if the smallest sum probability in 5 comparison of the test nucleic acid to a GPCR nucleic acid is less than about 1, preferably less than about 0.1, more preferably less than about 0.01, and most preferably less than about 0.001.

Homology searches were performed with the program BLAST version 2.08. A collection of 340 query amino acid sequences derived from GPCR's was used to search 10 the genomic DNA sequence using TBLASTN and alignments with an E-value lower than 0.01 were collected from each BLAST search. The amino acid sequences have been edited to remove regions in the sequence that produce non-significant alignments with proteins that are not related to GPCR's.

Multiple query sequences may have a significant alignment to the same 15 genomic region, although each alignment may not cover exactly the same DNA region. A procedure is used to determine the region of maximum common overlap between the alignments from several query sequences. This region is called the consensus DNA region. The procedure for determining this consensus involves the automatic parsing of the BLAST output files using the program MSPcrunch to produce a tabular report. 20 From this tabular report the start and end of each alignment in the genomic DNA is extracted. This information was used by a PERL script to derive the maximum common overlap. These regions were reported in the form of a unique sequence identifier, a start and the end position in the sequence. The sequences defined by these regions were extracted from the original genomic sequence file using the program 25 fetchdb.

The consensus regions were assembled into a non-redundant set by using the program phrap. After assembly with phrap a set of contigs and singletons was defined as candidate DNA regions coding for nGPCR-x. These sequences were then submitted for further sequence analysis.

30 Further sequence analysis involved the removal of sequences previously isolated and removal of sequences related to olfactory GPCRs. The transmembrane regions for the sequences that remained were determined using a FORTRAN computer

DOCKET NO.: 411USPHRM311

PATENT

program called "tmrest.all" [Parodi *et al.*, *Comput.Appl.Biosci.* 5:527-535(1994)].

Only sequences that contained transmembrane regions in a pattern found in GPCRs were retained.

cDNAs were sequenced directly using an ABI377 fluorescence-based sequencer (Perkin-Elmer/Applied Biosystems Division, PE/ABD, Foster City, CA) and the ABI PRISM™ Ready Dye-Deoxy Terminator kit with Taq FS™ polymerase. Each ABI cycle sequencing reaction contained about 0.5 µg of plasmid DNA. Cycle-sequencing was performed using an initial denaturation at 98°C for 1 minute, followed by 50 cycles using the following parameters: 98°C for 30 seconds, annealing at 50°C for 30 seconds, 10 and extension at 60°C for 4 minutes. Temperature cycles and times were controlled by a Perkin-Elmer 9600 thermocycler. Extension products were purified using Centriflex™ gel filtration cartridges (Advanced Genetic Technologies Corp., Gaithersburg, MD). Each reaction product was loaded by pipette onto the column, which is then centrifuged in a swinging bucket centrifuge (Sorvall model RT6000B tabletop centrifuge) at 1500 x g for 4 minutes at room temperature. Column-purified samples were dried under vacuum for about 40 minutes and then dissolved in 5 µl of a DNA loading solution (83% deionized formamide, 8.3 mM EDTA, and 1.6 mg/ml Blue Dextran). The samples were then heated to 90°C for three minutes and loaded into the gel sample wells for sequence analysis using the ABI377 sequencer. Sequence analysis 20 was performed by importing ABI377 files into the Sequencer program (Gene Codes, Ann Arbor, MI). Generally, sequence reads of 700 bp were obtained. Potential sequencing errors were minimized by obtaining sequence information from both DNA strands and by re-sequencing difficult areas using primers annealing at different locations until all sequencing ambiguities were removed.

25 The following Table 5 contains the sequences of the polynucleotides and polypeptides of the invention. Start and stop codons within the polynucleotide sequence are identified by boldface type. The transmembrane domains within the polypeptide sequence are identified by underlining.

PATENT

Table 5

The following DNA sequence beGPCR-**seq1** <SEQ ID NO. 1> was identified in *H. sapiens*:

GTCTGGGGTGGGGATGCTGGACAGGGTCAATTGCTGAAGCAAGTGCTCTCATCCCCCTAGCTCTGC
TGATCTAGTTGGGCTCCAGAGTGGGAGGAGAAAGGCACTTGAACACTTCTCTGCCCTTACCGTCTTAGCC
ATCAAACCTCTGAGCTGGAGAGATGTGACGATGTGACAGGAACCTTCCCTGGGCCTCTGGGCCACAATTCT
GGCGAGAGAAAGAGGAGGAATGAGGTGAGCACCTCTCACTCTAGGGCCATGTGGTAGAGCTGAGTC
CACCTCCTCTGCCATAGGCATAGATGAGTGGGTTGAGCAGGGAGTTGCCACGCCAGCAGCCACAGGA
CCGTCAGCACTAGGTAGAGGTGACACTCTGGCAGGCCACCTGCACAATGCCAGTGATAAGGAAGGGGTT
CCAGGATAGAGCAAAGCTCCAATGAGAACAGACACAGTACGGAGAGCTTGAAGTCGCTGGAGTCCGTGG
GGATCGATAACCTCCAGCCATGGCTCCTGCATGTTCCATCTTCGAATCTGCTGGCTGTGCATGGAGGCAAT
TTGAGCATGTCGAGTAGAAGAACAAAGAGGAGCATGGCTGGGAAGAACCCAACGCAGGAGAGGGTCAGC
ACGAAGTGGGGTGAATACAGCAAAGAACGCTGCACTGCCCTTGTAGGCAGTCGCTGGAACATGGGATT
CCGACTGGAGGAAGCCAATGAGGTAAAGACACTAACCAACAGCCGGCAATGCAGGCCCGGCCACGAACCCA
CTCATGATCTCAAGTAGCGGAAGGGCTGCTGATGGCAAGGTACCTGTCAAAGGTGATCAGCATGCCGTG
AGGACAGAGGCAGCTGCGGAGGAAGTGACAATGCCATCCGAGGCCTGCACAGGGCTTCTGTGTGGCCGA
GAAGGGCTGGAGAGCTGGCTGTGAGTAGGCCAGAGATGCCACACCAATCAAGGTGTCAGCCACAGCCAGA
TTCAAGGTGAAGCAGAGACTGACACCATCATCTGTGGATCAACAGCAGCACAGCCACAGCCACTAGTGTG
TTAGTAGCAATGATGAGGGAGGCCAGGACAGGAAGGATCACTCCAAATGAGAAAGATGATTCCATGTCTGA
AGTGGCAGGACTTACCTTACCAAGGCATG

The following amino acid sequence <SEQ ID NO. 2> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 1:

MESSFSFGVILAVLASLIIATNTLVAVAVLLIHKNDGVSLCFTLNLAVADTLIGVAISGLLTDQLSSPSRPT
QKTLCSLRMAFVTSSAAASVLTVMILITFDRYLAIKQPFRYLKIMSGFVAGACIAGLWLVSYLVIGFLPLGIPMF
QQTAYKGQCSFFAVFPHFVLTLSVGFFPAMLLFVFFYCDMLKIASMHSQQIRKMEHAGAMAGGYRSRTPS
DFKALRTVSVLIGSFALSWTPFLITGIVQVACQECHLYLVELRYLWLLGVGNSSLNPLIYAWQKEVRLQLYH
MALGVKKVLTSLFLSARNCGPERPRESSCHIVTISSEFDG

The following DNA sequence beGPCR-**seq3** <SEQ ID NO. 3> was identified in *H. sapiens*:

CAGCCGCAGGCCCTCATGGTACCGGTGTCATGCCCTGGCAGTGTCTGGTGCACCCGGCACCTGGAG
CGAGGTGAGGCAGAGCACCGCCAGCGCAGCAAGCCCACGGCATGGAGCGTGGCGGTGAAGGCTGCAGA
GCCGGCACGCTCAGGCTGGCGGCAGGCGCAGCGAACAGGACGCCAGGCGCTGTAGCCAAGGCCACGA
GCAGCCAAGTGCAGCGCTGAGAACGCCAGCGACTGTCCCAGGCACAGCCCAGCAGCAGGCCAGCATAGCG
CGGTGCGCAGGCCGTCCGGCTAGGCCAGTGGAAAGCCACTGCCAGGCCACTGGCTGCGCTCAGGCCGCCAC
GCTCAGGCCCGTGGACGCCAGGAAGGTGCCAGGAAGGCCATGACTTGGCATGCCCGGGGCCAGGG
TGTCCGCCCGGCATCACACCGAGCAGCGTGAAGGGCATGTCCAGCGCCAGCAGCAGGTGGCCAGAGA
CAGATTCAACAGGAGGACGCCCTGAGGCTGAGTGCAGCGCTGTAGGCAGCAACAAAGCAGCACCAAG
TGCCTTGGATAGCAGGCCACGCCAGTACCATCACCAAGGAGACCCGCCAGCAGGCCCTGCCGGGGCCAT
GGCGCTAGC

The following amino acid sequence <SEQ ID NO. 4> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 3:

SAMGPGEALLAGLVMVLAVALLSNALVLLCCAYSAELRTRASGVLLVNLISLGHLLAALDMPFTLLGVMRGR
TPSAPGACQVIGFLDTFLASNAALSAALSADQWLAVGFPLRYAGRLRPRYAGLLLGCAGQSLAFSGAALGC
SWLGYSSAFASCRLPPEPERPRAFTATLHAVGFVPLAVALCLTSLOVHVARRHQRMDTVTMKALA

The following DNA sequence beGPCR-**seq4** <SEQ ID NO. 5> was identified in *H. sapiens*:

TGTGCAGGTGTGATCTCCATTCTTGTACATCCCTCACACGCTGTCGATGGGATTGGAAAGGAAATCT
GTGTATTTGGCTCACTACTGACTATCTGTTATGTACAGCATCTGTATATAACATTGTCCTCATCAGCTATG

DOCKET NO.: 411USPHRM311

PATENT

ATCGATACCTGTCAGTCTCAAATGCTGTAAGTCGAACACATTAATTATCCCCCTAGAAGATTATGTAAATGTATA

The following amino acid sequence <SEQ ID NO. 6> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 5:

CAGVISIPLYIPHTLFEWDFGKEICVF~~WLTTDYL~~CTASVYNIVLISYDRYLSVSNAVSRTHFIPLRRLCKCI

The following DNA sequence beGPCR-**seq5** <SEQ ID NO. 7> was identified in *H. sapiens*:

GACGTCGAAGCAGGTGATGATGCCAGGGCGTGCACCGGGTAGGTGAGATCGGTGCGGCCAGCAGGGGACAGGCGGGTCAGGAGCAGCAGCCAGGTCCCTGCACACGCGGCCACCGCGTAACGACGGCGGCCAGCGCTTGGAGCTGAGCGGGTACAGGATCCCCAGGAAGCGCTCACGCTGATAACAGGTGATGGTGAGGATGCTGGAATACATGTTTGCGTAAAGGCCACGGTCAACCACGGTCAAAGCAGCACCCCGAATACCCAGTGGTGGCGGTTGCAATGGTAGTAGATTGGAAAGGCAACACGCTGCCAGCATCAGGTCCGTGACGCTCAGGTGATCATGAAGATGACCGACGGGATCTGGGCCCATGCGCCGGCACAGCACCCACAGAGAGAAGAGGTTGCCCGGGATGCTGACGCCGCCAC

The following amino acid sequence <SEQ ID NO. 8> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 7:

DNATLQMLRNP~~AI~~VALPVYSLVA~~VS~~IPGNL~~F~~SLWVL~~C~~RRM~~G~~PRSPSV~~I~~FM~~N~~LSVT~~D~~MLASVLPFQIYYHCNRHHWV~~F~~GVL~~C~~NLV~~V~~T~~V~~AFYAN~~Y~~SSIL~~T~~MTC~~I~~SVERFLG~~I~~LYPLSSKR~~W~~RR~~R~~YAVAACAGT~~W~~LL~~L~~T~~A~~SP~~L~~ART~~D~~LT~~P~~VHALG~~I~~ITCFDV

The following DNA sequence beGPCR-**seq9** <SEQ ID NO. 9> was identified in *H. sapiens*:

CCCATGTTCC~~T~~GCTC~~T~~GGCAGCCTCACG~~T~~GTG~~C~~GGATCTG~~C~~TGGCAGGCGCCG~~C~~CTACGCCGCCAACATCCTACTG~~T~~CGGGGCCG~~C~~T~~C~~ACG~~C~~TGAAACTG~~T~~CCCCCG~~C~~G~~C~~T~~C~~GGTTC~~G~~CACGGAGGGAGGC~~G~~T~~T~~CGTGGCACTCA~~T~~GC~~G~~T~~C~~CG~~T~~G~~C~~TGAGC~~C~~T~~C~~GGG~~C~~AT~~C~~GC~~G~~CT~~G~~GAGC~~G~~CAGC~~C~~CT~~C~~ACCCATGGCGCGCAGGGCCGCCG~~C~~GT~~C~~T~~C~~CCAGT~~C~~GGGGGCCACG~~C~~T~~C~~GGG~~C~~AT~~C~~GC~~G~~AGCCGCCG~~C~~CT~~G~~GG

The following amino acid sequence <SEQ ID NO. 10> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 9:

PM~~F~~LLLGS~~L~~TLSD~~L~~LAGAAYAAN~~I~~LLSG~~P~~TLKLSP~~W~~FA~~E~~GGVF~~V~~ALTASV~~L~~SLLGIALERSLT~~M~~ARRGPAPVSSRGRTLAMAAA~~W~~

The following DNA sequence beGPCR-**seq11** <SEQ ID NO. 11> was identified in *H. sapiens*:

CTGCTCATTGTGGC~~T~~TGTG~~C~~GGCGCACTAGGCAATGGGGT~~C~~CCCTGTG~~T~~GGTTCTG~~T~~CCACATGAAGACCTGGAAAGCCCAGCACTG~~T~~TAC~~T~~TC~~A~~ATTGGCC~~T~~GGCTG~~A~~T~~T~~CC~~T~~CC~~T~~TATGATCTG~~C~~CTCT~~C~~ACG~~T~~GGCC~~C~~ATGAACAGGGCCGGAGC~~A~~T~~C~~GTG~~T~~CC~~T~~TA~~C~~GGTGG~~C~~TG~~G~~GACAGGT~~T~~TTCAAAGTGGCCACCCCCAACACGCCGGTGAACACTAT~~C~~CCACCCGGGTGGCGCTGGC~~A~~T~~C~~GTCTG~~C~~ACCC~~T~~GTGGCCCTGGT~~C~~AT~~C~~CTGGGAACAGTGTAT~~T~~TTG~~C~~TGGAGAACC~~A~~T~~C~~T~~C~~GGT~~G~~CAAGAGACGGCCGTCTGTGAGAGCTTCATGGAGT~~C~~GGCAATGGCTGGCATGACATCATG~~T~~CC~~A~~GCTGGAG~~T~~CTTATG~~C~~CC~~C~~CTG~~G~~C~~A~~T~~C~~TTG~~G~~GAGC~~C~~TGAGGCGGAGGC~~A~~G~~C~~GTGGCCACAGGCTGGATGAAGAAGGC~~G~~ACCCGGTT~~C~~AC~~T~~ATGGTGG~~G~~CAAT~~T~~GTG~~T~~TCATCACATG~~C~~TACCTG~~G~~CCAGCGTGT~~C~~TG~~G~~ACTCT~~A~~TT~~T~~CC~~T~~CTGGACGGT~~G~~CCCTCGAGT~~G~~CCTG~~G~~GAT~~C~~CC~~C~~TGT~~C~~CA~~T~~GGGCC~~C~~CTG~~C~~ACATAACCC~~T~~CAG~~T~~TCAC~~T~~ACATGAACAGCATG~~T~~GG~~A~~T~~C~~CC~~C~~TGGT~~G~~TATT~~T~~TTTCAAGCCCC~~C~~CT~~C~~TTCC~~A~~ATTCTACAACAAAGCT~~C~~AAATCTG~~C~~AGT~~C~~TGAAACCC~~A~~AGCAGGCCAGGACAC

DOCKET NO.: 411USPHRM311

PATENT

TCAAAAACACAAAGGCCGGAAGAGATGCCAATTCG

The following amino acid sequence <SEQ ID NO. 12> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 11:

LLIVAFVLGALGNGVALCGFCFHMKTWKPSTVYLFNLAVADFLMICLPCFRDYYLRRRHWAFGDIPCRVLGF
TLAMNRAGSIVFLTVVAADRYFKVUHPPHAVNTISTRVAAGIVCTLWALVILGTVYLLLENHLCVQETAVSCE
SFIMESANGWHDIMFQLEFFMPLGIILFCFSFKIVWSLRRRQQLARQARMKKATRFIMVVAIVFITCYLPSVA
RLYFLWTVPSACDPSVHGALHITLSFTYMNMSLDPVYYFSSPSFPKFYNKLKICSLKPQPGHSKTQRPEE
MPIS

The following DNA sequence beGPCR-**seq12**<SEQ ID NO. 13> was identified in *H. sapiens*:

TGGAGCTGTGCCACCACCTATCTGGTGAACCTGATGGTGGCCGACCTGCTTTATGTGCTATTGCCCTTCCT
CATCATCACCTACTCACTAGATGACAGGTGGCCCTTCGGGGAGCTGCTCTGCAAGCTGGTGACTTCCTGT
TCTATATCAACCTTACGGCAGCATCCTGCTGCTGACCTGCATCTCTGTGACCAGTCCTAGGTGTGTGC
CACCCACTGTGTTCGTGCCTACCGGACCCGCAGGCATGCCGGCTGGCACCAGCACCACCTGGCCCT
GGTGGTCCTCCAGCTGCTGCCACACTGGCCTCTCCCACACGGACTACATCAATGGCCAGATGATCTGGT
ATGACATGACCAGCCAAGAGAAATTGATCGGCTTTGCTACGGCATAGTCTGACATTGTCTGGCTTT
CTTCCCTCCTGGTCATTTGGTGTGCTATTCACTGATGGTCAGGAGCCTGATCAAGCCAGAGGAGAAC
TCATGAGGACAGG

The following amino acid sequence <SEQ ID NO. 14> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 13:

W~~SCATTYLVNL~~M~~VA~~D~~LLYV~~~~L~~P~~F~~L~~I~~I~~T~~Y~~S~~L~~DD~~R~~W~~P~~G~~E~~L~~L~~C~~K~~V~~H~~F~~L~~F~~Y~~I~~N~~L~~Y~~G~~S~~I~~LL~~T~~C~~I~~S~~V~~H~~Q~~F~~G~~L~~V~~C~~H~~
L~~C~~S~~L~~P~~Y~~R~~T~~R~~R~~H~~A~~W~~L~~G~~T~~S~~T~~W~~A~~L~~V~~V~~L~~Q~~L~~P~~T~~L~~A~~F~~S~~H~~T~~D~~Y~~I~~N~~Q~~Q~~M~~I~~W~~D~~M~~T~~S~~Q~~E~~N~~F~~D~~R~~L~~F~~A~~Y~~G~~I~~V~~L~~T~~S~~G~~F~~L~~S~~L~~
G~~H~~F~~G~~V~~L~~F~~T~~D~~G~~Q~~E~~P~~D~~Q~~A~~R~~G~~E~~P~~H~~E~~D~~R~~

The following DNA sequence beGPCR-**seq14**<SEQ ID NO. 15> was identified in *H. sapiens*:

The following amino acid sequence <SEQ ID NO. 16> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 15:

RVRLVFLGVILVVAVAGNTTLCRLXXXXXXXXXKRRKMDFLVQLALADLYACGGTALSQLAWEALLGEPR
ATGDLACRFLQLLQASGRGASAHLVVLIALERRRAVRLPHGRPLPARALAALGWLLALLARGSGFVVRYXXX
XXXXXXXXSLQPGAPLSARAWPGMRRCHWIFALLQRWHVQVYAFYEAVAGFVAPVKIMGVACGHLLSWWRH
RLKAPAGAAAWSASPGGARAPSAMPRAKVQSLKMSQLLGLLFVGCELPFADRLEAAWSSGPAGEWEGEALSAC
CAWW

The following DNA sequence beGPCR-**seq15**<SEQ ID NO. 17> was identified in

DOCKET NO.: 411USPHRM311

PATENT

H. sapiens:

TCTAAGTTTCTCTGAACTTGAGCCTGTGAAAAAAGAAGGGATGCTGCCTCAGGCCACCCAGCCTAGA
 TACTCACTCTGAGTGCATGAGGTAGTAGAGGACACTGATGACAGTCATGGGGAGGAGGTAGAATAGGAAG
 GAGGTGACCTGGATGATGAAATTGTAGATCCACATGGGCTTGTGACCGTACAGGTGGCGAACCTGGGAC
 CAGGGACCCATTGGGAAGTAGTGGAACTTGTGATGCCATGGATGCTGGTGTGGCAGGGAGAACAGACCGG
 AGAACGCCCAGACGATGCCAGGGATCCTGAGGGCCGGCGCCGGGTGCTCTGCAGTTGGCGCGAACGGG
 TGTAGGATGGCCACGTAGCGCTCCACGCTGACGGTGGTGTGAGGATGGAGGCGAACACGGCTC
 AAAGAGGGCCGCTTGAAGTAGCAGCCCACGGGCCAACAGAAAGGGTAGTGCACGCCACATCTCATAGA
 CCTCCAGGGCATTCCAAGGAGCAGGACCAGGAGGTCAAGAGACCAGGCTGAAGAGGTAGTAGTTGGT
 GGCCTTCAAGCCTGGTGTGAGAACATCACCAGGCACACCAGGACATTGCAATGACCCCCACACAAA
 AATTGGCACATACACCACAGACACGGGAGGAAGAAGTGGCTGCAGGCTCGAGAGGAAGGGCAGAT
 ACTCCTCGGTGCTGTCAGGTGTTCTGGAATGGATCTCTAGTTCTGCTGGTAGATCCAGGAAGCATT
 TGAAGTTTCCATCCCTGA

The following amino acid sequence <SEQ ID NO. 18> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 17:

SGMEKLQNASWIYQQKLEDPFQKHLNSTEELYAFLCGPRRSHFFLPVSVVYPIFVVGVIGNVLVCLVILQHQ
 AMKTPNTYLFSLAVSDLLVLLGMPLEVYEMWRNYPFLFGPVGCVYFKTALFETVCFA
SILSITTVSVERYVA
 ILHPFRAKLQSTRRRRALRILGIVWGFSVLSPNTSIHGIKFHYFPNGSLVPGSATCTVIKPMWIYNFIIQVT
 SFLFYLLPMTVISVLYYLMALRVSIAGVAG

The following DNA sequence beGPCR-**seq18** <SEQ ID NO. 19> was identified in *H. sapiens*:

ATCAAGATGATTTTGCTATCGTCAAATTATTGGATTTCACCTCCATCTGTAATCCCATTGTCTATGC
 ATTATGAATGAAAATTCAAAAAAAATGTTTGTCTGCAGTTGTTATTGCATAGTAAATAAAACCTTCT
 CTCCAGCACAAAGGCATGGAAATTCAATTACAATGATGCGGAAGAAAGCAAAGTTCCCTCAGAGAG
 AATCCAGTG

The following amino acid sequence <SEQ ID NO. 20> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 19:

IKMIFAIVQIIGFSNSICNPIVYAFMENFKKNVLSAVCYCIVNKTFSPAQRHGNSGITMMRKKAKFSLRENP

The following DNA sequence beGPCR-**seq16** <SEQ ID NO. 21> was identified in *H. sapiens*:

GCCACAGCATGCAGTTTCTGTAGAATTCCACTTGTCTTGCACTTGAAGAAGATGAGGTATCTGGTGAC
 CAGGATCACCATAGAACCGTGAGGTACATGTGGATGTGCAGCATGGCACTCACAAATTGCA
 AAGGGCAGCCAAACATCCAAGTCTTGTAGGTCAGGTCAAGCGAAATGGCACTGTCA
 GAGGAGACCCACCAAGTTAATGACCGCCATGGTGGTCACTGACCCGGTTTCATTT
 CACCAGGAGGA
 AAAGAATGAAATGACACCCACCAGCCGCAATAAGCACTATGAAGTAGAGGCTGATTAAGTGGGGTGC
 ACTATAGGATCGCAAGAGGAATTCTGGAGGTATTGTGCCAGGCATACTGGGAAGTCACCTGGAGGAGA
 AAAAGCACCAGAGTA
 CTGAC

The following amino acid sequence <SEQ ID NO. 22> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 21:

VSYGAFSPPGDFPSMPGHNTSRNSCDPIVPHLISLYFIVLIGGLVGVISILFLLVKMNTRSVTTMAVINL
VVVHSVFLTVFRLTYLIKWTMFLPFCKFVSAMLHIHMYLTVPILCGDPGHQIPHLLQVQRQSGILQKTA
 CCG

The following DNA sequence beGPCR-**seq17** <SEQ ID NO. 23> was identified in *H. sapiens*:

DOCKET NO.: 411USPHRM311

PATENT

```
ACTGACCAAGGTCAGGGCATCGACTGAGGCTAGAAGGCCACAGGAAATGCCAGTCAGGTGTTGGCGCCTG
CAATCGCACCTACCACAAACTGACCAGGGGGCAGGGGGCAGGCCAGCGAACACGGTCAGCAGCACC
AGTCATTGCAGAGCACGGAGAGCAACACGATGGCCACACGGCCAGCGGATGCCAGCTTCAAAGAG
GTACTCACA
```

The following amino acid sequence <SEQ ID NO. 24> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 23:

CEYLFESWGIRLAVWAIVLLSVLCNGLVLLTVFAGGPAPLPPVKFVVGAIAGANTLTGISCGLLASVDALTLV
S

The following DNA sequence beGPCR-**seq20** <SEQ ID NO. 25> was identified in *H. sapiens*:

```
AACCCCATCATCTACACGCTCACCAACCGCAGCTGCCACGCCCTGCCCTGGTCTGCTGCCAG
CCACTCCTGCCAGAGACCCGAGTGGCTCCAGCAGTCGGCGAGCGCGCTGAGGCTTCCGGGGCCTGC
GCCGCTGCCCTGCCCGGGCCTTGATGGAGCTCAGCGCTCGGAGCGCTATGCCAGCGCAGCGG
CTGGACACCAGCGGCTCCACAGGCAGCCCCGGT
```

The following amino acid sequence <SEQ ID NO. 26> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 25:

NPIIYTLNRDLRHALLRLVCCGRHSCGRDPGSQQSASAAEASGLRRCLPPGLDGFSFGSERSSPQRDGLD
TSGSTGSPG

The following DNA sequence beGPCR-**seq21** <SEQ ID NO. 27> was identified in *H. sapiens*:

```
CGTGAAGAACAGGCCACCATGACCAGCATGTGCACCACGCCGCTCTGCCGCGATGCTCGCGGGTCCG
CAGCCTCTNNNNNNNNNNNNNNNNNNNNNNNTGGCAGAGCTGCGCGATGCCGCTACATGACC
ACGATGAGCGCCAGCGGCCAGGTAGATGTGCGAGAAAGAGCACAGTGGTGTAGACCTGCGATGCCCTT
CTCGGCCAGGCCCTCCAGCAGGAGTAGAGAGGGTAGGAGCGGTTGCGGGCTCCACCATGAAGTGGTGT
CCTCACGGGTGACGGTCAGCGTGACGCCAGGGACACATGATGAGCAGGCCAGGGCCAGATGACGGCG
ATGGTGACGAGCGCCTCCGCAGGGTCAGCTCTCGCGAAAGGGTGCACGATGAGCGAACCT
```

The following amino acid sequence <SEQ ID NO. 28> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 27:

FRCIVHPFREKLTIRKALVTIAVIWALLIMCPSAVTLTVTREHHFMVDARNRSYPLYSWEAWPEKGM
RRVYTTVLFSHIYLAPLALIVVMYARIARKLCXXXXXXXXXADPRASRRARVVHMLVMVALFFT

The following DNA sequence beGPCR-**seq22** <SEQ ID NO. 29> was identified in *H. sapiens*:

```
GCAGGGGGCGTGAGTCCTCAGGCACTTCTTGAGGTCTTGTTGAGCAGGAAGCAGACAATTGGTTGACGG
CAGCCTGGCGAACGCTCATCCAAACAGCATGCCAGGTAGCGGTGGGCACAGCACAGGCTTCACAAACA
CTCGCCAGTAGCAGGCCAGATGTAGGGTGACCGAGAGGAGCAGAAAGAGCAGTGTGATCGCGTAGAACATG
CGGCCAGCTGCTTTCACCCCTGACCTCGTCCATGCCAGTAGCCGCCGGCTGGCTGCATGCCATTCTG
CCGGATACCCAGCAGGGTTGGTGGCATGGGCC
```

The following amino acid sequence <SEQ ID NO. 30> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 29:

GPMPPTLLGIRQNGHAASRLLGMDEVKGEKQLGRMFYAITLLFLLWSPYIVACYWRVFVKACAVPHRYLAT
AVWMSFAQAAVNPIVCFLNKDLKKCLRTHAPC

The following DNA sequence beGPCR-**seq24** <SEQ ID NO. 31> was identified in

DOCKET NO.: 411USPHRM311

PATENT

H. sapiens:

TATTCTGTAATGAAGAATGTCATTACACTGCCATTGGCACATCCAGTGGCCTCACCTAGCATTGTGAAAG
 CCCTCGGTTGGTGTATTGCCACTTCATTTAAAAGGATGCACAAGTCCCTGGTGCCTTCCACAGCAATG
 CAGGTCAAGTGGAGATTCTGTACAACAGCGGTAGACTGGACAAATGGCACCATCTGCAAATGAAAGC
 ACCTGCAGTAAGGAAATAGGATAAATCATACATCAAAACAAAAAGAATAAAGGTTCATCTGTGTTGT
 AATTATCACTATCAGTCCATTCTGAGCCTCTGCCAAAAGTTGATAATTGTAATTACTCTGTAGACACA

The following amino acid sequence <SEQ ID NO. 32> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 31:

VYRVITI~~I~~LFGRGSEWTSDNYKDTDETFILFVLMYDSYFLTAGAFICKMVPFVQSTAVVTEILTMTCIAV
 ERHQGLVHPFKMKWQYTNRRAFTMLGEATGCANGSVNDILHYRI

The following DNA sequence beGPCR-**seq27** <SEQ ID NO. 33> was identified in *H. sapiens*:

GAGCAACATGATCTTTGAAGTACTTGACGGTGTGTTGACGGTCACGAAGCACAGAGTGTGATCA
 TGCTGTTGCTCATGGCGATGCACCGACGATGGTGAAGCCGTTAGAAGGGCGCCAGCATAGCACGTAGGGCGGTGAGGAT
 GCACATGAGCACCAGGACCGTCTCCTGCGGCAGCGCAGCCTCTGGGATCTGCTCTGGAATCCAG
 GGACCGCCTGAAACCAGAGCTCCCCGGAGATCCTGGCATAGCACAGGGCATGGTACCGACACGGGGCCACG
 AATTCTATGCCAAAGATAAAGAGGAAGTAGGACTTGTAGTAGAGCTGCTGGTCCACAGGCCAGATCTGGCC
 GCAGAAGATCTTCCTGGCTCTGACAATGACGAGGACCGTCTCGGTGGTAAGTAGGGCGGAAGGGATGG
 CGATCAGGATGGACACCGTCCACACCAAGGCAATCAGGCCAGTGGCTGTTGGCACTTCATTGTTGCTC
 AGCGGATGGACAATAGCCAGATACTAGGGCAAGAACACAAGTGGAGGCAGCC

The following amino acid sequence <SEQ ID NO. 34> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 33:

GCLHLCSCPRLAIVHPLRPRMKCQTATGLIALVWTVSILIAIPSA~~Y~~FTTETVLVIVKSQE~~K~~IFCGQIWPVDO
 QLYYSYFLIFGIEFVG~~P~~VVTM~~L~~CYARISRELWFKAVPGFQTEQIRKRLR~~CR~~RTV~~L~~VMCILTAYVLCWA
PFYGFTIVRDF~~F~~PTVFKHYLTAFY~~I~~VECIAMSNSMINTLCFVTVKNDTVKYFKKIMLL

The following DNA sequence beGPCR-**seq28** <SEQ ID NO. 35> was identified in *H. sapiens*:

CAGCCACACTGCAGTGAAATCAAATGTCCAACACCAACCATAAGTCACCATTACTAAAGAACCCAC
 AAAACTCCCTCCAGGGTGTTCAGCAGCAGGGACAGGGCCAGGGCACACATGACAGTTGACAGG
 TTTCTGGGCAGCAGCAGCAGTACCGAGATAGGCCGCAGGACAGACAGGCAGCAGTACTGATGGCACT
 CAGCATGCTCAGGCCTACAAAGGTAGGCAAAAGGTATCAGCCTGGTGAAGAAGCTAGGGAAATTGATGGAGA
 TGGAACAGAAGAAGTTACTGAGGTACACCAGGCATGGCAATTATAATCTGGAAAGCAGAGGAAGAGGAAGTCGGCC
 CCGGCCAGGCTGAGGACGTAGACAGAGAAGGGCTCTGGCATGGGAAGCCCAGGAGCCAGAGCACAAA
 CCCGTTCC~~T~~ACCAGCCCACCAGGGCAATGAAAGGATCAGGAAGACCGGGATCAG

The following amino acid sequence <SEQ ID NO. 36> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 35:

LIPVFLILFIALVGLVGNGFVWL~~L~~LGFRMRRNAFSVYVLSLAGADFLFLCFQIINCLVYLSNFFCSISINFPS
 FFTSVMTFAYLVGLSMLSAISTECCLS~~V~~LRPIWYCCCCPRNLSTVMCALPWALSLLLNTLEGKFCGFLVSN~~D~~
 YGWCWT~~F~~DFITAVWL

The following DNA sequence beGPCR-**seq31** <SEQ ID NO. 37> was identified in *H. sapiens*:

GAGAGTCTGATCTGACTTACATCACATATGTAGGCCTGGCATTCTATTG~~C~~AGCCTGATCCTTGCTTGT
 CCGTGAGGTCTAGTCTGGAGCCAAGTGACAAAGACAGAGATCACCTATTACGCCATGTGTGCATTGTTAA

DOCKET NO.: 411USPHRM311

PATENT

CATTGCAGCCACTTGCTGATGGCAGATGTGTGGTTCATTGTGGCTTCTTCTAGTGGCCAAATAACACAC
CACAAAGGGATGTGTGGCAGCCACATTTTGGTCATTCTTACCTTCTGTATTTCTGGATGCTTGCA
AGGCACCTCCTATCCTCATGGAATCATGATTGTTTC

The following amino acid sequence <SEQ ID NO. 38> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 37:

ESLILTYITYVGIGISICSLILCLSVEVLVWSQVTKTEITYLRHVCIVNIAATLLMADVWFIVASFLSGPITH
HKGCVAAFFGHFFYLSVFFWMLAKALLILYGIMIVF

The following DNA sequence beGPCR-**seq32** <SEQ ID NO. 39> was identified in *H. sapiens*:

TTGTGTGGCAGTAGAGAGATGTCAGGCTTCAGAGTCACAAAGAACTGGATTCAAACGGATTGAGGACCCC
CACCTTGGTAAGTGACTTATTATCTGCGAGCCCTGTGTTCTCTCTTAAATGAGGACAGTAAATCCCAC
ACGGCAGGGTGGTGGGGAGAACATCAGAGATGATACAGCTGGTGTACATCTGGTTGTGTTCCCAGGGGACCC
AGACTAGGGTTCTGAGCATGGATCCAACCGTCCCAGCTTCGGTACAAAAGTACACCAATCAACGGACGTG
AGGAGACTCCTGCTACAATCAGACCTGAGCTTCACGGTGTGACGTGCATCATTTCCCTGTGGACTGAC
AGGAAACGCGGTAGTGCTCTGGCTCTGGCTACCGCATGCGCAGGAACGCTGTCTCCATCACATCCTCAAC
CTGGCCGCAGCAGACTCCTCTTCCAGCTCCAGATTATACGTCGCCATTACGCCATCAATATCAGCC
ATCTCATCCGAAAATCTCGTTCTGTGATGACCTTCCACTTTACAGGCCTGAGTATGCTGAGCGCCAT
CAGCACCGAGCGCTGCCTGTCTGTGGCCATCTGGTACC

The following amino acid sequence <SEQ ID NO. 40> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 39:

LCGSREMSGFRVNKNWISNWIGPPPLVSDLLSASLCFSLLMRTVNPPIRQGGGENQRYWSHLVCVPRGTRLGF
LSMDPTVPVFGTKLTPINGREETPCYNQTLSFTVLTCIISLVGLTGNAVVLWLLGYRMRRNAVSIYILNLAAA
DFLFLSFQIIRSPRLINISHLIRKILVSVMTFPYFTGLSMLSAISTERCLSVLWPIWY

The following DNA sequence beGPCR-**seq33** <SEQ ID NO. 41> was identified in *H. sapiens*:

ACAGAAAGCAAGGCCACCAGGACCTTAGGCATAGTCATGGAGTTGTGCTGGCTGCCCTTCTTGT
TCTTGACGATCACAGATCCTTCATTAATTACAACCCCTGAAGATCTGTACAATGTCTCCTCTGGCTAGG
CTATTCAACTCTGCTTCATCCCATTATGGCATGCTTATCCTGGTTTCGCAAGGCATTGAGGATG
ATTGTCACAGGCATGATCTCCACCCCTGACTCTCCACCCCTAACGCTGTTCTGCCATGCTTAGGCTGTG
TCATCATTCAATAGGACTCTTCTGG

The following amino acid sequence <SEQ ID NO. 42> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 41:

TESKATRTLGLIVMGVFVLCWLPFFVLTIDPFINFTELEDLYNVFLWLGYFNSAFNPILYGMPLYPWFRKALRM
IVTGMIFHPDSSTLSLFSAAVFIIQDSF

The following DNA sequence beGPCR-**seq34** <SEQ ID NO. 43> was identified in *H. sapiens*:

TAGGAATCTCAGAGAAGAAAGTAAGGAACCAGAAAACCATAAAAGAATGTAATGGAAAAGAACATCAGCAAATC
TTATTCACCTTACACTAAATCTAAAATATGTCAAAATACATGAAGACAACAAATGCTTGTGAAACAATGTTGA
ATGTATTGTCCTACAACTTGGCATATGATCATGCTGCTCTCTATGTCAAGTGTGTTATTTTGCACTTGAC
CTTAATTCAAGTTAGTTGAGGTCTACAGTAATGTTTAATCTGTCTCTACTTCTTCAGAAAATAAT
TAGTTGTTGACGAATCAGTCCTTAAGACCTTGGCGCTTACAATAAGTTTATTGCCTCCAAACCATGGTA
AAAGAAAGCATAAAATCAAGGGTTCATAGCTGAATTATAAAACACACAAACTAAATCTCATAAACATAA
GGAGGAGTTATAAAATTCAATAGCATCAACTGCATCAACGAGGTATGGTAGCCAAGAGACAAGAAATG
CTGC

DOCKET NO.: 411USPHRM311

PATENT

The following amino acid sequence <SEQ ID NO. 44> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 43:

LHQGRGMVAKQEMLAFLVSWLPYLVDAVIDAYMNFITPPYVYEILVWCVYNSAMNPLIYAFFYQWFGKAIK
LIVSGKVLRTDSSTTNLFSEEVETDKHYCRDLKTNLKLRSATAINTWTRGKHDHMPSCRTIHSTVVLKHLLSS
CI

The following DNA sequence beGPCR-**seq35** <SEQ ID NO. 45> was identified in *H. sapiens*:

CTGGAAAGAGGTCCCTCGATCTATCCTCTACGCCGCTTGGTTGGGGCTGTGCTGGCAGCGTTGGAAACT
TACTGGTCATGATTGCTATCCTTCACTTCTAACAACTGCACACACCTACAAACACTTCTGATTGCGTCGCTGGC
CTGTGCTGACTCTGGTGGAGTCAGTGTGATGCCCTCAGCACAGTGGAGGCTGTGGAGAGCTGTTGGTAC
TTTGGGACAGTTACTGTAATCCATACATGTTGACACATCTTCTGTTGCTTCTTATTCATTAT
GCTGTATCTGTTGATAGATACTTGTGTTACTGATCCTCTGACCTATCCAACCAAGTTACTGTGTCAGT
TTCAGGGATATGCATTGTTCTTCTGGTCTTTCTGTCACATACAGCTTTCGATCTTACACGGGAGCC
AACGAAGAAGGAATTGAGGAATTAGTAGTTGCTCTAACCTGTGTTAGGAGGCTGCCAGGCTCCACTGAATCAA
ACTGGGTCTACTTGTCTTCTTCTTACCCATGTCGCCATGGTGTATATACAGTAAGATATT
TTTGGTGGCCAAGCATCAGGCTAGGAAGATAAGACTACAGCCAGCCAAGCTCAGTCCTCTCAGAGAGTTAC
AAGGAAAGAGTAGCAAAAGAGAGAAAGGCTGCCAAACCTTGGGATTGCTATGGCAGCATTCTT

The following amino acid sequence <SEQ ID NO. 46> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 45:

LERGPRSIYAVLGFGAVLAAGFNLVMIAILHFQLHTPTNFIASLACADFLVGTVMPFSTVRSVESCWYF
GDSYCKFHTCFDTSFCAFLFHLCISVDRYIAVTDPLOYTPKFTVSVSGICIVLSWFFSVTSFISFYTGAN
EEGIEELVVALTCVGGCQAPLQNWLCLFLLFFIPNVAMVFIYSKIFLVAKHQARKIESTASQAQSFSSESYK
ERVAKRERKAAKTLGIAMAFL

The following DNA sequence beGPCR-**seq36** <SEQ ID NO. 47> was identified in *H. sapiens*:

AACCAGGTGGCCTTACTCCTAACGACCCCTGGCCTTGTCTATGGCCTTATCACACAGCTGTCTCAATCCAGTT
TCTATGTCTCATTGGCATGACTCTGGGAGCACTGCTCCACTCCCTGCTAGCTGCCCTAGAACGGGCACT
TAGCGAGGAGCCAGATAGTGCCTGAATCCCAGCTCCCAGGCAGATGAGTCCTTATAACATGACCCATTCC
TACTCCATTCCCACCACTCAATCCTCTTCCAAACAGCTCTACCATATAACATCCAACAGAAATTAG
AGAATAAACACAACTTTAAGTGAGCTCTATGTGCTAGGTCTAGTTAGAATACAACCTTAAGTCCTGG
AGATGGAGGCAAGAACAAACAAGGTCTATTCTTAGAGGAAGACAGTTACCAAGACTCAAACAGAAAAAA
AGATAGTTATCTGTGACAAAACAAGTCATAAAATTGGTCAGGACCTGCAGCAATGACTTATGCTAGAATC
CAGAGCACTAGCAGGAAACTGCTAAATTACTTAATCAAAGTCAGTTGGACATACATGTCAGGTAAAC
CTAGCAGAGATGAGCTACCTGATTAAAACCTCAAGGGATAGCTCAATGTCATCAAGATCCTTGTGAC
TTG

The following amino acid sequence <SEQ ID NO. 48> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 47:

NQVALLRPLAISMAFINSCLNPVLYVFIGHDFWEHLLHSLLAALERALSEPDSAIAPAPRQMSPLHDPISYS
IFPPLNPLPKQLYHNPTSNSRIENKPQLLSELYVLGHVLEYNLKLEDGGKKQTRSHSLEEDSSPRLKQKKRLS
CDKTSHKIGSGPAAMTLCNPEHQETAILLNQSQVWTYMSGKTQRATLILKLQGIAQCHQDPFDDL

The following DNA sequence beGPCR-**seq37** <SEQ ID NO. 49> was identified in *H. sapiens*:

GCTTGGTCACGGCCACCATCCTCAAGCTGTTGCGCACGGAGGGCGCACGGCCGGGAGCAGCGGAGGCCGC
GGTGGGCCTGGCCGGTGGCTTGCTGGCCTTGTACCTGCTTCGCCCCCAACAACACTCGTGTCTGGCG
CACATCGTGAGCCGCCTGTTACGGCAAGAGCTACTACCAACGTGACAAGCTCACGCTGTCTCAGCTGCC
TCAACAACTGTCGGACCCGTTGTTATTACTTGCGTCCCAGGAAATTCCAGCTGCGCCTGCGGGAAATT

DOCKET NO.: 411USPHRM311

PATENT

```
GGGCTGCCGCCGGGTGCCAGAGACACCCTGGACACGCCGCCGAGAGCCTCTCCGCCAGGACCACGTCC
GTGCGCTCCGAGGCCGGTGCACCCCTGAAGGGATGGAGGGAGCCACCAGGCCCTCCAGAGGCAGGAGA
GTGTGTTCTGAGTCCCGGGGCGCAGC
```

The following amino acid sequence <SEQ ID NO. 50> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 49:

```
LFTATILKLLRTEEAHGREQRRRAVGLAAVLLAFVTCFAPNNFVLLAHIVSRLFYGKSYHVKLTLCCLSCL
NNCLDPFVYYFASREFQLRLREYLGRRVPRDTLDTRRESLFSARTTSVRSEAGAHPEGMEGATRPLQRQES
VFVPGQAAPPGLR
```

The following DNA sequence beGPCR-**seq38** <SEQ ID NO. 51> was identified in *H. sapiens*:

```
TTACTTATTCTGCCCTTATCCAACTTAATTCCCTTGCTATTCTCCTGCCTCATTCTGGCCTCATTTC
CCCTATTATCCTGCCTCACATTGATCAAGGGATGAGGCTGGCAGGATCCCGAACCCACAGGGCCCGTGGC
ATGAGAGGCTCTGGACTTGAACCTCAGGACACTCCCACCTCTGGCTGCCGGCAGGGATGGAAGCTGGATGAGC
AGGCAGGAGCTGGCAGTGGGGTGGAGAGCCATAGGCTATTGGGGTGGACAGGCTGGGTGCCTCATGGGAGC
TCCCCATGGGAGCTGTGGCCCTTGGGGCTTATTCTCACCCAGGCTTCCGGAGAGGTTCAAGTC
GAAGATGCCCAAAGATCCACGTGCCCTGGGTGGCAGCCTGTTCTCCTGAATCTGGCTTCTGGTCAATG
TGGGGAGTGGCTCAAAGGGTCTGATGCTGCCTGCTGGCCCGGGGGCTGCTTCAACTACCTCTGCTCTG
TGCCTTCACCTGGATGGGCTTGAAGCCTCACCTCACCTGCTGTCAGGGCTTCAACACCTACTTC
GGGCACTACTCCTGAAGC
```

The following amino acid sequence <SEQ ID NO. 52> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 51:

```
ETYSALYPTFNSLCYSPASFSGLIFPIILPHIDQGMRLAGSGTHRAPHAMRGWSWTSGHSHSGCRQGWKLDEQ
AGAGSGGGEPAIGVDRLLGCLMGAHGSCGPLISHPRLSRERFKSEDAPKIHVALGSSLFLNLIAFLVNVG
SGSKGSDAACWARGAVFHYFLLCAFTWMGLEAFHYLLAVRVFNTYFGHYFL
```

The following DNA sequence beGPCR-**seq40** <SEQ ID NO. 53> was identified in *H. sapiens*:

```
AATTGGTCGGAGAGTCAGCTGCTTGAAATGGAGGATTGAAATCATCACCAAGGAGTTCCAAACACAGCCAG
CACAGCCCCAAAGCCAAACACTATGTACAGAATCACCCGGATCCGGCGAGAAGGGATTTCACACAGGAC
CCATTCACGTTCGCGTAGCACAGCTGCACAGCCACCAGCAGGGATGAATTGCTGCTATAACGCTGGTATT
CATATGGAGAAATTTCGCTTGTGATTATCACAAAAAATACAGGATTGTTCTGATTTCATTGCTCCTGC
GGAAAAAAACACATATTCACCAAGGATGCCAGAGGAAATGATCA
```

The following amino acid sequence <SEQ ID NO. 54> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 53:

```
DHFLWHPGEYVFFSAGAMKIRNNPFFVIINKDKIISPYVNTSVMSSNSLLVAVQLCYANVNGSCVKIPFSPG
SRVILYIVFGFGAVLAVFGNLLVMISILHFKQLHSPTN
```

The following DNA sequence beGPCR-**seq41** <SEQ ID NO. 55> was identified in *H. sapiens*:

```
CACATCTTAACAAGACTGAAAAACATTGATTGTTTAAATTGAAGAGCAATTATTGCTATTCA
GTCTACTTGATTAAACACTCATTCGCTTGGTAATTAAAGGTATCTGAACCTCGTCTATCCAAC
CTTATATATGTTGAGAAAACAAATTGATGGTTGCTGAACCTGTTCTTAAACCTGACCAGTTACAATAACTT
TATTGCTTCTAAACCATGGTAAAATAAAGCATAAAATCAAAGGATTGATGGCTGAGTTATAATAAGCACAC
CAACAGCATATAAATACAGGCAGGGTTATAAAGCCATAAAAGGCATCAATTAAATGAATCAATGCTATATGG
TAACCATGAAATCATAAATGCTACCACTGTGACCCCCAGGGTTTAGCTGCTTTCTCTCTCCGTGGCCACT
CTGGCTTGTAACTCTGAGGATGATTCTGCTTGTACCAAGTATTCTATCTTCTGCGCTGCGTAG
CCACAAGAAATATGTTACCATACAGAATTATCATAATAAAGGTAGGTATAAGAAGGATAGAAAATCTGTCAA
```

DOCKET NO.: 411USPHRM311

PATENT

CA

The following amino acid sequence <SEQ ID NO. 56> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 55:

LTDPLSFFIPTFIMIILYGNIFLVARRQAKKIENTGSKTESSSESYKARVARRERKAAKTLGVTVAFMISWL
PYSIDSLIDAFMGFITPACIYEICCWCAYNSAMNPLIYALFYPWFRKAIKVIVTQVLKNSSATMNLFSEHI
AVGTKFRIPLKLPSEMSFKSSKTMNEQINCSSNKQINVFQSCDV

The following DNA sequence nGPCR-**seq53** <SEQ ID NO. 57> was identified in *H. sapiens*:

TTTGTGGCAAGGAGACCTGATCCGGTCTTCCTGATCCTTTCATTGCCCTGGTCGGCTGGTAGGAAACGG
 GTTTGTGCTCTGGCTCTGGGCTTCGCATGCGCAGGAACGCCCTCTGTCTACGTCCCTAGCCTGGCCGG
 GCCGACTTCCTCTTCCTGCTTCAGATTATAATTGCCCTGGTGACCTCAGTAACCTCTGTCCATCT
 CCATCAATTCCCTAGCTCTCACCACTGTGATGACCTGTGCCTACCTTGCAAGGCCCTGAGCATGTCGAC
 CGTCAGCACCGAGCGCTGCCCTGTCGCTGTGGCCCATCTGGTATCGCTGCCGCCAGACACCTGTCA
 GCGGTGCTGTGTGCTCTGCTCTGGCCCTGTCCTACTGCTGAGCATCTGGAAGGAAAGTTCTGTTCT
 TATTAGTGTGGTGACTCTGGTTGGTGTAGACATTGATTTCATCACTGCAAGCGTGGCTGATTTTTTATT
 CATGGTTCTCTGTGGGTCAGCTGGCCCTGCTGGTCAGGATCCTCTGTGGCTCCAGGGTCTGCCACTGACC
 AGGCTGTACCTGACCATCCTGCTCACAGTGTGGTGTCCCTCCTGCGGCCCTTGGCATTCACTGGT
 TCCTAATATTATGGATCTGGAAGGATTCTGATGTCTTATTGTATATTCACTCCAGTTCACTGGTCTGTC
 ATCTCTTAACAGCAGTCCAACCCATCATTACTTCTCGTGGCTCTTAGGAAGCAGTGGCCGSTGCAG
 CACCCGATCCTCAAGCTGGCTCTCCAGAGGGCTCTGCAGGACATTGCTGAGGTGGATCACAGTGAAGGATGCT
 TCCGTCAAGGGCACCCGGAGATTCAAAGAAGCATTCTGGTGTAGGGATGGACCCCTACTTCATCATATATA
 TGTGGCTTGAGAGGCAACTTGCCCC

The following amino acid sequence <SEQ ID NO. 58> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 57:

CGKETLIPVFLILFIALVGLVGNFVLWLLGFRMRRNAFSVYVLSLAGADFLFLCFQIINCLVYLSNFFCSIS
INFPSFFTVMTCAYLAGLSMLSTVSTERCLSVLPWIYRCRRPRHLSAVVCVLLWALSLLLSILEGKFCGFL
FSDGDSGWCQTFDFITAWLIFLFMVLCGSSLALLVRILCGSRGLPLTRLYLTILLTVLVSLLCGLPFGIQWF
LILWIWKDSDVLFCHIHPVSVVLSSLNSSANPIIYFFVGSFRKQWRXQHPILKLAQRALQDIAEVDHSEGCF
RQGTRRFKEAFWCRDGPLYFHHIYVALRGNFA

The following DNA sequence nGPCR-**seq54** <SEQ ID NO. 59> was identified in *H. sapiens*:

CTTTGCATCTCACTGTTGAGCAGACAGCCTGCTGAAAGTTGTCGCTGACCACCACATATAGTAACAGGTTACC
 AAAGGTGTTAGAGCAGCAGATAATGGTCTAGAACGATGTAAGCTTCATGGATCTGATTCTCAATGGAACA
 GATTGAAAGCAGGCTGAGATTGATCCTGAATGACCTCAAGATATGGAAGGGAAAAACATACGTAAATG
 CAAGGAGTAGCAGAATGGTTAGCCTCGTGTCTGCTTAAGGCAGCTGTCAGTTGCAAGTCCATGGTCAA
 AGTGTGGATAATCGTGGTATAGCAAAGTGTCACTATACCAAGGGAGGCAGAAAGTACTTGCAGTC
 AGGTTGTACCACTTAATAGTATTGAGTTATCCGAACGGTCAAGGCTGAGACAGGCTGATCTGGTCTGT
 TGGTGATGTGATCAAGAAGGTACATCGGAATGACAGCTACCGAGTCAAATGATCCACACCACAGCACAGGCTAC
 AACTGCACATCGAGTTGTGAATGGAAGCAGCTCATTGGTGAATGATCACACAGTAGCGGAAG

The following amino acid sequence <SEQ ID NO. 60> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 59:

FRYCVIIHPMSCFSIHKTRCAVVACVVWIISLVAVIPMFLITSTNRTNRSACLDLTSSDELNTIKWYNLLIL
TASTFCLPLVIVTLCYTTIIHTLTHGLQTDSLKQKKARLTLLLLAFYVCFLPFHILRVIQDRISACFQSV
PLRIRSMKLTSFLDHYAALNTFGNLLYVVSDNFQQAVCSTVRCK

The following DNA sequence nGPCR-**seq55** <SEQ ID NO. 61> was identified in *H. sapiens*, where the underlined ATG identifies a probable start codon:

DOCKET NO.: 411USPHRM311

PATENT

GGGAGGGCTCGTAGACACACTAACCTTACCCCTTCTGTTCTCCTCATCTTCCTTCCATCTGTTCTCAT
GGTCTCCTGTCGTCTCTCTCTCTCCCTCTTCTCTCGCTTCTCATCCCCCATTTCTGTG
TCAATCTCAATCCATTATCGGTGGCCACTTTCTATCTTGTCTATCTCTCTCTCTCTCTTCCC
ACTTTGTCTCTGCAGCCTGTTGTGTTCTGCCTGTCTCTCTTGCCTCATCTCTGTCTCTCTTG
CCCTCATCTCTGTCTCTGTCTGTCTCCCGCTCATCCCCATTGCAAGGTGCAATGTAGCAGGAC
AACTCATGGAGCCCCCGGGCCATCGAGTACCGGACTGGCTGACCCCCCTAGGGTTGGCAGTAGCCCCGTGAC
CCTCAGT**ATGG**CCAACACTACCGGAGAGCCTGAGGAGGTGAGCGGCGCTGTCCCCACCGTCCGCATCAGCT
TATGTGAAGCTGGTACTGCTGGACTGATTATGTGCGTGAGCCTGGGGTAACGCCATCTGTCCTGCTGG
TGCTCAAGGAGCGGCCCTGACAAGGCTCTACTACTTCTGCTGGACCTGTGCCCTGGCCATGGCATA
CTCTGCCGTCTGCTCCCCCTTGTGCTGGCTTCTGTGCGCACGGCTTCTCATGGACCTTCAGTGCACTCAGC
TGCAAGATTGTGGCTTATGGCGTGTCTTTGCTCCATGGCCCTCATGCTTCTGCATCAGCGTCA
CCCGCTACATGGCCATGCCAACACCGCTTACGCCAAGCGCATGACACTCTGGACATGCGGGCTG

The following amino acid sequence <SEQ ID NO. 62> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 61:

MANTTGEPEEVSGALSPPSASAYVKLVLLGLIMCVSLAGNAILSLLVLKERALHKAPYYFLLDLCLADGIRSA
VCFPFVLASVRHGSSWTFSAALSCKIVAFMAVLFCFAAFMLFCISVTRYMAIAHHRFYAKRMTLWTCAE

The following DNA sequence nGPCR-**seq56** <SEQ ID NO. 63> was identified in *H. sapiens*:

AAAAATTGCTGACTGAACATTGAATGGAACCTGGAAATAAGTCCCTCCAAAATAACTATTCTTCAACAGAGAGTAATAGGTAATGTTTAGAAGTGAGAGGACTCAAATTGCCAATGATTACTCTTTATTTTCTCCTAGGTTCTGGGATAAGTATGTGCAAATAAAACATGAGAAGGAACGTAACTGTGATTATGGATTGGGAAAAAGATAAAATCAACACACAAAGGGAAAAGTAAACTGATTGACAGCCCTCAGGAATGATGCCCTTTGCCACAAATATAATTAATTTCTGTGAAAAACAACCTGGTCAAATGATGTCGTGCTCCCTGTACAGTTAATGGTGCTCATAATTCTGACCACACTCGTTGCCAATCTGATAGTTATTGTTCTATATCACACTTCAAACAAACTCA TACCCCCAACAAATTGGCTCATTCATTCCATGCCACTGTGGACTTTCTCTGGGGTGTCTGGTATGCCCTTACAGTATGGTGAGATCTGCTGAGCACTGTTGGTATTGGAGAAGTCTCTGTAAAATTACACACAAGCACCAGACA TTATGCTGAGCTCAGCCTCATTTCATTGTCCTTCATCTCATTGACCGCTACTATGCTGTGATGCCACTGAGATATAAGCCAAGATGAATATCTGGTATTGTTGATGATCTCATTAGTTGGAGTGTCCCTGCTGTTTGCATTGGAATGATCTTCTGGAGCTAAACTCAAAGGCCTGAAGAGATATATTACAAACATGTTCACTGCAGAGGAGGGTGTCTGCTTCTTAGCAAAATATCTGGGGTACTGACCTTATGACTCTTTATATACCTGGATCTATTATGTTATGTCATTACAGAATATCTTATCGCTAAAGAACAGGCAAGATTAATTAGTGATGCCAATCAGA

The following amino acid sequence <SEQ ID NO. 64> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 63:

REKTDQPSGMMPCFHNIINISCVKNNWSNDVRASLYSLMVLILTTLVGNLIVIVSISHFKQLHTPTNWLIHS
MATVDFLLGCLVMPYSMVRSAEHCWYFGEVFCKIHTSTDIMLSSASIFHLSFISIDRYYACDPLRYKAKMNI
LVICVMIFISWSVPAVFAFGMIFLELNFKGAEEIYYKHVHCRGGCSVFFSKISGVLTFMTSFYIPGSIMLCVY
YRIYLIAKEQARLISDANQ

The following DNA sequence nGPCR-**seq57**<SEQ ID NO. 65> was identified in *H. sapiens*:

AACAGTCCGGTGGAACCTGGCATGTATATTGATTGTTTATGCATACTCCTAGTGAAGAACCAATGTC
TTGCTCAGATAGAACAGATACTCAGACTTAGTTCTCTGTAGCTCTGCTTTTATTATCCTGGTGGAT
TGCACCACTACTCAGTTCTATTATAACTGATTATAAAACATGGGAGGGAAATAACTTGTATTGGTT
TTATGGATAATTATTATTGTGTCTAGACTCTGGCTTGTCAAAAGAAGGACGTAAGAAGGCACGATGTATTA
TACTTGGGAATGATAGAACAGAGACTGACCTGGTATTCCACCCGGAAGAGGGAAAGGATTTAACACAAATAC
AGGAATCCAGCAGATGGCATCAGAGAACACTATAAAAGAACGATTGCAACAGCCACCTCTTCCAAAA
CAATTCCCTACTCTGTGGTCTGCAAGGCCTTTTGAATGGAACAGAACATAGTAATATAGGAAACACAA

DOCKET NO.: 411USPHRM311

PATENT

TGATGAGAAAAGCCAGCAAGTTCACACCTGTTGGGAAAAGCACACTTTAACATCTCAGGCATAAGTC
CAGTAAAATTACTGTGGTACAGGTTGAGTACCCCTACCCAAAATGTTGAAACCAGAAATGTTGGATTTC
GGATTCGGAATATTACACATTACATAATGATATATCTGGAAATGGTCCCAAGTCTAAACACAAAATTAT
TTATGTTCATATACACCTTACACATAGTCTGAAAGTAATTGTACAATATTAAATAATTGGGCAT
GAAACAAAGTTGCATACATTGAACCACAGACAGCAAAAGCTCAGGTGTGGAATTTCACATTGTGGCATC
ATGTTGATGCTAAAAGTCCATATTAGAGCATTCAAATTGGATTCAAATTACAAATGCTTAACC
TGTACTTAGATGTTAATACAGTGCTCTTCACGGCACTTCAGGAAGCATTCTTATATAAGGCC

The following amino acid sequence <SEQ ID NO. 66> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 65:

YIKECFLKVPVEEALYLTSKYRLSICNLKIQLKCSKIWNFLSINMMPQVENSTPEAFAVWFNVCKLCFMPKI
INIVQNYFQTMCMIRCININKFCVTWEPFPRYIIMNVIFRNPKSKTFLVSNILKGYSTCTVILLLTFTPEML
KVCFSPTGVNLLAFLIIVFSYITMFCSIQKTAQTTTEVRNCFGREVAANRFFFIVFSDAICWIPVFVVKILS
LFRVEIPGQSLLSFPSIIHRAFLRPSFDKARVDTIHKNQYKVISLPCFIISIIKKLSSGAIQPGIICKRSYR
ETKSEYLASIARHWFFTRSMHKTIKIYMPRFHPGL

The following DNA sequence nGPCR-**seq58** <SEQ ID NO. 67> was identified in *H. sapiens*:

ACTACCATGGAAGCTGACCTGGGTGCCACTGGCCACAGGCCAGCAGAGCTTGATGATGAGGACTCCTACC
CCCAAGGTGGCTGGGACACGGCTTCCCTGGTGGCCCTGCTGCTCCCTGGGCTGCCAGCCAATGGGTGATGGC
GTGGCTGGCCGGCTCCAGGCCGGCATGGAGCTGGCACCGCTGGCGCTGCTCCCTGCTCAGCCTGGCCCTC
TCTGACTTCTTGTCTGGCAGCAGCGGCCTCCAGATCCTAGAGATCCGGCATGGGGACACTGGCCGCTGG
GGACAGCTGCCTGCCGCTTACTACTTCCTATGGGGCGTGTCTACTCCTCCGGCTCTTCCCTGCTGGCCGC
CCTCAGCCTCGACCGCTGCCGTGGCGCTGTGCCACACTGGTACCCCTGGGCCAGCAGTCCGCTGCC
CTCTGGGTCTGCCGGTGTCTGGGTGCTGCCACACTCTCAGCGTGCCCTGGCTGGTCTTCCCCGAGGCTG
CCGCTGGTGGTACGACCTGGTACCTGCCCTGGACTTCTGGGACAGCGAGGAGCTGCGCTGAGGATGCTGGA
GGTCTGGGGGCTCCTGCCCTTCCTGCTGCTCGCTGCCACGTGCTCACCCAGGCCACAGCCTGTCG
ACCTGCCACGCCAACAGCAGCCCGCAGCCTGCCGGGCTCGCCCTGCTGAGGACCTCTGTCAGCCT
ATGTTGGTCTGGGAGGCTGCCCTACAGCTGGCCAGCTGCTCTACCTGCCCTTCCTGAGGACGTACTCTGG
CTACCTGCTCTGGGAGGCCCTGGTCTACTCCGACTACCTGATCCTACTCAACAGCTGCCCTAGCCCTTCCTC
TGCCCTATGCCAGTGCCACCTCCGGACCCCTGCTGCCCTCGCTCTCGCTGCCAGCTCTGCG
AGGAGCGGCCGGCAGCTCACGCCACTGAGCCACAGACCCAGCTAGATTCTGAGGGTCCAACCTGCG
GCCGATGGCAGAGGCCAGTCACAGATGGATCTGTGCCAGCCTCAGGTGAACCCACACTCCAGCCACGA
TCGGATCCCACAGCTCACGCCACAGCTGAACCCCTACGCCAGGCCACAGTCGGATCCCACAGCCAGGCC
TGAACCTCATGCCAGCCACAGTCAGATTCTGTGCCAGCCACAGGCAGACACTAACGTCCAGACCCCTGC
ACCTGCTGCC

The following amino acid sequence <SEQ ID NO. 68> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 67:

TTMEADLGATGHRPRTELDDEDSYPQGGWDTVFLVALLLGLPANGLMAWLAGSQARHGAGTRLALLL
LSLALSDFLFLAAAQFILEIRHGGHWPLGTAACRFYYFLWGVSYSSGLFLLAALSLDRCLLALCPHW
YPGHRPVRLPLWCVAGVWVLAFLFSPWLVFPEAAVWWYDLVICLDFWDSEELSRLMLEVGGFLPFL
LLLVCVLTQATACRTCHRQQPAACRGFARVARTILSAYVVLRLPYQLAQLLYLAFLWVDVYSGYLLW
EALVYSDYLILLNSCLSPFLCLMASADLRTLRSVLSSFAALCEERPGSFTPTEPQTQLDSEGPTLP
EPMAEAQSQMDPVAQPQVNPTLQPRSDPTAQPQLNPTAQPQSDPTAQPQLNMAQPQSDSVAQPQADT
NVQTPAPAA

The following DNA sequence nGPCR-**seq59** <SEQ ID NO. 69> was identified in *H. sapiens*:

TACAGGCCTGAGCATGCTGGCTCCATCAGCACCAAGCAGTGCCTGTCATCCTGTGGGCCATCTAGTACCGC
TGCCACCACCCACACACCTGTCAGCAGTCGTGTGCTCTGGCCCTGCTCAGAGCATTG
GAATGGATGTTCTGTGGCTTCGTCTAGTGGTGTGATTCTGTTGGTGTGAAACATCAGATTTCATCACAG
TCACATGGCTGATTTTATGTGTGGTTCTGCGGGTCCAGCCGGTCTGCTGGTCAGGATCCTTGTGG

DOCKET NO.: 411USPHRM311

PATENT

ATCCCGGAAGATGCCCTTGACCAGGCTGTACATGACCATCCTGCTCAGAGTGCTGGCTTCCTCCTGTGAC
 CTGCCCTTGGCATTCACTGATTCCATTTCCTGGATCCACGTGGATTGTCACTTCGTCTAGTTCCATT
 TTCCTGTCCACTCTAACAGCAGTCCAACCCCATTATTTACTTCTCATGGGCTCCTTAGGCAGCTCAA
 ACAGGAAGACTCTCTAGCTGGTCTCCAGAGGGCTCTGCAGGACACGCCTGAGGTGGAAGAAGGCAGATGGCG
 GCTTCTGAGGAAACCCTGGAGCTGTCAAGCAGATTGGGCCATGAGGAAGAGCCTCTGCCCTGTCACT
 AG

The following amino acid sequence <SEQ ID NO. 70> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 69:

YRPEHAGLHQHQALPVHPVAHLVPLPPPHTPVSSRVSCSGPCPCCRASWNGCSVASCLVVLILFGVKHQISSQ
SHGFFYVWFSAFPARFCWSGSFVDPGRCPGCTPSCSECWSSSVTCPLAFSDSYFSGSTWICHVRLVSIFLS
TLNSSANPIIYFFMGSFRQLQNRKTLLVLQRALQDTPEVEEGRWRLSEETLELSSRLGPGRASALSV

The following DNA sequence nGPCR-**seq60** <SEQ ID NO. 71> was identified in *H. sapiens*:

ATGCCGAAGGCAGGCCGAGAAGAGAAGAGGAGGACGGTGAGGAGGATGAGCCCAGGGAAGCCCCGGGTGGG
 GGCGCTGGGGCCTCGCTCCACCCCGAGCAGCAGCATAAGGCTGGCCCACACATGGTCAACACAGCAGAG
 CCAGCAGCACCGCTGCCACCAGCCACAGCTCCGGCACAAGTGGGGCTGGGCTCCCCAAGAACACTGGGTCCA
 GGCAGCTGAGCAGCAGGTGCAAGCAGGGAGAGGGCCAGGTGAGGGCGCACACACAGGTGGTCAGGTGG
 CGTGGGCGGGCACGAGTACCAAGGCTGGGAAGAGGGGGCCAGGGACTGCTCCACGCTGACGGCCGCCAGGA
 GACTCAGGCCACGATGTAGCAGAAGAAGCCAGCAGCTGGCAGGCTGGTCTGCAAGAAGCCGGGAAGTCCAG
 CCGGCTTGCAGCAAGTCGGGACCATGGCACCAGTGGCAGCCAAGGAAGATGAGATCCGCGCAGGCCACCG
 TCCAGGAGGTAGATGGCAGAAGGGTTCTGTAGACATTGGAGCTGAGC

The following amino acid sequence <SEQ ID NO. 72> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 71:

LSSNVYRNPFAYLLDVCADLIFLGCHMVAIPDLLQGRLDPPGFVQTSLATLRFFCYIVGLSLLA
AVSVEQCLAALFPAWYSCRRPRHLLTCVCALTWALCLLHLLTCVCALTWALCLLHLLSGACTLL
LSGACTQFFGEPSRHLCTRLWLVAAVLLALLCCTMCGASLMLLRVERGPQRPPRGFPGLILLTVL
LFSSAACLRH

The following DNA sequence **nGPCR-1** <SEQ ID NO. 73> was identified in *H. sapiens*:

ATGGAATCATCTTCTCATTTGGAGTGATCCTTGCTGTGCTGGCTCCCTCATCATTGCTACTAACACACTAG
 TGGCTGTGGCTGTGCTGTTGATCCACAAGAATGATGGTGTCACTCTGCTTCACCTTGAAATCTGGCTGT
 GGCTGACACCTTGATTGGTGTGGCCATCTCTGGCTACTCACAGACCAGCTCTCCAGCCCTCTGGCCACA
 CAGAAGACCTGTGCAGCCTGCGGATGGCATTGTCACCTCCCTCCGACTTGAAAGATCATGAGTGGGTTGTGGC
 TGATCACCTTGACAGGTACCTTGCATCAAGCAGCCCTCCGACTTGAAAGATCATGAGTGGGTTGTGGC
 CGGGCCTGCATTGCCGGCTGTGGTTAGTGTCTTACCTCATTGGCTTCCACTCGGAATCCCCATGTT
 CAGCAGACTGCTACAAAGGGCAGTGCAGCTTGTGTTACCTCATTGGCTTCCACTCGGAATCCCCATGTT
 GCGTGGCTTCTCCCAGCCATGCTCCTTTGTCTTACTGCGACATGCTCAAGATTGCGCTCCATGCA
 CAGCCAGCAGATTGAAAGATGGAACATGCAGGAGCCATGGCTGGAGGTTATCGATCCCCACGGACTCCAGC
 GACTCAAAGCTCTCGTACTGTGTTCTGTTCTATTGGAGCTTGCTCTATCTGGACCCCTTCTTATCA
 CTGGCATTGTGCAAGGTGGCCTGCCAGGAGTGTCACTCTACCTAGTGCTGGAACGGTACCTGTGGCTGCTCG
 CGTGGGCAACTCCCTGCTCAACCCACTCATCTATGCTTATTGGCAGAAGGAGGTTGCGACTGCAGCTCTACCAC
 ATGGCCCTAGGAGTGAAAGAAGGTGCTCACCTCATTCCTCTTCTCGGGCCAGGAATTGTGGCCAGAGA
 GGCCAGGGAAAGTTCTGTCACATCGTCACTATCTCCAGCTCAGAGTTGATGGCT**AA**

The following amino acid sequence <SEQ ID NO. 74> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 73:

MESSFSFGVILAVLASLIATNTLVAVAVVLLIHKNDGVSLCFTLNLAVALD**TLIGVAISGLLTDQLSSPSRPT**
QKTLCSLRMAFVTSSAAASVLTVMLITFDRYLAIKQPFRYLKIMSGFVAGACIAGLWLVSYLGFLPLGIPMF

DOCKET NO.: 411USPHRM311

PATENT

QQTAYKGQCSFFAVFHPHVLTLSVGFFPAMLLFVFFYCDMLKIASMHSQQIRKMEHAGAMAGGYRSPRTPS
 DFKALRTVSLIGSFALSWTPFLITGIVQVACQECHLYLVLERYLWLLGVNSLLNPLIYAYWQKEVRLQLY
 HMALGVKKVLTSLFLSARNCGPERPRESSCHIVTISSEFDG

The following DNA sequence **TL-GPCR-seq5** <SEQ ID NO. 75> was identified in *H. sapiens*.

AACTGGAAGGGCAGCCGCTGCGGCCACGAACACCTCTCAAGCAGTGGACTTGGACACGGCTTCAAGCTG
 GTGGCTGGCCCCCGAGTCCGGCTCTGAGGCACGGCGTCGACTTAAGCGTTGCATCCTGTTACCTGGAGA
 CCCTCTGAGCTCTCACCTGCTACTTCTGCCGCTGCTCTGCACAGAGCCGGCGAGGACCCCTCCAGG**ATGC**
 AGGTCCCACACGGACCGCCGGACAACCGACGCTGCAGATGCTGCGGAACCCGGCGATCGCGTGGCCCT
 GCCCGTGGTGTACTCGTGGTGGCCGGTCAAGCATCCGGCAACCTCTCTCTGTTGGGTGCTGTGCCGG
 CGCATGGGGCCACAGATCCCCGTGGTCATCTCATGATCAACCTGAGCGTCACGGACCTGATGCTGGCCAGCG
 TGTTGCCTTCCAATCTACTACCATTGCAACCGCCACCACTGGGTATTGGGGTGTGCTTGTCAACGTGGT
 GACCGTGGCCTTTACGAAACATGTATTCCAGCATCCTCACCATGACCTGTATCAGCGTGGAGCGCTTCTG
 GGGGTCTGTACCCGCTCAGCTCAAGCGCTGGCGCCGCGTGTACCGGGTGGCCGCGTGTGCAGGGACCT
 GGCTGCTGCTCTGACCGCCCTGTCCTCGTGGCGCACCGATCTCACCTACCCGGTGCACGCCCTGGGCAT
 CATCACCTGCTTCGACGTCTCAAGTGGACGATGCTCCCAGCGTGGCCATGTGGCCGTGTTCTCACC
 ATCTCATCCTGCTGTTCTCATCCGTTGATCACCGTGGCTGTTACACGGCCACCATCCTCAAGCTGT
 TGCACGGAGGGAGGCGACGGCCGGAGCAGCGGAGGGCGCGGGTGGGCTGGCCGCGGTGGTCTTGTGGC
 CTTTGTACCTGCTTCGCCCCCAACAACCTCGTGTCTCAGCTGCTCAACAACTGCTGGACCCGGTGGTTATT
 AGCTACTACCACTGTACAAGCTCACGCTGTCTCAGCTGCTCAACAACTGCTGGACCCGGTGGTTATT
 ACTTGCGTCCCCGGAAATTCCAGCTGCGCTGCGGAATATTGGGCTGCCGGGTGGCCAGAGACACCC
 GGACACCGCGCCCGAGAGCCTTCCGCGCAGGACACGTCGCGCTCCGAGGCGCAGCTGGTGTGCACCC
 GGGATGGAGGGAGGCCACCGAGGCCCCCTCCAGAGGCAGGGAGAGTGTGTTCT**TGAG**CTCCGGGGCGCAGCTTG
 GAGAGCCGGGGCGCAGCTGGAGGGATCCAGGGCGCATGGAGAGGCCACGGTGCAGAGGTTCAAGGGAGAAC
 AGCTGCGTTGCTCCCAGGCACTGCAAGAGGCCGGTGGGAAGGGTCTCCAGGCTTATTCCCTCCAGGC
 CAGAGGCACCGGTGAGGAAGGGTCTCCAGGCTTACTCAGGGTAGAGAAACAAGCAAAGCCAGCGCACA
 GGGTCTGTTATCCTGCAAGAGGGTGCCTCTGCCTCTGTGTCAGGGGACAGCTGTGTCACCACGCC
 TAATTTGTATTTTTAGTAGAGCTGGGTGTCACCCCGAGCTCCTAGACACTCCTCACACCTGTCCA
 TACCGAGGATGGATATTCAACCAGCCCCACCGCTACCCGACTCGGTTCTGGATATCCTCTGTGGCGAAC
 TGCGAGCCCCATTCCCAGCTCTCCCTGCTGACATCGTCCCTAGACACACTGTCCATACCGAGGATGG
 TATTCAACCAGCCCCACCGCTACCCGACTCGGTTCTGGATATCCTGTGGCGAACGTGCGAGCCCCATT
 CCAGCTCTCCCTGCTGACATCGTCCCTAGTTGTGGCTTCTCATTCTCCTCCAGGGGTTCTG
 GTCTCCGTAGCCGGTGCACGCCGAATTCTGTTATTCACTCAGGGGACTGTGGTTGTGGTTGGAA
 TTCTCTTCAGAGGAGGCCCTGGGCTCTGCAAGTCAGCTACTCCGTGCCACTTCCCTCACACACAC
 ACCCCCCCTCGTGCCGAATT

The following amino acid sequence <SEQ ID NO. 76> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 75.

MQVPNSTGPDNATLQMLRNP*AI*VALPVVSLVAVSI*PG*NLFSLWVLCR*RM*PRSP*S*VIF*M*INLSVT*D*MLA
 SVLP*Q*IYH*C*NRHHWVFGVLLCNVVT*V*AFYAN*M*YSS*I*LT*M*TC*S*VERFL*G*VLY*P*LSS*K*R*W*RR*R*Y*V*AA*C*
*T*W*L*LL*L*T*A*LS*P*L*A*RT*D*L*T*Y*P*HAL*G*i*I*TC*F*D*V*L*K*W*T*ML*P*S*V*AM*W*FL*F*IF*I*LL*F*IP*F*V*I*TV*A*CT*I*L*K*
 LL*R*TE*A*H*G*RE*Q*RR*A*V*G*LA*V*V*L*A*F*V*T*C*F*A*P*N*F*V*L*A*H*i*V*S*R*LF*Y*G*K*S*Y*H*V*Y*K*L*T**L**C**S**L**N**C**L**D**P**F*
 YY*F*AS*R*EF*Q*RL*R*RE*Y*LG*C*RR*V*PR*D*T*L*D*T*R*R*ES*L**F*SART*T*SV*R*SE*A*GA*H*PEG*M*EGAT*R*P*G*L*Q*RE*S**V*F

The following DNA sequence **nGPCR-9** <SEQ ID NO. 77> was identified in *H. sapiens*:

ATGGAGTCGGGGCTGCTGGCGCCGGCGCCGGTGAGCGAGGTCACTGTCCTGCATTACAACTACACCGCGAACGC
 TCCCGGGTGC*CG*CTACCGCGGGTGC*CG*CCGCGACGCCGTGGTGTGCCTGGCGGTGCGCCTT
 CATCGTGTAGAGAATCTAGCGTGTGTTGCTGCGACGCCACCCCGCGCTTCCACGCTCCATGTTCTG
 CTCCTGGCGAGCTCACGTTGTCGGATCTGCTGGCAGGCCGCCACGCCAACATCCTACTGTCGGGGC
 CGCTCACGCTGAAACTGCCCCCGCCTCTGGTTCGCACGGGAGGGAGGCCCTTCGACTCACGCGTC
 CGTGC*T*GAGCCCT*T*GGCCATCGCGCTGGAGGCCAGCCTCACCATGGCGCAGGGGGCCCGCCGTCTCC
 AGTGGGGGCCACGCTGGCGATGGCAGGCCGGCTGGGGCGTGTGCTCCTCGGGCTCTGCCAGCGC

DOCKET NO.: 411USPHRM311

PATENT

TGGGCTGGAATTGCCTGGGTCGCCCTGGACGCTTGCTCCACTGTCTTGCCGCTACGCCAAGGCCTACGTGCT
 CTTCTGCGTGCCTCGCCTTCGTGGGATCCTGCCGCTATCTGTGCACTCTACGCGCAGCTACTGCCAGGTA
 CGCGCCAACGCGCGCCTGCCGGCACGGCCGGACTGCCGGGACCACCTGACCCGGCGCTCGCAAGC
 CGCGCTCGCTGGCCTTGCTGCGCACGCTCAGCGTGGTGCCTCTGCCCTTGATGGCATGGGGCCCCCTT
 CCTGCTGCTGGCTGACGTGGCGCCGGCACCTGCTACTCCTGCAGGCCATCCCTCTGG
 GGACTGGCCATGGCCAACTCACCTCTGAACCCCATCATCTACACGCTACCAACCGCGACCTGCCACGCG
 TCCTGCGCTGGTCTGCGGACGCCACTCTGCGCAGAGACCCGAGTGGCTCCAGCAGTCGGCAGCG
 GGCTGAGGCTTCCGGGGCCTGCCGCTGCCCTGCCCTGATGGGAGCTTCAGCGGCTCGAGC
 TCATCGCCCCAGCGCACGGCTGGACACCAGCGGCTCACAGGCAGCCCCGGTCACCCACAGCGCCCGA
 CTCTGGTATCAGAACCGGCTGCAGACTGA

The following amino acid sequence <SEQ ID NO. 78> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 77:

MESGLLRPAPVSEVIVLHYNYTGKLRGARYQPGAGLRAADVCLAVCAFIVLENLAVLLVLGRHPRFHAPMFL
 LLGSLTLSDLLAGAAYAANILLSGPLTLKSPALWFAREGGVFVALTASVLSLLAIALERSLTMARRGPAPVS
 SRGRTLAMAAAAGVSVLLGLLPALGNCLGRLDACSTVLPLYAKAYVLFVLAFCVGLAIAICALYARIYCQV
 RANARRLPARPGTAGTTSTRARRKPRSLALLRTLSVLLAFVACWGPLFLLLLDVACPARTCPVLLQADPFL
 GLAMANSLLNPIIYTTLTNRDLRHALLRLVCCGRHSCGRDPSGSQQSASAAEASGGLRRCLPPGLDGSFSGSER
 SSPQRDGLDTSGSTGSPGAPTAARTLVSEPAAD

The following DNA sequence **nGPCR-11** <SEQ ID NO. 79> was identified in *H. sapiens*:

ATGTACAACGGGTCGTGCGCATCGAGGGGGACACCATCTCCAGGTGATGCCGCCGTGCTCATTTGTGG
 CCTTGTGCTGGGCGCACTAGGCAATGGGTCGCCCTGTGTGGTTCTGCTTCCACATGAAGACCTGGAAAGCC
 CAGCACTGTTACCTTCAATTGGCCGTGGCTGATTCCCTATGATCTGCCCTGCCCTTCGGACAGAC
 TATTACCTCAGACGTAGACACTGGGCTTTGGGACATCCCTGCCGAGTGGGCTCTCACGTTGCCATGA
 ACAGGGCCGGAGCATCGTCTCCTACGGTGGCTGGCGCTGGCATCGTCTGCCCTGTGGCCCTGGTACCTGGGA
 CGCGGTGAAACACTATCCACCCGGGTGGCGCTGGCATCGTCTGCCCTGTGGCCCTGGTACCTGGGA
 ACAGTGTATCTTGCTGGAGAACCATCTCGCTGCAAGAGACGCCGTCTCTGTGAGAGCTTCATCATGG
 AGTCGGCCAATGGCTGGCATGACATCATGTTCCAGCTGGAGTTCTTATGCCCTGGCATCATTTATTG
 CTCCTCAAGATTGTTGGAGCCTGAGGCGGAGGCAGCAGCTGGCCAGACAGGCTGGATGAAGAAGGCACC
 CGGTCATCATGGTGGTGGCAATTGTGTTCATCACATGCTACCTGCCAGCGTGTCTGCTAGACTCTATTCC
 TCTGGACGGTGCCCTCGAGTGCCTGCGATCCCTGTCCATGGGGCCCTGCAACATAACCCCTAGCTTCACCTA
 CATGAACAGCATGCTGGATCCCTGGTGTATTATTCAAGCCCTCCTTCCAAATTCTACAAACAGCTC
 AAAATCTGCAGTCTGAAACCCAAGCAGCCAGGACACTCAAAACACAAGGCCAGAGATGCCAATTTCGA
 ACCTGGTCGAGGAGTTGCATCAGTGTGGCAAATAGTTCAAAGCCAGTGTGATGGCAATGGGATCCCCA
 CATTGTTGAGTGGCACTGA

The following amino acid sequence <SEQ ID NO. 80> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 79:

MYNGSCCRIEGDTISQVMPLLIVAFVLGALGNVALCGFCFHMKTWKPSTVYLFNLAVADFLIMCLPFRD
 YYLRRRHWAEGDIPCRVGLFTLAMNRAGSIVFLTVVAADRYFKVVFPHAVNTISTRVAAGIVCTLWALVILG
 TVYLLLENHLCVQETAVSCESFIMESANGWHIDMFQLEFFMPLGIILFCFSFKIVWSLRRRQQLARQARMKKAT
 RFIMVVAIVFITCYLPSVSARLYFLWTPSSACDPSVHGALHITLSFTYMNSMLDPLVYYFSSPSFPKFYNKL
 KICSLPKQPGHSKTQRPEEMPISNLRRSCISVANSFQSQSDGQWDPHIVEWH

The following DNA sequence **nGPCR-16** <SEQ ID NO. 81> was identified in *H. sapiens*:

ATGACAGGGTACCTCCCAAGTATGCCCTGGCCACAATACCTCCAGGAATTCCCTTGCGATCCTATAGACACCC
 CACTTAATCAGCCCTACTTCATAGTCTTATTGGCGGGCTGGTGGGTGTCATTCCATTCTTCCCTGG
 TGAAAATGAACACCCGGTCAGTGACCAACATGGCGGTCAATTAACTGGTGGTGGTCCACAGCGTTTCTGCT
 GACAGTGCCATTGCTTGACCTACCTCATCAAGAAGACTGGATTTGGGCTGCCCTCTGCAAATTGTG
 AGTGCCATGCTGCACATCCACATGTACCTCACGTTCCATTCTATGTGGTATCCTGGTACCCAGATACTCA

DOCKET NO.: 411USPHRM311

PATENT

TCTTCTTCAGTCAAAGACAAAGTGGAAATTCTACAGAAAATGCATGCTGTCAGTGCCTGGCATGTCAGCTGGTATTGTCATTGTTGACCCCTGGTGTCTCCCGGTATGGAATCCATGAGGAATACAATGAGGAGCACTGTTAAATTCACAAAGAGCTGCTTACACATATGTGAAAATCATCAACTATATGATAGTCATTTTGTCATAGCCGTTGCTGTGATTCTGTTGGCTTCAGGTCTTCATCATTATGTTGATGGTCAGAAGCTACGCCAATCTTACTATCCCACCAGGAGTTCTGGGCTCAGCTGAAAACCTATTTTATAGGGGTCATCCTGTTGTTCCTCCCTACCAAGTCTTACAGGTTAGGATCTATTACTGAAATGTTGACGCATTCCAATGCCGTAAACAGCAAGGTTGCATTTATAACGAAATCTCTTGAGTGTAAACAGCAATTAGCTGCTATGATTGCTCTTTGCTTTGGGGAAAGCCATTGGTTAACGAAAAGATAATTGGCTTATGGAATTGTTGTTGTGCCGTTAGCCACAAACTACAGTATTTCATATTGCTTCCCTTATATTGGAATAAAATGGGTATAGGGGAGGTAAAGAATGGTATTTCATTACTTGATCAAAACCATGCCTTGATGTACCCAAAACAAAAGGACTATAAAATGCAAGAGCCCTCATTGAGTCCTATGGATCCCTCCATCTGAGTGTGGCGTACAAAGACAGTGTGTTGAATCCACCTGGAGTTGCAATATTACATTATTTCCAGTACAGAATGTCGTGGCCCATGAAAGCAACATAGGTTTAAGAGTTTAGAGTTTCATTAGCTCATTCTAAGTCCCTGTTGAAGCATGGCTCTTAGGTTTGACTGAACCTCAGACCTTAGTTCCTTTCATCCCACCTCACCTTAGGTAAGTAAATTCTGGCCACCACCCAGCTCAAAGACACAAACTCTCCTTCGCTAACCCAGGTTAGATGTCCTATTCTCATGCCGTATAAAACTGATAAGGGGAGAGAATAGTTAAAATTTTCTTAGGGTATCATAACTCTGGTAGGAAGTCATCTGTCAGAAATCAAGAGAAAAGAACGTTGCGCCCTCCTGTTATAACAAGGGTTCTAGATTGCTCTGTGAAAGGTCGTTAAGGACTTGGGATCAACTCCTCAATTATCACCAATTGCACTGTTGCTCCAAAATCATTAAAAGCTTACTGGACATATCTAÇATAATGGTAAAGTAAATTAGAGACTATCCCTGACTAATGTCGTGGTAGGCATTAAATGAGTTCCAAGGGAAAGTGAATTAAATTGTTTTGAGAGAATTTCTAGATGTCCTGGGCCACAGTTAATTAAAGATTAGGTTAGGGGGACAGAAAGTTATACTGAAATCTTAGGCTCCCTCCGCGTTAAAATTATATATATATATTTAAATTATACCTTAAAGTCTGGGATACATGTCAGGTTGTTACATAGGTATACACGTGCCATGGTGGTTGCGGCACCTGTCACACCATCTACATTAGGTATTCTCTTAATGCTCTCCCTAGCCCCCACCCCTGGACAGGCCCATTGTGTGATGTCCTCCCTGTGTCATGTGTTTCAATTGTCACCTCCACTTCTAAGTGAGAACATGCGGTGTTCTGTTAGTTGCTGAGAATGATGGTTCCAGGTTAAAATTATATATTTAAATAATGAAAATGTGTTTAAAGAGGACTTTGAGAAGTATATAGAAAACCATTAATTAGACTCTGTAAGATTAGGTTGCAAGAAGGTTCTGAATATTGAGAAGACTGGATAAAATATGCCCCAAAGCAATAAAATCATAATTCTTAAATAGGAAAATAACTAATGGGAACCTGGCTTAATACTCGGGATGAAATAATCTGTAACACAAACCTGCACATGTACCCCTGAACCTAAATAAAATTAAAGTATAATAATAATGGATTCTT

The following amino acid sequence <SEQ ID NO. 82> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 81:

MTGDFPSMPGHNTSRNSSCDPIVTPHLISLYFIVLIGGLVGVISILFLLVKMNTRSVTTMAVINLVVVHSVFL
LTVFRLTYLIKTKWMFGLPFCKFVSAMLHIMYLTFLYVVLVTRYLIFFKCKDKVEFYRKLHAVAASAGM
WTLVIVIVVPLVVSRYGIHEEYNEEHCFKFHKELAYTVKIIINYMIVIFVIAVAVILLVQVFIIMLMVQKLR
HSLLSHQEFWAQLKNLFIGVILVCFLPYQFFRIYYLNVVTHSNACNSKVAFYNEIFLSVTAISCYDLLLGVF
GGSHWFKQKIIIGLWNVCVLCR

The following DNA sequence **nGPCR-40** <SEQ ID NO. 83> was identified in *H. sapiens*:

GCAGGAGCACTGAAAATCAGGAACAATCCTGTATTTTGTCAGTAAATCAACAAGGACAAAATCTCCATATGTTAAATAACAGCGTTATGAGCAGCAATTCTCATCCCTGCTGGCTGTCAGCTGTGCTACCGAACGTGAATGGGTCCTGTGAAAATCCCTCTGCCGGGATCCGGGTGATTCTGTACATAGTGTGTTGGCTTGGGCTGTGCTGGCTGTGTTGGAAACCTCCTGGTGTGATTCAATTCTCCATTCAAGCAGCTGCACCTCTCCGACCAATTCTCGTTGCCCTCTGGCCTGCGCTGATTCTTGGTGGGTGTGACTGTGATGCCCTCAGCATGGTCAGGACGGTGGAGAGCTGCTGGTATTGGGAGGAGTTTGACTTTCCACACCTGCTGTGATGTGGCTTGTACCTTGTACCTCTCTTCACTTGTGCTTCACTCCATCGACAGGTACATTGCGGTTACTGACCCCCCTGGCTATCCTACAGCGGTGCTGTGTTCTACACAGGTGTATGACGATGGGCTGGAGGAATTATCTGATGCCCTAAACTGTATAGGAGGTTGTGAGACCCGGTTGAAATCAAAACTGGGTTGACAGATTCTATCCTTCTTATACCTACCTTATTATGATAAATTCTGTATGGTAACATATTCTTGTGGCTAGACGACAGGCAGAAAAGATAGAAAATACTGGTAGCAAGACAGAATCATCCTCAGAGAGTTACAAAGCCAGAGTGGCCAGGGAGAGAGAGAGAGAGCAGCTAAACCCCTGGGGTCACAGTGGTAGCATTGATGCCCTTATGGGTTATAACCCCTGCCGTATTGAGATTGCTGTTGCTTATTATAACTCAGCCATGAATCCTTGTGATTATGC

DOCKET NO.: 411USPHRM311

PATENT

TTTATTTACCCATGGTTAGGAAAGCAATAAAAGTTATTGTAACTGGTCAGGTTAAAGAACAGTCAGCA
ACCATGAATTGTTCTGAACATATA**TAA**

The following amino acid sequence <SEQ ID NO. 84> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 83:

MSSNSSLVAVQLCYANVNGSCVKIPFSPGSRVILYIVFGFGAVLAVFGNLLVMISILHFKQLHSPTNFLVAS
LACADFLVGVTVMPFSMVRTVESWCYFGRSFCFTFHCCDVAFCYSSLFHLCFISIDRYIAVTDPVYPTKFTV
SVSGICISVSWILPLMYSGAVFYTGTVYDDGLEELSDALNCIGGCQTVVNQNWLDFLSFFIPTFIMIILYGN
IFLVARRQAKKIENTGSKTESSSESYKARVARRERKAAKTLGVTVVAFMISWLPYSIDSLIDAFMGFITPACI
YEICCWCAYYNSAMNPLIYALFYPWFRKAIVKIVTQVLKNSSATMNLFSEHI

The following DNA sequence **nGPCR-54** <SEQ ID NO. 85> was identified in *H. sapiens*:

ACCATGAATGAGCCACTAGACTATTAGCAAATGCTCTGATTTCCCGATTATGCAGCTGCTTTGGAAATT
GCACTGATGAAAACATCCCACTCAAGATGCACTACCTCCCTGTTATTTATGGCATTATCTCCTCGTGGGATT
TCCAGGCAATGCGAGTAGTGATATCCACTTACATTTCAAATGAGACCTTGAAGAGCAGCACCATCATTATG
CTGAACCTGGCCTGCACAGATCTGCTGTATCTGACCAGCCTCCCCCTCCTGATTCACTACTATGCCAGTGGCG
AAAACCTGGATCTTGAGATTTCATGTAAGTTATCCGCTTCAGCTTCCATTCAACCTGTATAGCAGCAT
CCTCTCCTCACCTGTTCAGCATCTCCGCTACTGTGTGATCATTCACCCAAATGAGCTGCTTTCCATTAC
AAAACTCGATGTGCAGTTGAGCCTGTGCTGTTGAGTCACTGGTAGCTGTCAATTCCGATGACCT
TCTTGATCACATCAACCAACAGGACCAACAGATCAGCCTGTCTGACCTCACCAAGTCCGATGAACCTAAC
TATTAAGTGGTACAACCTGATTTGACTGCAAGTACTTCTGCCCTCCCTGGTGATAGTGACACTTGCTAT
ACCACGATTATCCACACTTGACCCATGGACTGCAAACACTGACAGCTGCCCTAACGAGAAAGCACGAAGGCTAA
CCATTCTGCTACTCCTGCATTAACTGATGTTTACCCCTCCATATCTTGAGGGTCATTCAAGGATCGAAT
CTCAGCCTGCTTCATCAGTTGTCATTGAGAACATGAGCTCATGAAGCTTACATCGTTCTAGACCATTAT
GCTGCTCTGAACACCTTGGTACCTGTTACTATATGTTGTCAGCAGCAACTTCAGCAGGCTGTCTGCT
CAACAGTGAGATGCAAAGTAAGCGGGAACCTTGAGCAAGCAAAGAAAATTAGTTACTCAAACAAACCT**TGA**

The following amino acid sequence <SEQ ID NO. 86> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 85:

MNEPLDYLNASDFPDYAAFGNCTDENIPLKMHYPVYGIIFLVGFPGNAVVISTYIFKMRPWKSSTIIML
NLACTDLLYLTSLPFLIHYYASGENWIFGDFMCKFIRFSFHFNLSSILFLTCFSIFRYCVIHPMSCFSIHK
TRCAVVACAVVWIISLVAVIPMTFLITSTNRTNRSACLDLSSDELNTIKWYNLILTASTFCLPLVIVTLCYT
TIIHTLTHGLQTDSDLKQKARRLTILLLAFYVCFLPFHILRVIQDRISACFQSVPRLRISMKLTSFLDHYA
ALNTFGNLLLYVVVSDNFQQAVCSTVRCKVSGNLEQAKKISYSN

The following DNA sequence **nGPCR-56** <SEQ ID NO. 87> was identified in *H. sapiens*:

AAAAATTGCTGACTGAACATTGAACTTGGAAATAAGTCCCTCCAAAATAACTATTCTTCAACAG
AGAGTAATAGGTAATGTTAGAAGTGAGAGGACTCAAATTGCCATGATTACTCTTTATTTCTCCT
AGGTTCTGGATAAGTATGTGCAAATAAAAATAACATGAGAAGGAAGTGTAACTGATTATGGATTGG
AAAAGATAATCACACACAAAGGAAAGTAAACTGATTGACAGCCCTCAGGA**ATGATGCC**CTTGTGCCAC
AATATAATTAAATTCTGTTGAAAAACAACACTGGTCAAATGATGTCGTGCTTCTGTACAGTTAATGG
TGCTCATAATTCTGACCAACTCGTTGGCAATCTGATAGTTATTGTTCTATATCACACTCAAACAAACTTC
TACCCCAACAAATTGGCTCATTCCATGCCACTGTGGACTTCTCTGGGGTGTCTGGTATGCCCTAC
AGTATGGTGAGATCTGCTGAGCACTGTTGGTATTGGAGAAGTCTCTGTAAAATTACACACAAGCACCGACA
TTATGCTGAGCTCAGCCTCCATTTCATTTGCTTCTGATCTCCATTGACCGCTACTATGCTGTGATCC
ACTGAGATATAAGCCAAGATGAATATCTTGGTTATTGTGTGATCTCATTAGTTGGAGTGTCCCTGCT
GTTTTGCTTGGATGATCTTCTGGAGCTAAACTTCAAAGGCGCTGAAGAGATATATTACAAACATGTC
ACTGCAGAGGGAGGTGCTCTGTCTTCTGAAATACTGGGGTACTGACCTTATGACTCTTTATAT
ACCTGGATCTATTATGTTATGTGTCTATTACAGAATATCTTATCGCTAAAGAACAGGCAAGATTAAATTAGT
GATGCCAATCAGAAGCTCAAATTGGATTGGAAATGAAATTTCACAAAGCAAAGGAAAGCTG
TGAAGACATTGGGGATTGTGATGGGAGTTCTTAATATGCTGGTGCCTTCTTATCTGTACAGTCATGGA

DOCKET NO.: 411USPHRM311

PATENT

CCCTTTCTTCACTACATTATTCCACCTACTTGAATGATGTA

The following amino acid sequence <SEQ ID NO. 88> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 87:

MMPFCHNIINISCVKNNWSNDVRASLYSLMVLIILTTLVGNLIVIVSISHFKQLHTPTNWLIHSMATVDFLLG
CLVMPYSMVRSAEHCWYFGEVFCKIHTSTDIMLSSASIFHLSFISIDRYYAVCDPLRYKAKMNLIVICVMIFI
SWSVPAVFAFGMIFLELNFKGAEEIYYKHVHCRGGCSVFFSKISGVLTMFMTSFYIPGSIMLCVYYRIYI
QARLISDANQKLQIGLEMKNGISQSKERKAVKTLGIVMGVFLICWPFFICTVMDPFLHYIIPPTLNDARGSR
ANSA

The following DNA sequence **nGPCR-56** <SEQ ID NO. 89> was identified in *H. sapiens*:

GGA**ATGATGCC**CTTTGCCACAATATAATTAAATTCTGTGTGAAAAACAACGGTCAAATGATGTCCGTG
CTTCCCTGTACAGTTAACGGTGCTCATAATTCTGACCACACTCGTTGGCAACTGATAGTTATTGTTCTAT
ATCACACTCAAACAACACTCATACCCCAACAAATTGGCTCATTCCATGCCACTGTGGACTTTCTCTG
GGGTGTCTGGTCATGCCTACAGTATGGTGAGATCTGCTGAGCAGTGTGGTATTGAGAAGTCTCTGTA
AAATTCAACACAAGCACCGACATTATGCTGAGCTCAGCCTCCATTTCATTTGCTTTCATCTCCATTGACCG
CTACTATGCTGTGTGATCCACTGAGATATAAGCCAAGATGAATATCTTGTTATTGATGATCTTC
ATTAGTTGGAGTGTCCCTGCTGTTTGCAATTGAATGATCTTCTGGAGCTAAACTCAAAGGCCTGAAG
AGATATATTACAAACATGTTCACTGCAGAGGAGGTGCTCTGTCTTTAGCAAAATATCTGGGTACTGAC
CTTATGACTCTTTATATACCTGGATCTATTATGTTATGTCATTACAGAATATATCTTATCGCTAA
GAACAGGCAAGATTAATTAGTGTGATGCCAATCAGAACGCTCAAATTGGATTGAAATGAAAATGGAATTTCAC
AAAGCAAAGAAGGAAAGCTGTGAAGACATTGGGATTGTGATGGAGTTCTCTAATATGCTGGTGCCTTT
CTTATCTGTACAGTCATGGACCCTTTCTCACTACATTATCCACCTACTTGAATGATGATTGATTG
TTTGCTACTTGAACCTACATTAACTCCAAATGGTTATGCATTTCATCTGGTTAGAAAAGACTGA
AGATGATGCTTTGGTAAAATTCCAAAAGATTCCAGGTGTAAATTATTTGGAATTGAGTT**CATA**
G

The following amino acid sequence <SEQ ID NO. 90> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 89:

MMPFCHNIINISCVKNNWSNDVRASLYSLMVLIILTTLVGNLIVIVSISHFKQLHTPTNWLIHSMATVDFLLG
CLVMPYSMVRSAEHCWYFGEVFCKIHTSTDIMLSSASIFHLSFISIDRYYAVCDPLRYKAKMNLIVICVMIFI
SWSVPAVFAFGMIFLELNFKGAEEIYYKHVHCRGGCSVFFSKISGVLTMFMTSFYIPGSIMLCVYYRIYI
QARLISDANQKLQIGLEMKNGISQSKERKAVKTLGIVMGVFLICWPFFICTVMDPFLHYIIPPTLNDV**LIWF**
GYLNSTFNPMVYAFFYPWFRKALKMMLFGKIFQKDSSRCKLFLESS

The following DNA sequence **nGPCR-58** <SEQ ID NO. 91> was identified in *H. sapiens*:

CTGTAAGACTAGATTGTATGAGGACTCCATGAGGTACACTTCAAGTCCTGGCATAGGATAATTACTCAA
AGGTGATGACAATGGCGCAGGGAGGGATGGTACTGCTGGAGATGCACAGCACCGTCTCCCATACTCGG
TCATTCACACCATCATTGATTCAACCAGGCACCAACTCCGTGTCAGCAGGACTCTGGGACCCAAATGGACAC
TACCA**ATGGA**ACTGACCTGGGTGCCACTGCCACAGGCCCGCACAGAGCTTGTGATGAGGACTCCTACCCC
CAAGGTGGCTGGACACGGTCTTCCCTGGTGGCCCTGCTGCTCTGGGCTGCCAGCCAATGGGTTGATGGCGT
GGCTGGCCGGCTCCAGGCCGGCATGGAGCTGGCACCGCTGCTGGGACACTGGCCCTCTGCTCAGCCTGGCCCTCTC
TGACTTCTTGTCTGGCAGCAGGCCCTCCAGATCTTAGAGATCCGGCATGGGGACACTGGCCCTGGGG
ACAGCTGCCTGGCGCTTCACTACTTCTATGGGGCTGTCTACTCCCTCCGGCTCTTCCCTGCTGGCCGCC
TCAGCCTCGACCGCTGCCGTGGCCACTGGTACCTGGTACCTGGTACGACCTGGTACCTGGTACGCGTCC
CTGGGTCTGCCCGGTGCTGGGTGCTGGCCACACTCTCAGCGTCCCTGGCTGGTCTTCCCGAGGCTGCG
GTCTGGTGGTACGACCTGGTACCTGGTACGCGTCCCTGGTACGCGTCCCTGGGACAGCGAGGAGCTGTC
TCCTGGGGGGCTTCCCTGCCCTTCCCTGCTGCTGCCACGTGCTCACCCAGGCCACAGCCTGTC
CTGCCACCGCCAAACAGCAGGCCAGCCTGCCGGCTGCCGGCTGTGGCCAGGACCATCTGTCAGCCTAT
GTGGCCTGAGGCTGCCCTACCACTGAGCTGGCCAGCTGCTACCTGGCCTTCCCTGTGGGACGTACTCTGGC
ACCTGCTCTGGGAGGCCCTGGTACTCCGACTACCTGATCCTACTCAACAGCTGCCAGGCCCTTCCCTG

DOCKET NO.: 411USPHRM311

PATENT

CCTCATGGCCAGTGGCAGACCTCCGGACCCCTGCTGCGCTCCGTGCTCTCGTCCTCGCGCAGCTCTGCGAG
 GAGCGGCCGGGCAGCTCACGCCACTGAGCCACAGACCCAGCTAGATTCTGAGGGTCCAACCTCTGCCAGAGC
 CGATGGCAGAGGCCAGTCACAGATGGATCTGTGGCCAGCCTCAGGTGAACCCCACACTCCAGCCACGATC
 GGATCCCACAGCTCAGCCACAGCTGAACCCCTACGGCCCAGCCACAGTCGGATCCCACAGCCAGCCACAGCTG
 AACCTCATGGCCCAGCCACAGTCAGATTCTGTGGCCAGCCACAGGCAGACACTAACGTCCAGACCCCTGCAC
 CTGCTGCCAGTTCTGTGCCAGTCCTGTGATGAAGCTCCCCAACCCCACCTCTGCATCCTACCCAGGGC
 CCTTGAGGACCCAGCCACACCTCCTGCCTCTGAAGGAGAAAGCCCCAGCAGCACCCGCCAGAGCGGGCC
 GGCAGGCCACAGTCAGGGTCCAGGAACACGCAGGCCACAGAGCAGTGAAGAGCCCAGGGCAGACAGA
 GGAACCAGCCAGTCAG

The following amino acid sequence <SEQ ID NO. 92> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 91:

LAWRCTAPSLPYSVIHTIIDSPGTTPCPAGLWGPQMDDTTMEADLGATGHRPTELDDEDSYPQGGWDTVFLVA
 LLLLGLPANGLMAWLAGSQARHGAGTRLALLLSLALSDFLFLAAAQFILEIRHGGHWPLGTAACRFYYFLW
 GVSYSSGLFLLAALSLSRCLLALCPHWYPGHRPVRPLWVCAGVWVLATLFSVPWLVPPEAAVWWYDLVICLD
 FWDSEELSLRMLEVLLGFLPFLLLVCVLTQATACTRCRQQPAAACRGFARVARTILSAYVVLRLPYQLAQ
 LLYLAFLWVDVYSGYLLWEALVYSDYLILLNSCLSPFLCLMASADLRTLLRSVLSSFAAALCEERPGSFTPTEP
 QTQLDSEGPTLPEPMAEAQSQMDPVAQPQVNPTLQPRSDPTAQPQLNPTAQPQSDPTAQPQLNLMQAQPQSDSV
 AQPQADTNVQTPAPAASSVPSPCDEASPTPSSHTPGALEDPATPPASEGESPSSTPPEAAPGAGPT

The following DNA sequence **nGPCR-58** <SEQ ID NO. 93> was identified in *H. sapiens*:

ATGGACACTACCATGGAAGCTGACCTGGGTGCCACTGGCCACAGGCCAGAGCTTGATGATGAGGACT
 CCTACCCCCAAGGTGGCTGGGACACGGTCTTCTGGTGGCCCTGCTGCTCCTGGGCTGCCAGCCA
 ATGGGTTGATGGCGTGGCTGGCCGGCTCCCAGGCCGGCATGGAGCTGGCACCGCTCTGGCGCTGCTCCTGCT
 CAGCTGGCCCTCTGACTTCTGTGACTCTGCAGCAGCTGGCTTCTACTACTTCCTATGGGCGTGTCTACTCCTCCGGCCTCT
 TCCGTGGCCGCCCTCAGCCTCGACCGCTGCCCTGCTGGCCTGTGCCCACACTGGTACCCCTGGGACCC
 AGTCCGCTGGCCCTCTGGGTCTGGCGCCGGTGTCTGGGTGCTGGCACACTCTTCAGCGTGCCCTGGCTGGTC
 TTCCCGAGGCTGCCGCTGGTGTACGACCTGGTACCTGCTGGGACAGCGAGGAGCTGTCGC
 TGAGGATGCTGGAGGTCTGGGGCTTCTGCCTTCCTGCTGCTGCTGCTGCCCACAGTCACCCAGGC
 CACAGCCTGCGCACCTGCCACCGCAACAGCAGCCGGCAGCCTGCCGGGGCTTCGCCCCGTGTGGCCAGGACC
 ATTCTGTCAGCTATGTGGTCTGTGAGGCTGCCCTACAGCTGGCCAGCTGCTCTACCTGGCCTTCAGGTGAACCC
 ACGTCTACTCTGGCTACCTGCTCTGGAGGCCCTGGCTACTCCGACTACCTGATCCTACTCAACAGCTGCC
 CAGCCCCCTCCTGCCTCATGCCAGTGGCCACCTCCGGACCCCTGCGCTCCGTGCTCTCGCG
 GCAGCTCTGCGAGGAGCGCCGGCAGCTCACGCCACTGAGCCACAGACCCAGCTAGATTCTGAGGGTC
 CAACTCTGCCAGAGCGATGGCAGAGGCCAGTCACAGATGGATCTGTGGCCAGCCTCAGGTGAACCC
 ACTCCAGCCACGATGGATCCCACAGCTCACGCCACAGCTGAACCCCTACGCCAGCCACAGTCGGATCCCACA
 GCCCAGCCACAGCTGAACCTCATGCCAGCCACAGTCAGACTCTGTGGCCAGCCACAGGCAGACACTAACG
 TCCAGACCCCTGCACCTGCTGCCAGTTCTGTGCCCAGTCCCTGTGATGAAGCTTCCCCAACCCCACCTCGCA
 TCCTACCCAGGGCCCTGAGGACCCAGCCACACCTCCTGCCCTGAAGGAGAAAGCCCCAGCAGCACCC
 CCAGAGGCGGCCCGGGCGCAGGCCACAGTCAG

The following amino acid sequence <SEQ ID NO. 94> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 93:

MDTTMEADLGATGHRPTELDDEDSYPQGGWDTVFLVALLLGLPANGLMAWLAGSQARHGAGTRLALLLSL
 ALSDFLFLAAAQFILEIRHGGHWPLGTAACRFYYFLWVSYSSGLFLLAALSLSRCLLALCPHWYPGHRPVR
 LPLWVCAGVWVLATLFSVPWLVPPEAAVWWYDLVICLDWDSEELSLRMLEVLLGFLPFLLLVCVLTQATA
 CRTCHRQQPAAACRGFARVARTILSAYVVLRLPYQLAQLLYLAFLWVDVYSGYLLWEALVYSDYLILLNSCLSP
 FLCLMASADLRTLLRSVLSSFAAALCEERPGSFTPTEPQTQLDSEGPTLPEPMAEAQSQMDPVAQPQVNPTLQ
 PRSDPTAQPQLNPTAQPQSDPTAQPQLNLMQAQPQSDSVAQPQADTNVQTPAPA

The following DNA sequence nGPCR-3 <SEQ ID NO. 185> was identified in *H. sapiens*:

DOCKET NO.: 411USPHRM311

PATENT

```

AGGCTCGGCCCGAAGCAGAGCCATGAGAACCCAGGGTGCCTGGCGAGCCGCTAGGCCATGGCCCCGGCG
AGGCCTGCTGGCGGTCTCCTGGTATGGTACTGGCGTGCTATCCAACGCACTGGTGTGCTTTG
TTGCCCTACAGCGCTGAGCTCCGACTCGAGCCTCAGCGTCCTCTGGTAATCTGCTCTGGCCACCTG
CTGCTGGCGCGCTGGACATGCCCTCACGCTCGGTGTATGCCGGGCGACACCGTCGGGCCCGCG
CATGCCAAGTCATTGGCTCCTGGACACCTTCTGGCGTCCAACGCCGCGCTGAGCGTGGCGCGTGAGCGC
AGACCAAGTGGCTGGCAGTGGGCTTCCACTCGCCTACGCCGACGCCCTGCGACCGCGCTATGCCGGCTGCTG
CTGGGCTGTGCTGGGACAGTCGCTGGCTCTCAGGGCTGCACTTGGCTGCTGCTGGCTACAGCA
GCGCCTCGCGCTGTCGCTGCCCTGCCCGAGGCTGAGCGTCCCGCTTCGCGACGCCCTCACGCCAC
GCTCCATGCCGTTGGCTCGTGTGCCGCTGGCGTCTGCCCTCACCTCGCTCCAGGTGACCGGGTGGCA
CGCAGACACTGCCAGCGCATGGACACCGTCACCATGAAGGCCTCGCGCTGCTGCCGACCTGACCCAGTG
TGCAGCGCTGCCTCATCCAGCAGAAGCGGCCACCAGGCCACAGGAAGATTGGATTGCTATTGC
GACCTCCATCTGCTTGGCCGTATGTCATGACAGGCTGGCGAGCTCGTGCCTCGTACCGTGAAC
GCCAGTGGGCATCCTCAGCAAGTGCCTGACCTACAGCAAGGCCTGGCCGACCGTTCACGTACTCTGC
TCCGCCGGCGTCCGCAAGTCCTGGCCGATGGTGCACCGGCTGCTGAAGAGAACCCGGCCAGCATC
CACCATGACAGCTCTGGATGTGGCCGGCATGGTGCACAGCTGCTGAAGAGAACCCGGCCAGCGTCC
ACCCACAACGGCTCTGGACACAGAGAATGATTGCTGCCCTGAGCAGACACACTGAGGGCTGGCAGGGCTC
ATGCCCTCACCTCTAAGA

```

The following amino acid sequence <SEQ ID NO. 186> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 185:

```

MPGGEALLAGLLVMVLAVALLSNALVLCCAYSAELRTRASGVLLVNLSLGHLLAALDMPFTLLGVMRGRTP
SAPGACQVIGFLDTFLASNAALSADQWLAVGFLRYAGRLRPRYYAGLLLGCAWQSLAFSGAALGCSW
LGYSSAFASCRLPPEPERPRFAFTATLHAVGFVPLAVLCLTSLQVHRVARRHCQMDTVMKALALLAD
LHPSVRQRCLIQQKRRRRHATRKIGIAIATFLICFAPYVMTRLAELVPFVTVNAQWGLSKCLTYSKAVADPF
TYSLRRPFRQVLAGMVHRLLKRTPRPASTHDSSLVAGMVHQLLKRTPRPASTHNGSVDTENDSCLQQTH

```

The following DNA sequence **nGPCR-58** <SEQ ID NO. 93> was identified in *H. sapiens*:

```

ATGGACACTACCATGGAAAGCTGACCTGGGTGCCACTGGCACAGGCCAGGGCCCCGACAGAGCTGATGAGGACT
CCTACCCCCAAGGTGGCTGGACACGGTCTTCTGGTGCCTGCTCCCTGGCTGCCAGCCA
ATGGGTTGATGGCGTGGCTGGCCGGCTCCAGGCCGGCATGGAGCTGGCACCGCTCTGGCGCTGCTCCCTGCT
CAGCCTGGCCCTCTGACTTCTTGTGCTGGCAGCAGGCCCTCCAGATCTAGAGATCCGGCATGGGGGA
CACTGGCCGCTGGGACAGCTGCCCTGCGCTTCTACTACTTCTATGGGGCTGTCCTACTCCTCCGGCCTCT
TCCTGCTGGCCGCCCTCAGCCTCGACCGCTGCCCTGCTGGCGCTGTGCCCCACACTGGTACCCCTGGCACCGCCC
AGTCGGCCTGCCCTCTGGGTCTGCAGGCCGTTCTGGGTACGACCTGGTACCTGCTGGCACACTCTGGGACAGCAGGAGCTGTCG
TTCCCCGAGGCTGCCGCTGGTACGACCTGGTACCTGCTGGCACACTCTGGGACAGCAGGAGCTGTCG
TGAGGATGCTGGAGGTCTGGGGCTTCTGCCCTTCTGCTGCTGCTGCTGCTGCCACGTGCTCACCCAGGC
CACAGCCTGTCGACCTGCCACCGCCAACAGCAGGCCAGCTGCCCTGGGGCTTCGCCCTGTGGCCAGGACC
ATTCTGTCAGCCTATGTGGCTCTGAGGCTGCCCTACCGACTGGCCAGCTGCTCTACCTGGCCTTGTGGGG
ACGCTACTCTGGCTACCTGCTGGAGGCCCTGGTCACTCCGACTACCTGATCCTACTCAACAGCTGCC
CAGCCCCCTCTGCCCTGAGGCCAGCTGCCACCGGCCAGCTGCCCTGGGGCTTCGCCCTGTGGCCAGGACC
GCAGCTCTGCGAGGAGGCCAGCTGCCAGGCCAGCTCACAGATGGATCTGTGGCCAGGCCCTGAGGTGAACCCAC
CAACTCTGCCAGGCCAGCTGCCAGGCCAGCTCACAGATGGATCTGTGGCCAGGCCCTGAGGTGAACCCAC
ACTCCAGGCCAGATGGATCCCACAGCTGCCACAGCTGAACCCCTAGGCCACAGCTGGATCCCACA
GCCCAAGCCACAGCTGAACCTCATGCCAGGCCACAGCTGAGACTCTGTGGCCAGGCCACAGGCCAGACACTAACG
TCCAGACCCCTGCACCTGCTGCCAGTTCTGTGCCCCAGTCCCTGTGATGAAGCTTCCCCAACCCATCCTCGCA
TCCTACCCAGGGCCCTTGAGGACCCAGGCCACACCTCTGCCCTGAGGAGAAAGCCCCAGCAGCACCCCG
CCAGAGGCCAGGCCAGGCCAGCTGA

```

The following amino acid sequence <SEQ ID NO. 94> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 93:

DOCKET NO.: 411USPHRM311

PATENT

```

MDTTMEADLGATGHRPRTIELDDEDSPQGGWDTVFLVALLLGLPANGLMAWLAGSQARHGAGTRLALLLSSL
ALSDFLFLAAAQFQILEIRHGGHPLGTAACRFYYFLWGVSYSSGLFLLAALSLDRCLLALCPHWYPGHRPVR
LPLWVCAGVWVLATLFSVPWLVPPEAAVWWYDLVICLDFWDSEELSRLMLEVGGFLFLLLVCVLTQATA
CRTCHRQQQPAACRGFARVARTILSAYVVLRLPYQLAQOLLYLAFLWDVYSGYLLWEALVYSDYLILLNSCLSP
FLCLMASADLRTLLRSVLSFAAALCEERPGSFTPTEPQTQLDSEGPTLPEPMAEAQSQMDPVAQPQVNPTLQ
PRSDPTAQPQLNPTAQPQSDPTAQPQLNLMQQPQSDSVAQPQADTNVQTPAPAA

```

The following DNA sequence **nGPCR-14** <SEQ ID NO. 191> was identified in *H. sapiens*:

```

ACTAACTTGGGAACTCGTATAGACCCAGCGTCGCTCCCCGCGCCGCTCGCCTCCACTTTGGTTCCCGCGT
CCTGCCCGCCCTCTCGGTGCCTCCCTTCCTCCGGGACAAGGATGAGGATCTCTTAGCCCTCAATTCTG
CCGCCGGCGCCAACATTCCGTGCCCATCTGCTGGGTGCTCAACCTGACCTGGGGCAAGGAGGCC
CTGCTCTGGGCCGCCAGCCCGGTGCGGGGACGGCGCTGTACAGCTGGCCTGGGAAGTGGCTGGCGAG
CCCCCGCGGGCACGGGGACCTGGCGTGCCTGCAGCTGCTGCAGGCATCGGGCGGGCGCTCGG
CCACCTAGTGGTGCTCATGCCCTCGAGCGCCGGCGCGGTGCTCTCCGACGGCGGCCGCTGCCG
GCGTGCCTCGCCGCCCTGGGTGCTGCTGGCACTGCTGCTGGCGTGCCTGGCGAGGCCGAGGCTGCG
GACTCCCCCTGCCGTGCCGCCGCCGCCGCCAACAGTCCCTGCAGCCAGGCGGCCGGCGCCGCCG
CCTGGCCGGGGAGCGTCGCTGCCACGGGATCTCGCCTGCCTGCAGCTGCTGGCACCTGCAGGTCTACGCGTT
CTACGAGGCCGTCGCGGGCTTCGTCGCGCTGTTACGGTCCCTGGCGTGCCTGCGGCCACCTACTCTCCGTC
TGGTGGCGGACCGGCCAGGGCCCCCGCGGTGCAAGGCCCTGGTCGGCGAGGCCAGGTCGAGGCCCTGCG
CCAGCGCGCTGCCCGGCCAACAGGTGCAAGGCTGAAGATGAGCCTGCTGCTGGCGTCTGTTCGTGGCTG
CGAGCTGCCCTACTTGGCGCCGGCTGGCGCCGCGTGGTCGTCCTGGGCCGGAGACTGGGAGGGAGAG
GGCCTGTCGGCGCGCTGCGCGTggTGGCGATGGCAACAGCGCTCTCAATCCCTCGTCTACCTCTTCC
AGGGGGCGACTGCTGGCTCCGGCACAGCTGCGGAAGGGCTGGCTCTGTGCTGCGGCCGAGGGAGG
CGCGGAGGACGAGGAGGGCCCCGGGCCACCAGGCCTCTACCGCAACGCTGGCCCCACCCCTCATTATCAC
CATGCTCGGCGGGAACCGCTGGACGAGGGCGCTGGCCCACCCCTCCGCGCCCCAGACCCCTGCGTGC
TCCTGCAAAGTGCCTCTAGGTGCTGGTCAAGAGACGGGTCATCTGTCGCTAAGGCACCTCCAGGG
AACTCGAGGCCGTCGCAAGGGCTGTCAGATACAAGGGCAGGAGAGTCTGTGAGAGAGTGAACACTGAAGTT
TCCCCTCCTCCACTCTCCTATTCCCTCTCATGTTACATTCCCTATGCTCTTCCAGTTCTCTTCC
TACAGTTCTCTCATATCTCCCATTGGAGACAGTGAGCCACTGAAAGTTGTAAAAAACAAAAGTTATT
TTTGCAGTTCTTCACGCATTATAGTGCCTGGATAATGCCATTATTTGCTGATTACCCAACTTCA
GTATTGCTGTATTACATCTGTATTACTTATTGAA

```

The following amino acid sequence <SEQ ID NO. 192> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 191:

```

MEDLFSPSILPPAPNISVPILLGWGLNLTLGQGAPASGPPSRRVRLVFLGVILVVAVAGNTTVCRLCGGGG
PWAGPKRRKMDFLVQLALADLYACGGTALSQALWELLGEPRAATGDLACRFLQLQASGRGASAHLVVLIA
LERRAVRLPHGRPLPARALAALGWLLALLALPPAFVVRGDSPSPLPPPPPTSLQPGAPPAARAWPGERR
CHGIFAPLPRWHLQVYAFYEAVAGFVAPVTVLGVACGHLLSVWRHRPQAPAAAAPWSASPGRAPAPSALPR
AKVQLSKMSLLALLFVGCELPYFAARLAAAASSGPAGDWEGEGLSAALRVVAMANSALNPVYLFQAGDC
WLRRQLRKRLGSLCCAPQGGADEEGPRGHQALYRQRWPHPHYHARREPAGRRLAPTPSAPQTPLALLRK
CLLGAWWSETGHLSLRRNLQGTRGLPGSVQITRGRRVCERVTLKLSPSSTLLFSPSHVYISLCSSSFSSLQF
LSYLPiWRQ

```

EXAMPLE 2: CLONING OF nGPCR-X

To isolate a cDNA clone encoding full length nGPCR-x, a DNA fragment corresponding to a nucleotide sequence set forth in odd numbered nucleotide sequences ranging from SEQ ID NO: 1-93, or a portion thereof, can be used as a probe for hybridization screening of a phage cDNA library. The DNA fragment is amplified by

DOCKET NO.: 411USPHRM311

PATENT

the polymerase chain reaction (PCR) method. The PCR reaction mixture of 50 μ l contains polymerase mixture (0.2mM dNTPs, 1x PCR Buffer and 0.75 μ l Expand High Fidelity Polymerase (Roche Biochemicals)), 1 μ g of plasmid, and 50 pmoles of forward primer and 50 pmoles of reverse primer. The primers are preferably 10 to 25 5 nucleotides in length and are determined by procedures well known to those skilled in the art. Amplification is performed in an Applied Biosystems PE2400 thermocycler, using the following program: 95°C for 15 seconds, 52°C for 30 seconds and 72°C for 90 seconds; repeated for 25 cycles. The amplified product is separated from the plasmid by agarose gel electrophoresis, and purified by Qiaquick™ gel extraction kit 10 (Qiagen).

A lambda phage library containing cDNAs cloned into lambda ZAPII phage-vector is plated with *E. coli* XL-1 blue host, on 15 cm LB-agar plates at a density of 50,000 pfu per plate, and grown overnight at 37°C; (plated as described by Sambrook 15 *et al.*, *supra*). Phage plaques are transferred to nylon membranes (Amersham Hybond NJ), denatured for 2 minutes in denaturation solution (0.5 M NaOH, 1.5 M NaCl), renatured for 5 minutes in renaturation solution (1 M Tris pH 7.5, 1.5 M NaCl), and washed briefly in 2xSSC (20x SSC: 3 M NaCl, 0.3 M Na-citrate). Filter membranes are dried and incubated at 80°C for 120 minutes to cross-link the phage DNA to the membranes.

20 The membranes are hybridized with a DNA probe prepared as described above. A DNA fragment (25 ng) is labeled with α -³²P-dCTP (NEN) using Rediprime™ random priming (Amersham Pharmacia Biotech), according to manufacturers instructions. Labeled DNA is separated from unincorporated nucleotides by S200 spin 25 columns (Amersham Pharmacia Biotech), denatured at 95°C for 5 minutes and kept on ice. The DNA-containing membranes (above) are pre-hybridized in 50 ml ExpressHyb™ (Clontech) solution at 68°C for 90 minutes. Subsequently, the labeled DNA probe is added to the hybridization solution, and the probe is left to hybridize to the membranes at 68°C for 70 minutes. The membranes are washed five times in 2x SSC, 0.1% SDS at 42°C for 5 minutes each, and finally washed 30 minutes in 0.1x 30 SSC, 0.2% SDS. Filters are exposed to Kodak XAR™ film (Eastman Kodak Company, Rochester, N.Y., USA) with an intensifying screen at -80°C for 16 hours.

DOCKET NO.: 411USPHRM311

PATENT

One positive colony is isolated from the plates, and replated with about 1000 pfu on a 15 cm LB plate. Plating, plaque lift to filters and hybridization are performed as described above. About four positive phage plaques are isolated from this secondary screening.

5 cDNA containing plasmids (pBluescript SK-) are rescued from the isolated phages by in vivo excision by culturing XL-1 blue cells co-infected with the isolated phages and with the Excision helper phage, as described by manufacturer (Stratagene). XL-blue cells containing the plasmids are plated on LB plates and grown at 37°C for 16 hours. Colonies (18) from each plate are replated on LB plates and grown. One colony 10 from each plate is stricken onto a nylon filter in an ordered array, and the filter is placed on a LB plate to raise the colonies. The filter is then hybridized with a labeled probe as described above. About three positive colonies are selected and grown up in LB medium. Plasmid DNA is isolated from the three clones by Qiagen Midi Kit™ (Qiagen) according to the manufacturer's instructions. The size of the insert is 15 determined by digesting the plasmid with the restriction enzymes *NotI* and *Sall*, which establishes an insert size. The sequence of the entire insert is determined by automated sequencing on both strands of the plasmids.

nGPCR-1: PCR AND SUBCLONING

20 cDNAs were sequenced directly using an AB1377 fluorescence-based sequencer (Perkin Elmer/Applied Biosystems Division, PE/ABD, Foster City, CA) and the ABI PRISM Ready Dye-Deoxy Terminator kit with Taq FS polymerase. Each ABI cycle sequencing reaction contained about 0.5 μ g of plasmid DNA. Cycle-sequencing was performed using an initial denaturation at 98°C for 1 min, followed by 50 cycles: 98°C for 30 sec, annealing at 50°C for 30 sec, and extension at 60°C for 4 25 min. Temperature cycles and times were controlled by a Perkin-Elmer 9600 thermocycler. Extension products were purified using AGTC® gel filtration block (Edge Biosystems, Gaithersburg, MD). Each reaction product was loaded by pipette onto the column, which was then centrifuged in a swinging bucket centrifuge (Sorvall model RT6000B table top centrifuge) at 1500 x g for 4 min at room temperature. 30 Column-purified samples were dried under vacuum for about 40 min and then dissolved in 5 μ l of a DNA loading solution (83% deionized formamide, 8.3 mM EDTA, and 1.6 mg/ml Blue Dextran). The samples were then heated to 90°C for three

DOCKET NO.: 411USPHRM311

PATENT

min and loaded into the gel sample wells for sequence analysis by the ABI377 sequencer. Sequence analysis was performed by importing ABI373A files into the Sequencher program (Gene Codes, Ann Arbor, MI).

The PCR reaction was performed in 50 μ L samples containing 41.9 μ L H₂O, 5 μ L 5 10x Buffer containing 15 mM MgCl₂ (Boehringer Mannheim Expand High Fidelity PCR System), 0.5 μ L 10mM dNTP mix, 1.5 μ L human genomic DNA (Clontech #6550-1, 0.1 μ g/ μ L), 0.3 μ L primer VR1A (1 μ g/ μ L), 0.3 μ L primer VR1B (1 μ g/ μ L), and 0.5 μ L High Fidelity Taq polymerase (Boehringer Mannheim, 3.5U/ μ l). The primer sequences for and, respectively were:

10 5'TCAAAGCTTATGGAATCATCTTCTCATTGGAGTGATCCTTGCTGTC, (VR1A)(SEQ ID NO: 95) corresponding to the 5' end of the coding region and containing a *HindIII* restriction site, and:

5' TTCACTCGAGTTAGCCATCAAACCTCTGAGCTGGAGATAGTGACGATGTG (VR1B)(SEQ ID NO: 96) corresponding to the 3' end of the coding region and 15 containing an *XhoI* restriction site (Genosys). The PCR reaction was carried out using a GeneAmp PCR9700 thermocycler (Perkin Elmer Applied Biosystems) and started with 1 cycle of 94°C for 2 min followed by 5 cycles at 94°C for 30 sec, 60°C for 2 min, 72°C for 1.5 min, followed by 20 cycles at 94°C for 30 sec, 60°C for 30 sec, 72°C for 1.5 min.

20 The PCR reaction was loaded onto a 0.75% agarose gel. The DNA band was excised from the gel and the DNA eluted from the agarose using a QIAquick gel extraction kit (Qiagen). The eluted DNA was ethanol-precipitated and resuspended in 4 μ L H₂O for ligation. The ligation reaction consisted of 4 μ L of fresh ethanol-precipitated PCR product and 1 μ L of pCRII-TOPO vector (Invitrogen). The reaction 25 was gently mixed and allowed to incubate for 5 min. at room temperature followed by the addition of 1 μ L of 6x TOPO cloning stop solution and mixing for 10 sec. at room temperature. The sample was then placed on ice and 2 μ L was transformed in 50 μ L of One Shot cells (Invitrogen) and plated onto ampicillin plates. Four white colonies were chosen and the presence of an insert was verified by PCR in the following manner.

30 Each colony was resuspended in 2 ml LB broth for 2 hrs. A 500 μ L aliquot was spun down in the microfuge, the supernatant discarded, and the pellet resuspended in 25 μ L of H₂O. A 16 μ L aliquot was removed and boiled for 5 min and the sample was placed

DOCKET NO.: 411USPHRM311

PATENT

on ice. The sample was microfuged briefly to pellet any bacterial debris and PCR was carried out with 15 μ L sample using primers VR1A and VR1B, described above.

Colonies from positive clones identified by PCR were used to inoculate a 4ml culture of LB medium containing 100 μ g/ml ampicillin. Plasmid DNA was purified 5 using the Wizard Plus Minipreps DNA purification system (Promega). Since the primers used to amplify the fragment of nGPCR-1 from genomic DNA were engineered to have *HindIII* and *XhoI* sites, the cDNA obtained from the minipreps was digested with these restriction enzymes. One clone was verified by gel electrophoresis to give a DNA band of the correct size. cDNA from this clone was then sequenced, 10 yielding the sequence of SEQ ID NO: 73.

nGPCR-3: PCR AND SUBCLONING

First-strand cDNA synthesis was performed following the directions for 3'-RACE ready cDNA from the SMARTTM RACE cDNA Amplification Kit (Clontech). First 3 μ l of H₂O, 1 μ l human whole brain poly A⁺ RNA (1 μ g/ μ l) (Clontech, 6516-1) 15 and 1 μ l 3'-CDS primer were mixed together, incubated at 70°C for 2 minutes, then placed on ice for 2 minutes. Added to the tube was 2 μ l 5X First-Strand buffer, 1 μ l 20 mM DTT, 1 μ l dNTP mix (10 mM) and 1 μ l Superscript II RT (200 units/ μ l) (GIBCO/BRL). The tube was incubated at 42°C for 1.5 hours then the reaction was diluted with 250 μ l of Tricine-EDTA buffer.

20 PCR was performed in a 50 μ l reaction using components that come with the Advantage[®]-GC cDNA PCR Kit. The PCR reaction contained 22.4 μ l H₂O, 10 μ l 5X GC cDNA PCR Reaction buffer, 10 μ l 5M GC Melt, 1 μ l 50X dNTP mix (10 mM each), 5 μ l human brain cDNA, 0.3 μ l of LW1649 (SEQ ID NO: 187)(1 μ g/ μ l), 0.3 μ l 25 of LW1650 (SEQ ID NO: 188)(1 μ g/ μ l), 1 μ l 50X Advantage-GC cDNA polymerase mix. The PCR reaction was performed in a Perkin-Elmer 9600 GeneAmp PCR System starting with 1 cycle of 94°C for 2 min then 8 cycles at 94°C for 15 sec, 72°C for 2 min (decreasing 1°C with each cycle), 72°C for 3 min, followed by 30 cycles of 94°C for 15 sec, 68°C for 3 min. The PCR reaction was loaded onto a 1.2 % agarose gel. The DNA band was excised from the gel, placed in GenElute Agarose spin column 30 (Supelco) and spun for 10 min at maximum speed in a microcentrifuge. The eluted

DOCKET NO.: 411USPHRM311

PATENT

DNA was EtOH precipitated and resuspended in 4 H₂O for ligation. The PCR primer sequence for LW1649 was:

GCATAAGCTGGCCATGGGCCCCGGCGAGG (SEQ ID NO: 187)

and for LW1650 was:

5 GCATTCTAGACCTCAGTGTGTGCTGC (SEQ ID NO: 188). The underlined portion of the primers matches the 5' and 3' areas, respectively, of the coding region.

10 The ligation reaction used solutions from the TOPO TA Cloning Kit (Invitrogen) which consisted of 4 μ l PCR product DNA, 1 μ l Salt Solution and 1 μ l pCRII-TOPO vector that was incubated for 5 minutes at room temperature and then placed on ice. Two microliters of the ligation reaction was transformed in One-Shot TOP10 cells (Invitrogen), and placed on ice for 30 minutes. The cells were heat-shocked for 30 seconds at 42°C, placed on ice for two minutes, 250 μ l of SOC was added, then incubated at 37°C with shaking for one hour and then plated onto 15 ampicillin plates. A single colony containing an insert was used to inoculate a 5 ml culture of LB medium. Plasmid DNA was purified using a Concert Rapid Plasmid Miniprep System (GibcoBRL) and then sequenced.

20 The DNA subcloned into pCRII-TOPO was sequenced using the ABI PRISM™ 310 Genetic Analyzer (PE Applied Biosystems) which uses advanced capillary electrophoresis technology and the ABI PRISM™ BigDye™ Terminator Cycle Sequencing Ready Reaction Kit. Each cycle-sequencing reaction contained 6 μ l of H₂O, 8 μ l of BigDye Terminator mix, 5 μ l mini-prep DNA (0.1 μ g/ μ l), and 1 μ l primer (25 ng/ μ l) and was performed in a Perkin-Elmer 9600 thermocycler with 25 cycles of 25 96°C for 10 sec, 50°C for 10 sec, and 60°C for 4 min. The product was purified using a Centriflex™ gel filtration cartridge, dried under vacuum, then dissolved in 16 μ l of Template Suppression Reagent (PE Applied Biosystems). The samples were heated at 95°C for 5 min then placed in the 310 Genetic Analyzer, yielding the sequence of SEQ ID NO: 95.

nGPCR-9: PCR AND SUBCLONING

30 The PCR reaction was performed in 50 μ l containing 34.5 μ l H₂O, 5 μ l Buffer II (PE Applied Biosystems AmpliTaq Gold system), 6 μ l 25 mM MgCl₂, 2 μ l 10 mM

DOCKET NO.: 411USPHRM311

PATENT

dNTP mix, 1.5 μ l human genomic DNA (Clontech #6550-1, 0.1 μ g/ μ l), 0.3 μ l primer VR9A (1 μ g/ μ l), 0.3 μ l primer VR9B (1 μ g/ μ l), and 0.4 μ l AmpliTaq GoldTM DNA Polymerase. The primer sequences for VR9A and VR9B were as follows:

5 VR9A 5' TTCAAAGCTTATGGAGTCGGGGCTGCTG 3' (SEQ ID NO: 101), corresponding to the 5' end of the coding region and containing a *HindIII* restriction site, and the reverse primer was:

VR9B 5' TTCACTCGAGTCAGTCTGCAGCCGGTCTG 3', (SEQ ID NO: 102), corresponding to the 3' end of the coding region and containing an *XhoI* restriction site (Genosys). The PCR reaction was carried out using a GeneAmp PCR 10 9700 thermocycler (Perkin Elmer Applied Biosystems) and started with 1 cycle of 95°C for 10 min, then 10 cycles at 95°C for 30 sec, 72°C for 2 min decreasing 1°C each cycle, 72°C for 1 min, followed by 30 cycles at 95°C for 30 sec, 60°C for 30 sec, 72°C for 1 min. The PCR reaction was loaded on a 0.75% gel. The DNA band was excised 15 from the gel and the DNA was eluted from the agarose using a QIAquick gel extraction kit (Qiagen). The eluted DNA was ethanol-precipitated and resuspended in 4 μ l H₂O for ligation. The ligation reaction consisted of 4 μ l of fresh ethanol-precipitated PCR product and 1 μ l of pCRII-TOPO vector (Invitrogen). The reaction was gently mixed and allowed to incubate for 5 min at room temperature followed by the addition of 1 μ l of 6x TOPO cloning stop solution and mixing for 10 sec at room temperature. The 20 sample was then placed on ice and 2 μ l was transformed in 50 μ l of One Shot cells (Invitrogen) and plated onto ampicillin plates. Five white colonies were chosen and were used to inoculate a 4 ml culture of LB medium containing 100 μ g/ml ampicillin. Plasmid DNA was purified using the Wizard Plus Minipreps DNA purification system (Promega). Since the primers used to PCR SEQ-9 from genomic DNA were 25 engineered to have *HindIII* and *XhoI* sites, the cDNA obtained from the minipreps was digested with these restriction enzymes. One clone was verified by gel electrophoresis to give a DNA band of the correct size. cDNA from this clone was then submitted for sequencing. One mutation was found (bp 621 T→G) and repaired as described as below.

30 The mutation in the identified clone was repaired using the QuikChange Site-Directed Mutagenesis Kit (Stratagene). The PCR reaction contained 39.3 μ l H₂O, 5 μ l

DOCKET NO.: 411USPHRM311

PATENT

10x reaction buffer, 50 ng mini-prep cDNA, 1.25 μ l primer VR9E (100 ng/ μ l), 1.25 μ l primer VR9F (100 ng/ μ l), 1 μ l 20 mM dNTP mix, 1 μ l Pfu DNA polymerase. The cycle conditions were 95°C for 30 sec, then 12 cycles at 95°C for 30 sec, 55°C for 1 min, 68°C for 10 min. One μ l of DpnI was added and the tube incubated at 37°C for 1 hr. One μ l of the DpnI-treated DNA was transformed into 50 μ l Epicurian coli XL1-Blue supercompetent cells and the entire insert was re-sequenced. The primer sequences used were:

VR9E: 5' GCATCCTGGCCGCTATCTGTGCACTCTACG 3' (SEQ ID NO: 103) and

VR9F: 5' CGTAGAGTGCACAGATAGCGGCCAGGATGC 3' (SEQ ID NO: 104) where the base underlined was the base being corrected.

The clone described above was sequenced directly using an ABI377 fluorescence-based sequencer (Perkin Elmer/Applied Biosystems Division, PE/ABD, Foster City, CA) and the ABI BigDye™ Terminator Cycle Sequencing Ready Reaction kit with Taq FS™ polymerase. Each ABI cycle sequencing reaction contained 0.5 μ g of plasmid DNA. Cycle-sequencing was performed using an initial denaturation at 98°C for 1 min, followed by 50 cycles: 96°C for 30 sec, annealing at 50°C for 30 sec, and extension at 60°C for 4 min. Temperature cycles and times were controlled by a Perkin-Elmer 9600 thermocycler. Extension products were purified using AGTC (R) gel filtration block (Edge Biosystems, Gaithersburg, MD). Each reaction product was loaded by pipette onto the column, which was then centrifuged in a swinging bucket centrifuge (Sorvall model RT6000B tabletop centrifuge) at 1500 x g for 4 min at room temperature. Column-purified samples were dried under vacuum for about 40 min and then dissolved in 3 μ l of a DNA loading solution (83% deionized formamide, 8.3 mM EDTA, and 1.6 mg/ml Blue Dextran). The samples were then heated to 90°C for 3.5 min and loaded into the gel sample wells for sequence analysis by the ABI377 sequencer. Sequence analysis was performed by importing ABI377 files into the 310 Genetic Analyzer, yielding the sequence of SEQ ID NO: 77.

nGPCR-11: PCR AND SUBCLONING

PCR was performed in a 50 μ l reaction containing 32 μ l H₂O, 5 μ l 10X TT buffer (140 mM Ammonium Sulfate, 0.1 % gelatin, 0.6 M Tris-tricine pH 8.4), 5 μ l 15

DOCKET NO.: 411USPHRM311

PATENT

mM MgS0₄, 2 μ l 10 mM dNTP, 5 μ l human genomic DNA (0.3 μ g/ μ l)(Clontech), 0.3 μ l of LW1564 (1 μ g/ μ l), 0.3 μ l of LW1565 (1 μ g/ μ l), 0.4 μ l High Fidelity Taq polymerase (Boehringer Mannheim). The PCR reaction was performed in a GeneAmp 9600 PCR thermocycler (PE Applied Biosystems) starting with 1 cycle of 94°C for 2 min followed by 17 cycles at 94°C for 30 sec, 72°C for 2 min decreasing 1°C each cycle, 68°C for 2 min, then 25 cycles of 94°C for 30 sec, 55°C for 30 sec, 68°C for 2 min. The PCR reaction was loaded onto a 1.2 % agarose gel. The DNA band was excised from the gel, placed in GenElute Agarose spin column (Supelco) and spun for 10 min at maximum speed in a microcentrifuge. The eluted DNA was EtOH precipitated and resuspended in 4 μ l H₂O for ligation. The forward PCR primer sequence was:

LW1564: GCATAAGCTTCCATGTACAACGGGTCGTGCTGC (SEQ ID NO: 107), and the reverse PCR primer was:

LW1565: GCATTCTAGATCAGTGCCACTCAACAATGTGGG (SEQ ID NO: 108).

The ligation reaction used solutions from the TOPO TA Cloning Kit (Invitrogen) which consisted of 4 μ l PCR product DNA and 1 μ l pCRII-TOPO vector that was incubated for 5 minutes at room temperature. To the ligation reaction one microliter of 6X TOPO Cloning Stop Solution was added then the reaction was placed on ice. Two microliters of the ligation reaction was transformed in One Shot TOP10 cells (Invitrogen), and placed on ice for 30 minutes. The cells were heat-shocked for 30 seconds at 42°C, placed on ice for two minutes, 250 Tl of SOC was added, then incubated at 37°C with shaking for one hour and then plated onto ampicillin plates. A single colony containing an insert was used to inoculate a 5 ml culture of LB medium. Plasmid DNA was purified using a Concert Rapid Plasmid Miniprep System (GibcoBRL) and then sequenced.

The DNA subcloned into pCRII was sequenced using the ABI PRISM™ 310 Genetic Analyzer (PE Applied Biosystems) which uses advanced capillary electrophoresis technology and the ABI PRISM™ BigDye™ Terminator Cycle Sequencing Ready Reaction Kit. Each cycle-sequencing reaction contained 6 μ l of H₂O, 8 μ l of BigDye Terminator mix, 5 μ l mini-prep DNA (0.1 μ g/ μ l), and 1 μ l primer

DOCKET NO.: 411USPHRM311

PATENT

(25 ng/ μ l) and was performed in a Perkin-Elmer 9600 thermocycler with 25 cycles of 96°C for 10 sec, 50°C for 10 sec, and 60°C for 4 min. The product was purified using a Centriflex™ gel filtration cartridge, dried under vacuum, then dissolved in 16 μ l of Template Suppression Reagent (PE Applied Biosystems). The samples were heated at 5 95°C for 5 min then placed in the 310 Genetic Analyzer, yielding the sequence of SEQ ID NO: 79.

nGPCR-16: PCR AND SUBCLONING

PCR was performed in a 50 μ l reaction containing 32 μ l H₂O, 5 μ l 10X TT buffer (140 mM Ammonium Sulfate, 0.1 % gelatin, 0.6 M Tris-tricine pH 8.4), 5 μ l 15 mM MgSO₄, 2 μ l 10 mM dNTP, 5 μ l 2445704H1 DNA (0.17 Tg/Tl), 0.3 μ l of LW1587 (1 μ g/ μ l), 0.3 μ l of LW1588 (1 μ g/ μ l), 0.4 μ l High Fidelity Taq polymerase (Boehringer Mannheim). The PCR reaction was performed on a Robocycler thermocycler (Stratagene) starting with 1 cycle of 94°C for 2 min followed by 15 cycles of 94°C for 30 sec, 55°C for 1.3 min, 68°C for 2 min. The PCR reaction was 15 loaded onto a 1.2 % agarose gel. The DNA band was excised from the gel, placed in GenElute Agarose spin column (Supelco) and spun for 10 min at maximum speed in a microcentrifuge. The eluted DNA was EtOH precipitated and resuspended in 12 μ l H₂O for ligation. The PCR primer sequence for the forward primer was:

20 LW1587: GATCAAGCTTATGACAGGTGACTTCCCAAGTATGC (SEQ ID NO: 111), and the sequence for the reverse primer was:

LW1588: GATCCTCGAGGCTAACGGCACAAACACAATTCC (SEQ ID NO: 112).

25 The ligation reaction used solutions from the TOPO TA Cloning Kit (Invitrogen) which consisted of 4 μ l PCR product DNA and 1 μ l pCRII-TOPO vector that was incubated for 5 minutes at room temperature. To the ligation reaction one microliter of 6X TOPO Cloning Stop Solution was added then the reaction was placed on ice. Two microliters of the ligation reaction was transformed in One-Shot TOP10 30 cells (Invitrogen), and placed on ice for 30 minutes. The cells were heat-shocked for 30 seconds at 42°C, placed on ice for two minutes, 250 μ l of SOC was added, then incubated at 37°C with shaking for one hour and then plated onto ampicillin plates. A single colony containing an insert was used to inoculate a 5 ml culture of LB medium.

DOCKET NO.: 411USPHRM311

PATENT

Plasmid DNA was purified using a Concert Rapid Plasmid Miniprep System (GibcoBRL) and then sequenced.

The DNA subcloned into pCRII was sequenced using the ABI PRISM™ 310 Genetic Analyzer (PE Applied Biosystems) which uses advanced capillary electrophoresis technology and the ABI PRISM™ BigDye™ Terminator Cycle Sequencing Ready Reaction Kit. Each cycle-sequencing reaction contained 6 µl of H₂O, 8 µl of BigDye Terminator mix, 5 µl mini-prep DNA (0.1 µg/µl), and 1 µl primer (25 ng/µl) and was performed in a Perkin-Elmer 9600 thermocycler with 25 cycles of 96°C for 10 sec, 50°C for 10 sec, and 60°C for 4 min. The product was purified using a 10 Centriflex™ gel filtration cartridge, dried under vacuum, then dissolved in 16 µl of Template Suppression Reagent (PE Applied Biosystems). The samples were heated at 95°C for 5 min then placed in the 310 Genetic Analyzer, yielding the sequence of SEQ ID NO: 81.

nGPCR-40: PCR AND SUBCLONING

15 PCR was performed in a 50 µl reaction containing utilizing Herculase DNA Polymerase blend (Stratagene), using the buffer recommendations provided by the manufacturer, 200 ng each of primers PSK 18 and 19 (SEQ ID NOS: 115 and 116), 150 ng of human genomic DNA (Clontech), and 2% DMSO. The PCR reaction was performed on a Robocycler thermocycler (Stratagene) starting with 1 cycle of 94°C for 20 2 min followed by 35 cycles of 94°C for 30 sec, 65°C for 30 sec, 72°C for 2 min. The PCR reaction was purified using the QiaQuick PCR Purification Kit (Qiagen), and then eluted in TE. The PCR primer sequences were:

PSK 18 GATC GAATTCGCAGGAGCAATG AAAATCAGGAAC (SEQ ID NO: 115), and:

25 PSK19: GATCGAATTCTTATATGTTCAGAAAACAAATTCATGG (SEQ ID NO: 116)). The underlined portion of the primer matches the 5' and 3' areas, respectively, of a portion of the 5' untranslated region and coding region. Initiation and termination codons are shown above in bold.

30 The PCR product was ligated into the pCR-BluntII-TOPO vector (Invitrogen) using the Zero Blunt Topo PCR TA cloning kit as follow: 3µl PCR product DNA, 1 µl pCRII-TOPO vector, and 1 µl TOPOII salt solution (1.2M NaCl, 0.06M MgCl₂). The

DOCKET NO.: 411USPHRM311

PATENT

mixture was incubated for 5 minutes at room temperature. To the ligation reaction one microliter of 6X TOPO Cloning Stop Solution was added, and then the reaction was placed on ice. Two microliters of the ligation reaction was transformed in One-Shot TOP10 cells (Invitrogen), and placed on ice for 30 minutes. The cells were heat-shocked for 30 seconds at 42°C, placed on ice for two minutes, 250 µl of SOC was added, then incubated at 37°C with shaking for one hour and then plated onto ampicillin plates supplemented with Xgal and IPTG. Single colonies were screened by PCR for the presence of the insert, and a plasmid DNA from colony 58 was purified using a Qiagen Endo-Free plasmid purification kit.

10 nGPCR-40 was sequenced directly using an ABI377 fluorescence-based sequencer (Perkin Elmer/Applied Biosystems Division, PE/ABD, Foster City, CA) and the ABI BigDye™ Terminator Cycle Sequencing Ready Reaction kit with Taq FS™ polymerase. Each ABI cycle sequencing reaction contained about 0.5 µg of plasmid DNA. Cycle-sequencing was performed using an initial denaturation at 98°C for 1
15 min, followed by 50 cycles: 96°C for 30 sec, annealing at 50°C for 30 sec, and extension at 60°C for 4 min. Temperature cycles and times were controlled by a Perkin-Elmer 9600 thermocycler. Extension products were purified using AGTC® gel filtration block (Edge Biosystems, Gaithersburg, MD). Each reaction product was loaded by pipette onto the column, which was then centrifuged in a swinging bucket
20 centrifuge (Sorvall model RT6000B tabletop centrifuge) at 1500 x g for 4 min at room temperature. Column-purified samples were dried under vacuum for about 40 min and then dissolved in 3 µl of DNA loading solution (83% deionized formamide, 8.3 mM EDTA, and 1.6 mg/ml Blue Dextran). The samples were then heated to 90°C for 3.5 min and loaded into the gel sample wells for sequence analysis by the ABI377
25 sequencer. Sequence analysis was performed by importing ABI377 files into the Sequencher program (Gene Codes, Ann Arbor, MI), which yielded a sequence identical to SEQ ID NO:83 with the exception that the nucleotide at position 10 was identified as an "A" which incorrectly indicated the presence of an initiation codon at that position. Subsequent analysis of genomic DNA samples indicated that this position was
30 incorrectly assigned and that the correct

DOCKET NO.: 411USPHRM311

PATENT

nucleotide at that position was a "C". The sequence reported at SEQ ID NO. 83 correctly identifies the nucleotide at position 10 and indicates that the first initiation codon occurs at position 88-90.

nGPCR-54: PCR AND SUBCLONING

5 Two microliters of a human genomic library (~10⁸ PFU/ml) (Clontech) was added to 6 ml of an overnight culture of K802 cells (Clontech), then distributed as 250 μ l aliquots into each of 24 tubes. The tubes were incubated at 37°C for 15 min. Seven milliliters of 0.8% agarose was added to each tube, mixed, then poured onto LB agar + 10 mM MgSO₄ plates and incubated overnight at 37°C. To each plate 5 ml of SM

10 (0.1M NaCl, 8.1 mM MgSO₄·7H₂O, 50mM Tris-Cl (pH 7.5), 0.0001% gelatin) phage buffer was added and the top agarose was removed with a microscope slide and placed in a 50 ml centrifuge tube. A drop of chloroform was added and the tube was place in a 37 °C shaker for 15 min, then centrifuged for 20 min at 4000 RPM (Sorvall RT6000 table top centrifuge) and the supernatant stored at 4°C as a stock solution.

15 Two μ l of phage from each tube was heated to 99°C for 4 min then cooled to 10°C. Added to the phage was a PCR mix containing 8.8 μ l H₂O, 4 μ l 5X Rapid-Load Buffer (Origene), 2 μ l 10xPCR buffer II (Perkin-Elmer), 2 μ l 25 mM MgCl₂, 0.8 μ l 10 mM dNTP, 0.12 μ l LW1634 (1 μ g/ μ l)(SEQ ID NO: 119), 0.12 μ l LW1635 (1 μ g/ μ l)(SEQ ID NO: 120), 0.2 μ l AmpliTaq Gold polymerase (Perkin Elmer). The PCR reaction involved 1 cycle at 95°C for 10 min followed by 35 cycles at 95°C for 45 sec, 53.5°C for 2 min, 72°C for 45 sec. The reaction was loaded onto a 2 % agarose gel. From the tube that gave a PCR product of the correct size, 10 μ l was used to set up five 1:10 dilutions that were plated onto LB agar + 10 mM MgSO₄ plates and incubated overnight. A BA85 nitrocellulose filter (Schleicher & Schuell) was placed on top of 25 each plate for 1 hour. The filter was removed, placed phage side up in a petri dish, and covered with 4 ml of SM for 15 min to elute the phage. One milliliter of SM was removed from each plate and used to set up a PCR reaction as above. The plate of the lowest dilution to give a PCR product was subdivided, filter-lifted and the PCR reaction was repeated. The series of dilutions and subdividing of the plate was continued until a 30 single plaque was isolated that gave a positive PCR band. Once a single plaque was isolated, 10 μ l phage supernatant was added to 100 μ l SM and 200 μ l of K802 cells per

DOCKET NO.: 411USPHRM311

PATENT

plate with a total of 8 plates set up. The plates were incubated overnight at 37°C. The top agarose was removed by adding 8 ml of SM then scrapping off the agarose with a microscope slide and collected in a centrifuge tube. To the tube, 3 drops of chloroform was added, vortexed, incubated at 37°C for 15 min then centrifuged for 20 min at 4000 5 RPM (Sorvall RT6000 table top centrifuge) to recover the phage, which was used to isolate genomic phage DNA using the Qiagen Lambda Midi Kit. The sequence for primer LW1634 was:

CTGAAAGTTGTCGCTGACC (SEQ ID NO: 119), and for primer LW1635 was:

10 CGATTATCCACACTTGACCC (SEQ ID NO: 120).

The PCR reaction for the coding region was performed in a 50 μ l reaction containing 33 μ l H₂O, 5 μ l 10X TT buffer (140 mM Ammonium Sulfate, 0.1 % gelatin, 0.6 M Tris-tricine pH 8.4), 5 μ l 15 mM MgSO₄, 2 μ l 10 mM dNTP, 4 μ l genomic phage DNA (0.25 μ g/ μ l), 0.3 μ l LW1698 (1 μ g/ μ l)(SEQ ID NO: 121), 0.3 μ l LW1699 (1 15 μ g/ μ l)(SEQ ID NO: 122), 0.4 μ l High Fidelity Taq polymerase (Boehringer Mannheim). The PCR reaction was started with 1 cycle of 94°C for 2 min followed by 30 cycles at 94°C for 30 sec, 55°C for 30 sec., 68°C for 2 min. The PCR reaction was loaded onto a 2 % agarose gel. The DNA band was excised from the gel, placed in GenElute Agarose spin column (Supelco) and spun for 10 min at maximum speed. The 20 eluted DNA was EtOH precipitated and resuspended in 8 μ l H₂O. The PCR primer sequence for primer LW1698 was:

GCATACCATGAATGAGCCACTAGAC (SEQ ID NO: 121), and for primer LW1699 was:

25 GCATCTCGAGTCAAGGGTTGTTGAGTAAC (SEQ ID NO: 122). The underlined portion of the primer matches the 5' and 3' areas, respectively, of the coding region of nGPCR-54.

The ligation reaction used solutions from the TOPO TA Cloning Kit (Invitrogen) which consisted of 4 μ l PCR product DNA, 1 μ l of salt solution and 1 μ l pCRII-TOPO vector that was incubated for 5 minutes at room temperature then the 30 reaction was placed on ice. Two microliters of the ligation reaction was transformed in One-Shot TOP10 cells (Invitrogen), and placed on ice for 30 minutes. The cells were

DOCKET NO.: 411USPHRM311

PATENT

heat-shocked for 30 seconds at 42°C, placed on ice for two minutes, 250 µl of SOC was added, then incubated at 37°C with shaking for one hour and then plated onto ampicillin plates. A single colony containing an insert was used to inoculate a 5 ml culture of LB medium. Plasmid DNA was purified using a Concert Rapid Plasmid 5 Miniprep System (GibcoBRL) and then sequenced.

nGPCR-54 genomic phage DNA was sequenced using the ABI PRISM™ 310 Genetic Analyzer (PE Applied Biosystems) which uses advanced capillary electrophoresis technology and the ABI PRISM™ BigDye™ Terminator Cycle Sequencing Ready Reaction Kit. The cycle-sequencing reaction contained 14 µl of 10 H₂O, 16 µl of BigDye Terminator mix, 7 µl genomic phage DNA (0.1 µg/µl), and 3 µl primer (25 ng/µl). The reaction was performed in a Perkin-Elmer 9600 thermocycler at 95°C for 5 min, followed by 99 cycles of 95°C for 30 sec, 55°C for 20 sec, and 60°C for 4 min. The product was purified using a Centriflex™ gel filtration cartridges, dried under vacuum, then dissolved in 16 µl of Template Suppression Reagent. The samples 15 were heated at 95°C for 5 min then placed in the 310 Genetic Analyzer.

The DNA subcloned into pCRII was sequenced using the ABI PRISM™ 310 Genetic Analyzer (PE Applied Biosystems) which uses advanced capillary electrophoresis technology and the ABI PRISM™ BigDye™ Terminator Cycle Sequencing Ready Reaction Kit. Each cycle-sequencing reaction contained 6 µl of 20 H₂O, 8 µl of BigDye Terminator mix, 5 µl mini-prep DNA (0.1 µg/µl), and 1 µl primer (25 ng/µl) and was performed in a Perkin-Elmer 9600 thermocycler with 25 cycles of 96°C for 10 sec, 50°C for 10 sec, and 60°C for 4 min. The product was purified using a Centriflex™ gel filtration cartridge, dried under vacuum, then dissolved in 16 µl of Template Suppression Reagent (PE Applied Biosystems). The samples were heated at 25 95°C for 5 min then placed in the 310 Genetic Analyzer, yielding the sequence of SEQ ID NO: 85.

nGPCR-56: PCR AND SUBCLONING

The PCR reaction for the coding region of nGPCR-56 used components that come with PLATINUM® Pfx DNA Polymerase (GibcoBRL) containing 35.5 µl H₂O, 5 30 µl 10X Pfx Amplification buffer, 1.5 µl 50mM MgS0₄, 2 µl 10 mM dNTP, 5 µl human genomic DNA (0.3µg/µl)(Clontech), 0.3 µl of LW1603 (1 µg/µl)(SEQ ID NO: 152),

DOCKET NO.: 411USPHRM311

PATENT

0.3 μ l of LW1604 (1 μ g/ μ l)(SEQ ID NO: 153), 0.4 μ l PLATINUM[®] *Pfx* DNA Polymerase (2.5 U/Tl). The PCR reaction was performed in a Robocycler Gradient 96 (Stratagene) starting with 1 cycle of 94°C for 5 min followed by 30 cycles at 94°C for 40 sec, 55°C for 2 min, 68°C for 3 min. Following the final cycle, 0.5 μ l of AmpliTaq 5 DNA Polymerase (5 U/ μ l) was added and the tube was incubated at 72°C for 5 min. The sequence of LW1603 is:

GATCAAGCTTGGAAATGATGCCCTTTGCCAC (SEQ ID NO: 152), and for LW1604 is:

10 GATCCTCGAGCATTCAAAGTAGGTGG. (SEQ ID NO: 153). The underlined portion of the primer matches the 5' and 3' areas, respectively, of a portion of the coding region of nGPCR-56.

15 The PCR reaction for the coding region was performed in a 50 μ l reaction containing 32 μ l H₂O, 5 μ l 10X TT buffer (140 mM Ammonium Sulfate, 0.1 % gelatin, 0.6 M Tris-tricine pH 8.4), 5 μ l 15 mM MgS0₄, 2 μ l 10 mM dNTP, 5 μ l human genomic DNA (0.3 μ g/ μ l)(Clontech), 0.3 μ l LW1603 (1 μ g/ μ l)(SEQ ID NO: 152), 0.3 μ l LW1696 (1 μ g/ μ l)(SEQ ID NO: 154), 0.4 μ l High Fidelity Taq polymerase (Boehringer Mannheim). The PCR reaction was started with 1 cycle of 94°C for 2 min followed by 25 cycles at 94°C for 40 sec, 55°C for 60 sec., 68°C for 2 min. The PCR reaction was loaded onto a 2 % agarose gel. The DNA band was excised from the gel, 20 placed in GenElute Agarose spin column (Supelco) and spun for 10 min at maximum speed. The eluted DNA was EtOH precipitated and resuspended in 12 μ l H₂O for ligation. The PCR primer sequence for LW1603 is:

GATCAAGCTTGGAAATGATGCCCTTTGCCAC (SEQ ID NO: 152), and LW1696:

25 GATCCTCGAGCTATGAACTCAATTCCAAAAATAATTACACC (SEQ ID NO: 154). The underlined portion of the primer matches the 5' and 3' areas, respectively, of a portion of the coding region.

30 The ligation reaction used solutions from the TOPO TA Cloning Kit (Invitrogen) which consisted of 4 μ l PCR product DNA, 1 μ l of salt solution and 1 μ l pCRII-TOPO vector that was incubated for 5 minutes at room temperature then the reaction was placed on ice. Two microliters of the ligation reaction was transformed in

DOCKET NO.: 411USPHRM311

PATENT

One-Shot TOP10 cells (Invitrogen), and placed on ice for 30 minutes. The cells were heat-shocked for 30 seconds at 42°C, placed on ice for two minutes, 250 μ l of SOC was added, then incubated at 37°C with shaking for one hour and then plated onto ampicillin plates. A single colony containing an insert was used to inoculate a 5 ml 5 culture of LB medium. Plasmid DNA was purified using a Concert Rapid Plasmid Miniprep System (GibcoBRL) and then sequenced.

The mutation in nGPCR-56 was repaired using the QuikChange Site-Directed Mutagenesis Kit (Stratagene). The PCR reaction contained 40 μ l H₂O, 5 μ l 10x Reaction buffer, 1 μ l mini-prep DNA, 1 μ l LW1700 (125 ng/ μ l) (SEQ ID NO: 155), 10 1 μ l LW1701 (125 ng/ μ l) (SEQ ID NO: 156), 1 μ l 10 mM dNTP, 1 μ l Pfu DNA polymerase. The cycle conditions were 95°C for 30 sec then 14 cycles at 95°C for 30 sec, 55°C for 1 min, 68°C for 12 min. The tube was placed on ice for 2 min, then 1 μ l of *Dpn*I was added and the tube incubated at 37°C for one hour. One microliter of the *Dpn*I-treated DNA was transformed into Epicurian coli XL1-Blue supercompetent cells 15 and the entire insert was re-sequenced. The primer sequences are:

GCTACTTGAACCTCACATTAAATCCAATGGTTATGCATTTCTATCC
(LW1700)(SEQ ID NO: 155), and:

GGATAGAAAAATGCATAAACCATGGATTAAATGTAGAGTTCAAGTAGC
(LW1701)(SEQ ID NO: 156).

20 The DNA subcloned into pCRII was sequenced using the ABI PRISM™ 310 Genetic Analyzer (PE Applied Biosystems) which uses advanced capillary electrophoresis technology and the ABI PRISM™ BigDye™ Terminator Cycle Sequencing Ready Reaction Kit. Each cycle-sequencing reaction contained 6 μ l of H₂O, 8 μ l of BigDye Terminator mix, 5 μ l mini-prep DNA (0.1 μ g/ μ l), and 1 μ l primer 25 (25 ng/ μ l) and was performed in a Perkin-Elmer 9600 thermocycler with 25 cycles of 96°C for 10 sec, 50°C for 10 sec, and 60°C for 4 min. The product was purified using a Centriflex™ gel filtration cartridge, dried under vacuum, then dissolved in 16 μ l of Template Suppression Reagent (PE Applied Biosystems). The samples were heated at 95°C for 5 min then placed in the 310 Genetic Analyzer, yielding the sequence of SEQ 30 ID NO: 89.

DOCKET NO.: 411USPHRM311

PATENT

nGPCR-58: PCR AND SUBCLONING

Isolation of a clone for nGPCR-58 from genomic DNA was performed by PCR in a 50 μ l reaction containing Herculase DNA Polymerase blend (Stratagene), with buffer recommendations as supplied by the manufacturer, 200 ng each primers PSK14 (SEQ ID NO: 157) and PSK15 (SEQ ID NO: 158), 150 ng of human genomic DNA (Clontech) and 6% DMSO. The PCR reaction was performed on a Robocycler thermocycler (Stratagene) starting with 1 cycle of 94°C for 2 min followed by 35 cycles of 94°C for 30 sec, 65°C for 30 sec, 72°C for 2 min. The PCR reaction was purified by the QiaQuick PCR Purification Kit (Qiagen) and eluted in TE. The PCR 10 primer sequences were:

PSK14: 5'GATCGAATTCATGGACACTACCATGGAAGCTGACC (SEQ ID NO: 157), and:

PSK15: 5'GATCCTCGAGTCACGTGGGGCTGCGCCCGG (SEQ ID NO: 158).

15 The underlined portion of the primers match the 5' and 3' areas, respectively, of a portion of the 5' untranslated region and coding region. Translation initiation and termination codons are shown above in bold.

The blunt ended PCR product was prepared for cloning by the addition of a single base "A" residue by AmpliTaq Gold (Perkin Elmer) in a reaction with 1X PCR 20 Buffer II, 1 mM MgCl₂, 200uM each dATP, dGTP, dCTP, and dTTP. The reaction was incubated at 94°C for 10 minutes followed by 72°C for 10 minutes. The products were cloned into the pCRII-TOPO vector (Invitrogen) using the TOPO TA cloning kit as follows: 3 μ l PCR product DNA, 1 μ l pCRII-TOPO vector, and 1 μ l TOPOII salt solution (1.2M NaCl, 0.06M MgCl₂) was incubated for 5 minutes at room temperature. 25 To the ligation reaction one microliter of 6X TOPO Cloning Stop Solution was added then the reaction was placed on ice. Two microliters of the ligation reaction was transformed in One-Shot TOP10 cells (Invitrogen), and placed on ice for 30 minutes. The cells were heat-shocked for 30 seconds at 42°C, placed on ice for two minutes, 250 μ l of SOC was added, then incubated at 37°C with shaking for one hour and then plated 30 onto ampicillin plates supplemented with X-gal and IPTG. Single colonies were screened by PCR for the presence of the insert, and a plasmid DNA from colony 58-6

DOCKET NO.: 411USPHRM311

PATENT

was purified using a Qiagen Endo-Free plasmid purification kit and deposited as nGPCR-58.

nGPCR-58 was sequenced directly using an ABI377 fluorescence-based sequencer (Perkin Elmer/Applied Biosystems Division, PE/ABD, Foster City, CA) and the ABI BigDye™ Terminator Cycle Sequencing Ready Reaction kit with Taq FS™ polymerase. Each ABI cycle sequencing reaction contained about 0.5 µg of plasmid DNA. Cycle-sequencing was performed using an initial denaturation at 98°C for 1 min, followed by 50 cycles: 96°C for 30 sec, annealing at 50°C for 30 sec, and extension at 60°C for 4 min. Temperature cycles and times were controlled by a Perkin-Elmer 9600 thermocycler. Extension products were purified using AGTC (R) gel filtration block (Edge Biosystems, Gaithersburg, MD). Each reaction product was loaded by pipette onto the column, which was then centrifuged in a swinging bucket centrifuge (Sorvall model RT6000B tabletop centrifuge) at 1500 x g for 4 min at room temperature. Column-purified samples were dried under vacuum for about 40 min and then dissolved in 3 µl of a DNA loading solution (83% deionized formamide, 8.3 mM EDTA, and 1.6 mg/ml Blue Dextran). The samples were then heated to 90°C for 3.5 min and loaded into the gel sample wells for sequence analysis by the ABI377 sequencer. Sequence analysis was performed by importing ABI377 files into the Sequencer program (Gene Codes, Ann Arbor, MI), yielding the sequence of SEQ ID NO: 93.

EXAMPLE 3: HYBRIDIZATION ANALYSIS TO DEMONSTRATE nGPCR-X EXPRESSION IN BRAIN

The expression of nGPCR-x in mammals, such as the rat, may be investigated by *in situ* hybridization histochemistry. To investigate expression in the brain, for example, coronal and sagittal rat brain cryosections (20 µm thick) are prepared using a Reichert-Jung cryostat. Individual sections are thaw-mounted onto silanized, nuclease-free slides (CEL Associates, Inc., Houston, TX), and stored at -80°C. Sections are processed starting with post-fixation in cold 4% paraformaldehyde, rinsed in cold phosphate-buffered saline (PBS), acetylated using acetic anhydride in triethanolamine buffer, and dehydrated through a series of alcohol washes in 70%, 95%, and 100% alcohol at room temperature. Subsequently, sections are delipidated in

DOCKET NO.: 411USPHRM311

PATENT

chloroform, followed by rehydration through successive exposure to 100% and 95% alcohol at room temperature. Microscope slides containing processed cryosections are allowed to air dry prior to hybridization. Other tissues may be assayed in a similar fashion.

5 A nGPCR-x-specific probe is generated using PCR. Following PCR amplification, the fragment is digested with restriction enzymes and cloned into pBluescript II cleaved with the same enzymes. For production of a probe specific for the sense strand of nGPCR-x, the nGPCR-x clone in pBluescript II is linearized with a suitable restriction enzyme, which provides a substrate for labeled run-off transcripts
10 (i.e., cRNA riboprobes) using the vector-borne T7 promoter and commercially available T7 RNA polymerase. A probe specific for the antisense strand of nGPCR-x is also readily prepared using the nGPCR-x clone in pBluescript II by cleaving the recombinant plasmid with a suitable restriction enzyme to generate a linearized substrate for the production of labeled run-off cRNA transcripts using the T3 promoter
15 and cognate polymerase. The riboprobes are labeled with [³⁵S]-UTP to yield a specific activity of about 0.40×10^6 cpm/pmol for antisense riboprobes and about 0.65×10^6 cpm/pmol for sense-strand riboprobes. Each riboprobe is subsequently denatured and added (2 pmol/ml) to hybridization buffer which contained 50% formamide, 10% dextran, 0.3 M NaCl, 10 mM Tris (pH 8.0), 1 mM EDTA, 1X Denhardt's Solution, and
20 10 mM dithiothreitol. Microscope slides containing sequential brain cryosections are independently exposed to 45 μ l of hybridization solution per slide and silanized cover slips are placed over the sections being exposed to hybridization solution. Sections are incubated overnight (15-18 hours) at 52°C to allow hybridization to occur. Equivalent series of cryosections are exposed to sense or antisense nGPCR-40-specific cRNA
25 riboprobes.

Following the hybridization period, coverslips are washed off the slides in 1X SSC, followed by RNase A treatment involving the exposure of slides to 20 μ g/ml RNase A in a buffer containing 10 mM Tris-HCl (pH 7.4), 0.5 M EDTA, and 0.5 M NaCl for 45 minutes at 37°C. The cryosections are then subjected to three high-
30 stringency washes in 0.1 X SSC at 52°C for 20 minutes each. Following the series of washes, cryosections are dehydrated by consecutive exposure to 70%, 95%, and 100%

DOCKET NO.: 411USPHRM311

PATENT

ammonium acetate in alcohol, followed by air drying and exposure to Kodak BioMax™ MR-1 film. After 13 days of exposure, the film is developed. Based on these results, slides containing tissue that hybridized, as shown by film autoradiograms, are coated with Kodak NTB-2 nuclear track emulsion and the slides are stored in the dark for 32 days. The slides are then developed and counterstained with hematoxylin. Emulsion-coated sections are analyzed microscopically to determine the specificity of labeling. The signal is determined to be specific if autoradiographic grains (generated by antisense probe hybridization) are clearly associated with cresyl violate-stained cell bodies. Autoradiographic grains found between cell bodies indicates non-specific binding of the probe.

Expression of nGPCR-x in the brain provides an indication that modulators of nGPCR-x activity have utility for treating neurological disorders, including but not limited to, schizophrenia, affective disorders, ADHD/ADD (*i.e.*, Attention Deficit-Hyperactivity Disorder/Attention Deficit Disorder), and neural disorders such as Alzheimer's disease, Parkinson's disease, migraine, and senile dementia. Some other diseases for which modulators of nGPCR-x may have utility include depression, anxiety, bipolar disease, epilepsy, neuritis, neurasthenia, neuropathy, neuroses, and the like. Use of nGPCR-x modulators, including nGPCR-x ligands and anti-nGPCR-x antibodies, to treat individuals having such disease states is intended as an aspect of the invention.

EXAMPLE 4: TISSUE EXPRESSION PROFILING

Tissue specific expression of the cDNAs encoding nGPCR-1, nGPCR-3, nGPCR-9, nGPCR-11, nGPCR-16, nGPCR-40, nGPCR-54, nGPCR-56, and nGPCR-58 was detected using a PCR-based system. Tissue specific expression of cDNAs encoding nGPCR-x may be accomplished using similar methods.

Primers were synthesized by Genosys Corp., The Woodlands, TX. PCR reactions were assembled using the components of the Expand Hi-Fi PCR System™ (Roche Molecular Biochemicals, Indianapolis, IN).

30 nGPCR-1

The RapidScan™ Gene Expression Panel was used to generate a comprehensive expression profile of the putative GPCR in human tissues. Human tissues in the array

DOCKET NO.: 411USPHRM311

PATENT

may include: brain, heart, kidney, spleen, liver, colon, lung, small intestine, muscle, stomach, testis, placenta, salivary gland, thyroid, adrenal gland, pancreas, ovary, uterus, prostate, skin, PBL, bone marrow, fetal brain, fetal liver. Human brain regions in the array may include: frontal lobe, temporal lobe, cerebellum, hippocampus, substantia nigra, caudate nucleus, amygdala, thalamus, hypothalamus, pons, medulla and spinal cord.

10 Expression of the nGPCR-1 in the various tissues was detected by using PCR primers designed based on the available sequence of the receptor that will prime the synthesis of a 212bp fragment in the presence of the appropriate cDNA. The forward primer was:

GCTCAACCCACTCATCTATGCC (SEQ ID NO: 97), and the reverse primer was:

AAACTTCTCTGCCCTTACCGTC (SEQ ID NO: 98)

15 The PCR reaction mixture was added to each well of the PCR plate. The plate was placed in a GeneAmp PCR9700 PCR thermocycler (Perkin Elmer Applied Biosystems). The plate was then exposed to the following cycling parameters: Pre-soak 94°C for 3 min; denaturation at 94°C for 30 seconds; annealing at primer T_m for 45 seconds; extension 72°C for 2 minutes; for 35 cycles. PCR products were then separated and analyzed by electrophoresis on a 1.5-% agarose gel.

20 The 4-log dilution range of cDNA deposited on the plate ensured that the amplification reaction is within the linear range and, hence, facilitated the semi-quantitative determination of relative mRNA accumulation in the various tissues or brain regions examined.

25 Expression of nGPCR-1 was found to be highest in the testis, adrenal gland and heart. Significant levels of expression were also found in the brain, kidney, spleen, ovary, prostate, muscle, PBL, stomach and bone marrow. Within the brain, expression levels were highest in the cerebellum, amygdala, thalamus and spinal cord, with significant levels of expression in the frontal lobe, hippocampus, substantia nigra, hypothalamus and pons.

30 Expression of nGPCR-1 in the brain provided an indication that modulators of nGPCR-1 activity have utility for treating neurological disorders, including but not limited to, schizophrenia, affective disorders, ADHD/ADD (*i.e.*, Attention Deficit-

DOCKET NO.: 411USPHRM311

PATENT

Hyperactivity Disorder/Attention Deficit Disorder), and neural disorders such as Alzheimer's disease, Parkinson's disease, migraine, and senile dementia. Some other diseases for which modulators of nGPCR-1 may have utility include depression, anxiety, bipolar disease, epilepsy, neuritis, neurasthenia, neuropathy, neuroses, and the like. Use of nGPCR-1 modulators, including nGPCR-1 ligands and anti-nGPCR-1 antibodies, to treat individuals having such disease states is intended as an aspect of the invention.

nGPCR-3

10 Tissue specific expression of the cDNA encoding nGPCR-3 was detected using a PCR-based method. Multiple ChoiceTM first strand cDNAs (OriGene Technologies, Rockville, MD) from 6 human tissues were serially diluted over a 3-log range and arrayed into a multi-well PCR plate. This array was used to generate a comprehensive expression profile of the putative GPCR in human tissues. Human tissues arrayed included: brain, heart, kidney, peripheral blood leukocytes, lung and testis. PCR 15 primers were designed based on the available sequence of the putative GPCR. The sequence of the forward primer used was:

5'TGCTGCTTGTGCGCCTAC3' (SEQ ID NO: 189), corresponding to base pairs 77 through 96 of the predicted coding sequence of nGPCR-3. The sequence of the reverse primer used was:

20 5'TTGGACGCCAGGAAGGTG3' (SEQ ID NO: 190), corresponding to base pairs 258 through 285 of the predicted coding sequence of nGPCR-3. This primer set primes the synthesis of a 298 base pair fragment in the presence of the appropriate cDNA. For detection of expression within brain regions, the same primer set was used with the Human Brain Rapid ScanTM Panel (OriGene Technologies, Rockville, MD). 25 This panel represents serial dilutions over a 3 log range of first strand cDNA from the following brain regions arrayed in a 96 well format: frontal lobe, temporal lobe, cerebellum, hippocampus, substantia nigra, caudate nucleus, amygdala, thalamus, hypothalamus, pons, medulla and spinal cord. Primers were synthesized by Genosys Corp., The Woodlands, TX. PCR reactions were assembled using the components of 30 the Expand Hi-Fi PCR SystemTM (Roche Molecular Biochemicals, Indianapolis, IN). Twenty-five microliters of the PCR reaction mixture was added to each well of the RapidScan PCR plate. The plate was placed in a GeneAmp 9700 PCR thermocycler

(Perkin Elmer Applied Biosystems). The following cycling program was executed: Pre-soak at (94°C for 3min.) followed by 35 cycles of [(94°C for 45 sec.), (53°C for 2 min.), and (72°C for 45 sec.)]. PCR reaction products were then separated and analyzed by electrophoresis on a 2.0% agarose gel stained with ethidium bromide.

5 The results indicated that nGPCR-3 was expressed in the brain, heart, kidney, peripheral blood lymphocytes, lung, and testis. In the brain, nGPCR-3 was expressed in frontal lobe, temporal lobe, cerebellum, hippocampus, substantia nigra, caudate nucleus, amygdala, thalamus, hypothalamus, pons, medulla, as well as in the spinal cord.

10 **nGPCR-9**

The RapidScan™ Gene Expression Panel was used to generate a comprehensive expression profile of the putative GPCR in human tissues. Human tissues arrayed include: brain, heart, kidney, spleen, liver, colon, lung, small intestine, muscle, stomach, testis, placenta, salivary gland, thyroid, adrenal gland, pancreas, ovary, uterus, 15 prostate, skin, PBL, bone marrow, fetal brain, fetal liver.

The forward primer used was to detect expression of nGPCR-9 was:

5' AACCCCATCATCTACACGC 3'(SEQ ID NO: 105), and, the reverse primer was:

5' TGCCTGTGGAGCCGCTGG 3'(SEQ ID NO: 106). This primer set will 20 prime the synthesis of a 238 base pair fragment in the presence of the appropriate cDNA.

For detection of expression within brain regions, the same primer set was used with the Human Brain Rapid Scan™ Panel (OriGene Technologies, Rockville, MD). This panel represents serial dilutions over a 2-log range of first strand cDNA from the 25 following brain regions arrayed in a 96 well format: frontal lobe, temporal lobe, cerebellum, hippocampus, substantia nigra, caudate nucleus, amygdala, thalamus, hypothalamus, pons, medulla and spinal cord.

Twenty-five microliters of the PCR reaction mixture was added to each well of the PCR plate. The plate was placed in a GeneAmp 9700 PCR thermocycler (Perkin 30 Elmer Applied Biosystems). The following cycling program was executed: Pre-soak at (94°C for 3 min.) followed by 35 cycles of [(94°C for 45 sec.) (52°C for 2 min.) (72°C for

DOCKET NO.: 411USPHRM311

PATENT

45 sec.)]. PCR reaction products were then separated and analyzed by electrophoresis on a 2.0% agarose gel and stained with ethidium bromide.

nGPCR-9 was expressed in the brain, peripheral blood leukocytes, heart, kidney, adrenal gland, spleen, pancreas, liver, lung, skin, bone marrow, testis, placenta, 5 salivary gland, uterus, small intestine, muscle, stomach, and fetal liver. Within the brain, nGPCR-9 was expressed in all areas examined including the frontal lobe, temporal lobe, cerebellum, hippocampus, substantia nigra, caudate nucleus, amygdala, thalamus, hypothalamus, pons, medulla and spinal cord.

10 Expression of nGPCR-9 in the brain provided an indication that modulators of nGPCR-9 activity have utility for treating disorders, including but not limited to, schizophrenia, affective disorders, movement disorders, metabolic disorders, inflammatory disorders, cancers, ADHD/ADD (i.e., Attention Deficit-Hyperactivity Disorder/Attention Deficit Disorder), and neural disorders such as Alzheimer's disease, 15 Parkinson's disease, migraine, and senile dementia. Use of nGPCR-9 modulators, including nGPCR-9 ligands and anti-nGPCR-9 antibodies, to treat individuals having such disease states is intended as an aspect of the invention.

nGPCR-11

20 The RapidScan™ Gene Expression Panel was used to generate a comprehensive expression profile of the putative GPCR in human tissues. Human tissues in the array included, *inter alia*: brain, heart, kidney, spleen, liver, colon, lung, small intestine, muscle, stomach, testis, placenta, salivary gland, thyroid, adrenal gland, pancreas, ovary, uterus, prostate, skin, PBL, bone marrow, fetal brain, fetal liver. Human brain regions in the array included, *inter alia*: frontal lobe, temporal lobe, cerebellum, hippocampus, substantia nigra, caudate nucleus, amygdala, thalamus, hypothalamus, 25 pons, medulla and spinal cord.

Expression of nGPCR-11 in the various tissues was detected by using PCR primers designed based on the available sequence of the receptor that will prime the synthesis of a 206bp fragment in the presence of the appropriate cDNA. The forward primer used to detect expression of nGPCR-11 was:

30 5'-GAAGCCCAGCACTGTTACC-3' (SEQ ID NO: 109), and the reverse primer was:

5'-TGAAATACCTGTCCGCAGCC-3 (SEQ ID NO: 110).

DOCKET NO.: 411USPHRM311

PATENT

Twenty-five microliters of the PCR reaction mixture was added to each well of the RapidScan PCR plate. The plate was placed in a GeneAmp 9700 PCR thermocycler (PE Applied Biosystems). The following cycling program was executed: Pre-soak 94°C for 3 min; denaturation at 94°C for 30 seconds; annealing at primer T_m for 45 5 seconds; extension at 72°C for 2 minutes; for 35 cycles. PCR reaction products were then separated and analyzed by electrophoresis on a 2.0% agarose gel stained with ethidium bromide.

The 4-log dilution range of cDNA deposited on the plate ensured that the 10 amplification reaction was within the linear range and, facilitated semi-quantitative determination of relative mRNA accumulation in the various tissues or brain regions examined.

nGPCR-11 was expressed in the thyroid gland, brain, heart, kidney, adrenal gland, spleen, liver, ovary, muscle, testis, salivary gland, colon, prostate, small intestine, skin stomach, bone marrow, fetal brain and placenta. Within the brain, 15 nGPCR-11 was expressed in the temporal lobe, amygdala, substantia nigra, pons, spinal cord, frontal lobe, and cerebellum.

Expression of the nGPCR-11 in the brain provided an indication that 20 modulators of nGPCR-11 activity have utility for treating disorders, including but not limited to, schizophrenia, affective disorders, metabolic disorders, inflammatory disorders, cancers, ADHD/ADD (*i.e.*, Attention Deficit-Hyperactivity Disorder/Attention Deficit Disorder), and neural disorders such as Alzheimer's disease, Parkinson's disease, migraine, and senile dementia. Some other diseases for which 25 modulators of nGPCR-11 may have utility include depression, anxiety, bipolar disease, epilepsy, neuritis, neurasthenia, neuropathy, neuroses, and the like. Use of nGPCR-11 modulators, including nGPCR-11 ligands and anti-nGPCR-11 antibodies, to treat individuals having such disease states is intended as an aspect of the invention.

Expression of nGPCR-11 in the thyroid gland, indicates that agonists or 30 antagonists could be of use in the treatment of thyroid dysfunction such as thyrotoxicosis and myxoedema. They could also be of use in the stimulation of thyroid hormone release leading to overall increase in metabolic rate and weight reduction. The expression of nGPCR-11 in liver and muscle indicate a use for agonists or antagonists in regulation of glucose metabolism applicable in diabetes type II.

DOCKET NO.: 411USPHRM311

PATENT

nGPCR-16

The RapidScan™ Gene Expression Panel was used to generate a comprehensive expression profile of the putative GPCR in human tissues. Human tissues in the array included, *inter alia*: brain, heart, kidney, spleen, liver, colon, lung, small intestine, 5 muscle, stomach, testis, placenta, salivary gland, thyroid, adrenal gland, pancreas, ovary, uterus, prostate, skin, PBL, bone marrow, fetal brain, fetal liver. Human brain regions in the array included, *inter alia*: frontal lobe, temporal lobe, cerebellum, hippocampus, substantia nigra, caudate nucleus, amygdala, thalamus, hypothalamus, pons, medulla and spinal cord.

10 Expression of nGPCR-16 in the various tissues was detected by using PCR primers designed based on the available sequence of the receptor that will prime the synthesis of a 205bp fragment in the presence of the appropriate cDNA. The forward primer used to detect expression of nGPCR-16 was:

15 5' CAGCCCAAACATCCAAGTC 3'. (SEQ ID NO: 113). The reverse primer used to detect expression of nGPCR-16 was:

5' ACCCCACTTAATCAGCCTC 3'(SEQ ID NO: 114).

For detection of expression within brain regions, the same primer set was used with the Human Brain Rapid Scan™ Panel (OriGene Technologies, Rockville, MD). This panel represents serial dilutions over a 2 log range of first strand cDNA from the 20 following brain regions arrayed in a 96 well format: frontal lobe, temporal lobe, cerebellum, hippocampus, substantia nigra, caudate nucleus, amygdala, thalamus, hypothalamus, pons, medulla and spinal cord.

Twenty-five microliters of the PCR reaction mixture was added to each well of the RapidScan PCR plate. The plate was placed in a GeneAmp 9700 PCR 25 thermocycler (Perkin Elmer Applied Biosystems). The following cycling program was executed: Pre-soak at (94° for 3min.) followed by 35 cycles of [(94°C for 45 sec.) (53°C for 2 min.) (72°C for 45 sec.)]. PCR reaction products were then separated and analyzed by electrophoresis on a 2.0% agarose gel, and stained with ethidium bromide.

The 4-log dilution range of cDNA deposited on the plate ensured that the 30 amplification reaction was within the linear range and, facilitated semi-quantitative determination of relative mRNA accumulation in the various tissues or brain regions examined.

DOCKET NO.: 411USPHRM311

PATENT

nGPCR-16 was expressed in the ovary, lung, prostate, bone marrow, salivary gland, heart, adrenal gland, spleen, liver, small intestine, skin, muscle, peripheral blood leukocytes, testis, placenta, fetal liver, brain, thyroid gland, kidney, pancreas, colon, uterus, and stomach.. Within the brain, nGPCR-16 was expressed in all areas examined 5 including the frontal lobe, temporal lobe, cerebellum, hippocampus, substantia nigra, caudate nucleus, amygdala, thalamus, hypothalamus, pons, medulla and spinal cord.

Expression of nGPCR-16 in the brain provides an indication that modulators of nGPCR-16 activity have utility for treating neurological disorders, including but not limited to, schizophrenia, affective disorders, ADHD/ADD (*i.e.*, Attention Deficit- 10 Hyperactivity Disorder/Attention Deficit Disorder), and neural disorders such as Alzheimer's disease, Parkinson's disease, migraine, and senile dementia. Some other diseases for which modulators of nGPCR-16 may have utility include depression, anxiety, bipolar disease, epilepsy, neuritis, neurasthenia, neuropathy, neuroses, and the like. Use of nGPCR-16 modulators, including nGPCR-16 ligands and anti-nGPCR-16 15 antibodies, to treat individuals having such disease states is intended as an aspect of the invention.

nGPCR-40

The RapidScan™ Gene Expression Panel (OriGene Technologies, Rockville, MD) was used to generate a comprehensive expression profile of the putative GPCR in 20 human tissues. Human tissues arrayed include: brain, heart, kidney, spleen, liver, colon, lung, small intestine, muscle, stomach, testis, placenta, salivary gland, thyroid, adrenal gland, pancreas, ovary, uterus, prostate, skin, PBL, bone marrow, fetal brain, fetal liver. The forward primer used was:

25 5'ACAGCCCCAAAGCCAAACAC3', (SEQ ID NO: 117), and the reverse primer was:

5'CCGCAGGAGCAATGAAAATCAG3', (SEQ ID NO: 118). This primer set primed the synthesis of a 220 base pair fragment in the presence of the appropriate cDNA. For detection of expression within brain regions, the same primer set was used with the Human Brain RapidScan™ Panel (OriGene Technologies, Rockville, MD). 30 This panel represents serial dilutions over a 2 log range of first strand cDNA from the following brain regions arrayed in a 96 well format: frontal lobe, temporal lobe,

DOCKET NO.: 411USPHRM311

PATENT

cerebellum, hippocampus, substantia nigra, caudate nucleus, amygdala, thalamus, hypothalamus, pons, medulla and spinal cord.

Twenty-five microliters of the PCR reaction mixture was added to each well of the RapidScan PCR plate. The plate was placed in a GeneAmp 9700 PCR thermocycler (Perkin Elmer Applied Biosystems). The following cycling program was executed: Pre-soak at (94°C for 3min.) followed by 35 cycles of [(94° for 45 sec.) (54°C for 2 min.) (72° for 45 sec.)]. PCR reaction products were then separated and analyzed by electrophoresis on a 2.0% agarose gel stained with ethidium bromide.

10 The dilution range of cDNA deposited on the plates ensured that the amplification reaction was within the linear range and, hence, facilitated semi-quantitative determination of relative mRNA accumulation in the various tissues or brain regions examined.

15 nGPCR-40 was expressed in the brain, peripheral blood lymphocytes, pancreas, ovary, uterus, testis, salivary gland, kidney, adrenal gland, liver, bone marrow, prostate, fetal liver, colon, muscle, and fetal brain, may be found in many other tissues, including, but not limited to, lung, small intestine, fetal brain cord, and bone. Within the brain, nGPCR-40 was expressed in the frontal lobe, hypothalamus, pons, cerebellum, caudate nucleus, and medulla.

20 Expression of nGPCR-40 in the brain provides an indication that modulators of nGPCR-40 activity have utility for treating neurological disorders, including but not limited to, movement disorders, affective disorders, metabolic disorders, inflammatory disorders and cancers. Use of nGPCR-40 modulators, including nGPCR-40 ligands and anti-nGPCR-40 antibodies, to treat individuals having such disease states is intended as an aspect of the invention.

25 **nGPCR-54**

Multiple Choice™ first strand cDNAs (OriGene Technologies, Rockville, MD) from 12 human tissues were serially diluted over a 3-log range and arrayed into a multi-well PCR plate. Human tissues arrayed include: brain, heart, kidney, peripheral blood leukocytes, liver, lung, muscle, ovary, prostate, small intestine, spleen and testis. PCR primers were designed based on the sequence of nGPCR-54 provided herein. The forward primer used was:

DOCKET NO.: 411USPHRM311

PATENT

5'CTGTCTCTGTCCTCTTCC3',(SEQ ID NO: 123). The reverse primer used was:

5'GCACCGATCTTCATTGAATTC3',(SEQ ID NO: 124). This primer set primes the synthesis of a 145 base pair fragment in the presence of the appropriate 5 cDNA. For detection of expression within brain regions, the same primer set was used with the Human Brain Rapid ScanTM Panel (OriGene Technologies, Rockville, MD). This panel represents serial dilutions over a 3 log range of first strand cDNA from the following brain regions arrayed in a 96 well format: frontal lobe, temporal lobe, cerebellum, hippocampus, substantia nigra, caudate nucleus, amygdala, thalamus, 10 hypothalamus, pons, medulla and spinal cord.

Twenty-five microliters of the PCR reaction mixture was added to each well of the RapidScan PCR plate. The plate was placed in a GeneAmp 9700 PCR thermocycler (Perkin Elmer Applied Biosystems). The following cycling program was executed: Pre-soak at (94°C for 3min.) followed by 35 cycles of [(94°C for 45 sec.) 15 (52.5°C for 2 min.) (72°C for 45 sec.)]. PCR reaction products were then separated and analyzed by electrophoresis on a 2.0% agarose gel stained with ethidium bromide.

nGPCR-54 was expressed in the brain, kidney, lung, muscle, testis, heart, liver, ovary, prostate, small intestine, spleen, and peripheral blood leukocytes. Within the brain, nGPCR-54 was expressed in the cerebellum, hippocampus, substantia nigra, 20 thalamus, hypothalamus, pons, frontal lobe, temporal lobe, caudate nucleus, medulla, spinal cord, and amygdala.

Expression of the nGPCR-54 in the brain provides an indication that modulators of nGPCR-54 activity have utility for treating neurological disorders, including but not limited to, movement disorders, affective disorders, metabolic disorders, inflammatory 25 disorders and cancers. Use of nGPCR-54 modulators, including nGPCR-54 ligands and anti-nGPCR-54 antibodies, to treat individuals having such disease states is intended as an aspect of the invention.

nGPCR-56

The RapidScanTM Gene Expression Panel was used to generate a comprehensive 30 expression profile of the putative GPCR in human tissues. Human tissues arrayed include: brain, heart, kidney, spleen, liver, colon, lung, small intestine, muscle,

DOCKET NO.: 411USPHRM311

PATENT

stomach, testis, placenta, salivary gland, thyroid, adrenal gland, pancreas, ovary, uterus, prostate, skin, PBL, bone marrow, fetal brain, fetal liver. The forward primer used was:

5' ACTTCAAACAACTTCATAACCC 3' (SEQ ID NO: 125), and the reverse primer used was:

5' ACACACAGCATAGTAGCG 3' (SEQ ID NO: 126). This primer set will prime the synthesis of a 231 base pair fragment in the presence of the appropriate cDNA. For detection of expression within brain regions, the same primer set was used with the Human Brain Rapid ScanTM Panel (OriGene Technologies, Rockville, MD). This panel represents serial dilutions over a 2 log range of first strand cDNA from the following brain regions arrayed in a 96 well format: frontal lobe, temporal lobe, cerebellum, hippocampus, substantia nigra, caudate nucleus, amygdala, thalamus, hypothalamus, pons, medulla and spinal cord.

Twenty-five microliters of the PCR reaction mixture was added to each well of the RapidScan PCR plate. The plate was placed in a GeneAmp 9700 PCR thermocycler (Perkin Elmer Applied Biosystems). The following cycling program was executed: Pre-soak at (94°C for 3min.) followed by 35 cycles of [(94°C for 45 sec.) (53°C for 2 min.) (72°C for 45 sec.)]. PCR reaction products were then separated and analyzed by electrophoresis on a 2.0% agarose gel stained with ethidium bromide.

nGPCR-56 was expressed in peripheral blood lymphocytes, testis, salivary gland, kidney, spleen, skin, stomach, placenta, ovary, bone marrow, fetal liver, small intestine, and fetal brain.

Expression of nGPCR-56 in the brain provides an indication that modulators of nGPCR-56 activity have utility for treating neurological disorders, including but not limited to, movement disorders, affective disorders, metabolic disorders, inflammatory disorders and cancers. Use of nGPCR-56 modulators, including nGPCR-56 ligands and anti-nGPCR-56 antibodies, to treat individuals having such disease states is intended as an aspect of the invention.

nGPCR-58

The RapidScanTM Gene Expression Panel was used to generate a comprehensive expression profile of the putative GPCR in human tissues. Human tissues in the array included: brain, heart, kidney, spleen, liver, lung, small intestine, muscle, testis, ovary, prostate, and PBL. Human brain regions in the array included: frontal lobe, temporal

DOCKET NO.: 411USPHRM311

PATENT

lobe, cerebellum, hippocampus, substantia nigra, caudate nucleus, amygdala, thalamus, hypothalamus, pons, medulla and spinal cord.

5 Expression of the nGPCR-58 in the various tissues was detected by using PCR primers designed based on the available sequence of the receptor that will prime the synthesis of a 282bp fragment in the presence of the appropriate cDNA. The forward primer was:

CAGAGCTTGATGATGAGGAC (SEQ ID NO: 127), and the reverse primer was:

CCCATAGGAAGTAGTAGAAG (SEQ ID NO: 128).

10 The PCR reaction mixture was added to each well of the PCR plate. The plate was placed in a GeneAmp PCR9700 PCR thermocycler (Perkin Elmer Applied Biosystems). The plate was then exposed to the following cycling parameters: Pre-soak 94° for 3 min; denaturation at 94° for 30 seconds; annealing at primer T_m for 45 seconds; extension at 72° for 2 minutes; for 35 cycles. PCR productions were then 15 separated and analyzed by electrophoresis on a 1.5-% agarose gel.

The 4-log dilution range of cDNA deposited on the plate ensured that the amplification reaction was within the linear range and, hence, facilitated semi-quantitative determination of relative mRNA accumulation in the various tissues or brain regions examined.

20 nGPCR-58 was expressed in all tissues included on the array, including brain, muscle, prostate, kidney, peripheral blood lymphocytes, liver, lung, small intestine, spleen, testis, heart, and ovary. Within the brain, nGPCR-58 was expressed in many regions including, but not limited to cerebellum, substantia nigra, thalamus, pons, spinal cord, frontal lobe, temporal lobe, hippocampus, caudate nucleus, amygdala, 25 hypothalamus, and medulla.

Expression of the nGPCR-58 in the brain provided an indication that modulators of nGPCR-58 activity have utility for treating disorders, including but not limited to, schizophrenia, affective disorders, ADHD/ADD (*i.e.*, Attention Deficit-Hyperactivity Disorder/Attention Deficit Disorder), neural disorders such as 30 Alzheimer's disease, Parkinson's disease, migraine, senile dementia, depression, anxiety, bipolar disease, epilepsy, neuritis, neurasthenia, neuropathy, neuroses, metabolic disorders, inflammatory disorders, cancers and the like. Use of nGPCR-58

DOCKET NO.: 411USPHRM311

PATENT

modulators, including nGPCR-58 ligands and anti-nGPCR-58 antibodies, to treat individuals having such disease states is intended as an aspect of the invention.

EXAMPLE 5: NORTHERN BLOT ANALYSIS

5 Northern blots are performed to examine the expression of nGPCR-x mRNA. The sense orientation oligonucleotide and the antisense-orientation oligonucleotide, described above, are used as primers to amplify a portion of the GPCR-x cDNA sequence of an odd numbered nucleotide sequence ranging from SEQ ID NO: 1 to SEQ ID NO: 93, SEQ ID NO: 185 and SEQ ID NO: 191.

10 Multiple human tissue northern blots from Clontech (Human II # 7767-1) are hybridized with the probe. Pre-hybridization is carried out at 42 C for 4 hours in 5xSSC, 1X Denhardt's reagent, 0.1% SDS, 50% formamide, 250 mg/ml salmon sperm DNA. Hybridization is performed overnight at 42°C in the same mixture with the addition of about 1.5×10^6 cpm/ml of labeled probe.

15 The probe is labeled with α -³²P-dCTP by RediprimeTM DNA labeling system (Amersham Pharmacia), purified on Nick ColumnTM (Amersham Pharmacia) and added to the hybridization solution. The filters are washed several times at 42 C in 0.2x SSC, 0.1% SDS. Filters are exposed to Kodak XAR film (Eastman Kodak Company, Rochester, N.Y., USA) with intensifying screen at -80°C.

20

EXAMPLE 6: RECOMBINANT EXPRESSION OF nGPCR-X IN EUKARYOTIC HOST CELLS**A. Expression of nGPCR-x in Mammalian Cells**

25 To produce nGPCR-x protein, a nGPCR-x-encoding polynucleotide is expressed in a suitable host cell using a suitable expression vector and standard genetic engineering techniques. For example, the nGPCR-x-encoding sequence described in Example 1 is subcloned into the commercial expression vector pzeoSV2 (Invitrogen, San Diego, CA) and transfected into Chinese Hamster Ovary (CHO) cells using the transfection reagent FuGENE6TM (Boehringer-Mannheim) and the transfection protocol 30 provided in the product insert. Other eukaryotic cell lines, including human embryonic kidney (HEK 293) and COS cells, are suitable as well. Cells stably expressing nGPCR-

DOCKET NO.: 411USPHRM311

PATENT

x are selected by growth in the presence of 100 µg/ml zeocin (Stratagene, LaJolla, CA). Optionally, nGPCR-x may be purified from the cells using standard chromatographic techniques. To facilitate purification, antisera is raised against one or more synthetic peptide sequences that correspond to portions of the nGPCR-x amino acid sequence, 5 and the antisera is used to affinity purify nGPCR-x. The nGPCR-x also may be expressed in-frame with a tag sequence (e.g., polyhistidine, hemagglutinin, FLAG) to facilitate purification. Moreover, it will be appreciated that many of the uses for nGPCR-x polypeptides, such as assays described below, do not require purification of nGPCR-x from the host cell.

10 B. Expression of nGPCR-x in 293 cells

For expression of nGPCR-x in mammalian cells 293 (transformed human, primary embryonic kidney cells), a plasmid bearing the relevant nGPCR-x coding sequence is prepared, using vector pSecTag2A (Invitrogen). Vector pSecTag2A contains the murine IgK chain leader sequence for secretion, the c-myc epitope for 15 detection of the recombinant protein with the anti-myc antibody, a C-terminal polyhistidine for purification with nickel chelate chromatography, and a Zeocin resistant gene for selection of stable transfectants. The forward primer for amplification of this GPCR cDNA is determined by routine procedures and preferably contains a 5' extension of nucleotides to introduce the *HindIII* cloning site and 20 nucleotides matching the GPCR sequence. The reverse primer is also determined by routine procedures and preferably contains a 5' extension of nucleotides to introduce an *XhoI* restriction site for cloning and nucleotides corresponding to the reverse complement of the nGPCR-x sequence. The PCR conditions are 55°C as the annealing temperature. The PCR product is gel purified and cloned into the *HindIII-XhoI* sites of 25 the vector.

The DNA is purified using Qiagen chromatography columns and transfected into 293 cells using DOTAP™ transfection media (Boehringer Mannheim, Indianapolis, IN). Transiently transfected cells are tested for expression after 24 hours of transfection, using western blots probed with anti-His and anti-nGPCR-x peptide 30 antibodies. Permanently transfected cells are selected with Zeocin and propagated. Production of the recombinant protein is detected from both cells and media by western blots probed with anti-His, anti-Myc or anti-GPCR peptide antibodies.

DOCKET NO.: 411USPHRM311

PATENT

C. Expression of nGPCR-x in COS cells

For expression of the nGPCR-x in COS7 cells, a polynucleotide molecule having an odd numbered nucleotide sequence ranging from SEQ ID NO: 1 to SEQ ID NO: 93, SEQ ID NO: 185 and SEQ ID NO:191 can be cloned into vector p3-CI. This 5 vector is a pUC18-derived plasmid that contains the HCMV (human cytomegalovirus) promoter-intron located upstream from the bGH (bovine growth hormone) polyadenylation sequence and a multiple cloning site. In addition, the plasmid contains the dhrf (dihydrofolate reductase) gene which provides selection in the presence of the drug methotrexane (MTX) for selection of stable transformants.

10 The forward primer is determined by routine procedures and preferably contains a 5' extension which introduces an *Xba*I restriction site for cloning, followed by nucleotides which correspond to an odd numbered nucleotide sequence ranging from SEQ ID NO: 1 to SEQ ID NO: 93, SEQ ID NO: 185 and SEQ ID NO:191. The reverse primer is also determined by routine procedures and preferably contains 5'- extension 15 of nucleotides which introduces a *Sall* cloning site followed by nucleotides which correspond to the reverse complement of an odd numbered nucleotide sequence ranging from SEQ ID NO: 1 to SEQ ID NO: 93, SEQ ID NO: 185 and SEQ ID NO:191. The PCR consists of an initial denaturation step of 5 min at 95°C 30 cycles of 30 sec denaturation at 95°C, 30 sec annealing at 58°C and 30 sec extension at 72°C, followed 20 by 5 min extension at 72°C. The PCR product is gel purified and ligated into the *Xba*I and *Sall* sites of vector p3-CI. This construct is transformed into *E. coli* cells for amplification and DNA purification. The DNA is purified with Qiagen chromatography columns and transfected into COS 7 cells using Lipofectamine™ reagent from BRL, following the manufacturer's protocols. Forty-eight and 72 hours 25 after transfection, the media and the cells are tested for recombinant protein expression.

nGPCR-x expressed from a COS cell culture can be purified by concentrating the cell-growth media to about 10 mg of protein/ml, and purifying the protein by, for example, chromatography. Purified nGPCR-x is concentrated to 0.5 mg/ml in an Amicon concentrator fitted with a YM-10 membrane and stored at -80°C.

30 D. Expression of nGPCR-x in Insect Cells

DOCKET NO.: 411USPHRM311

PATENT

For expression of nGPCR-x in a baculovirus system, a polynucleotide molecule having an odd numbered nucleotide sequence ranging from SEQ ID NO: 1 to SEQ ID NO: 93, SEQ ID NO: 185 and SEQ ID NO:191 can be amplified by PCR. The forward primer is determined by routine procedures and preferably contains a 5' extension
5 which adds the *NdeI* cloning site, followed by nucleotides which correspond to an odd numbered nucleotide sequence ranging from SEQ ID NO: 1 to SEQ ID NO: 93, SEQ ID NO: 185 and SEQ ID NO:191. The reverse primer is also determined by routine procedures and preferably contains a 5' extension which introduces the *KpnI* cloning site, followed by nucleotides which correspond to the reverse complement of an odd
10 numbered nucleotide sequence ranging from SEQ ID NO: 1 to SEQ ID NO: 93, SEQ ID NO: 185 and SEQ ID NO:191.

The PCR product is gel purified, digested with *NdeI* and *KpnI*, and cloned into the corresponding sites of vector pACHTL-A (Pharmingen, San Diego, CA). The pAcHTL expression vector contains the strong polyhedrin promoter of the *Autographa californica* nuclear polyhedrosis virus (AcMNPV), and a 6XHis tag upstream from the multiple cloning site. A protein kinase site for phosphorylation and a thrombin site for excision of the recombinant protein precede the multiple cloning site is also present.
15 Of course, many other baculovirus vectors could be used in place of pAcHTL-A, such as pAc373, pVL941 and pAcIM1. Other suitable vectors for the expression of GPCR polypeptides can be used, provided that the vector construct includes appropriately located signals for transcription, translation, and trafficking, such as an in-frame AUG
20 and a signal peptide, as required. Such vectors are described in Luckow *et al.*, Virology 170:31-39, among others.

The virus is grown and isolated using standard baculovirus expression methods,
25 such as those described in Summers *et al.* (A Manual of Methods for Baculovirus Vectors and Insect Cell Culture Procedures, Texas Agricultural Experimental Station Bulletin No. 1555 (1987)).

In a preferred embodiment, pAcHTL-A containing nGPCR-x gene is introduced into baculovirus using the "BaculoGold™" transfection kit (Pharmingen, San Diego,
30 CA) using methods established by the manufacturer. Individual virus isolates are analyzed for protein production by radiolabeling infected cells with ³⁵S-methionine at

DOCKET NO.: 411USPHRM311

PATENT

24 hours post infection. Infected cells are harvested at 48 hours post infection, and the labeled proteins are visualized by SDS-PAGE. Viruses exhibiting high expression levels can be isolated and used for scaled up expression.

For expression of a nGPCR-x polypeptide in a Sf9 cells, a polynucleotide molecule having the sequence of an odd numbered nucleotide sequence ranging from SEQ ID NO: 1 to SEQ ID NO: 93, SEQ ID NO: 185 and SEQ ID NO:191 can be amplified by PCR using the primers and methods described above for baculovirus expression. The nGPCR-x cDNA is cloned into vector pAcHLT-A (Pharmingen) for expression in Sf9 insect. The insert is cloned into the *NdeI* and *KpnI* sites, after elimination of an internal *NdeI* site (using the same primers described above for expression in baculovirus). DNA is purified with Qiagen chromatography columns and expressed in Sf9 cells. Preliminary Western blot experiments from non-purified plaques are tested for the presence of the recombinant protein of the expected size which reacted with the GPCR-specific antibody. These results are confirmed after further purification and expression optimization in HiG5 cells.

EXAMPLE 7: INTERACTION TRAP/TWO-HYBRID SYSTEM

In order to assay for nGPCR-x-interacting proteins, the interaction trap/two-hybrid library screening method can be used. This assay was first described in Fields *et al.*, *Nature*, 1989, 340, 245, which is incorporated herein by reference in its entirety. A protocol is published in Current Protocols in Molecular Biology 1999, John Wiley & Sons, NY, and Ausubel, F. M. *et al.* 1992, Short protocols in molecular biology, Fourth edition, Greene and Wiley-interscience, NY, each of which is incorporated herein by reference in its entirety. Kits are available from Clontech, Palo Alto, CA (Matchmaker 25 Two-Hybrid System 3).

A fusion of the nucleotide sequences encoding all or partial nGPCR-x and the yeast transcription factor GAL4 DNA-binding domain (DNA-BD) is constructed in an appropriate plasmid (*i.e.*, pGBKT7) using standard subcloning techniques. Similarly, a GAL4 active domain (AD) fusion library is constructed in a second plasmid (*i.e.*, pGADT7) from cDNA of potential GPCR-binding proteins (for protocols on forming cDNA libraries, see Sambrook *et al.* 1989, Molecular cloning: a laboratory manual, second edition, Cold Spring Harbor Press, Cold Spring Harbor, NY), which is

DOCKET NO.: 411USPHRM311

PATENT

incorporated herein by reference in its entirety. The DNA-BD/nGPCR-x fusion construct is verified by sequencing, and tested for autonomous reporter gene activation and cell toxicity, both of which would prevent a successful two-hybrid analysis.

Similar controls are performed with the AD/library fusion construct to ensure

5 expression in host cells and lack of transcriptional activity. Yeast cells are transformed (*ca.* 105 transformants/mg DNA) with both the nGPCR-x and library fusion plasmids according to standard procedures (Ausubel *et al.*, 1992, Short protocols in molecular biology, fourth edition, Greene and Wiley-interscience, NY, which is incorporated herein by reference in its entirety). *In vivo* binding of DNA-BD/nGPCR-x with
10 AD/library proteins results in transcription of specific yeast plasmid reporter genes (*i.e.*, lacZ, HIS3, ADE2, LEU2). Yeast cells are plated on nutrient-deficient media to screen for expression of reporter genes. Colonies are dually assayed for β -galactosidase activity upon growth in Xgal (5-bromo-4-chloro-3-indolyl- β -D-galactoside) supplemented media (filter assay for β -galactosidase activity is described in Breeden *et*
15 *al.*, Cold Spring Harb. Symp. Quant. Biol., 1985, 50, 643, which is incorporated herein by reference in its entirety). Positive AD-library plasmids are rescued from transformants and reintroduced into the original yeast strain as well as other strains containing unrelated DNA-BD fusion proteins to confirm specific nGPCR-x/library protein interactions. Insert DNA is sequenced to verify the presence of an open reading
20 frame fused to GAL4 AD and to determine the identity of the nGPCR-x-binding protein.

EXAMPLE 8: MOBILITY SHIFT DNA-BINDING ASSAY USING GEL ELECTROPHORESIS

25 A gel electrophoresis mobility shift assay can rapidly detect specific protein-DNA interactions. Protocols are widely available in such manuals as Sambrook *et al.* 1989, *Molecular cloning: a laboratory manual*, second edition, Cold Spring Harbor Press, Cold Spring Harbor, NY and Ausubel, F. M. *et al.*, 1992, *Short Protocols in Molecular Biology*, fourth edition, Greene and Wiley-interscience, NY, each of which
30 is incorporated herein by reference in its entirety.

DOCKET NO.: 411USPHRM311

PATENT

Probe DNA(<300 bp) is obtained from synthetic oligonucleotides, restriction endonuclease fragments, or PCR fragments and end-labeled with ^{32}P . An aliquot of purified nGPCR-x (ca. 15 μg) or crude nGPCR-x extract (ca. 15 ng) is incubated at constant temperature (in the range 22-37 C) for at least 30 minutes in 10-15 μl of buffer (i.e. TAE or TBE, pH 8.0-8.5) containing radiolabeled probe DNA, nonspecific carrier DNA (ca. 1 μg), BSA (300 $\mu\text{g}/\text{ml}$), and 10% (v/v) glycerol. The reaction mixture is then loaded onto a polyacrylamide gel and run at 30-35 mA until good separation of free probe DNA from protein-DNA complexes occurs. The gel is then dried and bands corresponding to free DNA and protein-DNA complexes are detected by 10 autoradiography.

EXAMPLE 9: ANTIBODIES TO nGPCR-X

Standard techniques are employed to generate polyclonal or monoclonal antibodies to the nGPCR-x receptor, and to generate useful antigen-binding fragments thereof or variants thereof, including "humanized" variants. Such protocols can be found, for example, in Sambrook *et al.* (1989) and Harlow *et al.* (Eds.), Antibodies A Laboratory Manual; Cold Spring Harbor Laboratory; Cold Spring Harbor, NY (1988). In one embodiment, recombinant nGPCR-x polypeptides (or cells or cell membranes containing such polypeptides) are used as antigen to generate the antibodies. In another embodiment, one or more peptides having amino acid sequences corresponding to an immunogenic portion of nGPCR-x (e.g., 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or more amino acids) are used as antigen. Peptides corresponding to extracellular portions of nGPCR-x, especially hydrophilic extracellular portions, are preferred. The antigen may be mixed with an adjuvant or linked to a hapten to increase antibody 25 production.

A. Polyclonal or Monoclonal antibodies

As one exemplary protocol, recombinant nGPCR-x or a synthetic fragment thereof is used to immunize a mouse for generation of monoclonal antibodies (or larger 30 mammal, such as a rabbit, for polyclonal antibodies). To increase antigenicity, peptides are conjugated to Keyhole Lympet Hemocyanin (Pierce), according to the manufacturer's recommendations. For an initial injection, the antigen is emulsified

DOCKET NO.: 411USPHRM311

PATENT

with Freund's Complete Adjuvant and injected subcutaneously. At intervals of two to three weeks, additional aliquots of nGPCR-x antigen are emulsified with Freund's Incomplete Adjuvant and injected subcutaneously. Prior to the final booster injection, a serum sample is taken from the immunized mice and assayed by western blot to 5 confirm the presence of antibodies that immunoreact with nGPCR-x. Serum from the immunized animals may be used as polyclonal antisera or used to isolate polyclonal antibodies that recognize nGPCR-x. Alternatively, the mice are sacrificed and their spleen removed for generation of monoclonal antibodies.

To generate monoclonal antibodies, the spleens are placed in 10 ml serum-free 10 RPMI 1640, and single cell suspensions are formed by grinding the spleens in serum-free RPMI 1640, supplemented with 2 mM L-glutamine, 1 mM sodium pyruvate, 100 units/ml penicillin, and 100 µg/ml streptomycin (RPMI) (Gibco, Canada). The cell suspensions are filtered and washed by centrifugation and resuspended in serum-free RPMI. Thymocytes taken from three naive Balb/c mice are 15 prepared in a similar manner and used as a Feeder Layer. NS-1 myeloma cells, kept in log phase in RPMI with 10% fetal bovine serum (FBS) (Hyclone Laboratories, Inc., Logan, Utah) for three days prior to fusion, are centrifuged and washed as well.

To produce hybridoma fusions, spleen cells from the immunized mice are combined with NS-1 cells and centrifuged, and the supernatant is aspirated. The cell 20 pellet is dislodged by tapping the tube, and 2 ml of 37°C PEG 1500 (50% in 75 mM HEPES, pH 8.0) (Boehringer-Mannheim) is stirred into the pellet, followed by the addition of serum-free RPMI. Thereafter, the cells are centrifuged, resuspended in RPMI containing 15% FBS, 100 µM sodium hypoxanthine, 0.4 µM aminopterin, 16 µM thymidine (HAT) (Gibco), 25 units/ml IL-6 (Boehringer-Mannheim) and 1.5 x 10⁶ 25 thymocytes/ml, and plated into 10 Corning flat-bottom 96-well tissue culture plates (Corning, Corning New York).

On days 2, 4, and 6 after the fusion, 100µl of medium is removed from the wells of the fusion plates and replaced with fresh medium. On day 8, the fusions are screened by ELISA, testing for the presence of mouse IgG that binds to nGPCR-x. 30 Selected fusion wells are further cloned by dilution until monoclonal cultures producing anti-nGPCR-x antibodies are obtained.

B. Humanization of anti-nGPCR-x monoclonal antibodies

DOCKET NO.: 411USPHRM311

PATENT

The expression pattern of nGPCR-x as reported herein and the proven track record of GPCRs as targets for therapeutic intervention suggest therapeutic indications for nGPCR-x inhibitors (antagonists). nGPCR-x-neutralizing antibodies comprise one class of therapeutics useful as nGPCR-x antagonists. Following are protocols to 5 improve the utility of anti-nGPCR-x monoclonal antibodies as therapeutics in humans by "humanizing" the monoclonal antibodies to improve their serum half-life and render them less immunogenic in human hosts (*i.e.*, to prevent human antibody response to non-human anti-nGPCR-x antibodies).

10 The principles of humanization have been described in the literature and are facilitated by the modular arrangement of antibody proteins. To minimize the 15 possibility of binding complement, a humanized antibody of the IgG4 isotype is preferred.

For example, a level of humanization is achieved by generating chimeric 20 antibodies comprising the variable domains of non-human antibody proteins of interest 25 with the constant domains of human antibody molecules. (See, *e.g.*, Morrison *et al.*, Adv. Immunol., 44:65-92 (1989)). The variable domains of nGPCR-x-neutralizing 30 anti-nGPCR-x antibodies are cloned from the genomic DNA of a B-cell hybridoma or from cDNA generated from mRNA isolated from the hybridoma of interest. The V region gene fragments are linked to exons encoding human antibody constant domains, and the resultant construct is expressed in suitable mammalian host cells (*e.g.*, myeloma or CHO cells).

To achieve an even greater level of humanization, only those portions of the 25 variable region gene fragments that encode antigen-binding complementarity determining regions ("CDR") of the non-human monoclonal antibody genes are cloned 30 into human antibody sequences. (See, *e.g.*, Jones *et al.*, Nature 321:522-525 (1986); Riechmann *et al.*, Nature 332:323-327 (1988); Verhoeyen *et al.*, Science 239:1534-36 (1988); and Tempest *et al.*, Bio/Technology 9: 266-71 (1991)). If necessary, the β -sheet framework of the human antibody surrounding the CDR3 regions also is modified to more closely mirror the three dimensional structure of the antigen-binding domain of the original monoclonal antibody. (See Kettleborough *et al.*, Protein Engin., 4:773-783 (1991); and Foote *et al.*, J. Mol. Biol., 224:487-499 (1992)).

DOCKET NO.: 411USPHRM311

PATENT

In an alternative approach, the surface of a non-human monoclonal antibody of interest is humanized by altering selected surface residues of the non-human antibody, *e.g.*, by site-directed mutagenesis, while retaining all of the interior and contacting residues of the non-human antibody. See Padlan, *Molecular Immunol.*, 28(4/5):489-98
5 (1991).

The foregoing approaches are employed using nGPCR-x-neutralizing anti-nGPCR-x monoclonal antibodies and the hybridomas that produce them to generate humanized nGPCR-x-neutralizing antibodies useful as therapeutics to treat or palliate conditions wherein nGPCR-x expression or ligand-mediated nGPCR-x
10 signaling is detrimental.

C. Human nGPCR-x-Neutralizing Antibodies from Phage Display

Human nGPCR-x-neutralizing antibodies are generated by phage display techniques such as those described in Aujame *et al.*, *Human Antibodies* 8(4):155-168 (1997); Hoogenboom, *TIBTECH* 15:62-70 (1997); and Rader *et al.*, *Curr. Opin. Biotechnol.* 8:503-508 (1997), all of which are incorporated by reference. For example, antibody variable regions in the form of Fab fragments or linked single chain Fv fragments are fused to the amino terminus of filamentous phage minor coat protein pIII. Expression of the fusion protein and incorporation thereof into the mature phage coat results in phage particles that present an antibody on their surface and contain the
15 genetic material encoding the antibody. A phage library comprising such constructs is expressed in bacteria, and the library is screened for nGPCR-x-specific
20 phage-antibodies using labeled or immobilized nGPCR-x as antigen-probe.

D. Human nGPCR-x-neutralizing antibodies from transgenic mice

Human nGPCR-x-neutralizing antibodies are generated in transgenic mice
25 essentially as described in Bruggemann *et al.*, *Immunol. Today* 17(8):391-97 (1996) and Bruggemann *et al.*, *Curr. Opin. Biotechnol.* 8:455-58 (1997). Transgenic mice carrying human V-gene segments in germline configuration and that express these transgenes in their lymphoid tissue are immunized with a nGPCR-x composition using conventional immunization protocols. Hybridomas are generated using B cells from
30 the immunized mice using conventional protocols and screened to identify hybridomas secreting anti-nGPCR-x human antibodies (*e.g.*, as described above).

DOCKET NO.: 411USPHRM311

PATENT

EXAMPLE 10: ASSAYS TO IDENTIFY MODULATORS OF nGPCR-X ACTIVITY

Set forth below are several nonlimiting assays for identifying modulators (agonists and antagonists) of nGPCR-x activity. Among the modulators that can be identified by these assays are natural ligand compounds of the receptor; synthetic analogs and derivatives of natural ligands; antibodies, antibody fragments, and/or antibody-like compounds derived from natural antibodies or from antibody-like combinatorial libraries; and/or synthetic compounds identified by high-throughput screening of libraries; and the like. All modulators that bind nGPCR-x are useful for identifying nGPCR-x in tissue samples (e.g., for diagnostic purposes, pathological purposes, and the like). Agonist and antagonist modulators are useful for up-regulating and down-regulating nGPCR-x activity, respectively, to treat disease states characterized by abnormal levels of nGPCR-x activity. The assays may be performed using single putative modulators, and/or may be performed using a known agonist in combination with candidate antagonists (or visa versa).

A. cAMP Assays

In one type of assay, levels of cyclic adenosine monophosphate (cAMP) are measured in nGPCR-x-transfected cells that have been exposed to candidate modulator compounds. Protocols for cAMP assays have been described in the literature. (See, 20 e.g., Sutherland *et al.*, *Circulation* 37: 279 (1968); Frandsen *et al.*, *Life Sciences* 18: 529-541 (1976); Dooley *et al.*, *Journal of Pharmacology and Experimental Therapeutics* 283 (2): 735-41 (1997); and George *et al.*, *Journal of Biomolecular Screening* 2 (4): 235-40 (1997)). An exemplary protocol for such an assay, using an Adenylyl Cyclase Activation FlashPlate® Assay from NEN™ Life Science Products, is 25 set forth below.

Briefly, the nGPCR-x coding sequence (e.g., a cDNA or intronless genomic DNA) is subcloned into a commercial expression vector, such as pzeoSV2 (Invitrogen), and transiently transfected into Chinese Hamster Ovary (CHO) cells using known methods, such as the transfection protocol provided by Boehringer-Mannheim when 30 supplying the FuGENE 6 transfection reagent. Transfected CHO cells are seeded into 96-well microplates from the FlashPlate® assay kit, which are coated with solid scintillant to which antisera to cAMP has been bound. For a control, some wells are

DOCKET NO.: 411USPHRM311

PATENT

seeded with wild type (untransfected) CHO cells. Other wells in the plate receive various amounts of a cAMP standard solution for use in creating a standard curve.

One or more test compounds (*i.e.*, candidate modulators) are added to the cells in each well, with water and/or compound-free medium/diluent serving as a control or 5 controls. After treatment, cAMP is allowed to accumulate in the cells for exactly 15 minutes at room temperature. The assay is terminated by the addition of lysis buffer containing [¹²⁵I]-labeled cAMP, and the plate is counted using a Packard Topcount™ 96-well microplate scintillation counter. Unlabeled cAMP from the lysed cells (or from standards) and fixed amounts of [¹²⁵I]-cAMP compete for antibody bound to the 10 plate. A standard curve is constructed, and cAMP values for the unknowns are obtained by interpolation. Changes in intracellular cAMP levels of cells in response to exposure to a test compound are indicative of nGPCR-x modulating activity.

Modulators that act as agonists of receptors which couple to the G_s subtype of G 15 proteins will stimulate production of cAMP, leading to a measurable 3-10 fold increase in cAMP levels. Agonists of receptors which couple to the G_{i/o} subtype of G proteins will inhibit forskolin-stimulated cAMP production, leading to a measurable decrease in cAMP levels of 50-100%. Modulators that act as inverse agonists will reverse these effects at receptors that are either constitutively active or activated by known agonists.

B. Aequorin Assays

20 In another assay, cells (*e.g.*, CHO cells) are transiently co-transfected with both a nGPCR-x expression construct and a construct that encodes the photoprotein apoaequorin. In the presence of the cofactor coelenterazine, apoaequorin will emit a measurable luminescence that is proportional to the amount of intracellular (cytoplasmic) free calcium. (See generally, Cobbold, *et al.* "Aequorin measurements of 25 cytoplasmic free calcium," *In: McCormack J.G. and Cobbold P.H., eds., Cellular Calcium: A Practical Approach*. Oxford:IRL Press (1991); Stables *et al.*, *Analytical Biochemistry* 252: 115-26 (1997); and Haugland, *Handbook of Fluorescent Probes and Research Chemicals*. Sixth edition. Eugene OR: Molecular Probes (1996).)

30 In one exemplary assay, nGPCR-x is subcloned into the commercial expression vector pzeoSV2 (Invitrogen) and transiently co-transfected along with a construct that encodes the photoprotein apoaequorin (Molecular Probes, Eugene, OR) into CHO cells

DOCKET NO.: 411USPHRM311

PATENT

using the transfection reagent FuGENE 6 (Boehringer-Mannheim) and the transfection protocol provided in the product insert.

The cells are cultured for 24 hours at 37°C in MEM (Gibco/BRL, Gaithersburg, MD) supplemented with 10% fetal bovine serum, 2 mM glutamine, 10 U/ml penicillin 5 and 10 µg/ml streptomycin, at which time the medium is changed to serum-free MEM containing 5 µM coelenterazine (Molecular Probes, Eugene, OR). Culturing is then continued for two additional hours at 37°C. Subsequently, cells are detached from the plate using VERSEN (Gibco/BRL), washed, and resuspended at 200,000 cells/ml in serum-free MEM.

10 Dilutions of candidate nGPCR-x modulator compounds are prepared in serum-free MEM and dispensed into wells of an opaque 96-well assay plate at 50 µl/well. Plates are then loaded onto an MLX microtiter plate luminometer (Dynex Technologies, Inc., Chantilly, VA). The instrument is programmed to dispense 50 µl cell suspensions into each well, one well at a time, and immediately read luminescence 15 for 15 seconds. Dose-response curves for the candidate modulators are constructed using the area under the curve for each light signal peak. Data are analyzed with SlideWrite, using the equation for a one-site ligand, and EC₅₀ values are obtained. Changes in luminescence caused by the compounds are considered indicative of modulatory activity. Modulators that act as agonists at receptors which couple to the 20 G_q subtype of G proteins give an increase in luminescence of up to 100 fold. Modulators that act as inverse agonists will reverse this effect at receptors that are either constitutively active or activated by known agonists.

C. Luciferase Reporter Gene Assay

25 The photoprotein luciferase provides another useful tool for assaying for modulators of nGPCR-x activity. Cells (*e.g.*, CHO cells or COS 7 cells) are transiently co-transfected with both a nGPCR-x expression construct (*e.g.*, nGPCR-x in pzeoSV2) and a reporter construct which includes a gene for the luciferase protein downstream 30 from a transcription factor binding site, such as the cAMP-response element (CRE), AP-1, or NF-kappa B. Agonist binding to receptors coupled to the G_s subtype of G proteins leads to increases in cAMP, thereby activating the CRE transcription factor and resulting in expression of the luciferase gene. Agonist binding to receptors coupled

DOCKET NO.: 411USPHRM311

PATENT

to the G_q subtype of G protein leads to production of diacylglycerol that activates protein kinase C, which activates the AP-1 or NF-kappa B transcription factors, in turn resulting in expression of the luciferase gene. Expression levels of luciferase reflect the activation status of the signaling events. (See generally, George *et al.*, *Journal of*

5 *Biomolecular Screening* 2(4): 235-240 (1997); and Stratowa *et al.*, *Current Opinion in Biotechnology* 6: 574-581 (1995)). Luciferase activity may be quantitatively measured using, *e.g.*, luciferase assay reagents that are commercially available from Promega (Madison, WI).

In one exemplary assay, CHO cells are plated in 24-well culture dishes at a
10 density of 100,000 cells/well one day prior to transfection and cultured at 37°C in
MEM (Gibco/BRL) supplemented with 10% fetal bovine serum, 2 mM glutamine, 10
U/ml penicillin and 10 µg/ml streptomycin. Cells are transiently co-transfected with
both a nGPCR-x expression construct and a reporter construct containing the luciferase
gene. The reporter plasmids CRE-luciferase, AP-1-luciferase and NF-
15 kappaB-luciferase may be purchased from Stratagene (LaJolla, CA). Transfections are
performed using the FuGENE 6 transfection reagent (Boehringer-Mannheim) according
to the supplier's instructions. Cells transfected with the reporter construct alone are
used as a control. Twenty-four hours after transfection, cells are washed once with
PBS pre-warmed to 37°C. Serum-free MEM is then added to the cells either alone
20 (control) or with one or more candidate modulators and the cells are incubated at 37°C
for five hours. Thereafter, cells are washed once with ice-cold PBS and lysed by the
addition of 100 µl of lysis buffer per well from the luciferase assay kit supplied by
Promega. After incubation for 15 minutes at room temperature, 15 µl of the lysate is
mixed with 50 µl of substrate solution (Promega) in an opaque-white, 96-well plate,
25 and the luminescence is read immediately on a Wallace model 1450 MicroBeta
scintillation and luminescence counter (Wallace Instruments, Gaithersburg, MD).

Differences in luminescence in the presence versus the absence of a candidate
modulator compound are indicative of modulatory activity. Receptors that are either
constitutively active or activated by agonists typically give a 3 to 20-fold stimulation of
30 luminescence compared to cells transfected with the reporter gene alone. Modulators
that act as inverse agonists will reverse this effect.

DOCKET NO.: 411USPHRM311

PATENT

D. Intracellular calcium measurement using FLIPR

Changes in intracellular calcium levels are another recognized indicator of G protein-coupled receptor activity, and such assays can be employed to screen for modulators of nGPCR-x activity. For example, CHO cells stably transfected with a 5 nGPCR-x expression vector are plated at a density of 4×10^4 cells/well in Packard black-walled, 96-well plates specially designed to discriminate fluorescence signals emanating from the various wells on the plate. The cells are incubated for 60 minutes at 37°C in modified Dulbecco's PBS (D-PBS) containing 36 mg/L pyruvate and 1 g/L glucose with the addition of 1% fetal bovine serum and one of four calcium indicator 10 dyes (Fluo-3™ AM, Fluo-4™ AM, Calcium Green™-1 AM, or Oregon Green™ 488 BAPTA-1 AM), each at a concentration of 4 μ M. Plates are washed once with modified D-PBS without 1% fetal bovine serum and incubated for 10 minutes at 37°C to remove residual dye from the cellular membrane. In addition, a series of washes with modified D-PBS without 1% fetal bovine serum is performed immediately prior to 15 activation of the calcium response.

A calcium response is initiated by the addition of one or more candidate receptor agonist compounds, calcium ionophore A23187 (10 μ M; positive control), or ATP (4 μ M; positive control). Fluorescence is measured by Molecular Device's FLIPR with an argon laser (excitation at 488 nm). (See, *e.g.*, Kuntzweiler *et al.*, Drug 20 Development Research, 44(1):14-20 (1998)). The F-stop for the detector camera was set at 2.5 and the length of exposure was 0.4 milliseconds. Basal fluorescence of cells was measured for 20 seconds prior to addition of candidate agonist, ATP, or A23187, and the basal fluorescence level was subtracted from the response signal. The calcium signal is measured for approximately 200 seconds, taking readings every two seconds. 25 Calcium ionophore A23187 and ATP increase the calcium signal 200% above baseline levels. In general, activated GPCRs increase the calcium signal approximately 10-15% above baseline signal.

E. Mitogenesis Assay

In a mitogenesis assay, the ability of candidate modulators to induce or inhibit 30 nGPCR-x-mediated cell division is determined. (See, *e.g.*, Lajiness *et al.*, Journal of Pharmacology and Experimental Therapeutics 267(3): 1573-1581 (1993)). For

DOCKET NO.: 411USPHRM311

PATENT

example, CHO cells stably expressing nGPCR-x are seeded into 96-well plates at a density of 5000 cells/well and grown at 37°C in MEM with 10% fetal calf serum for 48 hours, at which time the cells are rinsed twice with serum-free MEM. After rinsing, 80 μ l of fresh MEM, or MEM containing a known mitogen, is added along with 20 μ l

5 MEM containing varying concentrations of one or more candidate modulators or test compounds diluted in serum-free medium. As controls, some wells on each plate receive serum-free medium alone, and some receive medium containing 10% fetal bovine serum. Untransfected cells or cells transfected with vector alone also may serve as controls.

10 After culture for 16-18 hours, 1 μ Ci of [³H]-thymidine (2 Ci/mmol) is added to the wells and cells are incubated for an additional 2 hours at 37°C. The cells are trypsinized and collected on filter mats with a cell harvester (Tomtec); the filters are then counted in a Betaplate counter. The incorporation of [³H]-thymidine in serum-free test wells is compared to the results achieved in cells stimulated with serum (positive 15 control). Use of multiple concentrations of test compounds permits creation and analysis of dose-response curves using the non-linear, least squares fit equation: $A = B \times [C / (D + C)] + G$ where A is the percent of serum stimulation; B is the maximal effect minus baseline; C is the EC₅₀; D is the concentration of the compound; and G is the maximal effect. Parameters B, C and G are determined by Simplex optimization.

20 Agonists that bind to the receptor are expected to increase [³H]-thymidine incorporation into cells, showing up to 80% of the response to serum. Antagonists that bind to the receptor will inhibit the stimulation seen with a known agonist by up to 100%.

F. [³⁵S]GTP γ S Binding Assay

25 Because G protein-coupled receptors signal through intracellular G proteins whose activity involves GTP binding and hydrolysis to yield bound GDP, measurement of binding of the non-hydrolyzable GTP analog [³⁵S]GTP γ S in the presence and absence of candidate modulators provides another assay for modulator activity. (See, e.g., Kowal *et al.*, *Neuropharmacology* 37:179-187 (1998).)

30 In one exemplary assay, cells stably transfected with a nGPCR-x expression vector are grown in 10 cm tissue culture dishes to subconfluence, rinsed once with 5 ml

DOCKET NO.: 411USPHRM311

PATENT

of ice-cold $\text{Ca}^{2+}/\text{Mg}^{2+}$ -free phosphate-buffered saline, and scraped into 5 ml of the same buffer. Cells are pelleted by centrifugation (500 x g, 5 minutes), resuspended in TEE buffer (25 mM Tris, pH 7.5, 5 mM EDTA, 5 mM EGTA), and frozen in liquid nitrogen. After thawing, the cells are homogenized using a Dounce homogenizer (one ml TEE per plate of cells), and centrifuged at 1,000 x g for 5 minutes to remove nuclei and unbroken cells.

5 The homogenate supernatant is centrifuged at 20,000 x g for 20 minutes to isolate the membrane fraction, and the membrane pellet is washed once with TEE and resuspended in binding buffer (20 mM HEPES, pH 7.5, 150 mM NaCl, 10 mM MgCl_2 , 10 mM EDTA). The resuspended membranes can be frozen in liquid nitrogen and stored at -70°C until use.

10 Aliquots of cell membranes prepared as described above and stored at -70°C are thawed, homogenized, and diluted into buffer containing 20 mM HEPES, 10 mM MgCl_2 , 1 mM EDTA, 120 mM NaCl, 10 μM GDP, and 0.2 mM ascorbate, at a concentration of 10-50 $\mu\text{g}/\text{ml}$. In a final volume of 90 μl , homogenates are incubated with varying concentrations of candidate modulator compounds or 100 μM GTP for 30 minutes at 30°C and then placed on ice. To each sample, 10 μl guanosine 5'-O-(3[³⁵S]thio) triphosphate (NEN, 1200 Ci/mmol; [³⁵S]-GTP γ S), was added to a final concentration of 100-200 pM. Samples are incubated at 30°C for an additional 30 minutes, 1 ml of 10 mM HEPES, pH 7.4, 10 mM MgCl_2 , at 4°C is added and the reaction is stopped by filtration.

15 Samples are filtered over Whatman GF/B filters and the filters are washed with 20 ml ice-cold 10 mM HEPES, pH 7.4, 10 mM MgCl_2 . Filters are counted by liquid scintillation spectroscopy. Nonspecific binding of [³⁵S]-GTP γ S is measured in the presence of 100 μM GTP and subtracted from the total. Compounds are selected that modulate the amount of [³⁵S]-GTP γ S binding in the cells, compared to untransfected control cells. Activation of receptors by agonists gives up to a five-fold increase in [³⁵S]GTP γ S binding. This response is blocked by antagonists.

20 **G. MAP Kinase Activity Assay**

Evaluation of MAP kinase activity in cells expressing a GPCR provides another assay to identify modulators of GPCR activity. (See, e.g., Lajiness *et al.*, Journal of

DOCKET NO.: 411USPHRM311

PATENT

Pharmacology and Experimental Therapeutics 267(3):1573-1581 (1993) and Boulton *et al.*, Cell 65:663-675 (1991).)

In one embodiment, CHO cells stably transfected with nGPCR-x are seeded into 6-well plates at a density of 70,000 cells/well 48 hours prior to the assay. During this 5 48-hour period, the cells are cultured at 37°C in MEM medium supplemented with 10% fetal bovine serum, 2 mM glutamine, 10 U/ml penicillin and 10 µg/ml streptomycin. The cells are serum-starved for 1-2 hours prior to the addition of stimulants.

For the assay, the cells are treated with medium alone or medium containing either a candidate agonist or 200 nM Phorbol ester- myristoyl acetate (*i.e.*, PMA, a 10 positive control), and the cells are incubated at 37°C for varying times. To stop the reaction, the plates are placed on ice, the medium is aspirated, and the cells are rinsed with 1 ml of ice-cold PBS containing 1 mM EDTA. Thereafter, 200 µl of cell lysis buffer (12.5 mM MOPS, pH 7.3, 12.5 mM glycerophosphate, 7.5 mM MgCl₂, 0.5 mM EGTA, 0.5 mM sodium vanadate, 1 mM benzamidine, 1 mM dithiothreitol, 10 µg/ml 15 leupeptin, 10 µg/ml aprotinin, 2 µg/ml pepstatin A, and 1 µM okadaic acid) is added to the cells. The cells are scraped from the plates and homogenized by 10 passages through a 23 3/4 G needle, and the cytosol fraction is prepared by centrifugation at 20,000 x g for 15 minutes.

Aliquots (5-10 µl containing 1-5 µg protein) of cytosol are mixed with 1 mM 20 MAPK Substrate Peptide (APRTPGGRR (SEQ ID NO: 129), Upstate Biotechnology, Inc., N.Y.) and 50 µM [γ -³²P]ATP (NEN, 3000 Ci/mmol), diluted to a final specific activity of ~2000 cpm/pmol, in a total volume of 25 µl. The samples are incubated for 5 minutes at 30°C, and reactions are stopped by spotting 20 µl on 2 cm² squares of Whatman P81 phosphocellulose paper. The filter squares are washed in 4 changes of 25 1% H₃PO₄, and the squares are subjected to liquid scintillation spectroscopy to quantitate bound label. Equivalent cytosolic extracts are incubated without MAPK substrate peptide, and the bound label from these samples are subtracted from the matched samples with the substrate peptide. The cytosolic extract from each well is used as a separate point. Protein concentrations are determined by a dye binding 30 protein assay (Bio-Rad Laboratories). Agonist activation of the receptor is expected to

DOCKET NO.: 411USPHRM311

PATENT

result in up to a five-fold increase in MAPK enzyme activity. This increase is blocked by antagonists.

H. [³H]Arachidonic Acid Release

The activation of GPCRs also has been observed to potentiate arachidonic acid release in cells, providing yet another useful assay for modulators of GPCR activity. (See, e.g., Kanterman *et al.*, Molecular Pharmacology 39:364-369 (1991).) For example, CHO cells that are stably transfected with a nGPCR-x expression vector are plated in 24-well plates at a density of 15,000 cells/well and grown in MEM medium supplemented with 10% fetal bovine serum, 2 mM glutamine, 10 U/ml penicillin and 10 μ g/ml streptomycin for 48 hours at 37°C before use. Cells of each well are labeled by incubation with [³H]-arachidonic acid (Amersham Corp., 210 Ci/mmol) at 0.5 μ Ci/ml in 1 ml MEM supplemented with 10 mM HEPES, pH 7.5, and 0.5% fatty-acid-free bovine serum albumin for 2 hours at 37°C. The cells are then washed twice with 1 ml of the same buffer.

Candidate modulator compounds are added in 1 ml of the same buffer, either alone or with 10 μ M ATP and the cells are incubated at 37°C for 30 minutes. Buffer alone and mock-transfected cells are used as controls. Samples (0.5 ml) from each well are counted by liquid scintillation spectroscopy. Agonists which activate the receptor will lead to potentiation of the ATP-stimulated release of [³H]-arachidonic acid. This potentiation is blocked by antagonists.

I. Extracellular Acidification Rate

In yet another assay, the effects of candidate modulators of nGPCR-x activity are assayed by monitoring extracellular changes in pH induced by the test compounds.

(See, e.g., Dunlop *et al.*, Journal of Pharmacological and Toxicological Methods 40(1):47-55 (1998).) In one embodiment, CHO cells transfected with a nGPCR-x expression vector are seeded into 12 mm capsule cups (Molecular Devices Corp.) at 4 x 10⁵ cells/cup in MEM supplemented with 10% fetal bovine serum, 2 mM L-glutamine, 10 U/ml penicillin, and 10 μ g/ml streptomycin. The cells are incubated in this medium at 37°C in 5% CO₂ for 24 hours.

DOCKET NO.: 411USPHRM311

PATENT

Extracellular acidification rates are measured using a Cytosensor microphysiometer (Molecular Devices Corp.). The capsule cups are loaded into the sensor chambers of the microphysiometer and the chambers are perfused with running buffer (bicarbonate-free MEM supplemented with 4 mM L-glutamine, 10 units/ml penicillin, 10 µg/ml streptomycin, 26 mM NaCl) at a flow rate of 100 µl/minute. Candidate agonists or other agents are diluted into the running buffer and perfused through a second fluid path. During each 60-second pump cycle, the pump is run for 38 seconds and is off for the remaining 22 seconds. The pH of the running buffer in the sensor chamber is recorded during the cycle from 43-58 seconds, and the pump is re-started at 60 seconds to start the next cycle. The rate of acidification of the running buffer during the recording time is calculated by the Cytosoft program. Changes in the rate of acidification are calculated by subtracting the baseline value (the average of 4 rate measurements immediately before addition of a modulator candidate) from the highest rate measurement obtained after addition of a modulator candidate. The selected instrument detects 61 mV/pH unit. Modulators that act as agonists of the receptor result in an increase in the rate of extracellular acidification compared to the rate in the absence of agonist. This response is blocked by modulators which act as antagonists of the receptor.

20 **EXAMPLE 11: *IN SITU* HYBRIDIZATION**

DNA Probe Preparation For nGPCR-11, -16, -40, -54, and -56

DNA probes for *in situ* hybridization were prepared as follows. Two sets of primer pairs were prepared. The first set has the sequence for T7 polymerase promoter on the 5' primer to make the sense RNA, and the second set has the T7 polymerase promoter sequence on the 3' primer to make the antisense RNA. PCR was performed in a 50 µl reaction containing 36.5 µl H₂O, 5µl 10xTT buffer (140 mM Ammonium Sulfate, 0.1 % gelatine, 0.6 M Tris-tricine pH 8.4), 5 µl 25mM MgCl₂, 2 µl 10 mM dNTP, 0.4 µl Incyte clone 1722192 DNA, 0.5 µl AmpliTaq (PE Applied Biosystems), and 0.3 µl oligo1 (1 mg/ml) and 0.3 µl oligo2 (1mg/ml)[to make the sense RNA], or 0.3 µl oligo3 (1 mg/ml) and 0.3 µl oligo4 (1mg/ml)[to make the antisense RNA]. The PCR reaction involved one cycle at 94°C for 2 min followed by 35 cycles at 94°C for 30 sec,

DOCKET NO.: 411USPHRM311

PATENT

60°C for 30 sec, 72°C for 30 sec. The two PCR reactions were loaded onto a 1.2 % agarose gel. The DNA band was excised from the gel, placed in a GenElute Agarose spin column (Supelco) and spun for 10 min at maximum speed. The eluted DNA was EtOH precipitated and resuspended in transcription buffer. The primer sequences for 5 each nGPCR tested are listed below.

For nGPCR-11, the sense primers were:

5' GCGTAATACGACTCACTATAGGGAGACCGCGTCTGCTAGACTCTATTC
C 3' (LW1658) (SEQ ID NO: 159), and:

10 5' TGCCACACTGATGCAACTCC 3' (LW1661) (SEQ ID NO: 160). The antisense primers were:

5' GCGTAATACGACTCACTATAGGGAGACCTGCCACACTGATGCAACTCC
(LW1659) SEQ ID NO: 161) and:

5' GCGTGTCTGCTAGACTCTATTCC 3' (LW1660) (SEQ ID NO: 162). The primer pairs yielded a product of 275bp.

15 For nGPCR-16, the sense primers were:

5' GCGTAATACGACTCACTATAGGGAGACCGCACGCCACTTTACTATCCC
(LW1645) (SEQ ID NO: 163), and:

5' GCACAAAACACAATTCCATAAGCC 3' (LW1648) (SEQ ID NO: 164). The antisense primers were:

20 5' GCGTAATACGACTCACTATAGGGAGACCGCACAAAACACAATTCCATAA
GCC 3' (LW1646) (SEQ ID NO: 165), and:

5' GCTACGCCACTTTACTATCCC 3' (LW1647) (SEQ ID NO: 166). The primer pairs yielded a product of 283 bp.

For nGPCR-40, the sense primers were:

25 5' GCGTAATACGACTCACTATAGGGAGACCTTATGAGCAGCAATTCATCCC
3' (LW1704) (SEQ ID NO: 167), and:

5' CACACCCACCAAGAAATCAG 3' (LW1707) (SEQ ID NO: 168). The antisense primers were:

30 5' GCGTAATACGACTCACTATAGGGAGACCCACACCCACCAAGAAATCAG
3' (LW1705) (SEQ ID NO: 169), and:

5' TTATGAGCAGCAATTCATCCC 3' (LW1706) (SEQ ID NO: 170). The primer pairs yielded a product of 251bp.

DOCKET NO.: 411USPHRM311

PATENT

For nGPCR-54, the sense primers were:

5' GCGTAATACGACTCACTATAGGGAGACCCGATTATCCACACTTGACCC
3' (LW1803) (SEQ ID NO: 171), and:

5' CTGAAAGTTGTCGCTGACC 3' (LW1634) (SEQ ID NO: 172). The anti-sense
5 primers were:

GCGTAATACGACTCACTATAGGGAGACCCTGCTGAAAGTTGTCGCTGACC
3' (LW1804)(SEQ ID NO: 173), and:

5' CGATTATCCACACTTGACCC 3' (LW1635) (SEQ ID NO: 174). The primer
pairs yielded a product of 286 bp.

10 For nGPCR-56, the sense primers were:

GCGTAATACGACTCACTATAGGGAGACCCTGTAAAATTCACACAAGCACC
3' (LW1763) (SEQ ID NO: 175), and:

5' AGAAGACAGAGAACCTCC 3' (LW1766) (SEQ ID NO: 176). The anti-sense
primers were:

15 GCGTAATACGACTCACTATAGGGAGACCAGAACAGAGAACCTCC
(LW1764) (SEQ ID NO: 177) and:

CTGTAAAATTCACACAAGCACC (LW1765) (SEQ ID NO: 178). The primer pairs
yielded a product of 272 bp.

20 **DNA Probe Preparation For nGPCR-1**

Probes for nGPCR-1 were prepared as above with the following
modifications. Using a sense primer:

GCATGGATCCTTTGCTGTATTCACCCTC) (LW1595) (SEQ ID NO: 179) and
an antisense primer:

25 5' GCATGAATTACAATGCCAGTGATAAGGAAG 3' (LW1596) (SEQ ID NO:
180), a 271 bp fragment was generated by PCR. The fragment was digested with
BamHI and *EcoRI* and ligated into a BluescriptII vector that had been cut with *BamHI*
and *EcoRI*. The orientation of the insert was such that T7 polymerase generates the
anti-sense strand and T3 polymerase generates the sense strand.

30 **Histochemistry**

Coronal and sagittal oriented rat brain sections were cryosectioned (20 μ m
thick) using a Reichert-Jung cryostat. The individual sections were thaw-mounted onto

DOCKET NO.: 411USPHRM311

PATENT

silanated, nuclease-free slides (CEL Associates, Inc., Houston, TX), and stored at - 80°C. The sections were processed starting with post-fixation in cold 4% paraformaldehyde, rinsed in cold PBS, acetylated using acetic anhydride in triethanolamine buffer and dehydrated through 70%, 95%, and 100% alcohols at room 5 temperature (RT). This was followed with delipidation in chloroform then rehydration in 100% and 95% alcohol at room temperature. Sections were air-dried prior to hybridization. Two PCR fragments (~ 250 bp) were generated, one that contained T7 polymerase on the 5' end (sense) and the other with T7 polymerase on the 3' end (antisense). The PCR fragments were labeled with ^{35}S -UTP to yield a specific activity 10 of 0.655×10^6 cpm/pmol for antisense and 0.675×10^6 cpm/pmol for sense probe. Both riboprobes were denatured and added to hybridization buffer containing 50% formamide, 10% dextran, 0.3M NaCl, 10 mM Tris, 1 mM EDTA, 1X Denhardts, and 10 mM DTT. Sequential brain cryosections were hybridized with 45 μl /slide of the 15 sense and antisense riboprobe hybridization mixture, then covered with silanized glass coverslips. The sections were hybridized overnight (15-18 hrs) at 42°C in an incubator.

Coverslips were washed off the slides in 1X SSC, followed by RNase A treatment, and high temperature stringency washes (3X, 20 mins at 41°C) in 0.1X SSC. Slides were dehydrated with 70%, 95% NH₄OAc, and 100% NH₄OAc alcohols, air-dried and exposed to Kodak BioMax MR-1 film. After 9 days of exposure, the film 20 was developed. This was followed with coating selected tissue slides with Kodak NTB-2 nuclear track emulsion and storing the slides in the dark for 23 days. The slides were then developed and counterstained with hematoxylin. Emulsion-coated sections were analyzed microscopically to determine the specificity of labeling. Presence of 25 autoradiographic grains (generated by antisense probe hybridization) over cell bodies (versus between cell bodies) was used as an index of specific hybridization.

Results

In situ hybridization results indicated localization in the following brain areas:

nGPCR-1 was localized to the dentate gyrus of hippocampus, piriform cortex, and red nucleus.

30 nGPCR-11 was localized to the piriform cortex, hippocampus, red nucleus, subthalamic nuclei, dorsal raphe, interpeduncular nucleus, and habenula. nGPCR-16

DOCKET NO.: 411USPHRM311

PATENT

was localized to the cortex, piriform cortex, hippocampus, thalamus, subthalamic nuclei, hypothalamus, bed nucleus stria terminalis and posterior striatum. nGPCR-40 was localized to the cortex, piriform cortex, hippocampus, substantia nigra compacta, hypothalamus, lateral septus, bed nucleus stria terminalis, thalamus, ventral tegmental area, interpeduncular nucleus, dorsal raphe, medial geniculate, islands of Calleja, subthalamic nuclei, choroid plexus. nGPCR-54 was localized to the piriform cortex and hippocampus, including the dentate gyrus, CA1 and CA3. nGPCR-56 was localized to the piriform cortex, cortex, interpeduncular nucleus, red nucleus, hippocampus, habenula, substantia nigra pars compacta, mamillary body stria terminalis, hypothalamus, subthalamic nuclei, dorsal raphe, and ventral tegmental area.

EXAMPLE 12: CHROMOSOMAL LOCALIZATION

Methods

15 Chromosomal location of the genes encoding nGPCRs was determined using the Stanford G3 Radiation Hybrid Panel (Research Genetics, Inc., Huntsville, AL). This panel contains 83 radiation hybrid clones of the entire human genome created by the Stanford Human Genome Center. PCR reactions were assembled containing 25ng of DNA from each clone and the components of the Expand Hi-Fi PCR System™ (Roche Molecular Biochemicals, Indianapolis, IN) in a final reaction volume of 15 μ l. PCR primers were synthesized by Genosys Corp., The Woodlands, TX. PCR reactions were incubated in a GeneAmp 9700 PCR thermocycler (Perkin Elmer Applied Biosystems). The following cycling program was executed: Pre-soak at (94° for 3min.)(94° for 30 sec.)(52°C for 60 sec.)(72° for 2 min.]) for 35 cycles. PCR reaction products were then separated and analyzed by electrophoresis on a 2.0% agarose gel, and stained with ethidium bromide. Lanes were scored for the presence or absence of the expected PCR product and the results submitted to the Stanford Human Genome Center via e-mail for analysis (<http://www-shgc.stanford.edu/RH/rhserverformnew.html>).

30 nGPCR-40

PCR primers were designed based on the available sequence of the Celera sequence HUM_IDS|Contig|11000258115466. The forward primer used was:

DOCKET NO.: 411USPHRM311

PATENT

5'ACAGCCCCAAAGCCAAACAC3' (SEQ ID NO: 181). The reverse primer was:

5'CCGCAGGAGCAATG-AAAATCAG3' (SEQ ID NO: 182). This primer set will prime the synthesis of a 220 base pair fragment in the presence of the appropriate 5 genomic DNA.

G3 Radiation Hybrid Panel Analysis places nGPCR-40 on chromosome 6, most 10 nearly linked to Stanford marker SHGC-1836 with a LOD score of 11.84. This marker lies at position 6q21. In a genome scanning data set, Cao *et al.* (Genomics 1997 Jul 1: 43(1): 1-8) found excess allele sharing for markers on 6q13-q26. Greatest allele 15 sharing was at interval 6q21-q22.3 with a maximum multipoint MLS value of 3.06 close to marker D6S278. Replication data from a second data set found maximum multipoint MLS at the interval D6S424-D6S275. These results provide suggestive evidence for a susceptibility locus for schizophrenia in chromosome 6q from two independent data sets.

15 nGPCR-54

PCR primers were designed based on the available sequence of the Celera sequence GA_11824020. The forward primer used was:

5'CTGTCTCTGTCCCTTTCC3', (SEQ ID NO: 183). The reverse primer used was:

20 5'GCACCGATCTCATTGAATTC3', (SEQ ID NO: 184). This primer set will prime the synthesis of a 145 base pair fragment in the presence of the appropriate genomic DNA.

G3 Radiation Hybrid Panel Analysis places nGPCR-54 on chromosome 13, most 25 nearly linked to Stanford marker SHGC-68276 with a LOD score of 6.31. This marker lies at position 13q32. Numerous investigations have found significant suggestion of linkage of schizophrenia to this region of chromosome 13q32. See, for example, Brzustowicz *et al.*, Am J Hum Genet 1999 Oct; 65(4): 1096-1103; Blouin *et al.*, Nat Genet 1998 Sep; 20(1): 70-3; Shaw *et al.*, Am J Med Genet. 1998 Sep 7; 81(5): 364-76; Lin *et al.*, Hum Genet 1997 Mar; 99(3): 417-20; Pulver *et al.*, Cold Spring 30 Harb Symp Quant Biol 1996; 61:797-814.

Genes localized to chromosomal regions in linkage with schizophrenia are candidate genes for disease susceptibility. Genes in these regions with the potential to

DOCKET NO.: 411USPHRM311

PATENT

play a biochemical/functional role in the disease process (like G protein coupled receptors) have a high probability of being a disease-modifying locus. nGPCR-40 and -54, because of their chromosomal location, are attractive targets therefore for screening ligands useful in modulating cellular processes involved in schizophrenia.

5

EXAMPLE 13: CLONE DEPOSIT INFORMATION

In accordance with the Budapest Treaty, clones of the present invention have been deposited at the Agricultural Research Culture Collection (NRRL) International Depository Authority, 1815 N. University Street, Peoria, Illinois 61604, U.S.A.

10 Accession numbers and deposit dates are provided below in Table 6.

Table 6: DEPOSIT INFORMATION

Clone	Accession Number NRRL	Budapest Treaty Deposit Date
nGPCR-1 (SEQ ID NO:73)	B-30243	2000 Jan 18
nGPCR -5 (SEQ ID NO: 75)	B-30244	2000 Jan 18
nGPCR -16 (SEQ ID NO: 81)	B-30245	2000 Jan 18
nGPCR -11 (SEQ ID NO: 79)	B-30258	2000 Feb 02
nGPCR -17 (SEQ ID NO: 23)	B-30259	2000 Feb 03
nGPCR -9 (SEQ ID NO: 77)	B-30262	2000 Feb 22
nGPCR -58 (SEQ ID NO: 91)	B-30274	2000 March 23
nGPCR -56 (SEQ ID NO: 89)	B-30288	2000 May 5
nGPCR -3 (SEQ ID NO:185)	B-30290	2000 May 5
nGPCR -54 (SEQ ID NO: 85)	B-30291	2000 May 5
nGPCR -40 (SEQ ID NO: 83*)	B-30299N	2000 June 02

15 * The clone deposited with NRLL Accession Number B30299N comprises a sequence identical to SEQ ID NO:83 but with the substitution of an "A" at nucleotide position 10.

Example 14 - Using nGPCR-x proteins to isolate neurotransmitters

20 The isolated nGPCR-x proteins can be used to isolate novel or known neurotransmitters (Saito *et al.*, *Nature* 400: 265-269, 1999). The cDNAs that encode

DOCKET NO.: 411USPHRM311

PATENT

the isolated nGPCR-x can be cloned into mammalian expression vectors and used to stably or transiently transfect mammalian cells including CHO, Cos or HEK293 cells. Receptor expression can be determined by Northern blot analysis of transfected cells and identification of an appropriately sized mRNA band (predicted size from the 5 cDNA). Brain regions shown by mRNA analysis to express each of the nGPCR-x proteins could be processed for peptide extraction using any of several protocols ((Reinscheidk R.K. *et al.*, *Science* 270: 243-247, 1996; Sakurai, T., *et al.*, *Cell* 92; 573-585, 1998; Hinuma, S., *et al.*, *Nature* 393: 272-276, 1998). Chromotographic fractions of brain extracts could be tested for ability to activate nGPCR-x proteins by measuring 10 second messenger production such as changes in cAMP production in the presence or absence of forskolin, changes in inositol 3-phosphate levels, changes in intracellular calcium levels or by indirect measures of receptor activation including receptor stimulated mitogenesis, receptor mediated changes in extracellular acidification or receptor mediated changes in reporter gene activation in response to cAMP or calcium 15 (these methods should all be referenced in other sections of the patent). Receptor activation could also be monitored by co-transfected cells with a chimeric $GI_{q/i3}$ to force receptor coupling to a calcium stimulating pathway (Conklin *et al.*, *Nature* 363; 274-276, 1993). Neurotransmitter mediated activation of receptors could also be monitored by measuring changes in $[^{35}S]$ -GTPKS binding in membrane fractions 20 prepared from transfected mammalian cells. This assay could also be performed using baculoviruses containing nGPCR-x proteins infected into SF9 insect cells.

The neurotransmitter which activates nGPCR-x proteins can be purified to homogeneity through successive rounds of purification using nGPCR-x proteins activation as a measurement of neurotransmitter activity. The composition of the 25 neurotransmitter can be determined by mass spectrometry and Edman degradation if peptidergic. Neurotransmitters isolated in this manner will be bioactive materials which will alter neurotransmission in the central nervous system and will produce behavioral and biochemical changes.

30 **Example 15 - Using nGPCR-x proteins to isolate and purify G proteins**

cDNAs encoding nGPCR-x proteins are epitope-tagged at the amino terminus end of the cDNA with the cleavable influenza-hemagglutinin signal sequence followed

DOCKET NO.: 411USPHRM311

PATENT

by the FLAG epitope (IBI, New Haven, CT). Additionally, these sequences are tagged at the carboxyl terminus with DNA encoding six histidine residues. (Amino and Carboxyl Terminal Modifications to Facilitate the Production and Purification of a G Protein-Coupled Receptor, B.K. Kobilka, *Analytical Biochemistry*, Vol. 231, No. 1, 5 Oct 1995, pp. 269-271). The resulting sequences are cloned into a baculovirus expression vector such as pVL1392 (Invitrogen). The baculovirus expression vectors are used to infect SF-9 insect cells as described (Guan, X. M., Kobilka, T. S., and Kobilka, B. K. (1992) *J. Biol. Chem.* **267**, 21995-21998). Infected SF-9 cells could be grown in 1000-ml cultures in SF900 II medium (Life Technologies, Inc.) containing 10 5% fetal calf serum (Gemini, Calabasas, CA) and 0.1 mg/ml gentamicin (Life Technologies, Inc.) for 48 hours at which time the cells could be harvested. Cell membrane preparations could be separated from soluble proteins following cell lysis. nGPCR-x protein purification is carried out as described for purification of the $\vartheta 2$ receptor (Kobilka, *Anal. Biochem.*, 231 (1): 269-271, 1995) including solubilization of 15 the membranes in 0.8-1.0 % *n*-dodecyl -D-maltoside (DM) (CalBiochem, La Jolla, CA) in buffer containing protease inhibitors followed by Ni-column chromatography using chelating SepharoseTM (Pharmacia, Uppsala, Sweden). The eluate from the Ni-column is further purified on an M1 anti-FLAG antibody column (IBI). Receptor containing fractions are monitored by using receptor specific antibodies following western blot 20 analysis or by SDS-PAGE analysis to look for an appropriate sized protein band (appropriate size would be the predicted molecular weight of the protein).

This method of purifying G protein is particularly useful to isolate G proteins that bind to the nGPCR-x proteins in the absence of an activating ligand.

25 Some of the preferred embodiments of the invention described above are outlined below and include, but are not limited to, the following embodiments. As those skilled in the art will appreciate, numerous changes and modifications may be made to the preferred embodiments of the invention without departing from the spirit of the invention. It is intended that all such variations fall within the scope of the 30 invention.

The entire disclosure of each publication cited herein is hereby incorporated by reference.